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Abstract
This study aimed to explore and develop the role of PCR in the investigation of human 
Helicobacter infections. Overall performance of PCR assays (both conventional and 
real-time) was influenced by certain key factors, notably specimen transport conditions, 
DNA extraction methods, primers, and inherent target sequence variation. PCR-based 
detection and characterisation of non-viable H. pylori in gastric biopsies demonstrated the 
benefit of this approach as an alternative to culture, while the design and application of 
the first PCR test to detect both H. pylori and 'H. heilmanniV-VikQ organisms (HHLOs) 
showed a higher rate of HHLO infection (2.3 %) than had been reported previously. The 
potential of PCR for further strain characterisation was demonstrated by determining 
clarithromycin susceptibility direct from gastric biopsy by a real-time PCR (LightCycler) 
assay for mutation detection. Development of an analogous test for metronidazole 
appears less feasible, as examination of a unique strain set suggested that, contrary to 
earlier reports, genetic mutations in rdxA and frxA  may not be the principal resistance 
mechanism. Additionally, development of a novel multiplex PCR assay to determine 
vacA genotypes direct from gastric biopsies provided a useful tool to facilitate 
surveillance and confirmed that the s 1ml genotype is a common feature of peptic ulcer 
disease-associated isolates. Application of three novel LightCycler PCR assays to detect 
cagA tyrosine phosphorylation motifs (TPMs) demonstrated that TPM A was common in 
South East England. No significant associations were observed between disease status 
and cagA TPM. Extension of the PCR-based approach for non-invasive detection of H. 
pylori from stool specimens showed that it was less sensitive and less specific than stool 
antigen testing. Nevertheless, development of real-time nested PCRs that performed 
identically to conventional assays demonstrated the potential for next-day diagnosis from 
stools and offered the possibility of future screening of larger populations. Application of 
PCR to investigate extra-gastric chronic inflammatory conditions provided the first 
evidence of H  pylori DNA in the human bladder, although its significance as a causal 
factor in human disease remains unclear. The study provides new evidence to support 
wider use of conventional and real-time PCR-based assays as powerful tools for future 
investigation of gastric and extra-gastric Helicobacter infections.
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Glossary of abbreviations
A Adenine
AFLP Amplified Fragment Length Polymorphism
Ala Alanine
AMO Amoxicillin
Arg Arginine
BB Brucella Broth
BIS Bismuth Salts
BSA Bovine Serum Albumin
BLASTn Basic Alignment Sequence Tool nucleotide
C Cytosine
CBA Columbia Blood Agar
CD Crohn’s Disease
cDNA Copy Deoxyribonucleic Acid
CPU Colony Forming Units
CHD Chronic Heart Disease
CLA Clarithromycin
CLA-S Clarithromycin Sensitive
CLA-R Clarithromycin Resistant
CLO Campylobacter-LUke, Organism
CPC Chronic Infant Death Syndrome
CPHL Central Public Health Laboratory
CT Crossover Threshold
CTAB Cetyltrimethyl Ammonium Bromide
dNTPs Deoxynucleotide Trisphosphates
ddNTPs Dideoxynucleotide Trisphosphates
DNA Deoxyribonucleic acid
DU Duodenal Ulcer
EDTA Ethylene Diamine Tetraacetic Acid
EHPSG European Helicobacter pylori Study Group
ELISA Enzyme Linked Immunosorbent Assay
FISH Fluorescent In Situ Hybridisation
FRET Fluorescence Energy Resonance Transfer
G Guanine
GC Gastric Carcinoma
GERD Gastro-oesophageal Reflux Disease
GU Gastric Ulcer
GuSCN Guanidium Isothiocyanate
HHLO '’Helicobacter heilmannii -Like Organism
His Histidine
HpNAP H  pylori Neutrophil Activating Protein
HRU Helicobacter Reference Unit
IBD Inflammatory Bowel Disease
IC Interstitial Cystitis
IgA Immunoglobulin A
IX
IgG Immunoglobulin G
IMS Immuno Magnetic Separation
Leu Leucine
LiPa Line Probe Assay
LPS Lipopolysaccharide
MALT Mucosal Associated Lymphoid Tissue
MIC Minimum Inhibitory Concentration
MTZ Metronidazole
MTZ-S Metronidazole Sensitive
MTZ-R Metronidazole Resistant
MTZCBA Metronidazole Columbia Blood Agar
NADPH Nicotinamide Adenine Dinucleotide Phosphate (reduced form)
NCLD Non Cholestatic Liver Disease
NCTC National Collection of Type Cultures
NIH National Institute of Health
NUD Non Ulcer Dyspepsia
OD Optical Density
ORF Open Reading Frame
PAI Pathogenicity Island
PBC Primary Biliary Cirrhosis
PCR Polymerase Chain Reaction
PHL Public Health Laboratory
POR Pyruvate Oxidoreductase
PPIs Proton Pump Inhibitors
Pro Proline
PSC Primary Sclerosing Cholangitis
PUD Peptic Ulcer Disease
PVP Polyvinyl Pyrrolidone
RE Restriction Endonuclease
RFLP Restriction Fragment Length Polymorphism
rRNA ribosomal Ribonucleic Acid
RT-PCR Reverse Transcription Polymerase Chain Reaction
RUT Rapid Urease Test
SDS Sodium Dodecylsulphate
SIDS Sudden Infant Death Syndrome
T Thymine
Ta Annealing Temperature
TET Tetracycline
Tm Melting Temperature
TPM Tyrosine Phosphorylation Motif
Thr Threonine
UBT Urea Breath Test
UC Ulcerative Colitis
VAIN Variable Atmospheric Incubator
Val Valine
5-ASA 5-Aminosalicyclic Acid
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Chapter 1 : INTRODUCTION
1.1 History of Helicobacter pylori
The first description of gastric spiral organisms in animals can probably be attributed 
to Bottcher in 1875. At the end of the 19^  ^century, ‘Spirochaetes’ in the stomachs of 
dogs and of rodents were reported by Bizzozero and Salomon, respectively. Human 
gastric spiral organisms were not reported until the early 20^  ^century when, in 1906, 
Krienitz identified spiral bacteria in the gastric contents of a patient with gastric 
carcinoma (Kidd and Modlin 1998).
Gastric spiral organisms received little further attention until spiral bacteria 
observed on the gastric mucosa epithelial surface were proposed to influence 
polymorphonuclear white blood cell migration (Steer 1975), but these were 
subsequently misidentified as Pseudomonas aeruginosa (Steer and Colin-Jones 1975). 
Robin Warren, an Australian pathologist, also had observed spiral organisms in 
histopathological specimens for some years and believed that these may play a role in 
gastric disease: a controversial view at that time (Kidd and Modlin 1998). In 1983 
spiral ''Campylobacter-\\kQ'' organisms were cultured for the first time from human 
gastric biopsies by Warren and his colleague Barry Marshall (Warren and Marshall 
1983). The bacteria were present in the majority of patients with chronic active 
gastritis or ulcers of the stomach or duodenum, and a possible causative role in the 
development of these diseases was proposed (Marshall and Warren 1984). Initially 
this organism was named ''Campylobacter pyloridis'" on the basis of guanine-cytosine 
(G + C) content and cell morphology (Marshall and Warren 1984). A later 
grammatical correction renamed the organism "Campylobacter pylorC  (Marshall and 
Goodwin, 1987). It soon became apparent that C. pylori was ultrastructurally atypical
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of Campylobacters and possessed a distinct fatty acid profile and flagellar apparatus 
(Goodwin et al. 1985). Moreover, partial sequencing and DNA-16S rRNA 
hybridisation analysis clearly distinguished C. pylori from other species of 
Campylobacter (fivikholm et al. 1989;Lau a/. 1987;Romaniuk gr a/.
1987;Thompson et al. 1988). This evidence suggested that C. pylori was sufficiently 
different, both biochemically and genetically, to merit creation of a new genus, 
Helicobacter {PcaonymovLS 1989;Goodwin zz/. 1989).
1.2 T\ïq Helicobacter
Helicobacter and its closest relatives that include Campylobacter and Arcobacter 
collectively belong to the class Epsilobacteria, that is part of the subdivision 
Thiobacteria of the division Proteobacteria (On et al. 2002). Since it was first 
described (Goodwin et al. 1989), the genus Helicobacter has expanded substantially 
and at present comprises 22 formally named species (http://www.bacterio.cict.ff), and 
at least 35 additional novel helicobacters awaiting formal naming (Fox 2002). 
Helicobacters principally occupy gastric, intestinal and hepatobiliary niches and have 
been recovered from a wide range of mammals and birds (Table 1.1). A subset of 
these have been isolated from humans and have in some cases been associated with 
specific gastric and extra-gastric disease (O'Rourke et al. 2001). These other 
helicobacters are described in sections 1.13 and 1.14.
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Table 1.1 Gastric and enterohepatic members of the Helicobacter genus.
(Compiled from Fox et al. 2002;Fox 2002;Patterson et al. 
2000;Robertson et al. 2001;Solnick and Schauer 2001 ;Won et al. 
2002)
Gastric Helicobacter taxa Enterohepatic Helicobacter taxa
Species Natural host Species Natural host
H. pylori'^ Humans 77 cinaedi'f Humans, hamsters
‘H.heilmannii ’ Humans, pigs, cats. 77 fennelliae Humans, dogs.
dogs, monkeys. macaques
cheetahs
‘H. rappini’ Humans, sheep, dogs. 77 pullorum Humans, chickens
mice
77. suncus ’ House musk shrews 77 canis Humans, dogs, cats
77 acinonychis Cheetahs 77 canadensis Humans
77 mustelae Ferrets 77. winghamensis ’ Humans
77 felis Cats, dogs, cheetahs 77 pametensis Wild birds, pigs
77 bizzozeronii Cats, dogs 77 bilis Mice, dogs, cats
77 salomonis Cats, dogs 77. marmotae’ Woodchucks, cats
Candidatus H. suis Pigs 77 hepaticus Mice
Candidatus H. bovis Cattle 77 rodentium Mice
77 typhlonius Mice
77 ganmani Mice
77 muridarum Mice, rats
77. muricola ’ Korean wild mouse
77 trogontum Rats
77 mesocricetorum Hamsters
77 cholecystus Hamsters
77. aurati Syrian hamsters
*This species now includes H. nemestrinae.
tThis species now includes 'H. mainz" and 'H. westmeadiV.
1.2.1 Biochemical characteristics of 77. pylori
The original report by Warren and Marshall described H. pylori as a curved Gram 
negative rod (2.5 pm x 0.5 pm) that possessed up to five sheathed unipolar flagella. 
The bacterium was also shown to be slow-growing and relatively fastidious, requiring 
prolonged incubation of 3 - 4 days at 37 °C under microaerophilic conditions (Warren
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and Marshall 1983). Further investigation demonstrated that these bacteria were 
positive for oxidase, catalase and H2S production but negative for indole and nitrate, 
and that the DNA G + C content was similar to that of Campylobacters (36 % mol) 
(Marshall and Warren 1984). Although mis-leadingly described in this study as 
urease-negative, potent urease activity is characteristic of H. pylori and this has since 
become a key biochemical test in its identification, along with the demonstration of 
catalase and cytochrome oxidase activity.
1.2.2 Characteristics of the H. pylori genome
Studies throughout the early 1990s demonstrated that the H. pylori genome ranged in 
size from 1.6 to 1.73 M bp and displays much inter-strain diversity in terms of gene 
order (Ge and Taylor 1999). Comparison of the two H. pylori strains for which the 
entire genome sequence is now described, namely, 26695 (Tomb et a l 1997) and J99 
(Aim et a l 1999), has demonstrated that both strain genomes are within this size 
range and both have a G + C composition of 39 % mol (Aim and Noonan 2001). 
Considerable diversity was identified between the two strains, with 89/1496 and 
117/1590 of the putative open reading frames unique to strains J99 and 26695, 
respectively (Aim and Noonan 2001). Many genotyping-based studies have 
confirmed this high-level inter-strain variation in H. pylori also (Maggi et a l 
2001 ;Salaun et a l 1998). It is now recognised that the panmictic population structure 
of 77 pylori is likely to have arisen by virtue of the fact that these bacteria are often 
naturally competent and thus transformable, allowing free genetic recombination 
between strains (Achtman et a l 1999;Suerbaum et a l 1998).
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1.3 Epidemiology and transmission ofH, pylori
H. pylori infection has been reported in human populations worldwide. Recent 
reviews summarising numerous serological studies confirmed that in the developed 
world, prevalence of H. pylori increases with age, with overall reported incidences 
ranging from 25 - 50 % (Brown 2000;Go 2002;Vaira et al. 1998). Studies that 
compared sera in matched populations collected in the last four decades have 
demonstrated an overall decline in prevalence of infection, suggesting decreasing 
rates of infection (Fujisawa et al. 1999;Roosendaal et al. 1997). In contrast, infection 
rates in developing countries remain high (50 % -100 %) (Brown 2000), with the 
majority of individuals seroconverting early in childhood. These differences probably 
relate to socio-economic differences, with overcrowded living conditions, poor 
hygiene and multiple siblings all recognised as potential risk factors for infection 
(Brown 2000;Go 2002;Vaira et al. 1998). In the UK, a recent serological surveillance 
study demonstrated that approximately 7.5 million people in England and Wales are 
likely to have active H. pylori infection (Vyse et al. 2002). Thus, even in developed 
countries where the incidence is decreasing, H. pylori infection remains a significant 
public health problem.
With the exception of one research group that reported infection in sheep (Dore et 
al. 1999;Dore et al. 2001) and reports of induced H. pylori infection in some 
laboratory animals (Go 2002), there has been little evidence to suggest a non-human 
reservoir for this organism. Studies providing evidence of possible intra-familial 
transmission (Bamford et al. 1993;Dominici et al. 1999) as well as reports of higher
H. pylori prevalence in institutionalised populations (Harris et al. 1995;Lambert et al.
1995) suggests person to person transmission. The demonstration of a strong 
correlation between H. pylori and hepatitis A virus infection in 434 hospital staff
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suggested that transmission occurs by a faecal oral route (Rudi et al. 1997) although 
other studies were unable to support this concordance (Fujisawa et al. 1999;Luzza et 
al. 1997). Numerous studies have identified H. pylori DNA fragments (Makristathis 
et al. 1998;Makristathis et al. 2000;Mapstone et al. 1993b;Monteiro et al. 2001b) and 
antigens in stool specimens (Konstantopoulos et al. 2001 ;Makristathis et al. 
2000;0derda et al. 2000;Vaira et al. 1999), but few groups have successfully cultured 
the organism from stools (Dore et al. 2000b;Kelly et al. 1994;Thomas et al. 1992). 
One early study of Peruvian children suggested that faecally contaminated water may 
be a risk factor for infection (Klein et al. 1991), a possibility supported by the 
subsequent demonstration of H. pylori DNA in drinking water (Bunn et al. 
2002;Hulten et al. 1996) and viable cells in untreated waste water (Lu et al. 2002).
An alternative route of transmission for H. pylori is by oral-oral or gastro-oral 
spread. Evidence of transmission via saliva was provided by studies that identified 
maternal pre-mastication to feed infants in Western Africa (Megraud 1995b) and use 
of chopsticks to eat from a communal food dish (Chow et al. 1995) as risk factors for 
infection. While numerous reports have successfully amplified H. pylori DNA from 
saliva and dental plaque (Berroteran et al. 2002;Li et al. 1996;Namavar et al. 1995), 
culture has proved to be unsuccessful in many cases and so the significance of the oral 
cavity as a potential source of infection remains unclear. Furthermore, no evidence of 
a common route of transmission was found for H. pylori and Epstein Barr virus, a 
common infection transmitted in saliva (Luzza et al. 1998). However the same group 
later identified vomiting siblings as a risk factor for infection (Luzza et al. 2000). 
Further evidence that aspiration via vomitus may transmit infection was provided by 
the demonstration of 77 pylori by culture and PCR in induced (Parsonnet et al. 1999) 
and naturally occurring vomitus (Leung et al. 1999) as well as in the surrounding air
Introduction
(Parsonnet et al. 1999). Further development of tools to facilitate investigations of 
each of these possibilities will be essential in establishing the route of transmission of
H. pylori.
I.4 Clinical presentation of 7T. pylori infection
All patients infected with H. pylori develop chronic gastritis, although the majority 
remain asymptomatic (Go 2002). Spontaneous clearance of infection once acquired 
can occur, but is uncommon (Go 2002). For a small proportion of patients, infection 
will progress to clinically significant disease, including gastric ulcer (GU), duodenal 
ulcer (DU), B-cell mucosa-associated lymphoid tissue (MALT) lymphoma and gastric 
carcinoma (GC) (Suerbaum and Michetti 2002). The precise mechanisms of these 
differential disease outcomes are not well understood, although the distribution of H. 
pylori in the gastric mucosa and the effect of this on acid secretion will influence 
clinical progression (Calam and Baron 2001). For instance, infections focused in the 
gastric antrum lead to increased gastrin release by gastric G cells and acid 
hypersecretion. As a result, protective gastric metaplasia form in the duodenum, 
allowing colonisation of 77 pylori and formation of duodenal ulcers. In contrast, 
more diffuse bacterial colonisation of the gastric corpus can lead to decreased acid 
secretion by the inflamed gastric parietal cells and to development of gastric ulcers 
(Calam and Baron 2001). Acid hyposecretion and gastric atrophy are also recognised 
as potential pre-cursors to development of gastric cancer. The factors involved in 
these differing disease progressions are poorly defined, but are likely to be related to 
the individual host (Nguyen et al. 1999) as well as to bacterial strain virulence. 77 
pylori virulence factors are considered in more detail in section 1.12.
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1.5 Diagnosis oïH, pylori infection
A recent UK survey revealed that 9.0 % of all adults interviewed had consulted their 
doctor about dyspepsia in the previous year (Logan and Delaney 2001). The approach 
to management of dyspeptic patients is still a matter of some debate, but testing 
patients for H. pylori infection is a key component of their initial investigation. 
Furthermore, patient testing as a follow-up after treatment to assess success of 
eradication therapy is often necessary, particularly in persistently symptomatic 
patients. A consensus meeting of the European Helicobacter pylori Study Group 
(EHPSG) established European guidelines for the management of H  pylori infection 
(1997). The recommendations were subsequently refined following an update 
meeting (Malfertheiner et al. 2002). A “test and treat” strategy was recommended for 
persistently dyspeptic adult patients under 45 years of age, where testing was by urea 
breath test or stool antigen test, described in sections 1.5.2.1 and 1.5.2.3, respectively. 
There are many tests available for diagnosis of 77 pylori infection, so selection of an 
appropriate method requires an appreciation of the relative merits of each approach. 
Methods of 77 pylori diagnosis can be subdivided into two main categories, invasive 
and non-invasive.
1.5.1 Invasive diagnostic methods
It has been recommended that at the initial presentation of a symptomatic patient, 
endoscopy should be conducted to exclude any (pre) malignant disease, particularly in 
patients > 55 years old or in those with ‘alarm’ symptoms, such as weight loss or 
signs of gastrointestinal bleeding (Braden and Caspary 2001). Not only does 
endoscopy allow macroscopic evaluation of disease, but gastric biopsies can be 
collected at the same time for examination by one or more of the many tests available
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for H. pylori. One disadvantage of all invasive tests is the potential sampling error 
that may arise from the patchy distribution of H. pylori in the gastric mucosa (Vaira et 
al. 2002). In addition, any invasive method like endoscopy carries a potential, albeit 
small, risk of complications for the patient.
1.5.1.1 Histology
Histological analysis of biopsies to identify H. pylori is now widely used and has the 
advantage that it also allows the degree of inflammation and any other associated 
pathologies to be assessed (El Zimaity 2000). Although histology is considered by 
some to be the “gold standard” diagnostic method, its sensitivity depends largely on 
the expertise of the pathologist, the extent of biopsy sampling and the staining method 
used. It has been recommended that ideally, to maximise sensitivity, three biopsies 
should be taken from the antrum and from the greater and lesser curvature of the 
gastric corpus (El Zimaity 2000). Routine haematoxylin and eosin staining is not 
sufficiently reliable and can miss low-density infections. Various other stains are 
available that are reported to improve sensitivity, including Warthin-Starry stain, 
Giemsa and Genta, as well as immunostaining for improved specificity. Although 
these approaches vary in terms of labour, expense and ease of interpretation, none 
have been shown to be significantly superior to others. However, Giemsa staining is 
inexpensive, sensitive and easy to perform (Vaira et al. 2002).
1.5.1.2 Culture
Culture provides definitive evidence of infection and so is the most specific of all 
diagnostic tests. However, as H. pylori is a fastidious, slow-growing organism that 
requires microaerobic conditions, culture is both time-consuming and technically 
demanding. Sensitivity depends on both the biopsy transport conditions and the 
expertise of the individual laboratory (Perez-Perez 2000). Many studies have
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demonstrated that the composition of transport media used is critical for H. pylori 
survival, with normal saline, Stuart’s transport medium and 20 % glucose having been 
suggested (Vaira et a l 2002), while the inclusion of antibiotics in other media (e.g. 
Dent’s supplement) prevents overgrowth of bacterial contaminants from the oral 
cavity. To date no recommended transport medium is used universally, and this lack 
of standardisation possibly contributes to inter-laboratory variations in sensitivity of 
the technique. Additionally, delay (>24 hr) in processing of biopsies significantly 
decreases bacterial viability and sensitivity (Perez-Perez 2000). In specialised 
laboratories, sensitivity of culture can be over 90 % (Nakamura 2001), but this can be 
reduced in patients that have had prior antibiotic therapy, while lowering gastric pH 
with proton pump inhibitors (PPIs) can lead to overgrowth of contaminating oral 
bacteria. The major advantage of culture over all other methods is that it provides the 
means for gaining further strain information that may be key in appropriate patient 
management, including examination of virulence potential and determination of 
antibiotic susceptibilities. The importance of these will be discussed in subsequent 
sections (1.12 and 1.11).
1.5.1.3 Rapid urease test (RUT)
This test is based on the characteristic rapid urease activity of H. pylori that splits urea 
to form ammonia and CO2. The original Campylobacter-YùiQ organism (CLO) test 
comprises a calibrated amount of buffered gel containing urea and pH indicator, with 
bacteriostatic agents to prevent growth of other urease-producing organisms. A 
biopsy containing H. pylori will hydrolyse urea within 1-24 h, resulting in release of 
ammonia and a change in pH indicator colour from yellow to red. The urease enzyme 
can denature in an acid environment, so intensity and speed of a positive reaction 
depends not only on the number of organisms present but also on the thickness of the
10
Introduction
protective mucus layer (Midolo and Marshall 2000). Other gel-based tests (e.g. 
Hpfast) and paper-based tests (e.g. PyloriTek®), based on similar principles are now 
available (Vaira et al. 2002). A major advantage of the RUT is that it is rapid and 
inexpensive. Pre-treatment, sensitivities can range from 80 -  95 % while specificities 
range from 9 5 -1 0 0  % (Vaira et al. 2002). Buffered urea tests require a minimum of 
1000 organisms to produce a positive result, and false-negatives can also result from 
previous patient medications such as PPIs, antibiotics and H2 receptor antagonists. 
Inactivation of H. pylori by the raised pH found in the stomachs of achlorhydric 
patients can lead to falsely negative results also, while lower sensitivities, ranging 
from 69 -  75 % have been observed in paediatric populations (Midolo and Marshall
2000). Falsely positive RUT results are less common, but can occur in patients taking 
PPIs whose gastric mucosa may be contaminated with urease-positive oral bacteria 
(Midolo and Marshall 2000). Therefore this test may not be appropriate for accurate 
diagnosis in certain patient groups.
1.5.2 Non-invasive methods
Diagnostic methods that do not require prior endoscopy have the obvious advantage 
that they do not incur the considerable associated costs of an invasive approach and 
they overcome the small, but recognised risk to the patient.
1.5.2.1 Urea breath test
This test also exploits the potent urease activity of H. pylori. Urea labelled with 
or isotopes is ingested by patients and this is split by H. pylori urease, to evolve 
labelled CO2 that diffuses into the bloodstream and is transported to the lungs. 
Patient’s breath is collected and analysed for either "^^ C02 or ^^C02. An elevated ratio 
of isotopically labelled CO2 relative to unlabelled CO2 indicates H. pylori infection
11
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(Vaira et a l 2000). Although lower doses of have been administered in children, 
there are concerns about the use of radioactive isotopes in paediatric patients and in 
pregnant women. A safer alternative is the non-radioactive isotope but detection 
of this by mass spectrometry restricts its use to specialist centres. A recent review 
summarising numerous studies showed that UBT was sensitive (90 - 100 %) and 
specific (86 - 100 %) (Vaira et a l 2000), although false-negative results can occur in 
patients that have had prior antibiotic or PPI therapy. In spite of this, UBT is well- 
recognised as a rapid and accurate means of non-invasive H. pylori diagnosis. 
Additionally, UBT is particularly suitable for non-invasive follow-up patient testing 
after specific eradication therapy.
1.5.2.2 Serology
H. pylori infection leads to local mucosal and systemic immune responses, including 
raised systemic IgA and IgG antibody levels. This has led to the development of a 
wide range of specific serology tests for H. pylori, many in an enzyme linked 
immunosorbent assay (ELISA) format as well as western blotting, immunochemistry 
and complement fixation-based approaches (Ho and Marshall 2000). Serology has 
been invaluable in epidemiological studies of H. pylori infection (Vyse et a l 2002). 
As well as being comparatively inexpensive, one major advantage of serology is that 
it is less likely to be adversely affected by the patient having had prior PPI or 
antibiotic therapy. A survey of over 50 PHLS laboratories in England and Wales 
indicated that serology is widely used as a diagnostic tool in the management of 
dyspeptic patients (R. J. Owen, personal communication). However several studies 
have demonstrated that specific antibody can persist for many months or years after 
resolution or eradication of H. pylori. Thus, a major limitation of this approach is that 
it cannot distinguish between past and active, ongoing infection. For this reason.
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serology is unsuitable for monitoring success of eradication therapy (Vaira et al.
2002). The accuracy of different serology tests varies considerably, with reported 
sensitivities and specificities ranging from 70 -  100% and 31 -  100%, respectively 
(Ho and Marshall 2000). Additionally, the cut-off values of tests often require 
adjustment for different geographical population groups (Graham and Qureshi 2001), 
while testing in young children may be unreliable, possibly due to an immature 
immune response (Kolho et al. 2002;0kuda et al. 2002). It is thus evident that 
although convenient, serology is not a reliable method for diagnosing active infection.
1.5.2.3 Stool antigen test
The recent development of an ELISA-based kit for detection of specific antigen in 
stool specimens has been met with considerable interest as it is non-invasive, does not 
require highly specialised equipment and, unlike serology, is more likely to provide 
evidence of active, rather than past infection. Furthermore, it may be more 
appropriate for use in paediatric patients than serology or invasive methods. Two 
such commercial ELISA kits are now available in the UK, namely the Premier 
Platinum HpSA kit and the Amplified IDEIA HpStAR kit, (formerly the FemtoLab 
Cnx H. pylori kit). Numerous evaluative studies have been conducted to date, the 
majority of which have examined the performance of the Premier Platinum HpSA kit 
as a means of primary diagnosis as well as post-eradication follow-up. A recent 
review of 43 studies comprising a total of 4769 patients reported that overall the 
HpSA kit was a highly sensitive (92.4 %) and specific (91.9 %) means of diagnosing 
infection in untreated patients (Gisbert and Pajares 2001), although performance of 
this assay was reported to be considerably lower in some individual studies included 
in this analysis. Analysis of 25 studies examining a total of 2078 post-treatment 
patients demonstrated that HpSA could also be used as a sensitive (88.3 %) and
13
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specific (92,0 %) follow-up test at > 4  weeks to assess eradication outcome.
However, some studies presented evidence contradictory to this (Gisbert and Pajares
2001). Results reported from one of the few studies that have compared the HpSA kit 
with the newer IDEIA HpStAR kit suggested that the latter is marginally more 
sensitive (93.8 % v .^ 98.0 %) for primary diagnosis of paediatric infection 
(Makristathis et a l 2000). Similarly, the IDEIA HpStAR kit was reportedly more 
specific than the HpSA kit for post treatment follow up of paediatric patients 
(Makristathis et a l 2000). A different study of 148 adult dyspeptic patients 
demonstrated that the sensitivity of the IDEIA HpStAR kit for follow-up of patients 
after eradication therapy was higher (88.6 %) than that of the HpSA kit (80.0 %) 
(Leodolter et a l 2002), while a large prospective multi-centre study of 302 
symptomatic children showed that the kit was sensitive (97.8 %) and specific (99.0 
%) for primary diagnosis, compared with culture, histology and RUT (Koletzko et a l
2003). A comparative evaluation of these two kits, as well as a recently-available 
rapid immunochromatographic test is presented in Chapter 8.
1.6 Polymerase Chain Reaction (PCR)
It is evident from the previous section that no single diagnostic method is markedly 
superior to others. As discussed, while non-invasive methods are preferable, it is 
culture alone that offers a means of further strain characterisation. However the 
associated delays as well as the limited availability of this method has prompted the 
search for alternative molecular methods, to examine the H. pylori genome directly 
from clinical samples. One technique central to these developments has been the 
polymerase chain reaction (PCR). The utility of this technique in the examination of 
human Helicobacter infections is the focus of the work presented in this thesis.
14
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1.6.1 History of PCR
The polymerase chain reaction (PCR) is a sensitive amplification technology that 
generates many millions of copies of a gene or gene fragment from as little as a single 
DNA molecule. PCR was devised in 1983 by Kary Mullis, who demonstrated the 
potential of his hypothesis in a single-tube experiment that amplified a 25-bp 
fragment of a plasmid. Further experimentation demonstrated that much larger 
fragments could be amplified almost exponentially (Mullis and Faloona 1987). PCR 
was a revolutionary development in molecular biology and its potential in medical 
diagnostics was quickly realised following the first description of PCR-based 
diagnosis of Sickle Cell anaemia (Saiki et al. 1985). PCR is now widely accepted as 
an invaluable diagnostic tool for numerous medical conditions, as it is not only rapid, 
but also potentially highly sensitive and specific.
1.6.2 The principle of PCR
PCR-based synthesis of specific DNA fragments is usually catalysed by thermo-stable 
Taq polymerase (originally purified from Thermus aquaticus), in a reaction mix also 
containing the following: specific DNA template to be copied, two short 
oligonucleotides (approximately 20 -  30 bp in length) that prime further strand 
extension by complementing sequences flanking the specific area or gene of interest, 
all four dNTPs to build the synthesised strand and MgCb that acts as a co-factor for 
Taq polymerase and also alters DNA charges to facilitate primer-template interactions 
(Clewley 1999). Specific DNA is amplified by a process of thermal cycling, 
conventionally in a metal block, as summarised in Figure 1.1.
Briefly, double stranded DNA is denatured at 94 °C to form single strands. This 
enables specific oligonucleotide primers to access and hybridise complementary 
sequences, when the reaction temperature is lowered to an annealing temperature (Ta)
15
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First amplification cycle
Dénaturation Primer annealing Strand extension
1 copy ds DNA 2 copies ds DNA
Second amplification cycle
Dénaturation Primer annealing Strand extension
—    ►
  — "4----------------
>
4"
2 copies ds DNA 4 copies ds DNA
Figure 1.1: Schematic representation of specific DNA amplification by the
Polymerase Chain Reaction (PCR). Double stranded (ds) DNA is 
denatured at 95°C and oligonucleotide primers annealed to specific 
complementary sequences at an appropriate temperature based on the 
primer Tm. DNA polymerase extends complementary strands and the 
thermal cycling is repeated, leading to an exponential increase in DNA 
copy numbers at the end of each cycle.
16
Introduction
(typically in the range of 50 -  60°C) that varies according to the melting temperature 
(Tm) of the individual primer. Sequence immediately downstream of the primer is 
then extended by Taq polymerase at 72 °C by dNTP incorporation. Extension time 
varies according to the size of the fragment to be amplified, with approximately 35 - 
100 nucleotides extended per second at 75 °C (Wittwer and Garling 1991). Cycling 
of dénaturation, annealing and extension temperatures 2 5 -5 0  times leads to 
exponential increase in copy numbers of the DNA fragment (Figure 1.1). 
Conventionally, PCR products (amplicons) are visualised by ethidium bromide 
staining in an agarose gel, following electrophoresis.
1.6.3 PCR modifications
The basic format of PCR outlined in section 1.6.2 offers rapid and sensitive DNA 
amplification. However over the last two decades, many modifications of this format 
to tailor the methods for specific applications have been described, some of which are 
considered below.
1.6.3.1 Nested PCR
Although conventional PCR is reported to be highly sensitive, low levels of target 
may not be amplified to an extent that allows visualisation in an agarose gel. In a 
nested format, amplicon from the first PCR serves as template for a second 
amplification reaction involving two novel primers complementary to sequences 
internal to the first primer set, and so within the template DNA (Figure 1.2). 
Alternatively one novel primer plus one of the original primers can be used in a hemi- 
nested format. As specific target DNA levels will have been amplified in the first 
round of PCR, there will be greater copy numbers of starting template added to the 
second PCR reaction for further amplification. Thus a major advantage of nested 
PCR is that it can increase sensitivity of an assay 10 to 1000 fold or more (Bamford et
17
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a l 1998;Hoe^fl/. 1991; Wang a/. 1993). Additionally, use of a second pair of 
primers should improve specificity of a test, theoretically, as four, instead of two, 
specific primer hybridisations to complementary template sequence are necessary to 
generate specific product. However, as the potential for contamination of second- 
round reactions with exogenous amplicons from previous first-round reactions is high, 
falsely positive results are a potential limitation of this approach, highlighting the 
need for strict adherence to appropriate preventative measures.
Amplicon template ‘ Annealing o f internal Strand extension Nested amplieon
from PCR round #1 complementary primers
--- ►
  ■ ^  — ----
 ►
Figure 1.2 Schematic representation of nested format PCR.
A second round of PCR is performed where primers anneal to 
complementary sequences found within amplicon template from a 
previous PCR. Strands are extended to form copies of DNA fragments 
internal to the first-round PCR amplicon.
1.6.3.2 Multiplex PCR assays
Multiplex PCR is a modification of a conventional PCR assay where, by the inclusion 
of multiple primer sets, more than one target can be simultaneously amplified in a
18
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single PCR reaction. This approach has the obvious advantage of reducing both 
reagent costs and labour. Factors that are critical for efficient single-reaction 
(uniplex) PCR, such as good primer design, adequate, good quality template and 
ready availability of reagents will also affect the performance of multiplex PCR. 
However combination of more than one primer pair in a reaction presents some 
additional problems. Specificity can be reduced by the increased risk of primer dimer 
formation, due to internal sequence complementarity, leading to spurious 
amplification. This can deplete the reaction components available and therefore 
decrease sensitivity of specific target amplification also. In addition, some targets 
will be preferentially amplified for various reasons, including differences in target 
fragment or gene length, availability, secondary structure or levels in a sample as well 
as differences in primer binding efficiency. Although it can be difficult to predict 
accurately the performance of combined primer sets, ideally those that amplify their 
respective target with similar efficiency should be selected. This can be predicted by 
selecting primers with similar annealing temperatures (based on length, and G + C 
content), and the possibility of primer dimer formation should be minimised also by 
avoiding sequence homologies (Elnifro et a l 2000).
1.6.3.3 Real-Time PCR
Conventional PCR can be completed in 2 -  4 hours, but the time taken to visualise 
amplicons by agarose gel electrophoresis can add considerably (1 -  2 hr) to the total 
test time. PCR has been revolutionised in recent years by the development of various 
instruments including the LightCycler (Roche), the Taqman (Applied Biosystems), 
the Smart Cycler (Cepheid) and the Rotor-Gene (Corbett Research) that monitor 
amplicon generation in real-time, as the reaction progresses. Although the precise 
chemistry used varies for individual instruments, typically changes in specific
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fluorescent dye emissions are recorded and related to increased levels of amplified 
DNA. Studies presented in Chapters 5, 7, 8 and 10 examined the potential role of the 
LightCycler for investigating H. pylori infections. A detailed explanation of the 
principles and applications of the LightCycler is provided in section 2.20.
1.7 PCR assays available for detection oi Helicobacter^ and their applications
Numerous PCR detection assays have been described that amplify a range of different 
specific fragments of the genome of 77. pylori and other helicobacters. Initially such 
assays were applied to bacterial cultures and gastric biopsies. Some have been used 
in the detection of helicobacters from extra-gastric sites also. As PCR-based 
detection of helicobacters is explored in Chapters 3 ,4 ,8  and 9, the relative merits of 
each target gene/fragment and individual PCR assays will be considered in detail.
As illustrated in the following sections, generally many studies report similar levels 
of sensitivity and specificity for PCR-based detection in gastric biopsies, but detection 
in oral specimens and faeces would appear to be more variable. Comparison of PCR 
assay performances for a given application is difficult, as there are numerous 
variables between studies, including specimen type, sample collection and DNA 
extraction methods, as well as specific amplification target and primers applied. 
Individual assay performance may also be affected by inter-laboratory variation in 
equipment and reagents used. Additionally, most studies examined relatively small 
numbers of specimens, and patient inclusion often had a selection bias. Many studies 
of dyspeptic patients contained a disproportionately high number of H. ^ /on-positive 
individuals in relation to local geographical prevalence, while most studies 
investigating potential associations between helicobacters and extra-gastric disease 
include non-dyspeptic patients that are less likely to be 77. /?y/or/-positive. These 
aspects will influence the positive and negative predictive values of tests and prevent
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accurate determination of assay sensitivities and specificities. A summary of the H. 
pylori specific assays available and their applications is presented in Table 1.2.
1.7.1 16S rRNA assays
PCR assays for detection and identification of bacterial species frequently are 
designed to target ribosomal RNA as this molecule is universally present in all 
bacterial species, with subunit genes typically arranged in an operon in the order 
16S:23S:5S. In contrast 16S and 23S:5S are not adjoining in either of the sequenced 
strains of H. pylori (Aim and Noonan 2001). While some regions of 16S rDNA are 
highly conserved, others are hypervariable, as illustrated in Figure 1.3. Extensive 
investigation of 16S rRNA has defined bacterial phylogenetic and evolutionary 
relationships - analysis of 16S rRNA was central to the creation of the new genus 
Helicobacter, distinct from Campylobacter (Goodwin et a l 1989). By designing 
primers that span appropriate regions of this gene, specificity of a PCR assay can be 
tailored to detect DNA at the prokaryotic, genus or species level. As most bacteria 
possess multiple copies of rRNA genes, a PCR assay targeting this part of the genome 
should theoretically be more sensitive. H. pylori possesses at least two copies of 16S 
rRNA and 23 S rRNA (Linton et a l 1992), although the relative location of these in 
the genome can vary (Taylor et a l 1992). Over 15 000 16S rRNA gene sequences 
from a diverse range of bacterial species are available in public databases, such as the 
ribosomal database project (http://www.rdp.cme.mus.edu), facilitating development 
of specific assays. Furthermore, the 16S rRNA gene is small enough (approx. 1500 
bp) for relatively simple sequence determination but large enough to contain 
sufficient information for spéciation and classification purposes. Several H. pylori 
specific PCR assays targeting 16S rRNA have been developed to investigate gastric 
and extra-gastric Helicobacter infections in humans, summarised in Figure 1.3.
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1.7.1.1 Helicobacter genus specific primers
Helicobacter genus-specific primers have been developed and applied in the 
investigation of helicobacters in extra-gastric disease (section 1.9). Primer pair 
H276F/H696R that amplifies a 400-bp fragment of 16S rRNA (Figure 1.3) was 
originally reported to have a detection limit of 5 pg of Helicobacter DNA (Riley et al.
1996). In contrast, a study investigating the potential bacterial involvement in 
primary biliary cirrhosis (PBC) demonstrated that these would amplify specific 
product in H. pylori positive gastric biopsies and could detect as little as 10 fg of 
specific DNA when mixed with liver tissue (Tanaka et a l 1999). Very similar to this 
assay is that described by Shen et al (1997). Primer pair C97/C98 amplifies a 
slightly larger (422 bp) fragment of the same region of the 16S rRNA gene (Figure
1.3). Specificity of this assay was confirmed by the demonstration of successful 
amplification of DNA from a range of helicobacters but not from other bacterial 
species (Shen et al. 1997). Larger (749 bp) fragments of 16S rDNA were amplified 
by the primer pair H297F/H1026R, designed and validated as part of a system to 
distinguish the different bacterial genera of the E-subclass of the Proteobacteria 
(Logan et al. 2000). However as these were not applied for detection purposes, assay 
sensitivity was not determined. One other assay, using primer pair HGF/HGR 
amplifies a slightly smaller fragment (639 bp) of the same 16S rDNA region (Figure
1.3). The preliminary report of this assay indicated that it could detect as little as 0.1 
pg Helicobacter DNA and did not amplify fragments of any of the other bacterial 
species tested, including genera of the E-subclass (Bohr et al. 1998).
1.7.1.2 H. pylori-siptciüc detection PCR assays
The first H. /?y/or/-specific PCR assay was developed by Hoshina et al in 1990. 
Examination of gastric biopsies from 10 dyspeptic patients by culture, histology, RUT
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and prokaryote as well as H. pylori specific PCR demonstrated that all five biopsies 
positive by conventional tests were also PCR-positive. Three additional biopsies were 
positive by PCR alone (Hoshina et al. 1990). Although it was concluded that PCR 
was a more sensitive means of H. pylori detection, the possibility of poor assay 
specificity was not excluded.
A different assay, developed by Ho a/ (1991) (Figure 1.3, Table 1.2) was shown 
to be 100 % specific, by analysis of bacterial species other than H. pylori and a range 
of human tissue including gastric biopsies from H. jcy/ori-negative patients. 
Application of this to 12 gastric biopsies from H. py/on-positive patients generated 
specific product in all cases (Ho et al. 1991). One subsequent study in 1998 identified
H. pylori by PCR in a significantly higher number of gastric biopsies (116/208) than 
had been demonstrated by culture and UBT (Oshowo et al. 1998). However, while a 
previous study had generated specific amplicon in 12 gastric biopsies and 12 gastric 
aspirates of 13 if. /?y/on-positive patients, faint bands were observed in all eight 
gastric biopsies that were /7/?y/or/-negative by histology (Mapstone et al. 1993a). 
These results may suggest poor assay specificity. Certainly the reported generation of 
109 bp amplicons in a range of human tissues raised the possibility that this assay 
non-specifically amplified human DNA (Chong et al. 1996). However this was not 
supported by other groups (Leung 1998;Song et al. 1999).
An assay developed by Weiss et al (1994) (Figurel.3, Table 1.2) generated specific 
amplicon in 47/50 and 0/45 gastric biopsies from patients that were confirmed H. 
pylori positive or negative, respectively, by a combination of culture, RUT, histology 
and serology and so was considered 94 % sensitive and 100 % specific (Weiss et al. 
1994). A further study confirmed this high sensitivity and specificity by successfully
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detecting gastric infection in all \ IH . /?y/on-positive patients of the 22 subjects 
examined in total (Gramley et al. 1999).
A different assay, described by Wahlfors et al in 1995 (Figurel.3, Table 1.2) 
amplified specific product in 15 of 29 gastric biopsies, whereas fewer positives had 
been determined by culture (n = 11), histology (n = 12) or RUT (n = 9). This may 
indicate that PCR is the most sensitive method, although further tests to confirm 
amplicon specificity were not conducted.
Sensitivity of an assay, developed by Thoreson et al (1995) (Figure 1.3, Table 1.2) 
when applied to 56 gastric biopsies was reported to be higher than observed for 
histology but slightly less than that of culture. The assay performance also depended 
on the method of gastric biopsy DNA extraction. A subsequent study examining 101 
gastric biopsies demonstrated that this PCR may be more sensitive than culture and 
histology combined (Thoreson et al. 1999). However, H. pylori status was not 
confirmed by UBT or serology in four of the nine patients that were PCR-positive 
only, possibly indicating falsely positive results.
One 16S rRNA detection assay that differed from all others was a reverse- 
transcription PCR (RT-PCR) described by Engstrand et al. (1992) (Figure 1.3, Table 
1.2). Specific 16S rRNA was first reverse-transcribed to copy DNA (cDNA) for 
amplification. This assay also amplified 522-bp fragments from other intestinal 
helicobacters {H. cinaedi and H. mustelae) and so was not species-specific. Analysis 
of 15 gastric biopsies demonstrated that the assay was of comparable sensitivity to 
UBT and culture, but a subsequent study of a larger sample set of 45 gastric biopsies 
demonstrated a low sensitivity of 47 % compared with UBT (el Zaatari et al. 1995).
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1.7.2 Urease genes
Potent urease activity is a key phenotypic characteristic of H. pylori and other gastric 
Helicobacter species, and probably provides protection against the acidic gastric 
environment. The genes comprising the urease operon {ure ABDEFGHI) (Labigne et 
a l 1991) have therefore been a popular target for the development of specific assays 
for detection of the various gastric helicobacters, including H. pylori, 'H  heilmannii ' 
and H  felis. As for 16S rRNA, urease genes have been a preferred target for 
development of H  pylori-spQcific assays, the more widely used of which will be 
considered.
1.7.2.1 Urease A
Analysis of 12 bacterial species other than H  pylori confirmed that the assay of 
Clayton et al (1991) (Table 1.2) was species-specific. PCR amplicon was generated 
in 15 of 23 gastric biopsies tested, whereas only ten, seven and three biopsies were 
positive by histology, culture and urease testing, respectively (Clayton et a l 
1991;Clayton et a l 1992). However, a subsequent study of 66 gastric biopsies, 
comparing this assay with culture, was unable to demonstrate superior sensitivity of a 
PCR-based approach (van Zwet et a l 1993), while another group that examined 33 
formalin fixed gastric biopsies, demonstrated a higher level of positive results with 
immunohistochemistry (66 %) compared with this PCR assay (45 %) (Ashton-Key et 
al 1996).
This assay was subsequently modified to develop a nested PCR that increased assay 
sensitivity 1000 fold and amplified product in 14/17 gastric biopsies tested, ten of 
which had been positive after the first PCR round. No product was generated in any 
of the three H. pylori negative biopsies although this number of samples is insufficient 
to determine assay specificity accurately (Wang et a l 1993).
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1.7.2.2 Phosphoglucosamine mutase (glmM/ureQ
PCR assays amplifying this target were originally described as targeting the ureC 
gene that was thought to be involved in the urease activity of H. pylori and was 
therefore species-specific. Subsequent studies demonstrated that ureC had greater 
homology with genes that encodes a phosphoglucosamine mutase enzyme that is also 
found in other bacterial species and the target was renamed glmM  (De Reuse et a l
1997). Details of the assays developed to amplify fragments of this gene are 
summarised in Table 1.2.
Application of the assay described by Brisou et al (1990) to 62 gastric biopsies 
fi*om 14 patients demonstrated comparable sensitivity and specificity to that of culture 
(Bickley et a l 1993). Further examination of 104 gastric biopsies by culture, 
histology, RUT and PCR demonstrated that the latter was 100 % sensitive and 97 % 
specific, using culture as the gold standard (Lage et a l 1995). Modification of this 
assay to a nested format and application of this to gastric biopsies, oral fluids, dental 
plaque and faeces seeded with H. pylori cells, demonstrated a 10 to 1000 fold increase 
in sensitivity, depending on the specimen type (Bamford et a l 1998).
Initial evaluation of another assay, developed by Goosen et al (2002), demonstrated 
specific amplification in 12 isolates of H. pylori but not in any of the 31 other 
bacterial species tested. Performance of this test on gastric biopsies was not 
evaluated.
1.7.3 26 kDa antigen assays
In 1991, O’Toole and colleagues isolated a protein of 26 kDa that was abundant in H. 
pylori. Subsequent cloning of the gene encoding this protein and hybridisation 
analyses suggested that it was species-specific (O'Toole et a l 1991). A later study 
demonstrated by complementation experiments that this antigen had alkyl
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hydroperoxide reductase (AhpC) activity (Lundstrom and Bolin 2000). This protein 
is discussed further with respect to metronidazole resistance in section 1.11.6.3. A 
PCR assay amplifying a fragment of this gene was developed by Hammar et al (1992) 
(Table 1.2). Application of this to gastric biopsies of 27 patients indicated that it was 
as sensitive as culture, but four additional positive results, three of which were not 
corroborated by high anti-Æ pylori antibody titres suggested that this assay may lack 
specificity, although amplicon specificity was confirmed by probe hybridisation also.
1.7.4 0.86 kb cloned fragment
A 0.86 kb cloned DNA segment had been characterised previously and proposed to be
H. /?y/on-specific by Li and colleagues in 1996. Application of the subsequent assay 
developed (Table 1.2) to 88 gastric biopsies, generated product in all 71 specimens 
that were H. />y/or/-positive by histology and in none of the 17 77. j^y/on-negative 
patient samples (100 % sensitive and specific).
1.7.5 1.9 kb fragments
The observation that a cloned 1.9 kb fragment would hybridise with 77. pylori strains 
but not with 306 other clinical isolates led to development of an 77. ^ /on-specific 
assay (Valentine et al. 1991), (Table 1.2). Analysis of 33 gastric biopsies 
demonstrated a sensitivity of 93 % and specificity of 100 %, compared with culture 
and histology. Sensitivity of PCR-based detection was lower (85 %) for matched 
gastric aspirates.
I.8 Non-invasive PCR-based detection of 77. pylori
While most of the assays discussed thus far allowed sensitive and specific detection of 
77. pylori in gastric biopsies, the intrinsic disadvantages of an invasive approach 
remain. For this reason, numerous studies have examined the potential of PCR for
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non-invasive diagnosis of H. pylori gastric infection by specific detection in 
specimens either collected from the oral cavity or in stools. The PCR assays applied 
to these specimen types are summarised in Table 1.2.
1.8.1 PCR-based detection oîH, pylori from the oral cavity 
Numerous studies have applied PCR in the detection of H. pylori from oral specimens 
(e.g. saliva and dental plaque), but the success of this has varied considerably. This is 
likely to relate to the sensitivities and specificities of the individual PCR assays as 
well as to the methods of specimen collection, transport and DNA extraction. The 
latter factor is particularly critical in dental plaque specimens, that contain high levels 
of DNA from other bacterial species as well as substances inhibitory to the PCR 
reaction. Furthermore, differences in study populations such as H. pylori prevalence 
and oral hygiene are likely to influence test outcome.
Some studies were unable to detect specific DNA in oral specimens by PCR assays 
targeting 16S rRNA (Wahlfors et a l 1995) or g-/mM genes (Bickley et a l 1993), 
while primers Hpl and Hp2 of Ho et al {\99l) amplified 16S rDNA in oral samples 
from only 15 of 116 77. j^y/on-positive patients (Oshowo et a l 1998). In contrast a 
much higher rate of 77. pylori carriage in the oral cavity (85 %) and fingernails (58 %) 
was demonstrated in a study that applied the nested version of this PCR assay to 
plaque samples from 242 subjects in Guatemala, although amplicon specificity was 
not confirmed by any other method (Dowsett et a l 1999). The same assay 
previously was reported to amplify specific product in at least one oral sample (saliva 
or plaque) for five of 13 77. jcy/on-positive patients (Mapstone et a l 1993a).
The RT-PCR assay of Engstrand et al amplified specific DNA in dental plaque of 
7/18 77. ^/on-positive patients. All amplicons were confirmed by specific probe
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hybridisation, while H. pylori was confirmed in two plaque samples by indirect 
immunofluorescence also (Nguyen et al. 1993).
A high rate of detection was reported by a modification of the assay of Li et al 
(1995), involving a second nested round of PCR with primers ET-5U and ET-5L 
(Song et al. 2000). H. pylori DNA was amplified in 97 % of dental plaque samples 
from 41 patients, in spite of a lower rate of gastric infection (26 %) indicated by UBT. 
Specificity of PCR product was confirmed by Southern hybridisation, however these 
discrepant results may indicate sample contamination, a potential problem with nested 
PCR. Similarly, a study using the assay of Clayton et a l{\99 \)  amplified ureA DNA 
fi-agments in matched gastric biopsies and dental plaque samples fi*om seven patients, 
but also in dental plaque from five other patients that had no PCR-based evidence of 
gastric infection (Berroteran et al. 2002).
A lower rate of detection was reported for a study investigating oral specimens of 
clinically healthy volunteers by a g/wMPCR assay (Goosen et al. 2002). Specific 
amplicons were generated in only 2/58 specimens, while the primer pair of Clayton et 
al, amplifying ureB generated product in 3/58 patients. Sequencing of ureB 
amplicons confirmed the specificity of the novel gZ/wM assay and identified one 
falsely positive ureB result, due to amplification of Staphylococcus epidermidis DNA.
1.8.2 PCR-based detection of 77. pylori in stool samples 
The possibility that stools could be examined for evidence of gastric 77. pylori 
infection was first indicated by a report that successfully cultured the organism from 
the stools of Gambian patients (Thomas et al. 1992). However the limited success of 
this approach (Dore et al. 2000b;Kelly et al. 1994) suggests that the presence of 
viable bacterial cells in patient stools may be transient, and variable between different 
patient groups. These limitations have provided the impetus for development of
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alternative detection methods. As discussed (section 1.5.2.3) stool antigen testing is 
one approach that has proven to be both sensitive and specific, but does not allow any 
further strain characterisation. Numerous studies have described PCR-based detection 
of H. pylori in stools, with varying degrees of success. Similarly to dental plaque, 
stool specimens contain high levels of competing bacterial DNA as well as substances 
inhibitory to PCR. Thus the DNA extraction method is as critical to test performance 
as the individual PCR assay applied. These aspects are examined in the study 
presented in Chapter 8.
The ureA assay described by Clayton et al in 1992 was shown to detect 2.5 x 10"^  
cells per g faeces in artificially seeded specimens and in 11/17 clinical stool samples. 
Faecal DNA had been extracted by an immunomagnetic separation (IMS) technique 
whereby H. pylori cells are captured by magnetic beads coated in specific antibody 
and separated from other bacteria and inhibitors (Nilsson et al. 1996). Provided the 
antibody used does not cross-react with other bacterial species, IMS has the potential 
to improve assay specificity as well as concentrating specific DNA, if H. pylori cells 
are intact in stools specimens. However the lack of success of culture suggests that 
many H. pylori cells are fi*agmented at this site, and so IMS may decrease sensitivity 
by capturing specific antigen but not DNA. Nevertheless, a larger study that extracted 
DNA by an IMS-based method also, combined with the same PCR assay, amplified 
specific DNA in 61.4 % of faecal samples from 57 patients that had evidence of 
gastric H. pylori infection, but not in 15 uninfected patients (specificity 100 %) 
(Watanabe et al. 1998). Similarly, a different IMS-PCR approach to investigate 
faecal samples from 47 H. ^y/on-positive and 51H. /7y/ori-negative patients 
demonstrated 100 % specificity and also higher sensitivity (80.9 %) (Monteiro et al. 
2001a). A different study that extracted DNA by another method (using Tri reagent)
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reported 100 % sensitivity of the Clayton assay, with amplicons generated in all 30 
faecal samples from patients that had gastric evidence of H. pylori infection also 
(Russo et a l 1999). Amplicon identity was confirmed by HinfL restriction enzyme 
digestion. The same PCR assay has also been applied in the evaluation of different 
methods for faecal DNA extraction, including an aqueous two-phase system (Lantz et 
a l 2000) and macroporous polypropylene filters (Cavallini et a l 2000) for removal of 
PCR inhibitors.
Application of the Ho et al assay to DNA extracted from faecal samples by a 
cetyltrimethyl ammonium bromide (CTAB) method, to remove inhibitory 
polysaccharides, amplified 16S rDNA fragments in 28 of 31 patients with gastritis but 
not in any of the 11 patients with histologically normal gastric biopsies (Mapstone et 
al 1993b). In contrast, single round PCR with the Ho et al primers Hpl and Hp2 
failed to amplify product in faecal samples from 24 H. ^y/on-positive patients, 
although specific detection in artificially seeded faeces was possible (van Zwet et a l
1994). A different study that used a relatively complex DNA extraction method 
involving CTAB as well as polyvinylpyrrolidone (PVP) treatment, to remove 
inhibitory substances, detected specific 16S rDNA fragments by the Weiss assay in 
8/11 stools from H. j^y/on-positive patients (Gramley et a l 1999). None of the 11 
stools from uninfected patients were PCR-positive. An alternative approach was 
described where faecal DNA was extracted by a comparatively simple method and 
then specific DNA captured by a biotinylated probe prior to analysis by the Weiss 
PCR assay (Shuber et a l 2002). Application of this to 25 patients, 11 of whom were
H. /?y/on-positive, demonstrated high sensitivity and specificity (100 %). Additional 
analyses of three of these patients suggested that this system was suitable for patient 
follow-up after therapy also. The Weiss assay was also applied in a study
33
Introduction
investigating transmission of H. pylori (Parsonnet et a l 1999), that amplified specific 
product in induced stools, post emesis saliva and vomitus specimens of, respectively,
11/16, 9/16 and 16/16 H. /?y/orz-positive asymptomatic patients. All samples had 
been extracted by an IMS-based method. Unusually, specificity of this approach was 
also confirmed by culture in many of these induced samples.
Less successful was an approach described by Li et al in 1996, that amplified 
fi-agments of 0.86 kb H. pylori DNA, extracted from stools by a CTAB-based method, 
from only 15/61 infected patients and in 1/10 uninfected patients tested. In contrast, 
development of the assay of Hammar et al (1992) to a hemi-nested assay using a 
novel reverse primer allowed sensitive and specific H. pylori detection from stool 
specimens extracted by a complex multiple-step method that included adsorption of 
nucleic acids on a commercial chromatography column containing silica (QIAgen) 
(Makristathis et a l 1998). Specific ahpC (26 kDa antigen) fragments were generated 
in 59/63 and 0/37 samples from H. pylori positive and negative patients, respectively. 
Further testing of patients post-eradication demonstrated that PCR may not be suitable 
for patient follow-up within one month. Subsequent study of a paediatric population 
(n = 49) also demonstrated the high sensitivity of this assay (93.0 %), although no 
negative patients were included to assess specificity (Makristathis et a l 2000). 
However patient follow-up post-eradication demonstrated that false positive PCR 
results could persist for up to eight weeks.
1.9 PCR-based detection of helicobacters in the investigation of extra-gastric 
diseases
The potential role of helicobacters in various extra-gastric chronic inflammatory 
conditions has been the focus of increasing numbers of studies. Given the fastidious
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nature of many species of Helicobacter, PCR has been central to these investigations. 
This thesis presents a PCR based analysis of four such inflammatory conditions of the 
bladder, colon and bronchi (Chapter 9).
1.9.1 Oral disease
The possibility that helicobacters are in the oral cavity has led to a number of groups 
investigating the potential contribution of these to inflammatory oral diseases. 
Development of a nested assay using the Clayton assay in the first PCR round and 
primers HPUlb and HPU2b in the second round amplified DNA from at least one of 
seven oral sites in 21/161 patients with oral disease and in none of the 20 controls 
(Mravak-Stipetic et al. 1998). However no associations between oral disease and 
patient H. pylori status or ulcerated versus non-ulcerated lesions and bacterial 
presence were identified. Similarly, application of the Brisou glmM  assay to oral 
ulcer swabs, dental plaque and saliva, demonstrated specific DNA in 11 of 16 ulcer 
swabs from patients with oral aphthous ulcers and in none of the 23 control patients 
(Birek et al. 1999). However it is difficult to ascribe potential associations between
H. pylori and recurrent oral ulcers as no further confirmation of amplicon specificity 
was performed, and H  pylori status of the patients was unknown. Furthermore, non­
specific amplicons of approximately 294 bp were generated from some strains of 
Actinomyces naeslundii, which is frequently found in the oral cavity. Another study 
that used the Weiss primer JW22 along with novel primer JW23 (Table 1.2), reported 
amplicon generation, confirmed by specific probe hybridisation and sequencing, in 
24/73 plaque samples collected from 29 periodontitis patients (Riggio and Lennon
1999). More recently, H. pylori DNA was amplified in both diseased and healthy 
areas of the oral cavity of 14 of 36 patients with recurrent oral stomatitis, and in 16 of 
the 48 control patient samples. The significance of this cannot be interpreted, as
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specificity and sensitivity of the novel nested PCR assay applied, amplifying a 
fragment of the sequenced strain 26695, had not been evaluated (Victoria et al. 2003).
1.9.2 Diseases of the hepatobiliary tract
Associations are reported between several Helicobacter infections and hepatitis in 
animals (Fox et al. 1994;Fox et al. 1995;Stanley et al. 1994). Consequently, a 
number of studies have investigated the potential association between helicobacters 
and human liver and biliary tract diseases.
H. pylori DNA in bile was demonstrated by Lin et al (1995) for the first time by a 
novel nested PCR assay (Table 1.2) developed by the authors that generated ureA 
fragments in three of seven bile samples from patients with biliary tract disease. 
Although specificity of this assay had not been fully validated, partial amplicon 
sequencing (87 bp) was reported to confirm specificity, despite observed mismatches 
with a published ureA sequence. Similarly, a subsequent study provided PCR-based 
evidence of helicobacters in the hepatobiliary tract (Roe et al. 1999). The Clayton H. 
pylori specific assay (Table 1.2) amplified 411-bp fragments in 12 of 32 bile samples 
from biliary tract disease patients. DNA was amplified in ten bile samples also by the 
genus-specific assay of Riley et al (section 1.7.1.1), but the authors did not state if 
these results were corroborative, from the same patient samples, nor was the 
specificity of the amplicon confirmed (Roe et al, 1999). In contrast, the assay 
described by Shen et al (section 1.7.1.1) identified possible presence of helicobacters 
in 13 of 23 bile samples and 9 of 23 gall bladder specimens, collected from a total of 
46 Chilean cholecystis patients (Fox et al. 1998). Subsequent amplification of larger 
amplicons (1200 bp) using primer C97 and a novel reverse primer (C05) allowed 
sequence characterisation of PCR products from seven bile and four gall bladder 
samples. This analysis indicated that sequences were most similar to H. bills.
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''Flexispira rappini” and H. pullorum. A different study amplified a specific fragment 
of ureB from the gallbladder mucosa of a single patient, using the assay of Clayton et 
al (1991) (Table 1.2). Although sensitivity and specificity of this assay has not been 
extensively evaluated, PCR results were validated also by histological evidence of 77. 
pylori at this site (Kawaguchi et a l 1996), providing compelling confirmatory 
evidence that 77. pylori can be found in the biliary tract. However, the Shen assay 
failed to amplify any specific DNA in bile samples from a larger population of 125 
Canadian patients with a range of hepatobiliary conditions (Fallone et a l  2003), 
possibly due to geographical differences in prevalence of bile-resistant helicobacters. 
Further evidence that these may be less prevalent in the bile of patients from Western 
countries is provided by a Dutch study that amplified 16S rDNA fragments in only 
one of 31 patients (Roosendaal et a l  2002). A novel PCR assay had been applied that 
was reported to be of comparable sensitivity to those applied in the study of Fox and 
colleagues in 1998.
Additionally, evidence suggests that helicobacters may also be found in the liver. 
One study of 55 liver specimens, 29 of which were from primary biliary cirrhosis 
(PBC) patients, amplified Helicobacter DNA by the Riley assay (section 1.7.1.1) in a 
single PBC patient only. Amplicon specificity was confirmed subsequently by 
sequencing (Tanaka et a l 1999). In a later study, the Shen assay (section 1.7.1.1) 
amplified Helicobacter DNA in 20 of 24 liver samples from patients with PBC or 
primary sclerosing cholangitis (PSC), but in only one of the 23 samples from non 
cholestatic liver disease (NCLD) or control patients. Nine of the positive samples 
were also positive for at least one of the two specific assays of Thoreson or Hammar, 
targeting 16S rRNA or ahpC fragments of the 77. pylori genome, respectively. 
Sequencing of four Helicobacter-spocific amplicons demonstrated >98 % identity
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with 77 pylori dcnà Helicobacter spp. liver 16S rRNA sequences (Nilsson et a l 2000). 
Similarly, the Shen primers amplified DNA in nine of 15 liver tissue samples from 
Chinese patients with hepatocellular carcinoma and in none of the 13 control samples. 
Amplicon specificity was confirmed not only by probe hybridisation, but direct 
sequence analyses demonstrated that these were 99 % similar to 16S rRNA of 77 
pylori and Helicobacter spp. liver sequences (Fan et a l  2002)
1.9.3 Cardiovascular disease
Several serological studies have suggested that 77. pylori infection could be a risk 
factor for chronic heart disease (CHD), particularly for the two major types of CHD - 
atherosclerosis and myocardial infarction. However a meta-analysis of 28 studies 
(Pellicano et a l 1999), including full papers and abstracts showed that studies varied 
considerably in terms of patient and control selection criteria, methods of 77 pylori 
detection and consideration of other co-factors. Although the analysis suggested a 
weak association between 77. pylori infection and CHD, study heterogeneity 
highlighted the difficulty in demonstrating this clearly. PCR has been applied in a 
small number of studies as an alternative means of investigating the role of 
helicobacters in this condition.
The first demonstration of 77 pylori DNA in the cardiovascular system was 
provided by a study investigating potential association between this infection and 
coronary atherosclerosis (Danesh et a l 1999). Amplicons, subsequently validated by 
specific probe hybridisation, were generated by the nested Ho assay (Table 1.2) in 
1/77 buffy coat samples and 1/39 atheromatous specimens. However, the authors 
were unable to fully exclude the possibility of specimen contamination. Similarly, 77. 
pylori ureA fragments were amplified by Clayton’s assay (Table 1.2) in 17/46 
atherosclerotic plaques from patients with ischaemic vascular disease (Farsak et a l
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2000). Specificity of amplification was confirmed by PCR analysis with the Ho et al 
16S rRNA assay (Table 1.2), but no further amplicon analysis was conducted. In 
contrast, the assay of Wang et al (Table 1.2) was unable to amplify H. pylori DNA 
from atherosclerotic plaques of 51 patients undergoing aortic aneurysm surgery, in 
spite of the enhanced sensitivity of a nested PCR format (Blasi et a l 1996).
Similarly, a recent study of atherosclerotic plaques from 32 chronic atherosclerosis 
patients was unable to amplify H. pylori DNA by either of the two Helicobacter 
genus-specific or the two H  /?y/on-specific PCR assays applied, despite high 
seroprevalence (72 %) in this group (Dore et al. 2003).
1.9.4 Lower intestine
As discussed in section 1.8.2, numerous studies have detected H. pylori by PCR in 
stool specimens, to allow diagnosis of gastric infection. However few studies have 
examined the potential role of helicobacters in inflammatory conditions of the lower 
intestine. One study that examined ten inflamed appendix biopsies by the nested 16S 
rRNA assay of Ho et al (Table 1.2) was unable to provide any evidence of 77 pylori 
colonisation or an association with appendicitis (Fanning et a l 1998). In contrast, 
another PCR-based study reported helicobacter DNA from the colon of Crohn’s 
disease (CD) patients by universal amplification of prokaryotic 16S rRNA followed 
by Helicobacter-spQcific probe hybridisation (Tiveljung et a l 1999). Specific 
examination of colonic tissue of patients with inflammatoiy bowel disease (IBD) for 
helicobacters was not described until late in 2002. A novel 16S rRNA Helicobacter 
genus-specific assay using modifications of primers C97 and HGR (section 1.7.1.1) 
amplified fragments of DNA from four intestinal biopsies, two of which were from 
CD patients. Sequence based analyses identified amplicons as 77. pylori in three 
patients and 77 pullorum in the remaining sample (Bohr et al. 2002).
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1.9.5 Sudden Infant Death Syndrome
The nested assay of Bamford et al was later applied in the investigation of the 
potential role of H. pylori in Sudden Infant Death Syndrome (SIDS) (Kerr et a l 
2000). Specificity of PCR products generated was confirmed by specific probe 
hybridisation in an ELISA format, as an alternative to gel electrophoresis and 
Southern blotting. This approach identified H. pylori DNA in at least one of the 
tissue types (stomach, lungs or trachea) from 25 of the 28 SIDS cases examined and 
in one of the eight control patients. PCR-based detection of the cagA gene was also 
reported in 25/28 SIDS cases and 1/8 controls. However, only 19 SIDS cases were 
positive by both assays. This may suggest non-specific amplification in some 
samples, particularly as the cagA gene is not present in all H. pylori (Xiang et al.
1995). Additionally, other studies were unable to substantiate these findings (Ho et 
a l 2001).
1.10 Treatment of H, pylori infections
H. pylori eradication therapy is strongly recommended in patients with PUD or 
MALT lymphoma, in patients with signs of gastric atrophy and in relatives of gastric 
carcinoma patients. Treatment can improve symptoms in <10 % of patients with non- 
ulcer dyspepsia (NUD) and may be advisable in patients with gastro-oesophageal 
reflux disease (GERD) who are on long-term acid suppressive therapy (Malfertheiner 
et a l 2002). Ideally, treatment regimens should be of short duration (no more than 7 
days), should achieve a high cure rate (>90 %) and induce minimal bacterial antibiotic 
resistance and patient side-effects (Tytgat 1997). Although many antibiotics are 
active against H. pylori in vitro, few are available for treatment due to problems of in 
vivo drug bioavailability. The agents most commonly used in anti-77, pylori regimes
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include metronidazole (MTZ), clarithromycin (CLA), amoxycillin (AMO), 
tetracycline (TET) and bismuth salts (BIS). Monotherapy has been shown to achieve 
poor eradication rates due to development of resistance as well as poor activity of 
some drugs (e.g. CLA) in the acid gastric environment (Goodwin 1997;Tytgat 1997). 
The inclusion of agents such as PPIs (e.g. omeprazole, lansoprazole) or H2 receptor 
antagonists (e.g. ranitidine) to increase gastric pH improves efficacy of acid-sensitive 
drugs. In addition PPIs may have some anti-bacterial properties and improve 
bioavailability of AMO by reducing gastric juice volume (Tytgat 1997). However 
dual therapy still fails to achieve high cure rates. In contrast triple therapies 
comprising two antibiotics and a PPI or even quadruple therapy regimens that also 
include a bismuth compound have been shown in clinical trials to achieve high-level 
eradication rates ranging from approximately 88 -  98 % (de Boer and Tytgat 
1996;Qasim and O’Morain 2002).
1.10.1 Current treatment recommendations
One other important development from the Maastricht consensus meeting, described 
earlier (section 1.5) was the issue of guidelines concerning eradication therapy, 
summarised in Figure 1.4.
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First line therapy
Second-line therapy
PPI + CLA + AMO or MTZ (7 days)
i Treatment failure
PPI + BIS + MTZ + TET (7 days)
i Treatment failure
Patients referred to specialist for case-by-case management
Figure 1.4 Summary of the recommended eradication strategy for H, pylori
(adapted from the Maastricht 2-2000 Consensus Report)
1.10.2 Treatment failure
Although triple and quadruple therapies can achieve high rates of eradication, H. 
pylori can persist in as many as 12 % of patients following treatment (de Boer and 
Tytgat 1996). This may be partially attributable to the physician’s reportedly poor 
adherence to recommended treatment regimens in the primary care setting (Lee et al. 
2000). Patient compliance with therapy is also likely to be an important contributing 
factor in treatment failure, although the significance of this is less evident with more 
potent antibiotic regimens (Tytgat 1997). The recommended EHPSG guidelines of 
reduced therapy duration of 7 days are likely to improve patient compliance. The 
positive effects of enhanced patient compliance programmes also have been well- 
demonstrated (Lee et al. 1999). One other factor that has a significant impact on 
treatment outcome is antibiotic resistance, considered below.
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1.11 Antibiotic resistance in H. pylori
A vast amount of data from numerous studies is available regarding the prevalence of 
antibiotic resistance in H. pylori to the key therapeutic drugs in different geographical 
areas. Such studies are essential as they provide invaluable information that could 
direct appropriate therapy. However the current lack of inter-laboratory 
standardisation of antibiotic susceptibility testing methods can complicate direct 
comparisons of individual studies. Multiple-centre surveillance studies of antibiotic 
susceptibilities allow more accurate comparison of resistance levels between states 
and countries.
1.11.1 Clarithromycin resistance
A multinational trial conducted in Europe that examined 485 isolates collected from 
47 centres in six west European countries demonstrated CLA resistance rates ranging 
from 1 to 5 % (Megraud et a l 1999). A similar study examining 1274 isolates 
collected from 22 centres in 17 European countries reported resistance rates ranging 
from 0 % to over 23 % in Italy, Belgium and Austria (Glupczynski et a l 2001). A 
recent meta-analysis of 20 nationwide trials conducted in the USA that included data 
from over 3600 patients demonstrated overall CLA resistance levels of 10.1% (Meyer 
et a l 2002).
A meta-analysis of 12 studies comprising a total of 501 isolates, including 33 that 
were CLA resistant, suggested that although the effects varied between individual 
studies, overall CLA resistance reduced treatment efficacy by an average of 55 % 
(Dore et a l 2000a). This, combined with high reported rates of CLA resistance 
highlights the importance of enhanced surveillance of antibiotic resistance in H. 
pylori, not only for individual patient management but also to influence local and 
national prescribing policies. As discussed (section 1.11), accurate surveillance of
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antibiotic resistance is hindered by poor inter-laboratory standardisation.
Furthermore, culture-based methods such as disk diffusion. E-test or agar dilution 
require laboratory expertise, are laborious and can take up to two weeks to obtain a 
result from the initial receipt of gastric biopsy. PCR-based tests and other molecular 
tests, such as specific probe hybridisation allow rapid, potentially simple 
determination of antibiotic susceptibility.
1.11.2 The mechanism of CLA resistance
CLA belongs to the class of antibiotics known as the macrolides; bacteriostatic agents 
that interact with the 5 OS ribosome and inhibit polypeptide elongation. Areas of the 
peptidyltransferase loop in domain V of bacterial 23 S rRNA are proposed to bind the 
macrolide, while mutation in this region prevents this interaction, leading to bacterial 
resistance (Weisblum 1995).
A study that examined this region of 23S rRNA sequence from four pairs of CLA 
sensitive (CLA-S) and CLA resistant (CLA-R) H. pylori, recovered before and after 
eradication therapy, respectively, demonstrated single point mutations. Sequence 
analysis of 12 CLA-R isolates in total showed that all strains had adenine to guanine 
transition mutations at positions 2058 or 2059, according to the Escherichia coli 
numbering system (Versalovic et al. 1996), later numbered 2142 and 2143 (Taylor et 
al. 1997). Further analysis of this region of the 23 S rRNA gene in three CLA-R 
isolates demonstrated that A2142C transversion mutations can confer CLA resistance 
also (Stone et al. 1996).
1.11.3 Molecular tests for CLA susceptibility testing
As a more economical alternative to DNA sequencing, several PCR-based methods 
were developed to facilitate collation of data concerning the relative incidences of 
each mutation type. All studies reported that adenine to guanine mutations (A2142G)
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and (A2143G) were significantly more frequent than the transversion mutation to 
cytosine (A2142C). Some reports, particularly those from Asian countries, indicated 
that A2143G is identified more frequently than A2142G (Dzierzanowska-Fangrat et 
al. 2001;Maeda et al. 1998b;Maeda et al. 2000;Pan et al. 2002;Sevin et al. 1998), but 
evidence suggests that the latter mutation may be associated with higher CLA MlCs 
(Alarcon et al. 2000;Dzierzanowska-Fangrat et al. 2001;Marais et al. 1999;Piana et 
al. 2002;Pina fl/. 1998;Stone e/a/. 1997;Versalovic 1997).
1.11.3.1 PCR-Restrictioii Fragment Length Polymorphism (RFLP) assays 
One approach that has been widely used for CLA susceptibility testing is PCR 
followed by RFLP. Fragments of 23S rDNA, amplified by PCR, are digested by 
restriction enzymes such as MboH (or BbsX) and Bsal {ox Alw26\) that recognise and 
cut DNA at specific target sequences created by A2142G or A2143G mutations, 
respectively (Versalovic et al. 1997). This approach has been applied to clinical 
isolates (Occhialini et al. 1997;Dzierzanowska-Fangrat et al. 2001;Hulten et al. 
1997;Piana et al. 2002;Szczebara et al. 1997;Wolle et al. 2002;Yang et al. 2001) and 
later to gastric biopsies (Bjorkhohn et al. 1998;Sevin et al. 1998) and gastric aspirates 
(Maeda et al. 1998b). While PCR-RFLP is faster than culture-based susceptibility 
testing, one disadvantage was that most studies could not identify all CLA-R isolates 
as there was not a suitable assay available to detect the A2142C mutation. That 
problem has since been rectified, with the recent description of such an assay (Menard 
et al. 2002).
1.11.3.2 Primer mismatch PCR-based assays
The failure of PCR-RFLP to detect the A2142C mutation led to the development of a 
primer mismatch PCR assay. This is based on the principle that PCR can be 
optimised so that if  template sequence is not complementary to the last base at the 3’
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end of a primer, initiation of strand extension and amplification is prevented. The 
design of a primer that would only complement with template DNA containing 
mutation A2142C meant that only isolates with this sequence would be amplified. 
This approach successfully identified A2142C mutation in five CLA-R isolates that 
were shown by PCR-RFLP to lack either A to G mutation (Alarcon et al. 2000). Two 
additional assays were later designed to detect both A to G mutations also, and this 
approach successfully identified A2143G mutations in 5 of 96 clinical isolates tested. 
All results were confirmed by culture-based susceptibility testing (Pan et al. 2002). 
Although this approach can be performed in most laboratories that perform standard 
PCRs, multiple reactions are required. Furthermore, assays would probably require 
some optimisation for different models of thermal cycler.
1.11.3.3 Hybridisation probe-based assays
The limitations of the original PCR-RFLP assays led to the development of a number 
of assays that distinguished wild-type from all three mutated sequences by the 
hybridisation of complementary probes. In most cases, these required multiple 
reactions with up to four different probes (complementary to the wild type and the 
three mutated sequences). One hybridisation assay used multiple specific probes that 
would hybridise and capture complementary amplicon. Subsequent detection of this 
hybridisation allowed identification of mutation type and so CLA susceptibility (Pina 
et al. 1998). This approach was reported to be accurate when compared with PCR- 
RFLP and sequencing (Pina et al. 1998) and allowed direct testing of gastric biopsies 
for CLA resistance (Marais et al. 1999). A variation of the hybridisation strategy was 
the development of a homoduplex formation assay, based on the principle that exactly 
complementary sequences preferentially anneal to form homoduplexes compared with 
any mismatched sequences. By mixing unknown DNA with double-labelled DNA
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duplexes of known sequence, denaturing all DNA and then monitoring the ratio of re­
annealed double labelled DNA to single labelled DNA homoduplexes, sequence of 
the unknown DNA and so CLA susceptibility could be determined (Maeda et a l 
2000). This approach enabled sensitive detection of CLA susceptibilities directly 
from gastric aspirates, as well as identifying mixed-susceptibility infections. A 
different study described an assay that used a panel of fluorescently-labelled probes 
(wild type plus three probes containing each mutation type) that were hybridised in 
situ to H. pylori DNA in gastric biopsies (Trebesius et al 2000). Although this assay 
was reported to be highly accurate, compared with culture-based methods, and more 
rapid (3 hr) than PCR, the absence of any amplification step may also decrease the 
sensitivity of this approach.
Another group described a PCR-line probe assay that amplified 23 S rDNA with 
biotinylated primers. Single-stranded amplicons were subsequently analysed by 
reverse hybridisation to one of eight different probes immobilised on a nitrocellulose 
membrane (van Doom et a l 1999a). Unlike other studies, isolates were also 
examined for the additional mutations G2141A and A2115G that had been proposed 
to cause CLA resistance in H. pylori (Hulten et a l 1997) and for mutations A2143C 
and A2142T, that can be induced in vitro (Debets-Ossenkopp et a l 1998). However 
this and a subsequent larger multi-centre study that examined a collective total of 182 
CLA-R strains only detected the three commonly described mutations, either singly or 
in multiple combination. Three strains lacked any of the seven potential mutations 
(van Doom et a l 1999a;van Doom et a l 2001). This assay was subsequently applied 
to gastric biopsies (Ryan et a l 2001).
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1.11.3.4 Real-time PCR probe hybridisation-based assays
Two real-time LightCycler assays that are faster than conventional PCR have been 
described (Gibson et al. 1999;Matsumura et al. 2001). In both cases, mutation 
detection is based on the principle of probe hybridisation melting point analysis, as 
described in section 2.20.2.2. However while the assay described for the Roche 
LightCycler required three separate PCR reactions (Matsumura et al. 2001), CLA 
susceptibility could be determined in a single reaction by the assay designed for the 
Idaho model (Gibson et al. 1999). The development of the latter assay for application 
directly to gastric biopsies is explored in Chapter 5, and the relative merits of the tests 
available will be discussed more fully in subsequent sections.
1.11.4 MTZ resistance
The mean rates of resistance to the nitroimidazole drug MTZ in Europe were reported 
as 27 % and 33 % by the two European multi-centre antimicrobial surveillance studies 
described in section 1.11.1 (Glupczynski et al. 2001;Megraud et al. 1999). However 
MTZ resistance levels were considerably higher (> 44 %) in countries such as Italy, 
Austria, Poland and Finland (Glupczynski et al. 2001) and can be as high as 90% in 
developing countries where MTZ is a key therapeutic agent for parasitic infections 
(Alarcon et al. 1999). Culture-based surveillance of MTZ resistance is difficult as 
there are no standardised methods for susceptibility testing, so inter-laboratory 
reproducibility and interpretation of results is problematic. This complicates 
comparison of studies examining effects of MTZ resistance on treatment outcome. 
However, one meta-analysis of 91 studies that evaluated various triple and quadruple 
therapy combinations suggested that treatment success decreased from an average of 
more than 90 % to less than 75 % if the patient was infected with a nitroimidazole-
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resistant strain (van der Wouden et a l 1999). Similarly a later meta-analysis of a total 
of 3594 isolates from 65 studies showed an overall risk of treatment failure of 37 % 
(Dore et a l 2000a). Thus, as discussed for CLA, there is a need for enhanced 
surveillance of MTZ resistance. Problems associated with culture-based susceptibility 
testing could be overcome by the development of simple molecular tests for MTZ 
resistance, analogous to those described for CLA in section 1.11.3. However the 
development of these has not been possible to date, as the understanding of the 
mechanism of MTZ action and also resistance development in H. pylori remains 
incomplete. An overview of the current hypotheses will follow.
1.11.5 MTZ activation and resistance in anaerobic bacteria 
MTZ is administered in an inactive form and enters bacterial cells by passive 
diffusion where it is reduced to form a toxic nitro anion radical (Figure 1.5) as well as 
nitroso groups and hydroxylamine that damage bacterial DNA, leading to cell death.
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Figure 1.5 Reduction of MTZ pro-drug by donation of electrons (Land and 
Johnson 1999).
As MTZ has a low redox potential, this can only occur in anaerobic or 
microaerophilic organisms that have pathways with suitably low redox potentials. In
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the electron transport chain of anaerobic bacteria, electrons produced by pyruvate 
oxidoreductase (POR) are transferred via ferredoxin or flavodoxin proteins to a 
terminal electron acceptor such as a proton. MTZ accepts electrons from these 
proteins in the cell cytoplasm, creating a concentration gradient that increases the rate 
of drug uptake (Land and Johnson 1999). Resistance develops by inactivation of 
components of the electron transport chain, particularly POR and ferredoxin (Jenks 
and Edwards 2002).
1.11.6 MTZ resistance in H, pylori
As oxygen tensions are higher in microaerophilic conditions, it was thought that this 
may allow oxidisation of nitro anion radicals to re-form the MTZ pro-drug as well as 
toxic oxygen by-products that could damage DNA. However, subsequent 
investigation of this possibility failed to support the hypothesis of MTZ activity by 
‘futile cycling’ (Smith and Edwards 1995a). Evidence that MTZ was activated by 
reduction in H. pylori rather than futile cycling was provided by early studies, 
including one that demonstrated increased MTZ uptake in conditions that influence 
the environmental redox potential and thus rate of MTZ reduction (Smith and 
Edwards 1995b) and a later study that demonstrated slower MTZ reduction in MTZ-R 
strains (Smith and Edwards 1997). Some of the bacterial enzymes that may be 
involved in this reduction process and resistance development are considered in 
subsequent sections.
1.11.6.1 The potential role of rdxA in MTZ resistance oiH. pylori
An oxygen-insensitive NADPH nitroreductase encoded by the rdxA gene has been the 
focus of numerous investigations following a report that rdxA inactivation was 
associated with the MTZ resistant (MTZ-R) phenotype (Goodwin et a l 1998). In the 
original study, a cosmid library was constructed from a MTZ-R strain and the cosmid
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DNA capable of transforming a MTZ-S strain to a MTZ-R phenotype identified. 
Sequence analysis of this revealed a protein with high-level homology to classical 
oxygen independent NADPH nitroreductases. Subsequent cloning of rdxK fi*om a 
MTZ-S strain and transformation of this into the intrinsically MTZ resistant E. coli 
resulted in a MTZ-S phenotype and a marked increase in nitroreductase activity. 
Furthermore, sequencing of rdxA in MTZ-S and MTZ-R clinical isolates recovered 
from patients before and after eradication therapy revealed a range of different genetic 
mutations in the MTZ-R isolates only. It was proposed that MTZ is activated by 
RdxA-mediated reduction in sensitive strains and that resistance develops as a result 
of functional inactivation of this gene (Goodwin et al. 1998). Further studies have 
confirmed that inactivation of the rdxA gene can occur by a range of mutation types 
(Debets-Ossenkopp et al. 1999; Jenks et al. 1999;Kwon et al. 2001a;Paul et al. 
2001;Solca et al. 2000;Tankovic et al. 2000). Furthermore mutated rdxA genes can 
transform MTZ-S strains to a resistant phenotype and conversely lethal effects of 
MTZ can be restored in resistant strains by introduction of functional rdxA (Goodwin 
et al. 1998;Jeong et al. 2000;Paul et al. 2001;Wang et al. 2001). Introduction of MTZ 
resistance by construction of rdxA knockout mutants (Kwon et al. 2000a;Kwon et al. 
2000b;Kwon et al. 2001b) and virtual absence of rdxA mRNA levels (Kwon et al. 
2000c) and RdxA protein expression (Latham et al. 2001) in MTZ-R strains provides 
further evidence of the importance of rdxA in the MTZ resistance mechanism. The 
contribution of genetic mutations in rdxA to MTZ resistance in the UK will be 
explored in Chapter 10.
1.11.6.2 The potential role of the frxA gene in MTZ resistance oiH . pylori
Although there is substantial evidence in support of a role for the oxygen insensitive 
nitroreductase RdxA protein, the occurrence of MTZ-R strains that possess an
51
Introduction
apparently wild type rdxA is well documented (Goodwin et a l 1998;Jenks et a l 
1999;Kwon et a l 2001a;Tankovic et a l 2000;Wang et a l 2001).
Inactivation of the frxA  gene that encodes NADPH flavin oxidoreductase, was 
recently shown to increase the Minimum Inhibitory Concentration (MIC) of MTZ-S 
strains to resistant levels, whilst dual inactivation in combination with rdxA resulted 
in even higher level MICs. In addition inactivated frxA genes from clinical isolates 
could transform H. pylori from a MTZ-S to MTZ-R resistotype (Kwon et a l 2000a). 
In contrast, another study conducted at this time demonstrated that frxA  inactivation 
alone was insufficient to confer a MTZ-R phenotype, but it would raise MTZ MIC in 
rdxA deficient mutants (Jeong et a l 2000). Further investigations suggested that frxA  
inactivation may slow bacterial killing by MTZ but not cause resistance, and that two 
types of H. pylori could be defined; Type I, where resistance can develop by mutation 
in rdxA only and Type II that requires dual mutation of both rdxA and frxA  for a 
MTZ-R phenotype (Jeong et a l 2001). However, while a survey of 12 clinical isolate 
pairs confirmed that high-level resistance was linked to mutations in both rdxA and 
frxA  (Kwon et a l 2001a), this and one other study that examined clinical isolates 
demonstrated that intermediate or low level resistance could occur in isolates that 
contained mutated frxA  only (Kwon et a l 2001a;Marais et a l 2003). It is thus evident 
that the exact contribution offrxA inactivation to MTZ resistance remains 
controversial and is considered further in Chapter 10.
1.11.6.3 The potential role of the ahpC gene in MTZ resistance oiH , pylori
Alkyl hydroperoxide reductases (AhpC), encoded by the ahpC gene, reduce harmful 
alkyl hydroperoxides to their corresponding alcohol and are found in various bacterial 
species including some helicobacters (Lundstrom et a l 2001;Lundstrom and Bolin
2000). A recent study that compared protein profiles of MTZ-S and MTZ-R strains of
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H. pylori demonstrated higher oxidase and reductase activities in the MTZ-S strains. 
These activities were largely localised in a protein band comprising several different 
proteins, including a homologue of subunit of AhpC (Trend et ah 2001). In contrast, 
a proteomic-based study suggested that AhpC expression is upregulated in MTZ-R 
strains when grown on MTZ-containing agar, and that this was linked to mutations in 
rdxA (McAtee et al. 2001). Thus there is conflicting evidence for a potential role of 
this protein in MTZ resistance, and no study has yet examined the possible 
involvement of ahpC mutations analogous to those described for other genes.
I.12 Virulence factors
As discussed in section 1.4, H. pylori infection is associated with a broad spectrum of 
clinical outcomes in different patients. As a chronic pathogen that occupies the 
gastric niche, H. pylori has evolved a variety of adaptive features and virulence 
factors. Numerous studies have identified potential factors that are involved in 
survival and orientation in the gastric mucosa, colonisation and adherence to gastric 
epithelial cells and evasion of the immune response to establish a chronic infection. 
Additionally, H. pylori can cause tissue damage, either directly or as part of a 
modulation of the host response. It is now evident that the pathogenesis of H. pylori 
infection is complex and multifactorial, also involving host and environmental factors. 
Table 1.3 provides a list summarising the key bacterial factors that are currently 
thought to play a role in the virulence of H. pylori.
Two virulence factors, vacuolating cytotoxin (VacA) and cytotoxin associated antigen 
(CagA), encoded by vacA and cagA, respectively are the focus of further study in 
Chapters 6 and 7 and so will be considered in more detail in subsequent sections.
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Table 1.3: The putative virulence factors oiH. pylori, (Summarised from
reviews by (Gerhard et al. 2002;Haas et al. 2001;Jenks and Kusters 
2000;Moran et al. 2002;Shimoyama and Crabtree 1998;Suerbaum and 
Michetti 2002)
Virulence Factor* Potential pathogenic role
Urease
LPS
Flagella
Phospholipase A
Hop proteins 
(BabA, SabA)
VacA
CagPAI
HpNAP
Survival in gastric environment; entry into mucous layer; colonisation
Molecular mimicry (Le^, Le  ^antigens) —> persistence; 
?autoimmunity; colonisation
Entry into mucous layer; flagellins involved in colonisation 
Colonisation
Adhesion by binding fucosylated Le  ^blood group antigen (BabA) or 
sialyl -Le’^ glycosphingolipid (SabA)
Forms channel in epithelial membranes, —> provides bacteria with 
nutrients; stimulates inflammatory response; mitochondrial apoptosis; 
?decreases gastric mucin levels
Recruitment of inflammatory cells by IL-8 induction; possible host 
cytoskeletal rearrangements
Induces mast cell degranulation and IL-6 release —> recruits 
neutrophils and monocytes; ?iron acquisition
* Abbreviations are frilly defined in the Glossary section.
1.12.1 Vacuolating cytotoxin (VacA)
Approximately 50 % of 77. pylori display vacuolating activity in vitro (Leunk et al. 
1988) due to production of a cytotoxin of approximately 87 kDa (Cover and Blaser 
1992), but virtually all strains possess vacA, the gene that encodes this protein (Cover
1996). The vacA gene, characterised by four independent groups in 1994 (Dunn et al.
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1997), is 3.9 kb in length and encodes a 139 kDa protoxin, from which a 33-kDa 
leader sequence is cleaved to yield the mature toxin (Cover et a l 1994).
Analysis of Tox + and Tox -  strains by PCR and Southern hybridisation 
demonstrated differences in the middle of the vacA sequence (Cover et a l 1994). 
Further alignment of vacA middle region sequences from Tox + and Tox -  strains 
demonstrated that these regions were closely related within the two respective 
phenotypes but were markedly different between Tox + and Tox -  strains. Two 
different families were thus proposed, type m l alleles, and type m2 alleles that 
contain an insertion of 23 amino acids (Atherton et a l 1995). Further examination of 
sequences encoding the 33 amino acid signal sequence of VacA identified two basic 
families of signal sequences, those from tox + strains (allele si, that could be 
subdivided further into type si a and type sib) and those from tox -  strains (allele s2) 
(Atherton et a l 1995). Further examination of the si allele demonstrated that sub- 
type si a comprised two distinct types, designated si a and sic (van Doom et a l 
1998b). VacA of s2 strains was subsequently shown to have an additional 12 amino 
acids that would appear to account for the lack of cytotoxic activity, compared with si 
isolates (Letley and Atherton 2000). Determination of s type, on the basis of 
amplicon size following PCR, and of m type, by specific probe hybridisation and two 
PCR assays, in 59 clinical isolates demonstrated that this gene has a mosaic stmcture, 
with different allele combinations (slm l, si m2 and s2m2) possible (Atherton et a l 
1995). Genotype s2ml was subsequently reported but is a rare occurrence (Letley et 
a l 1999). A summary of the stmcture of the vacA gene and encoded polypeptide is 
presented in Figure 1.6.
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Figure 1.6 Schematic representation of the vacuolating cytotoxin gene (vacA) 
and protein (VacA), not to scale. Alleles can be classified according 
to signal and mid region type. The translated polypeptide is a protoxin, 
processed during secretion (Atherton et a l 2001).
The Atherton study in 1995 suggested that slm l isolates were more toxigenic than 
those of si m2 and s2m2 genotype, and that the si allele was more frequently 
associated with peptic ulcer disease. Previous studies had suggested that strains 
associated with peptic ulcer disease were more likely to produce cytotoxin (Tee et a l 
1995), and it was hypothesised that type s2 isolates export the VacA protoxin less 
efficiently across the bacterial cytoplasmic membrane, or that differences in signal 
sequence cleavage sites may alter protein function. Alternatively s types may be 
markers for other unidentified elements that influence cytotoxic activity (Atherton et 
al 1995). This early study stimulated numerous investigations of potential 
associations between vacA genotype and virulence potential, described below.
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1.12.1.1 Geographical distribution and disease associations of vacA genotypes 
Sub-types of si appear to vary with geographical location. Type si a predominates in 
Australia and Northern and Eastern Europe, type sib  is more prevalent in Southern 
Europe, Africa, Central USA and South America, while most isolates from Eastern 
Asia are type sic  (Andreson et al. 2002;de Gusmao et al. 2000;Karhukorpi et al. 
2000;Kidd et al. 1999;Mattar and Laudanna 2000;Strobel et al. 1998;van Doom et al. 
1998b;van Doom 1998a;van Doom a/. 1998c;van Doom e /«/.
1999b;Yamaoka et al. 1999). However no specific association with disease and si 
sub-type was reported in most of these studies. In contrast, many of these and other 
studies that analysed either clinical isolates or gastric biopsies directly reported 
significant associations between the si allele and peptic ulcer disease (Arents et al. 
2001 ;de Gusmao et al. 2000;Evans et al. 1998;Kidd et al. 1999;Rudi et al. 
1999;Strobel e /«/. 1998;van Doomed a/. 1998a;van Doom er a/. 1998c;van Doom gr 
al. 1999b) but other studies did not substantiate this (Andreson et al. 2002;Gold et al. 
2001;Gunn et al. 1998;Yamaoka et al. 1999). Some evidence has been presented to 
suggest an association between vacA genotype s lm l and development of gastric 
cancer also (Evans et al. 1998;Kidd et al. 1999;Miehlke et al. 2000;Miehlke et al. 
2001). The vacA m type has been reported to correlate with in vitro toxicity and 
gastric epithelial damage in vivo, but not with peptic ulceration (Atherton et al. 1997). 
These observations may explain the overall lack of apparent association between m 
type and PUD reported in most of the studies described. Interestingly, however, 
potential differences in m type of PUD and gastric cancer isolates has been proposed 
(van Doom et al. 1999b).
It is evident that the association between vacA genotype and specific disease 
remains inconclusive. Further examination of larger study populations from wide
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geographical areas may improve understanding of this. However the current tools 
available for determination of vacA genotype, described below, do not appear to be 
amenable to large-scale application.
1.12.1.2 Methods of vacA genotyping
Most studies determined vacA genotype by multiple PCR assays, not only to 
distinguish si and s2 and m l and m2 alleles, but also to sub-type si. Overall the 
preferred strategy for vacA genotyping has been to use the original primers described 
by Atherton et al, (1995) (Evans et al. 1998;Gunn et al. 1998;Ito et al. 1997;Letley et 
al. 1999;Miehlke e/ûf/. 2000;Miehlke e/a/. 2001;Rudi fl/. 1999;Strobel e/a/. 1998). 
Often s type has been defined using additional primers developed to distinguish sub- 
types si a and sic (de Gusmao et al. 2000;Karhukorpi et al. 2000;Yamaoka et al.
1999). However the original primers (VA3-F and VA3-R and VA4-F and VA4-R) 
could not determine m type in some isolates due to sequence variation at the primer 
binding sites (Gunn gr a/. 1998;Ito e/a/. 1997;Strobel e/a/. 1998). This led to 
development of a simpler method that could differentiate types m l and m2 on the 
basis of amplicon size with a single PCR reaction using one primer pair (VAG-F and 
VAG-R) (Atherton et al. 1999). Several studies have adopted these primers as a first 
or second-line strategy for mid region genotyping (Karhukorpi et al. 2000;Kidd et al. 
1999;Yamaoka et al. 1999). These PCR assays also allow determination of vacA 
genotype directly from gastric biopsies, with reported sensitivities of > 90 % (Gunn et 
al. 1998;Mattar and Laudanna 2000;Rudi e /a/. 1999).
One alternative strategy was a line probe assay (LiPa) that first involves two 
separate PCRs to amplify vacA signal and mid regions using two and five biotinylated 
primers, respectively. Labelled amplicons were then added in a reverse hybridisation 
reaction to a panel of probes, immobilised on nitrocellulose strips, that corresponded
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to eight different s types and five m types (van Doom et al. 1998a). Numerous multi­
centre studies have applied LiPa to provide more specific and detailed definition of 
vacA genotypes, discriminating within the s and m alleles. Furthermore this approach 
has demonstrated that mixed genotype infections are not uncommon (Gold et al. 
2001;van Doom e/ a/. 1998b;van Doom g/ a/. 1999b;van Doom e/ a/. 2000a;van 
Doom et al. 2000b;van Doom 2001). The LiPa method has been shown to be a 
highly sensitive means of vacA genotyping directly from gastric biopsies (Arents et 
al. 2001;van Doom et al. 1998c). However, LiPa is a more complex and expensive 
method than simple PCR and this is likely to limit its use, unless commercially 
synthesised probe strips become available.
PCR-based vacA genotyping has the advantage that it is sensitive, rapid and 
relatively simple. However the requirement for multiple reactions increases overall 
workload and cost of these tests. Chapter 6 describes the development and evaluation 
of a single-step multiplex assay for vacA genotyping. One other such assay that is 
described in the literature (Han et al. 1999) will be discussed further in that chapter.
1.12.2 Cytotoxin associated gene (CagA)
Early studies reported that culture supematant of cytotoxic H. pylori strains contained 
a protein ranging fi*om 120-130 kDa in size. The purified protein was shown to lack 
cytotoxic activity but to be associated with the cytotoxin encoded by vacA (Cover and 
Blaser 1992). Subsequent constmction and screening of an expression library from a 
cytotoxic strain demonstrated that the protein was encoded by a large, variable, gene 
of approximately 3.5 kb, that was named cytotoxin associated gene (cagA) (Covacci 
et al. 1993). Westem blotting had demonstrated that the immunodominant CagA 
protein was only expressed in cytotoxic strains, and probe hybridisation analyses 
suggested that this was due to absence of the cagA gene in non-cytotoxic strains
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(Covacci et a l 1993). Patients with gastroduodenal pathologies have been shown to 
have significantly higher anti-CagA antibody titres than for patients with normal 
gastric mucosa (Atherton 1998;Covacci et a l 1993). However, while analysis of 43 
clinical isolates demonstrated that most, but not all, strains could be subdivided into 
type I strains that possess cagA and express VacA protein and type II strains that lack 
cagA and are non-cytotoxic, strong associations between type I strains and duodenal 
ulceration could not be found (Xiang et a l 1995). Although inactivation of cagA does 
not affect VacA expression or the ability of a strain to induce the pro-inflammatory 
cytokine interleukin 8 (IL-8) (Tummuru et a l 1994), genomic mapping demonstrated 
that cagA was part of a 40-kb region of about 30 genes that had a different G + C 
content from the rest of the H. pylori genome (Censini et a l 1996). This region had 
features analogous to those of bacterial pathogenicity islands; fragments of DNA 
acquired later in bacterial evolution that enhance strain virulence, and so was named 
the cag pathogenicity island {cag PAI) (Akopyants et a l 1998;Censini et a l 1996).
The cag PAI contains genes homologous with a type IV secretion system that may 
be involved in export of CagA or other proteins (Akopyants et a l 1998;Censini et al 
1996;Odenbreit et a l 2000). Additionally inactivation of several individual genes of 
the PAI, excluding cagA, can abolish the ability of a strain to induce IL-8 in vitro 
(Akopyants et a l 1998;Censini et a l 1996;Tummuru et a l 1995). The structure of 
the cag PAI can vary, being either continuous or split in two (Akopyants et a l 
1998;Audibert et a l 2001;Censini et a l 1996), as summarised in Figure 1.7. While 
both structures can induce IL-8, it is interesting to note that some strains that lack an 
intact cag PAI can also induce IL-8, albeit rarely, indicating the involvement of other 
bacterial factors in this process (Audibert et a l 2001). Furthermore, while a high 
proportion of strains associated with duodenal ulceration contain the cag PAI, strains
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lacking this can also be found in DU patients (Audibert et a l 2001; Jenks et a l 1998) 
The precise link between cagA, the production of the CagA protein, and strain 
virulence thus remains controversial (Graham and Yamaoka 2000;Mitchell et a l 
1996;Peters et a l 2001). About 68 % of strains isolated from dyspeptics in the United 
Kingdom have cagA present in the genome (Owen et a l 2001) and similar or higher 
frequencies have been reported in France (Jenks et a l 1998), Japan (Maeda et a l 
1998a) and Costa Rica (Occhialini et a l 2001). Nevertheless, cagA status alone is 
insufficient to reliably predict either the virulence of H. pylori or its association with 
gastric ulcer (Blaser and Berg 2001).
Until recently, the biological role of the CagA protein was not known. However 
there is now considerable evidence to suggest that CagA is involved in inducing 
cytoskeletal rearrangements in epithelial cells, as summarised in Figure 1.8. 
Investigation of the interaction of epithelial cells with wild type H. pylori and mutant 
strains lacking components of the cagPAI demonstrated that, following attachment of 
cag4-positive H. pylori to host epithelial cells, CagA is exported from the bacterial 
cell via the type IV secretion system encoded by the cagPAI, and translocated into 
epithelial cells (Odenbreit et a l 2000;Stein et a l 2000). An earlier study had 
demonstrated that infection of epithelial cell lines with H. pylori led to 
phosphorylation of an unknown protein of 145 kDa and pedestal formation (Segal et 
a l 1996), later defined as the “hummingbird phenotype” (Segal a/a/. 1999). Several 
groups subsequently identified the unknown protein as CagA, that, following 
translocation, localises in the epithelial membrane in proximity to the site of bacterial 
adhesion (Asahi et a l 2000;Backert et a l 2000;0denbreit et a l 2000;Segal et a l 
1999;Stein et a l 2000). Tyrosine residues of CagA are phosphorylated by host cell 
kinases (Asahi et a l 2000;Backert et a l 2000;0denbreit et a l 2000;0denbreit et a l
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2001;Segal et al. 1999;Stein et al. 2000) including those of the c-Src and Lyn families 
(Stein et al. 2002) and this in turn activates eukaryotic signal transduction pathways 
and cytoskeletal plasticity. A recent study of a cell line (AGS) transfected with CagA 
demonstrated that CagA^^^ interacts with the SH 2 domain of SHP-2, a cytoplasmic 
tyrosine phospatase, leading to upregulation of phosphatase activity that is central to 
development of the hummingbird phenotype, either directly or by dephosphorylating 
other host cell proteins (Higashi et al. 2002). It is proposed that the resultant 
abnormalities in gastric epithelial cell proliferation and movement may play a critical 
role in the development of disease, particularly gastric cancer. The recent 
demonstration of CagA^^^-SHP-2 complexes, only in the gastric mucosa of patients 
with atrophic gastritis may indicate the involvement of this process in early stage 
carcinogenesis (Yamazaki et al. 2003).
Three putative tyrosine phosphorylation motifs in the CagA protein were predicted 
with the MOTIF algorithm and designated TPM-A (KFGDQRY), TPM-B 
(KNSTEPIY) and TPM-C (KLKDSTKY) (Odenbreit et al. 2000;0denbreit et al.
2001) although other analyses predict additional motifs (Evans, Jr. and Evans 2001) 
such as the EPIYA sequences in the repeat region of CagA (Stein et al. 2000). The 
relationship between cagA TPM and clinical progression of H. pylori infection is not 
well defined. To date, most studies have characterised TPM status of a strain by 
sequencing regions of cagA. While this approach allows accurate identification of 
TPMs, the high associated reagent and labour costs limits the number of isolates that 
can be surveyed and prevents extensive evaluation of the clinical significance of cagA 
TPMs. Chapter 7 describes the development and application of three novel real-time 
LightCycler assays for rapid screening of a larger study population to examine 
potential associations of specific TPMs with disease.
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Figure 1.8 Schematic representation of the interactions between H. pylori 
CagA and host epithelial cells. (Compiled from Segal et al. 
1999;Stein et a l 2002)). H. pylori binds to epithelial cells and 
translocates CagA (1) that is then phosphorylated on TPMs by host 
kinases (2) leading to upregulation of host phosphatases (3), protein 
dephosphorylation and host cytoskeletal rearrangements (4).
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1.13 Other helicobacters associated with human gastric infection
Although H. pylori is the predominant human gastropathogen, gastric infection with 
'H. heilmanniV (Hilzenrat et al. 1995;Holck et al. 1997;Ierardi et al. 2001;Jalava et 
al. 2001;Jhala et al. 1999;McNulty et al. 1989) and, rarely, H. bizzozeronii (Jalava et 
al. 2001), H. felis (Germani et al. 1997;Lavelle et al. 1994) and H. cinaedi (Pena et al.
2002) have been reported also, and are considered further in subsequent sections.
1.13.1 History o f ‘fy. heilmanniV
Spiral organisms that were morphologically distinct from H. pylori had been reported 
in the stomach of various animals , but the only early description of such bacteria in 
the human stomach was by Krienitz in 1906 (Kidd and Modlin 1998). It was not until 
the discovery of H. pylori almost 80 years later, and the consequent intensive 
investigation of the human gastric mucosa, that these organisms were reported in 
three patients (Dent et al. 1987). In 1989, spiral bacteria were observed by Gram 
stain, histology or by electron microscopy in the gastric mucosa of six patients, all of 
whom had histological evidence of gastritis, similar to that induced by H. pylori. The 
distribution of the organism was patchy and sparse and it could not be cultivated 
under conditions that promotes growth of H. pylori. However, there were sufficient 
numbers of organisms present in one biopsy to produce a positive result by RUT. 
Repeat testing of patients over a number of months demonstrated that, like H. pylori, 
this was a chronic infection. It was proposed that the organism be classified on the 
basis of its morphology along with other similar gastric spiral bacteria, into a new 
genus Gastrospirillum, and the organism observed in these patients was named G. 
hominis (McNulty et al. 1989). Subsequent analyses of urease genes as well as 16S 
rDNA demonstrated that this organism was likely to be part of the Helicobacter genus
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(Solnick et a l 1993;Solnick et a l 1994) and G. hominis was renamed ‘Helicobacter 
heilmannii \  although this has not yet been formally validated.
‘H  heilmanniV infection has since been shown to have a high incidence (7 8 -1 0 0  
%) in a wide range of other animal hosts including cats, dogs and pigs (De Groote et 
al 1999;Eaton a/. 1996;Neigere? «/. 1998).
1.13.2 Definition of “IT. heilmannii-\i\^é’’ organisms (HHLO)
Although the nomenclature implies a defined species, 16S rDNA phylogenetic 
analyses demonstrate that ‘H  heilmannii ’ comprises two related but distinct types 
(O’Rourke et a l 2001;Solnick et a l 1993). Type 1 is closely related to 'Candidatus
H. suis’, found in pigs (De Groote et a l 1999), whereas Type 2 is more closely related 
to the H  bizzozeronii/H felis/H  salomonis group that most commonly infect cats and 
dogs (Jalava et a l 1997;Solnick et a l 1993). These morphologically complex, often 
non-culturable bacteria, from various human and animal hosts represent part of an ill- 
defined taxonomic group of closely related forms which, for convenience, have been 
referred to as ‘Helicobacter heilmanniV-like organisms (HHLO).
1.13.3 Clinical features, incidence and diagnosis of human HHLO infection 
Human HHLO infection possibly occurs via a zoonotic route, and may lead to the 
development of PUD (Hilzenrat et a l 1995;Jhala et a l 1999) or low-grade MALT 
lymphoma (Morgner et a l 2000).
The reported incidence of human ‘H  heilmanniV infection based on histology is 
low (0.1 - 2 %) in dyspeptic adults (lerardi et a l 2001;Jhala et a l 1999;Svec et a l
2000) and in paediatric patients (Mention et al 1999;Svec et a l 2000). As HHLOs 
from human tissue remain uncultivable with rare exceptions (Andersen et a l 1996), 
diagnosis is primarily reliant on histology, although touch cytology is also described 
(Debongnie et a l 1994). Recently, another microscopy-based system, fluorescent in
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situ hybridisation (FISH), was described that detected, by a panel of probes, all known 
types of ‘H. heilmanniV and several new forms direct from paraffin embedded gastric 
biopsies (Trebesius et a l 2001), PCR-based studies have identified HHLOs in both 
human (Morgner et a l 2000) and animal (Norris et a l 1999) gastric biopsies by 
amplification of Helicobacter genus-specific fragments of 16S rDNA followed by 
sequencing. One PCR detection assay, based on the ureB gene was described for 
detection o ï ‘H. heilmanniV in domestic cat biopsies (Neiger et a l 1998), but specific 
PCR has only been applied for detection of human infection in a single patient 
(Dieterich et a l 1998). A number of histologically-based studies have provided 
valuable information on the clinical features of HHLO infections (Hoick et a l 
1997;Jhala et a l 1999;Mention et a l 1999;Stolte et a l 1994) and have suggested that 
when compared with H. pylori, HHLO distribution tends to be focused in the antrum 
(Jhala et a l 1999) as well as being patchy and sparse (Hoick et a l 1997). 
Microscopy-based methods of detection can be relatively insensitive when bacterial 
numbers are low (Hoick et a l 1997;Megraud 1995a). In the original case report of 
this infection, it was stated that slides had to be examined for at least five minutes, to 
minimise falsely negative results (McNulty et a l 1989). It is thus possible that the 
incidence of human HHLO infection may be under-reported. Development and 
evaluation of a novel PCR-based method to detect HHLOs is presented in Chapter 4.
1.14 Helicobacters associated with human extra-gastric infection 
Several helicobacters that typically occupy extra-gastric niches in a range of non­
human animal reservoirs have been cultured from human diarrhoea specimens (Table 
1.1). H  cinaedi and H  fennelliae have both been associated with chronic enteritis 
and proctitis (Totten et a l 1985), in immunocompromised patients and less frequently 
in immunocompetent individuals (Fox 2002). H  cinaedi also has the potential to
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become bacteraemic and cause systemic disease (Hung et al. 1997;Kiehlbauch et al. 
1994;Orlicek et al. 1993;Tee et al. 1996). Several reports suggest potential 
associations between human H. pullorum infection, probably acquired from chickens, 
and development of gastroenteritis (Bumens et al. 1994;Stanley et al.
1994;Steinbrueckner et al. 1997). Other species recovered from human diarrhoeal 
specimens include H. canis, H. canadensis, H. winghamensis, ‘H. rappinV and ‘H. 
westmeadii’ (Fox 2002), although the causal relationship between these infections and 
gastroenteritis is less well-understood (O'Rourke et al. 2001). As has been 
demonstrated in section 1.9, numerous studies have presented PCR-based evidence of 
extra-gastric Helicobacter infections also and this is explored further in Chapter 9.
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1.15 Aims and Objectives
This study was initiated as part of a PHLS funded research project that aimed to 
explore and develop the role of conventional and real-time PCR in the investigation of 
human Helicobacter infections. Within this aim are several specific objectives.
1. To examine the factors that could influence outcome of PCR-based analyses of 
clinical specimens, including sample transport conditions, DNA extraction 
methods and primers used.
2. To develop and evaluate PCR assays to detect all species of Helicobacter as well 
as specifically Æ pylori and ‘H  heilmanniV-Wko organisms, and to apply these in 
the examination of gastric and extra-gastric chronic inflammatory disease.
3. To explore non-invasive detection of H  pylori in stool specimens by PCR 
compared with specific antigen detection.
4. To apply PCR-based methodologies in the examination of antibiotic resistance in 
H  pylori, for CLA susceptibility testing direct from gastric biopsy and for further 
exploration of the mechanism of MTZ resistance.
5. To develop and evaluate PCR based assays for the investigation of putative 
virulence factors vacA and cagA, both from culture and direct from gastric biopsy.
A PCR-based approach not only has the facility to allow rapid, potentially non- 
invasive, detection of helicobacters associated with human disease, but could provide 
further strain information that could directly impact on patient management as well as 
enhancing surveillance of specific markers of antibiotic resistance and strain 
virulence.
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Chapter 2. MATERIALS AND METHODS
Unless stated otherwise, all reagents and reactions were prepared or performed in 
sterile distilled water. Latex gloves were worn for all molecular methods and for all 
procedures handling clinical specimens. All routine culture media used were prepared 
in-house by the CPHL media preparation suite. Manufacturers and suppliers are 
given in squared parentheses. Reference strains are listed in Appendix A.
2.1 Bacterial isolates used
2.1.1 Sources of bacterial isolates
Type strains were obtained from the National Collection of Type Cultures (NCTC) in 
lyophilised form (Appendix A). Other bacterial isolates were obtained from the 
stored (-80 °C) Helicobacter Reference Unit (HRU) collection, comprising strains 
referred routinely from primary diagnostic laboratories that cultured H. pylori from 
gastric biopsy and also from collaborating laboratories world wide. The collection 
also contained isolates cultured in HRU from gastric biopsies referred routinely from 
collaborating gastroenterology clinics and microbiology laboratories. Exact numbers 
of isolates used are provided in subsequent chapters.
2.1.2 Culture and storage of bacterial isolates
All bacterial strains were cultured on Columbia Blood agar (CBA) - Columbia agar 
base CM331 [Oxoid Ltd, Basingstoke, Hampshire, UK] with 10 % (v/v) defrbrinated 
horse blood [E&O Laboratories, Bonnybridge, UK] - at 36 °C in a variable 
atmospheric incubator (VAIN) [Don Whitley Scientific Ltd, Shipley, West Yorkshire, 
UK] which maintained a microaerophilic atmosphere of 4 % Og, 5 % CO2, 86 % Ng, 5
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% H2. Stock cultures were stored long-term in duplicate by preparation of a heavy 
bacterial suspension in a sterile vial containing commercial cryopreservative and 25 
porous glass beads [Microbank'^^, Pro-Lab Diagnostics, Wirral, UK]. Bacterial 
suspensions were mixed with the beads by gentle inversion. Excess liquid was 
transferred to a second 2-ml screw-cap tube containing 20-30 glass beads, mixed and 
liquid discarded. Beads were stored (-80 °C) in two separate freezers.
2.1.3 Recovery of stored cultures
Beads were streak-plated onto CBA with a plastic sterile 10 pi loop [Technical 
Services Consultant, Heywood, Lanes, UK] and incubated at 36 °C under 
microaerobic conditions for 48 - 72 h and then sub-cultured onto CBA and incubated 
for 48 h as described in section 2.1.2.
2.2 Transport of cultures and biopsies
Clinical specimens can contain contaminating bacteria that multiply rapidly, 
suppressing growth of slow-growing organisms like H, pylori. Inclusion of 
antibiotics in transport media can partially overcome this. Vancomycin inhibits 
growth of most Gram-positive bacteria; trimethoprim lactate and cefsulodin suppress 
growth of other Gram-negative bacteria, while amphotericin B inhibits fungal growth.
All biopsies referred to HRU for culture or molecular analyses and all referred 
cultures were transported in Dent’s transport medium - 3.7 % {w/v) Brain Heart 
Infusion broth [CM225, Oxoid Ltd], 2.5 % (w/v) yeast extract [L21, Oxoid Ltd], 5.0 
% (v/v) sterile horse serum and Helicobacter Supplement [SRI 47, Oxoid Ltd] (10 
pg/ml vancomycin, 5 pg/ml trimethoprim lactate, 5 pg/ml cefsulodin, 5 pg/ml 
amphotericin B).
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Where possible, cultures and biopsies were transported to the HRU with minimal 
delay (preferably within 24 h). For biopsies that were to undergo molecular analyses 
and where delays in transport were unavoidable, these were stored at -20 °C and 
transported on ice to the HRU. The effects of a range of different transport conditions 
for gastric biopsies on PCR was considered in Chapter 3.
2.3 Clinical Specimens
A range of different clinical specimens were examined during the course of this study. 
Human and feline gastric biopsies (sections 2.3.1 and 2.3.6) were collected from 
subjects as part of their routine investigation. Other biopsies (sections 2.3.3 -  2.3.5) 
were collected as part of specific studies investigating clinical conditions for which no 
microbiological cause has yet been established. The design of these studies in terms 
of patient inclusion criteria and definition of control subjects was established at the 
primary participating centre. Molecular analyses were performed (described in 
Chapter 9) as part of an HRU collaboration with these centres. Where appropriate, 
ethical approval and patient consent for investigations was obtained locally at each 
primary clinical centre.
2.3.1 Human gastric biopsies
These were collected from patients at endoscopy for diagnostic tests as part of the 
gastroenterologist’s routine investigation of dyspepsia. A total of 317 gastric biopsies 
included in this work were collected from the hospitals and clinics listed in sections 
below. The methods by which H. pylori status had been determined prior to 
molecular testing varied according to the local policy for preferred diagnostic tests.
23.1.1 Broomfield Hospital, Chelmsford. Separate biopsies were collected for 
histological examination and for culture. Biopsies that had been cultured by the
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Chelmsford Public Health Laboratory were sent to the HRU for molecular analyses. 
All matched H. pylori cultures and histology reports were forwarded to the HRU also.
2.3.1.2 North Middlesex University Hospital, London. Gastric biopsies were 
collected and H. pylori status determined by rapid urease testing (CLO test [Delta 
West Pty Ltd, Bentley, Western Australia]) in the department of gastroenterology. 
CLO test biopsies were then sent to the hospital’s PHLS Collaborating Centre where 
they were batched and sent weekly to the HRU for culture and molecular analyses.
2.3.1.3 St George’s Hospital, London; University College Hospitals, London; Royal 
Free Hospital, London, King’s College Hospital, London. Gastric biopsies were 
collected and sent to local microbiology departments from where they were 
immediately referred to the HRU for culture (section 2.5) and molecular analyses.
2.3.2 Stool specimens
Stool samples were provided by dyspeptic patients attending the open access 
endoscopy clinic at Broomfield Hospital (Chelmsford), collected as part of their 
routine investigation. All patients who provided stool specimens had given informed 
consent prior to endoscopy. Stools were brought to the endoscopy clinic in a sterile 
faecal sample container [Bibby Sterilin Ltd, Stone, Staffordshire, UK] and sent, along 
with the gastric biopsy taken at endoscopy, to Chelmsford Public Health Laboratory. 
Stools were then immediately stored at -20 °C, and subsequently transported frozen in 
batches to the HRU for stool antigen testing (section 2.23) and for molecular analyses.
2.3.3 Bladder biopsies
Bladder biopsies were collected from 27 patients with a range of urological 
symptoms, including Interstitial Cystitis (IC) (n = 10), haematuria and incontinence
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(n=17) who were attending a urology clinic for cystoscopy as part of their routine 
investigation at Broomfield Hospital (Chelmsford).
Biopsies obtained from the left and right bladder wall were, along with urine 
samples for each patient, cultured for helicobacters at Chelmsford Public Health 
Laboratory. Biopsies were stored at -20 °C and sent in batches at <0 °C to the HRU 
for DNA extraction (section 2.11.2) and for further molecular testing.
2.3.4 Colonic biopsies
Colonic biopsies were collected from inflamed and non-inflamed areas of the colon 
from 30 patients undergoing investigation at the Department of Gastroenterology, St 
Mark's Hospital, Northwick Park, Harrow (Middlesex) and transported on ice to the 
HRU the same day as colonoscopy. Patient groups had been defined on the basis of 
their disease state, namely ulcerative colitis (UC) patients (n = 11), Crohn’s disease 
(CD) patients (n = 9) or control patients (n = 10) who had other conditions including 
rectal bleeding, diarrhoea, polyps and constipation. Local ethical approval had been 
obtained for this study and all patients gave their informed consent. DNA extraction 
was performed as described in section 2.11.2 on the day of biopsy receipt. Separate 
biopsies were examined by routine haematoxylin and eosin staining by 
histopathologists at St Mark’s Hospital.
2.3.5 Bronchial biopsies
Bronchial biopsies were collected from 10 patients, all of whom had chronic 
persistent cough (CPC) and were undergoing bronchoscopy at Taunton and Somerset 
Hospital (Somerset). PHLS ethical approval had been granted for this study and all 
participating patients gave informed consent to further investigation for helicobacters.
74
Materials and Methods
Biopsies were stored (-20°C) at Taunton PHL and forwarded to the HRU at 4°C. 
DNA was extracted from biopsies (section 2.11.3) on the day of receipt.
2.3.6 Feline gastric biopsies
Gastric biopsies from 15 domestic cats under investigation at The Village Veterinary 
Practice (Belsize Park, London) for various symptoms were collected and cultured for 
species o ïHelicobacter as described in section 2.5. Biopsies were examined 
microscopically by Gram stain (section 2.6.1), and then stored (-20 °C) until DNA 
was extracted as stated in section 2.11.2.
2.4 Faecal spiking experiments
These were conducted following a modification of the protocol described by Lawson 
et al (1997). Bacterial isolates were cultured as described in section 2.1.2. and 
harvested during the exponential phase of growth (after 48 h). Bacterial suspensions 
of a turbidity equivalent to a MacFarland’s Standard of 1.0 [Pro Lab Diagnostics, 
South Wirral, Cheshire, UK] were prepared in brucella broth (BB) -  2.0 % (w/v) 
peptone 180, 0.1 % (w/v) dextrose, 0.2 % (w/v) yeast extract, 0.5 % (w/v) sodium 
chloride, 0.01 % (w/v) sodium bisulphite [Invitrogen, Paisley, Strathclyde, UK] - and 
serially diluted from 10'^  to 10'^ . Faecal specimens (1 g) were suspended in 9 ml of 
inoculated Brucella Broth. In subsequent experiments, serial dilutions containing 
skimmed milk powder [Marvel, Premier Foods, Merseyside, UK] (330 mg/ml), to 
block binding of PCR inhibitors to silica or diatoms, were emulsified with 1 g stool.
Bacterial cell suspensions were quantified by a viable count method where 20 pi 
volumes of the 10'\ 10"^  and 10'^  solutions were cultured in triplicate under 
microaerobic conditions described in section 2.1.2.
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2.5 Culture of H. pylori from gastric biopsies
H. pylori was cultured from gastric biopsies by streak-plating with a 10 pi plastic 
sterile loop [Technical Service Consultants Ltd] on CBA and oniL pylori selective 
Dent’s agar - Columbia base [Oxoid Ltd], 7 % (v/v) laked horse blood and 
Helicobacter selective supplement [SRI, Oxoid Ltd] - and incubated at 36 °C under 
microaerophilic conditions. Plates were examined for growth after three, five and 
seven days.
2.6 Characterisation ofÆ  py/on
H  pylori was identified on the basis of the following simple biochemical tests:
2.6.1 Gram stain
The structure of a bacterial cell wall is a key feature in its classification. Gram 
staining allows cell walls composed of a single membrane and thick peptidoglycan 
layer (Gram positive) to be distinguished from those that have both inner and outer 
membranes and less peptidoglycan (Gram negative). The thick peptidoglycan layer of 
Gram-positive bacteria enables the cell to retain the crystal violet-iodine complex and 
stain violet. In contrast, this complex is decolourised by acetone in Gram-negative 
bacteria and cells stain the pale pink colour of the counterstain. H  pylori cells 
typically stain as Gram negative, slender spiral curved rods.
Bacterial cells were emulsified in sterile water on a glass microscope slide [Chance 
Propper Ltd, Smethwick, Warley, UK] with a sterile loop, air dried and fixed to the 
glass surface by brief heating. Cells were serially stained with crystal violet [Pro-Lab 
Diagnostics] for 1 min, Lugol’s iodine [Pro-Lab Diagnostics] for 1 min, decolourised 
by the addition of acetone [BDH, Merck Ltd, Lutterworth, Leicestershire, UK] for 30
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s, washed with water, and counter-stained with safranin [Pro-Lab Diagnostics], Slides 
were examined under oil immersion at a X 100 magnification.
2.6.2 Urease test
H. pylori possesses very potent, rapid urease activity and this is a key biochemical test 
in identification. Urea is catabolised to carbon dioxide and ammonia, resulting in an 
increased pH that can be detected by a suitable indicator (e.g. phenol red).
Christensen’s urea agar slopes - 2.4 % (w/v) urea agar base [Oxoid Ltd] 2 % (w/v) 
urea solution [Sigma Ltd, Dorset, UK] - were stab-inoculated with bacterial cells on a 
sterile loop and incubated at room temperature. A urease reaction was considered 
positive if  the pH indicator changed the colour of the medium fi'om orange to pink 
within minutes.
2.6.3 Catalase test
Many bacterial species, including K  pylori, possess the enzyme catalase to survive 
the toxic by-products of oxygen metabolism. Two molecules of hydrogen peroxide 
(H2O2) are hydrolysed to produce an O2 molecule and two H2O molecules.
Bacterial cells were spotted via a sterile loop into a sterile petri dish [Bibby Sterilin 
Ltd] and a drop of 3.0 % (v/v) hydrogen peroxide [BDH] added. Catalase activity is 
demonstrated by rapid evolution of bubbles of oxygen gas within 5 s.
2.6.4 Oxidase test
Cytochrome oxidase is a vital component of the cytochrome metabolic pathway of 
many bacterial species, including H. pylori, and will oxidise tetramethyl-p- 
phenylenediamine dihydrochloride in a test strip to indophenol blue.
Bacterial cells were smeared via a sterile plastic loop across the surface of an 
oxidase test strip [Pyo-test, Medical Wire and Equipment Co Ltd, Wiltshire, UK]. A
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positive reaction was recorded if the paper changed colour from white to purple 
within 5 s.
2.7 Antibiotic susceptibility testing
Bacterial susceptibility to antibiotics was assessed in vitro by diffusion-based methods 
- disk diffusion and Epsilometer (E)-test. In both tests a bacterial lawn was applied to 
the surface of an appropriate agar medium and a disk or strip containing antibiotic was 
added. The antibiotic diffuses into the media, creating a concentration gradient; the 
size of which depends on the solubility and molecular weight of the antibiotic as well 
as the depth of the agar. Plates were incubated for a specified period of time and then 
examined for bacterial growth. A sensitive organism cannot grow in the presence of 
antibiotic and a zone of inhibition where the antibiotic has diffused will be observed. 
In contrast, a resistant organism will grow in the presence of the antibiotic: thus a 
reduced or no zone of growth inhibition will be seen. Disk diffusion testing provides 
a qualitative assessment of antibiotic resistance. E-test strips contain a predefined and 
continuous antibiotic concentration gradient, allowing determination of the minimum 
concentration at which bacterial growth is inhibited. This minimum inhibitory 
concentration (MIC) provides a quantitative assessment of the level of bacterial 
resistance.
2.7.1 Disk diffusion method
Approximately 10  ^cfu (MacFarland’s standard 4.0) H. pylori cells were suspended in 
Maximum Recovery Diluent (MRD) - 0.1 % (w/v) peptone and 0.85 % (w/v) sodium 
chloride [BDH], pH 7.0 - and a bacterial lawn was prepared by application of this 
with a sterile cotton tip [Technical Service Consultants Ltd] to CBA using a rotary
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plater [Denley, Life Sciences International UK Ltd, UK]. Paper disks impregnated 
with either clarithromycin (CLA) (2 pg) or metronidazole (MTZ) (5 pg) [Oxoid Ltd] 
were applied to the surface of the plate. Antibiotic susceptibilities were recorded by 
measuring the diameter of the zone of inhibition after microaerobic incubation for 48 
h at 36 °C. A strain was considered CLA resistant (R) if there was no zone of 
inhibition, while MTZ resistance was defined as a zone of inhibition < 20 mm.
2.7.2 Minimum Inhibitory Concentration (MIC) determination 
Bacterial lawns were prepared as described (2.7.1) and E-test strips [AB Biodisk, 
Solna, Sweden] containing either CLA or MTZ of concentration ranges 0.016 -  256 
pg/ml for each were applied to the plate and read after microaerobic incubation for 48 
h at 36 °C. MICs were defined as the concentration point at which the zone of 
inhibition intercepted the E-test strip. CLA resistance was defined as a bacterial strain 
with an MIC of >2 pg/ml. MTZ susceptibilities of bacterial strains were classified on 
the basis of MIC as sensitive (<8.0 pg/ml) or resistant (>8.0 pg/ml) (Megraud et a l 
1999).
2.8 Separation of mixed strain populations
All mixed strain populations of MTZ sensitive (S) and resistant (R) phenotypes that 
were identified by the E-test method were separated by selective and replicate plating.
2.8.1 Preparation of MTZ Blood Agar
MTZ stock solutions (16 mg/ml) were prepared by dissolving 0.16 g powdered MTZ 
[Sigma Ltd] in 0.5 ml dimethyl formamide [Sigma Ltd] and 9.5 ml sterile water. This 
was then filter-sterilised [0.2 pm MiniSart NML, Sartorius, Gottingen, Germany].
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10 % (v/v) CBA was prepared by adding 100 ml sterile defrbrinated horse blood 
[E&O Laboratories] to 900 ml Columbia agar [Oxoid Ltd] that had been melted (100 
°C for 30 min) and cooled to 50 °C. MTZ CBA plates (8.0 pg/ml) were prepared by 
the addition of 0.5 ml stock MTZ solution. Following gentle mixing, 20-ml aliquots 
of media were poured into sterile Petri dishes [Bibby Sterilin Ltd] and once set, stored 
at 4 °C until used (within 24 h).
2.8.2 Separation of mixed MTZ sensitive and resistant populations
MTZ-R sub-populations were separated from MTZ-S sub-populations by subculture 
on MTZ CBA plates (8 pg/ml) under standard microaerobic growth conditions. To 
obtain a pure culture of MTZ-S sub-populations, sterile velvet blots were applied to 
the surface of a CBA plate of well-separated mixed culture colonies and replicate 
plates of this were prepared on CBA and MTZ CBA. Following incubation 
(microaerobically at 36°C for 48 h) and comparison of plates, MTZ-S colonies that 
grew on the CBA but not on MTZ CBA were identified and subcultured on CBA for 
storage. Purity of MTZ-S populations was confirmed by demonstration of an inability 
to grow on MTZ CBA. Stock cultures of all sub-populations were prepared as 
described in section 2.1.2.
2.9 Extraction of DNA from bacterial culture
DNA was prepared by a described method (Wilson 1987) that uses cetyltrimethyl- 
ammonium-bromide (CTAB) and organic solvents phenol and chloroform, to separate 
genomic DNA of lysed cells from other contaminating cellular components such as 
protein and polysaccharide.
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Briefly, bacteria, cultured as stated in section 2.1.2, were harvested and suspended 
in 900 pi saline (0.85 % w/v). Bacterial cells were pelleted by centrifugation (13 000 
g  for 5 min), and resuspended in 500 pi TE buffer - O.IM Tris, 0.05M EDTA, pH 8.0 
[Sigma Ltd]. Cells were lysed and contaminating protein degraded by the addition of 
30 pi SDS (10 % w/v) [BDH] and 5 pi proteinase K (25 mg/ml) [Sigma Ltd] 
respectively. The solution was mixed and incubated at 37 °C for 1 h until lysis was 
complete. DNA was retained in solution by the addition of 100 pi of NaCl (5 M) 
[BDH], and 80 pi of CTAB solution (10 % w/v CTAB in 0.7 M NaCl [Sigma Ltd]) 
was added to remove polysaccharide and protein contaminants. This was mixed and 
incubated at 65 °C for 10 min. Remaining impurities such as proteins were removed 
from the suspension by addition of chloroformiisoamyl alcohol (24:1 v/v) [Fluka 
Biochemica, Sigma Ltd] followed by centrifugation (13 000 g  for 5 min). The upper 
aqueous layer containing DNA was transferred to a new 1.5-ml polypropylene tube 
[Anachem Ltd, Luton, Bedfordshire, UK], phenol:chloroform:isoamyl alcohol 
(25:24:1) [Fluka Biochemica, Sigma Ltd] added, mixed and the solution centrifuged 
(13 000 g  for 5 min). The upper aqueous layer was transferred to a fi*esh tube and 
nucleic acid precipitated by the addition of 0.6 vol cold (- 20 °C) isopropanol [AnalR, 
BDH] and repeated tube-inversion. DNA was pelleted by brief centrifugation (10 000 
g  for 1 min) and washed in 1 ml of 70 % (v/v) ethanol [Molecular Grade, BDH] that 
was subsequently discarded. The DNA pellet was dried in a DNA 110 Speed Vac® 
vacuum drier [Thermosavant, Holbrook, New York, USA] and resuspended by 
incubation at 4 °C overnight in 100 pi sterile distilled water [Promega UK Ltd, 
Southampton, UK]. DNA was stored long-term at -20 °C.
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2.10 Quantification of extracted DNA
DNA extracted from culture was quantified by spectrophotometry. DNA absorbs 
light at a peak wavelength of 260 nm, where an optical density (OD) of one is 
equivalent to 50 pg/ml of double stranded DNA. Contaminating protein and other 
molecules such as RNA, and polysaccharide frequently remain in DNA extracts and 
have peak absorbances at 280 nm and 230 nm, respectively. By recording 
absorbances at all three wavelengths, the purity of a DNA preparation can be 
calculated by the OD ratio at 260 nm against 230 nm and 280 nm and the DNA 
concentration calculated on the basis of ODjeo measurements (Sambrook et a l 1989).
The spectrophotometer [Eppendorf BioPhotometer, Eppendorf, Cambridge, UK] 
was set to zero by absorbance measurement of sterile distilled water in a sterile 
disposable UVette® [Eppendorf]. Extracted DNA was diluted 1/100 in sterile 
distilled water [Promega UK Ltd] in a UVette® and the optical density recorded at 
230 nm, 260 nm and 280 nm, using the stored double stranded DNA program. DNA 
preparations were considered sufficiently pure if the ODjgo/zso ratio was > 1 .8  and the 
OD260/230 ratio was >2 .0 .
2.11 DNA Extraction from human biopsies
Three methods for DNA extraction from human biopsies were examined in this study.
2.11.1 Boiling method
DNA extractions were performed following a method described previously (Bickley 
et a l 1993). Biopsies were suspended in 300 pi sterile distilled water, agitated by 
vortexing for 1 min, then incubated at 100 °C for 10 min and centrifuged at 14 000 g.
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2.11.2.1 Digestion method
Genomic DNA was extracted from human gastric, bladder and colonic biopsies using 
a modification of a described method (Marais et a l 1999). Briefly, biopsies were 
homogenised in Griffith’s tubes [Sigma Ltd] containing 400 pi sterile saline (0.85 % 
w/v), transferred to 1.5 ml tubes [Anachem] centrifuged (10,000 g  for 2 min) and the 
supernatant discarded. Pellets were resuspended in extraction buffer (20 mM TrisHCl 
[Sigma Ltd], pH 8.0, 0.5 % v/v Tween20 [BDH]) and proteinase K [Sigma Ltd] (0.5 
mg/ml), vortexed (5 s) and incubated at 56 °C for 1 h, then 100 °C for 10 min 
[Intelligent Heating Block, Hybaid Ltd, Ashford, Middlesex, UK]. DNA extracts 
were stored ( -20 °C) until required.
2.11.2.2 Sterilisation of Griffith’s tubes
Homogenisation tube components were sterilised after use by heating to 121 °C for 15 
min in an autoclave [Cabbum Sterilisers, Denley, Thermo Life Sciences, Basingstoke, 
Hampshire, UK]. Tubes were then washed with hot water and detergent, to remove 
residual biopsy material, rinsed in molecular grade water and immersed in 
depurinating solution (1 M HCl, [BDH]) for 1 h to degrade any potentially 
contaminating DNA. Following three washes in molecular grade water, tubes were 
air dried, wrapped in aluminium foil and sterilised by incubation at 160 °C for 2 h in a 
hot air oven [Sanyo Gallenkamp, Loughborough, Leicestershire, UK].
2.11.3 Spin column method
It is well recognised that various blood components are potent inhibitors of Taq 
polymerase (Wilson 1997). As bronchial biopsies are highly vascular, DNA was 
extracted from these according to the manufacturer’s protocol [QIAGEN Ltd,
83
Materials and Methods
Crawley, West Sussex, UK] using the commercial QIAmp® DNA Mini Kit, designed 
specifically for extraction of tissue and blood products.
2.12 DNA extraction from stool specimens
Faecal specimens contain many substances that inhibit Taq polymerase and thus the 
PCR reaction (Wilson 1997). The chosen method of DNA extraction should aim to 
remove as much of these as is possible while still retaining high yields of template. 
The following methods were tested to establish the optimal method for extraction of 
H. pylori DNA.
2.12.1 Guanidium isothiocyanate/silica (or diatoms)
The chaotropic agent guanidium isothiocyanate (GuSCN) not only lyses cells but also 
inactivates nucleases - thus its use in DNA and RNA extraction is widespread (Pitcher 
et al. 1989). DNA binds silica or diatomaceous particles (diatoms) in the presence of 
high GuSCN concentrations and this approach was first described for DNA extraction 
from clinical samples by Boom et al in 1990. The two variations of the original 
method described, using either silica or diatoms, were evaluated during this study -  as 
was a further modification where the GuSCN buffer L6  contained milk to block 
binding of inhibitory substances to the silica or diatoms (Boom et al. 1999).
DNA was extracted from faeces using a modification of the method described 
(Boom et al. 1990). Briefly, 100-200 pi sample was added to 900 pi L6  buffer -  10 
M GuSCN, 0.1 M Tris HCl, pH 6.4, 35 mM EDTA, 2 % (w/v) Triton X-100 [Severn 
Biotech Ltd, Kidderminster, Worcestershire, UK] -  or modified L6  buffer containing 
skimmed milk powder (50 mg/ml) [Marvel] (Boom et al. 1999) and incubated at room 
temperature for 5 min. Insoluble faecal particles were sedimented by brief 
centrifugation (12000 g  for 15 s), the supernatant transferred to a fresh 1.5 ml tube
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[Anachem Ltd] and nucleic acids removed from solution by the addition of 100 pi 
coarse silica [Severn Biotech Ltd] or diatoms [Celite, Sigma Ltd UK] followed by 
vortexing and agitation at room temperature for 10 min. The silica (or diatoms) was 
pelleted by centrifugation (12 000 g for 15 s) and washed twice with 1 ml L2 buffer -  
10 M GuSCN 0.1 M Tris-HCl, pH 6.4 - [Severn Biotech Ltd], washed twice with 1 ml 
cold ethanol (80 % v/v) [Molecular Grade, BDH] then once with 1 ml cold acetone 
[AnalR BDH]. The pellet was dried (55 °C for 15 min), and nucleic acids dissociated 
from the silica/diatoms by incubation in 150 pi sterile distilled water [Promega UK 
Ltd] (55 °C for 5 min). The extracted DNA was transferred, following brief 
centrifugation, to a 0.5-ml tube [Anachem Ltd] and stored at -20 °C until required.
2.12.2 Spin Columns
Spiked stools were extracted by the commercial QIAamp® DNA Stool Mini Kit 
[QIAGEN Ltd], following the manufacturer’s protocol. The principle of this kit is 
similar to that of the method described in section 2.12.1, based on binding of DNA to 
silica in the presence of chaotropic salt. However the DNA is bound to a silica gel 
membrane in a mini-column format that facilitates the multiple rapid washing steps 
required before final DNA elution. Pre-treatment of specimens with the InhibitEX kit 
component allows adsorption of substances that may inhibit PCR or degrade DNA.
2.12.3 Automated DNA extraction (MagNA Pure)
The MagNA Pure system [Roche Diagnostics Ltd, Lewes, East Sussex, UK] is an 
automated means of DNA extraction that is based on similar principles to the Boom 
method, although guanidine hydrochloride is used instead of GuSCN. Bacterial cells 
are lysed and DNA stabilised by chaotropic salts and detergent, but an additional 
proteinase K step is included to degrade protein contaminants. Nucleic acids are then
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bound to the silica surface of magnetic glass particles and these are subsequently 
retained during a series washing steps by the application of a magnet to the reaction 
cartridge (Figure 2.1). Nucleic acid is subsequently eluted at an elevated temperature 
in elution buffer [Roche Diagnostics Ltd] and transferred to a cooling block. All 
processes are performed robotically, as illustrated in Figure 2.1.
1. Transfer o f  reagents into 
processing cartridge
3. Sequential transfer o f  reaction  
m ix to each reagent
5. Transfer o f  com plex to 
cartridge containing elution  
buffer
2. Transfer o f  lysed  sam ples into 
processing cartridge
4. Separation o f  magnetic 
particles/D N A  com plex from  
solution by application o f  magnet
6. Transfer o f  eluted, purified  
nucleic acid to storage cartridge
Figure 2.1 Illustration of the stages of nucleic acid extraction on the MagNA 
Pure System [Roche] (adapted from w w w .rocbe-applied-science.com l
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Two kits based on this principle, the MagNA Pure LC Total Nucleic Acid Isolation 
Kit and the MagNA Pure LC DNA Isolation Kit III (Bacteria, Fungi) [Roche 
Diagnostics Ltd], were evaluated for DNA extraction from stool samples. However, 
for the latter kit, specifically for bacterial DNA extraction, an additional pre-lysis step 
that included proteinase K digestion and heating of specimens (65 °C and 95 °C for 
10 min each) was required prior to loading samples onto the MagNA Pure instrument 
[Roche Diagnostics Ltd] for automated extraction. Aliquots (200 pi) of artificially 
seeded stool suspensions (10 % w/v) prepared in BB or in BB-milk [Marvel] solution 
(330 mg/ml) were extracted according to the manufacturer’s protocol for each kit.
2.13 Removal of PCR inhibitors
Faecal DNA extracts were processed by additional methods for further removal of 
PCR inhibitory substances.
2.13.1 Dilution
All faecal DNA extracts were diluted 1/10 in sterile distilled water [Promega UK Ltd] 
for PCR analysis. DNA extracted by the MagNA Pure LC DNA Isolation Kit III 
(Bacteria Fungi) [Roche Diagnostics Ltd] (section 2.12.3) were diluted 1/100 also.
2.13.2 Polyvinyl Pyrrolidone (PVP) treatment
PVP has been shown to remove some PCR inhibitors from faecal DNA extracts, 
probably by forming hydrogen bonds with phenolic compounds and other charged 
molecules (Lawson et a l 1997).
Faecal DNA extracts in this study were PVP-treated following the protocol 
described previously (Lawson et a l 1997). DNA extracts (50 - 150 pi) were mixed 
with 150 pi PVP/TE (10 % w/v) [Sigma Ltd] and incubated at room temperature for
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10 min. 100 pi ammonium acetate (2 M) [BDH] was added, mixed by vortexing (5 s) 
and DNA precipitated by incubation at -20 °C in 600 pi isopropanol [AnalR BDH] 
for 20 min followed by centrifugation (13000 g  for 10 min). After the supernatant 
was discarded, the DNA pellet was dried in a DNA 110 SpeedVac® vacuum drier 
[Thermosavant], reconstituted in 50 pi sterile distilled water and stored at -20 °C until 
further use.
2.14 Conventional PCR assays
PCR is a rapid, simple means of amplifying a specific gene to generate many 
thousands of copies. Specific oligonucleotide primers that flank the gene (or gene 
fragment) of interest bind to complementary sequences on the DNA template, 
allowing thermo stable DNA polymerase to extend the copy strand. This reaction is 
repeated 3 0 -4 0  times by thermal cycling, amplifying the target gene. A detailed 
explanation of PCR is provided in section 1.6.
2.14.1 Precautions against PCR contamination
Contamination of PCR reactions with extraneous PCR product (amplicon) or DNA 
can generate falsely positive results. All PCR reactions carried out in this study were 
subject to strict precautions to minimise this. The workflow was designed so that 
reactions were performed in a direction of low- to high-level risk of amplicon 
contamination, using designated pipettes and plastic consumables at each stage -  
sterile RNase and DNase free filtered tips were used throughout [RAININ Instrument 
Co. Inc, Leiden, The Netherlands]. PCR master mixes were prepared in a room free 
from DNA and PCR amplicons. Template DNA was then added in a separate 
laboratory where all DNA extractions had been performed but no amplicons had been
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handled. Thermal cycling and amplicon analysis was carried out in a separate 
designated laboratory. Template for the second round of nested PCR was added in a 
room separate from the area of routine amplicon analysis. In addition, all PCR 
experiments included a negative control tube containing sterile distilled water instead 
of template to ensure that amplicons were only generated from specific template DNA 
and not from extraneous contaminants.
2.14.2 Primer design
Primers were designed to target conserved regions of specific genes, identified by 
multiple gene alignments. Although primer sequences were limited in some cases by 
the availability of such conserved regions, where possible the basic rules of primer 
design were adhered to. Namely, primers ranged in length from 1 5 -3 0  bp, did not 
contain long runs of a single base or internal complementary sequences that could 
lead to secondary structure. Primers were not complementary to each other, so 
avoiding potential for primer dimer formation, and unbalanced G/C and A/T 
distributions were avoided, as was an overall low G + C content. As amplification 
starts at the 3’ end of the primer, this is the most important end for specific priming. 
The 3’ end was designed to minimise the possibility of secondary structure, or 
repetitive or palindromic sequence and primers were designed so that any unavoidable 
mismatches with the template, due to intrinsic heterogeneity, were positioned close to 
the 5’ end. Primer pairs were designed to have similar melting temperatures (Tm). 
Many different formulae are available to calculate primer Tm. In this study the 
formula Tm = 4 °C(G + C) + 2 °C(A + T), that is simple and accurate for Tm 
calculation of primers in the range 18 -  24 bp was applied (Suggs et a l 1981).
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2.14.3 Conventional block PCR reactions
PGR master mixes were prepared in a final reaction volume of 50 pi as described in 
Table 2.1, unless stated otherwise. Volumes per reaction were multiplied by the 
number of samples tested plus two extra reactions for an appropriate positive control 
(specific DNA) and for a negative control (distilled water). The manufacturers of 
individual PCR reagents stated in this section were used throughout this study. All 
PCR reactions were carried out in sterile RNase and DNase-free thin-walled 0.5-ml 
Thermo tubes [ABgene, Epsom, Surrey].
Table 2.1 Reaction conditions for conventional block PCR assays
Reagent [Manufacturer] Concentration Volume (pi) Final Concentration
Sterile distilled water 31.3
PCR Buffer* [Invitrogen] lOX 5.0 1 X
dNTPs [Invitrogen] 2 mM each 5.0 200 pM each
MgClz [Invitrogen] 50 mM 1.5 1.5 mM
Primer [MWGt] 20 pM each 1 .0 0.4 pM each
Taq polymerase [Invitrogen] 5U/pl 0 . 2 l U
Template DNA 2 0  ng/pl 5 1 0 0  ngt
*1 X PCR buffer is 20 mM TrisHCl, pH 8.4, 50 mM KCl, 0.2 % v/v glycerol. 
t[MWG Biotech UK Ltd, Milton Keynes, UK].
}5 pi DNA extract from clinical samples added (specific DNA concentration not 
known).
Unless otherwise stated, all reaction mixes were held for 5 min at a dénaturation 
temperature of 95 °C and target genes amplified by 35 cycles of dénaturation at 95 °C 
for 30 s, annealing for 30 - 60 s at an annealing temperature (Ta) based on the melting
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temperature (Tm) of the specific primer, and elongation at 72 °C for 45 - 60 s. Strand 
extensions were completed by a final 5-min incubation at 72 °C. Thermal cycling for 
detection assays (section 2.16) were carried out in a PCR Sprint thermal cycler 
[Hybaid Ltd]. With the exception of the vacA genotyping multiplex assay (section
2.18.1.2) that was performed in a DNA Engine [MJ Research, Genetic Research 
Instrumentation Ltd, Braintree, Essex], all other assays described in sections 2.15 - 
2.18 were performed in both models of thermal cycler.
2.14.4 PCR modifications for analysis of highly inhibitory specimens 
Binding of inhibitory substances to Taq DNA polymerase can be blocked by the 
inclusion of Bovine Serum Albumen (BSA) in the PCR reaction mix. In cases where 
specimens are particularly inhibitory, Taq polymerase can be replaced with Tth DNA 
polymerase that is less sensitive to such effects. Combination of these approaches has 
been shown to reduce the effects of PCR inhibitors in a range of specimens including 
stools (Abu al-Soud and Radstrom 1998). PCR reactions were prepared as described 
in Table 2.2 but were otherwise processed as stated in section 2.14.3. These modified 
conditions were used for analysis of DNA extracted firom stools by the MagNA Pure 
LC DNA kit III (Bacteria) [Roche Diagnostics Ltd] (section 2.12.3) that had been 
further processed as described in section 2.13.
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Table 2.2 Reaction conditions of PCR using Tth polymerase
Reagent [Manufacturer] Concentration Volume (pi) Final Concentration
Sterile distilled water 29.6
Chelate PCR Buffer* [Promega Ltd] 10 X 5.0 I X
dNTPs [Invitrogen] 2 mM each 5.0 200 pM each
MgClj [Promega Ltd] 50 mM 2.5 2.5 mM
Primer [MWG] 20 pM each 1.25 0.5 pM each
BSA, acetylated [Promega Ltd] 0.2 0.4 %
Tth polymerase [Promega Ltd] 5U /p l 0.2 l U
Template DN A (faecal extract) 5
*1 X  chelate buffer is -  lOmM Tris-HCl, pH 8.3, 100 mM KCl, 0.75 mM EGTA, 0.05 % 
(v/v) Tween 20 and 5 % (v/v) glycerol
2.14.5 Applications of conventional block PCR
In the course of this study, PCR was applied in the following four main areas:
i) Evaluation of DNA extracts from clinical samples for residual substances 
inhibitory to the PCR reaction.
ii) Detection of species of Helicobacter from a range of clinical samples.
iii) Investigation of H. pylori antibiotic resistance genes.
iv) Investigation of virulence potential of H. pylori strains.
Details of the assays applied will be provided in subsequent sections 2.15-2 .18.
2.15 Internal control PCR
PCR can be inhibited by a wide range of substances found in clinical specimens, such 
as haem, urea or bile acids and salts (Wilson 1997). Failure of an extraction method 
to remove such material from a DNA preparation could potentially lead to the
92
Materials and Methods
generation of false-negative results. Internal control PCR assesses extracted samples 
for presence of PCR inhibitors. Primers were selected to amplify an endogenous 
target that was always present in the specimen, regardless of patient disease status. 
Specific amplicon should always be generated, and failure to do so indicates presence 
of residual PCR inhibitors in the specimen extract.
2.15.1 Human mitochondrial PCR
All tissue specimens of human origin will contain the human mitochondrial 
cytochrome oxidase subunit 3 gene. DNA extracts from human gastric, bladder, 
colonic and bronchial biopsies were initially tested by a PCR assay using the primer 
pair H6 A and H6 B (Table 2.3) that amplifies this target (Cadieux et a l 1993), as an 
internal control to ensure that extraction methods applied were sufficient to remove 
PCR-inhibitory substances.
2.15.2 Universal prokaryote-specific PCR
DNA extracts from stool specimens contain large amounts of nucleic acid from a wide 
range of bacterial species, as well as numerous PCR inhibitors. The primer pair 
Epsilon (e) and 1510 (Table 2.3) target a region of the 16S rRNA gene that is 
universally conserved in bacterial species (Gibson and Owen 1998). All stool DNA 
extracts were analysed by this internal control assay, to compare efficacy of different 
extraction methods and post-extraction modifications described in sections 2 . 1 2  and 
2.13, respectively, for removal of PCR inhibitors.
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Table 2.3 Details of primers, annealing temperatures (Ta) and amplicon 
sizes of internal control PCR assays for analysis of human biopsy
and stool specimen DNA extracts.
Target
gene
Primer Sequence 
name (5' -> 3')
Ta
CC)
Amplicon 
size (bp)
Human tissue-specific
Cytochrome
oxidase
H6A ATG ACC CAC CAA TCA CAT GCC TAT CA 
H6B a c t  AGT TAA TTG GAA GTT AAC GGT ACT A
55 823
Universal prokaryote-specific
16SrRNA S AAG AGT TTG ATC ATG GCT GAG 
1510 GGT TAG CTT GTT ACG ACT T
50 1462
2.16 PCR detection assays
Thirteen PCR detection assays amplifying five different target genes were applied in 
the course of this study. These were either uniplex, single-round format (n = 9), 
nested format (n = 3) or multiplex single-round format (n = 1). The principles of 
these different formats have been described earlier (section 1.6 ). Assays were 
selected, or new tests designed, according to the required application, while different 
target genes were selected after consideration of the relative merits of each.
2.16.1 16S rRNA genes
The rationale of 16S rRNA as a potential target for genus and species-specific PCR 
assays has been discussed in section 1.7.1. A number of published and novel 16S 
rRNA specific PCR assays were applied in the course of this study as follows:
2.16.1.1 Helicobacter genus-specific assays.
Prokaryote-specific primers C70/B37, previously applied in the characterisation of H. 
bills (Fox et al. 1995), and published Helicobacter-speciûc primer pairs HGF/HGR
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(Bohr et a l 1998) and H297F/1026R (Logan et a l 2000) (Table 2.4) were applied to 
detect helicobacters in bladder, colonic and bronchial biopsies. The latter PCR assay, 
described by Logan et al (2000), was also applied to stool DNA extracts in both a 
single-round format and as the first round of a nested PCR assay (section 2.16.1.3).
2.16.1.2 H. pj/on-specific PCR assay (single round format)
The published primers Hpl and Hp2 (Ho et a l 1991) (Table 2.4) were initially 
applied to gastric biopsies and the performance compared with other H. pylori specific 
assays. This assay was subsequently applied to bladder, colonic and bronchial 
biopsies and to stool samples.
2.16.1.3 H. py/on-specific PCR assay (nested format)
Stool DNA extracts were examined for H. pylori by combining two assays targeting 
16S rDNA in a nested format. In the first PCR round, the Logan assay described in 
section 2.16.1.1 (primer pair H277F/H1026R, Table 2.4) was applied to amplify 
Helicobacter-speciûc DNA. The resultant amplicon was the template for the second 
PCR round using the H. j^y/on-specific Ho assay (primer pair Hpl/Hp2, Table 2.4) 
described in section 2.16.1.2. To prevent carry-over of first-round primers, reaction 
conditions of the second PCR round were modified so that less template (0.5 pi) was 
added to reaction mix (49.5 pi). The volume of water added to each reaction was 
adjusted accordingly so that reagent concentrations remained constant.
2.16.1.4 HHLO-specific PCR (HHLO-16)
Primers (HeilF and HeilR, Table 2.4) for a novel PCR assay that could detect all 
HHLOs (defined in section 1.13.2) were designed following in silico alignment in 
GeneBase version 1.0 [Applied Maths, Kortjivik, Belgium] of 51 16S rRNA gene 
sequences fi"om 19 species of Helicobacter held in public databases [Entrez
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nucleotide, includes GenBank, RefSeq and PDB, http://www.ncbi.nlm.nih.gov] 
(Appendix B.2). This assay was applied to human and feline gastric biopsies, and the 
performance was compared with an existing published assay targeting the urease B 
(ureB) gene (section 2.16.2.2).
Table 2.4 Details of primers, annealing temperatures (Ta) and product sizes 
of PCR detection assays amplifying 16S rRNA genes.
Assay
specificity (*)
Primer
name
Sequence 
( 5 '^ 3 0
Ta
CC)
Amplicon 
size (bp)
Prokaryote C70
B37
AGA GTT TGA TYM TGG C 
TAG GGY TAG CTT GTT ACG A
50 1505
Helicobacter HOF
HGR
CGC GTG GAG GAT GAA GG 
GGT GCA GCA CCT GTT TTC
58 639
Helicobacter
(nl)
H297F
H1026R
GGC TAT GAG GGG TAT CCG GC 
GCC GTG GAG CAC CTG TTT TC
58 749
H. pylori 
(n2)
Hpl
Hp2
CTG GAG AGA CTA AGC CCT CC 
ATT ACT GAG GCT GAT TGT GC
60 109
HHLOt HeilF
HeilR
AAG TCG AAC GAT GAA GCC TA 
ATT TGG TAT TAA TCA CCA TTT C
53 112
* n l and n2 denotes primers also used in first and second round of nested PCR, 
respectively
"[Novel primers designed for this study
2.16.2 Urease genes
As discussed in section 1.7.2, urease genes have frequently been targets for specific 
PCR assays in Helicobacter.
2.16.2.1 H. pylori-speciüc assay (glmM)
As described in section 1.7.2.2, the PCR assay of Brisou et al (1990) was originally 
thought to target a urease gene. For this reason, this assay has been described in this
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section, although ureC has since been renamed glmM  (De Reuse et a l 1997). This 
assay was applied, using primer pair ureCF/ureCR (Table 2.5), to detect H. pylori in 
the initial phases of PCR-based analysis of gastric biopsies, and the performance 
compared with other 77. pylori specific assays targeting 16S rRNA genes (section
2.16.1.2) and vacA (section 2.16.3.1).
2.16.2.2 heilmannW-spQCiÜQ, assay
A published assay using a primer pair (ureBHeilF/ureBHeilR, Table 2.5) that 
amplifies an ‘H. heilmannii ' specific fragment of the ureB gene was applied following 
the protocol described (Neiger et a l 1998). PCR conditions were similar to those 
described in section 2.14, except that 2.5 U of Taq polymerase was included in each 
reaction and thermal cycling conditions comprised one cycle of dénaturation, 
annealing and extension at 94 °C for 3 min, 57 °C for 2 min and 72 °C for 3 min, 
respectively followed by 31 cycles of 94 °C for 30 s, 57 °C for 30 s and 72 °C for 1 
min and a single final 5-min extension at 72 °C. Performance of this assay was 
compared with that of the novel HHLO-16 assay (section 2.16.1.4) by application to 
human and feline gastric biopsies.
2.16.2.3 H, /e//s-specific assay
The published H. felis-spQcific PCR assay, where primer pair ureBFelF/ureBFelR 
(Table 2.5) amplified regions of the ureB gene was performed following the stated 
protocol as described in section 2.16.2.2 (Neiger et a l 1998). This assay also was 
applied to human and feline gastric biopsies to evaluate the specificity of the novel 
HHLO-16 assay described in section 2.16.1.4.
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Table 2.5 Details of primers, annealing temperatures (Ta) and amplicon 
sizes of PCR detection assays amplifying urease genes
Target Prim er 
Gene name
Sequence 
(S '-^ 3 ')
Ta
CC)
Amplicon  
size (bp)
H. pylori -specific
glmM ureCF 
(-'ureC ’) ureCR
AAG CTT TTA GGG GTG TTA GGG GTT T 
AAG CTT ACT ACT TTC TAA CAC TAA CGC
55 294
‘H. -specific
ureB ureBHeilF 
ureBHeilR
GGG CGA TAA AGT GCG CTT G 
CTG GTC AAT GAG AGC AGG
57 580
H. yè/w-specific
ureB ureBFelF 
ureBFelR
ATG AAA CTA ACG CCT AAA GAA CTA G 
GGA GAG ATA AAG TGA ATA TGC GT
60 1150
2.16.3 Vacuolating cytotoxin {vacA) gene
As discussed in section 1.12.1, virtually all strains of H. pylori possess the vacA gene 
(Xiang et al. 1995). As vacA is found in H. pylori only, this is a potentially highly 
specific target for a PCR-based detection assay. Numerous partial and complete vacA 
gene sequences are available in public databases, facilitating design of primers. 
Alignment of vacA genes demonstrates that some regions such as the mid-region are 
highly diverse, but that other more conserved areas are potential regions for primer 
design.
2.16.3.1 H, p^Wf-speciflc assay HpVac (single round format)
Primers vac3624F and vac3853R (Table 2.6) for this novel assay were designed by 
multiple alignment and analysis of the 30 complete sequences of vacA that were 
available in the public databases at the time [Entrez nucleotide] (Appendix B .l). All
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alignments were performed in GeneBase version 1 [Applied Maths], Gastric, bladder, 
colonic and bronchial biopsies as well as stool specimens were analysed by this assay.
2.16.3.2 H, py/ori-specific assay (nested format)
DNA extracted from stool samples were analysed by a nested-format PCR assay. 
Specific DNA fragments were initially amplified by primers vac3533F and vac4041R, 
also designed by multiple alignment of the 30 sequences listed in Appendix B .l, 
(Table 2.6) and 0.5 pi of the resultant amplicon was added to 49.5 pi reaction mix 
containing internal primers vac3624F and vac3853R (Table 2.6).
2.16.4 Multiplex JT. pylori and HHLO-specific assay (HpHh)
Two assays targeting vacA and 16S rRNA genes, described in section 2.16.3 and 
2.16.1.4, respectively, were combined to create a novel multiplex assay (HpHh) that 
could detect either H. pylori or HHLOs. PCR reactions were performed as described 
in section 2.14.3, except that 0.6 pM (each) primer HeilF and HeilR (Table 2.4) and 
0.28 pM (each) primer vac3624F and vac4041R (Table 2.6) were added. The volume 
of sterile water added was adjusted accordingly to give a final reaction volume of 50 
pi. Following dénaturation at 95 °C (5 min), specific targets were amplified in the 
reaction mix through 35 cycles as follows: 94 °C for 30 s, 54 °C for 30 s and 72 °C 
for 45 s each; extension was completed at 72 °C for 5 min. This assay was applied to 
human and feline gastric biopsies as well as to human bladder, colon and bronchial 
biopsies. Amplicons were separated by gel electrophoresis as described in section 
2.19, except that the agarose concentration was 2  % (w/v), to prevent diffusion of the 
small 112-bp HHLO fragment.
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Table 2.6 Details of primers, annealing temperatures (Ta) and amplicon 
sizes of novel H, pylori-spQciüc PCR detection assays amplifying 
vacA
Prim er
name
Sequence 
(S '-^ 3 ')
Ta
(°C)
Am plicon  
size (bp)
*Assay
Form at
vac3624F
vac3853R
GAG CGA GCT ATG GTT ATG AC 
ACT CCA GCA TTC ATA TAG A
53 230 Single-round 
& nested
vac3624F
vac4041R
GAG CGA GCT ATG GTT ATG AC 
CAT TCC TAA ATT GGA AGC GAA
54 417 Multiplex
vac3533F
vac4041R
GGA GTG ATC AAT CAA GCT TGA 
CAT TCC TAA ATT GGA AGC GAA
53 509 First round o f  
nested
^Different primer combinations used for assays described (sections 2.16.3 and 2.16.4)
2.16.5 Specific 26 kDa antigen (ahpQ
As discussed earlier (section 1.7.3), this 26 kDa protein was originally thought to be 
unique to H. pylori (O'Toole et a l 1991) and so was considered a suitable target for 
development of specific PCR assays (Hammar et a l 1992;Makristathis et a l 1998). 
The protein has subsequently been identified as an alkyl hydroperoxide reductase 
(encoded by gene ahpC) (Lundstrom and Bolin 2000) and has been found in other 
helicobacters, including H. cinaedi, H. fennelliae and H. pullorum (Lundstrom et a l 
2001).
2.16.5.1 H, /ij/ori-specific assay (hemi-nested format)
DNA extracts from stools were analysed by a hemi-nested PCR assay described 
previously for this application (Makristathis et a l 1998). The first round of PCR, 
using primers SA-F (5’ - TGG CGT GTC TAT TGA CAG CGA GC - 3’) and SA-R 
(5’ - CCT GCT GGG CAT ACT TCA CCA TG - 3’) was carried out using a
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modification of the original protocol (Hammar et a l 1992). Reagent concentrations 
differed from those outlined (Table 2.1) in that reactions contained 100 pM (each) 
dNTP, 0.1 pM (each) primer and 2.5 mM MgClj. Specific DNA fragments (281 bp) 
were amplified after dénaturation (95 °C for 5 min) by 38 cycles of incubation at 6 8  
°C (1 min) and 92 °C (30 s), followed by six cycles where an extension step (72 °C 
for 2  min) was inserted between the annealing and dénaturation steps.
Amplicon (0.5 pi) from the first round PCR was added as template to the second 
round PCR that amplified specific DNA using SA-F and primer SA-R2 (5’ - TGA 
TCA CTG CAT GTC TTA CTT TCA TGT TTT T - 3’) according to the described 
protocol (Makristathis et a l 1998). Assay conditions differed from those described 
earlier (2.14.3) in that reactions contained 100 pM (each) dNTP, 0.1 pM (each) 
primer, 2.5 mM MgClj and 0.5 U Taq DNA polymerase. Following dénaturation (94 
°C for 5 min), DNA fragments (209 bp) were amplified during 30 cycles of 
dénaturation, annealing and extension at 94 °C (30 s), 6 8  °C (1 min) and 72 °C (45 s), 
respectively. Extension was completed by a final incubation at 72 °C for 5 min.
2.17 Conventional PCR assays for investigating H, pylori MTZ resistance 
genes
The contribution of genes rdxA.frxA and ahpC that encode oxygen-insensitive 
NADPH nitroreductase, NADPH flavin oxidoreductase and alkyl hydroperoxide 
reductase, respectively, to MTZ resistance was examined in a strain set comprising 13 
paired isolates recovered from dyspeptic patients before and after specific eradication 
therapy, four isolates recovered pre-treatment from the gastric antrum of patients and
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four patient isolate pairs cultured from the gastric antrum and the gastric corpus, pre­
treatment. These genes were also analysed in the separated MTZ-S and MTZ-R sub­
populations (section 2.8.2) observed in 11/21 patients. Thus, 50 isolates were 
investigated in total.
2.17.1 rdxAVCR
A  6 8 6 -bp fragment of DNA containing all 630 bp of the rdxA gene was amplified 
from DNA of 50 isolates from 21 patients by the primer pair rdxF863 (modified from 
a primer of Jenks et al. (1999) and the novel primer rdxR1544 (Table 2.7). Primer 
rdxR1544 was designed for this study by multiple alignment of six rdxA gene 
sequences (Appendix B.4) in GeneBase version 1 [Applied Maths] held in public 
databases [Entrez nucleotide] at the time. All amplicons were purified by the protocol 
described for the Wizard® PCR Preps kit [Promega UK Ltd] in section 2.22.1. rdxA 
PCR products were either quantified and sequenced in-house (n= 23) following the 
method described in section 2 . 2 2  or were sequenced commercially by companies 
MWG Biotech Ltd [Germany] (n=l 1) and Cytomyx [Cambridge, UK] (n=16).
2.17.2 frxA PCR
All 651 bp of frxA was sequenced by PCR amplification of two overlapping fragments 
of the gene. Different combinations of the primers pairs EFR-l/BFR-3 and EFR- 
2/BFR-4 (Kwon et al. 2001), frxA-F/fi%A-R (Jeong et al. 2001) and novel primers 
fi%A2-F/fi%A2-R (Table 2.7) were necessary to amplify PCR products in 48 isolates. 
The latter primer pair was designed later in the study, by multiple alignment of 16 
frxA  genes that had been sequenced earlier. The two fragments offrxA were amplified 
by primers EFR-l/BFR-3 and EFR-2/BFR-4 in 30 isolates, by primers fi%A-F/BFR-3
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and EFR-2/BFR-4 in 13 isolates, by primers EFR-l/BFR-3 and fixA2-EfixA2-R in 
three isolates and by primers EFR-l/BFR-3 and EFR-2/fixA-R in two isolates. The 
same Ta was used during thermal cycling for all primer combinations (Table 2.7). All 
PCR products were purified in MultiScreen®-PCR plates [Millipore Ltd, Watford, 
UK], quantified and sequenced following the protocols described in section 2.22.
2.17.3 ahpC VCK
A 542-bp firagment of the 591-bp ahpC gene was amplified in all 50 strains from 21 
patients by the primer pair H26F/H26R (Table 2.7) described previously (Lundstrom 
et a l 2001). All products were purified in MultiScreen®-PCR plates [Millipore Ltd], 
and sequenced as described in section 2 .2 2 .
Table 2.7 Details of primers, annealing temperatures (Ta) and amplicon 
sizes of PCR assays used to investigate the contribution of rdxAy 
frxA and ahpC to MTZ resistance in H. pylori
Target
gene
Prim er
name
Sequence
(5 '-> 3 ')
Ta
CQ
A m plicon  
size (bp)
rdxA* rdxF863
rdxR1544
TTA GGG ATT TTA TTG TAT GCT A 
TCA CAA CCA AGT AAT TGC ATC AA
53 686
frxA EFR-1
BFR-3
TCT CAA GCG GAA AAA TCC GG 
AAT TTT TGA TGA TTT GAG CG
48 445
frxA EFR-2
BFR-4
ATT ATG ACA CTA ATT CTA GG 
CTA ACG CCA AGC TTT TTA TG
48 388
frxA FrxA-F
FrxA-R
GGA TAT GGC AGC CGT TTA TCA TT 
GAA TAG GCA TCA TTT AAG AGA TTA
48 780
frxA* FixA2-F
FrxA2-R
AGG TTC GCT CAA ATC ATC A 
TTC AAT CAC TTC ATA AAT AAC
48 315
ahpC Hp26F
Hp26R
TTA GTT ACA AAA CTT GCC CC 
GCT TTC ATC CCT TTA TCG CC
53 542
*Novel PCR primers designed for this study
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2.18 Conventional PCR assays for investigation oiH, pylori virulence potential
Two loci, vacA and cagA, that may be associated with H. pylori virulence were 
examined in this study.
2.18.1 Vacuolating cytotoxin {yacA)
As discussed in section 1.12.1, vacA has a mosaic structure comprising two families 
of allelic variants at the signal sequence region (si, s2) and at the mid-region (ml, 
m2) (Atherton et a l 1995). Some specific combinations of these families {vacA 
genotype) may enhance virulence potential of H. pylori (Atherton et a l 1995).
2.18.1.1 vacA genotype determination (uniplex format)
Signal and mid-regions of vacA were amplified from culture or gastric biopsy extracts 
in separate uniplex assays by primer pairs VAI-FA7AI-R and VAG-F/VAG-R (Table 
2.8), respectively that had been described previously (Atherton et a l 1999).
2.18.1.2 vacA genotype determination (multiplex format)
The primers used in separate assays (section 2.18.1.1) were combined in a novel 
multiplex format and conditions optimised to allow co-amplification of both regions 
of vacA. PCR reagent concentrations were as described (section 2.14.3), except that 
MgClj concentration was raised to 2.0 mM, and concentrations of primer pairs VAl- 
FW Al-R and VAG-F/VAG-R were 0.3 pM (each) and 0.48 pM (each), respectively. 
PCR products were separated by gel electrophoresis as described in section 2.19, 
except that the agarose concentration was 2 % (w/v), to improve separation of the 
different amplicon sizes.
2.18.2 Cytotoxin associated gene {cagA)
Approximately 70 % of H. pylori strains possess the cagA gene (Owen et a l 2001). 
This study investigated the potential involvement of this gene in bacterial virulence.
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2.18.2.1 Amplification of cagA from gastric biopsies
H. j9y/ori-positive gastric biopsies were screened for the cagA gene by a PCR assay 
described previously using primer pair D008/R008 (Table 2.8) (Covacci and Rappuoli 
1996). Following a 5-min incubation at 94 °C fragments of cagA were amplified by 
38 cycles of dénaturation, annealing and extension at 94 °C (1 min), 60 °C (1 min) 
and 72 °C (1 min), respectively. A final cycle of 94 °C for 1 min, 60 °C for 1 min and 
72 °C for 5 min completed the reaction (Covacci and Rappuoli 1996).
2.18.2.2 Amplification of cagA tyrosine phosphorylation motif (TPM) regions 
Three regions of the cagA gene, proposed to contain the putative TPMs A, B and C 
(Odenbreit et al. 2001) discussed in section 1.12.2, were amplified by novel primer 
pairs MotAF/TPMAR, MotBF/MotBR and MotCF/MotCR, respectively (Table 2.8). 
Twenty-six TPM A, two TPM B and nine TPM C amplicons were purified, quantified 
and sequenced following the protocol described in section 2.22. TPM B fragments 
from four other strains that had given equivocal results by the assay described in 
section 2.20.7 were sequenced commercially [MWG Biotech Ltd].
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Table 2.8 Details of primers, annealing temperatures (Ta) and amplicon
sizes of PCR assays used to investigate vacA and cagA as markers 
of H, pylori virulence potential
Target Primer Sequence Ta Amplicon
gene name (5 '^ 3 ') (°C) size (bp)
vacA VAGF
VAGR
CAA TCT GTC CAA TCA AGC GAG 
GCG TCA AAA TAA TTC CAA GG
53 570/645
vacA VAIF
VAIR
ATG GAA ATA CAA CAA ACA CAC 
CTG CTT GAA TGC GCC AAA C
53 259/286
cagA D008
R008
ATA ATG CTA AAT TAG ACA ACT TGA GCG A 
TTA GAA TAA TCA ACA AAC ATC ACG CCA T
60 298
cagA* CagMotAF
TPMAR
GAT AGG GAT AAC AGG CAA G 
CCT GCA AAA GAT TGT TTG GC
53 356
cagA* CagMotBF
CagMotBR
AAC CCT AGT CGC TAA TGG 
GCA ACT TGA GCG TAA ATG G
51 216f
cagA* CagMotCF
CagMotCR
CAA GCG GTA TCA GAA GCT A 
TTA ATG CGT GTG TGG CTG TT
53 179
*Novel PCR primers designed in this study
"[Product size varied as some strains have insertions in this region of the cagA gene
2.19 DNA electrophoresis
DNA fragments and amplicons were separated by agarose gel electrophoresis and 
visualised by ethidium bromide staining. The DNA molecule possesses a net negative 
charge and will therefore migrate towards the positively charged anode in an electric 
field. Rate of migration of a molecule is inversely proportional to its mass, so smaller 
DNA fragments of faster mobility can be separated from larger molecules. Mobility 
of DNA during electrophoresis is also affected by temperature, ionic strength, voltage 
applied, and by the concentration and pore size of the separating matrix. The mobility 
of molecules in an individual gel can be calibrated by the inclusion of a molecular 
weight standard comprising DNA fragments of known size. Size of unknown DNA
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can therefore be determined by comparison with standard fragments’ mobility 
(Sambrook fl/. 1989).
Unless stated otherwise, all DNA fragments and amplicons were electrophoresed in 
a 1.0 % (w/v) agarose gel [UltraPure, Invitrogen]
Small (8 cm x 6cm), medium (14 cm x 11 cm) and large gels (24 cm x 20cm) were 
prepared by the addition of 0.3 g, 0.8 g and 2.0g agarose to 30 ml, 80 ml and 200 ml 
TBE Buffer (0.1 M Tris, 0.09 M boric acid, 0.001 M EDTA) [Invitrogen], 
respectively. Agarose was melted in a microwave oven [Deltawave, Toshiba] for 2 -
3.5 min, depending on gel size, poured into the appropriate gel casting tray 
[Invitrogen] on a level surface and left at room temperature until set. Well combs 
were removed and gels transferred to an electrophoresis tank [Horizon®58 or 20.25, 
Invitrogen or H5, Bethesda Research Life Technologies Inc, USA] containing TBE 
buffer.
DNA fragments and amplicons were mixed in a 5:1 ratio with 6 X stop solution 
(4.0 % w/v sucrose [Sigma Ltd], 0.25 % w/v bromophenol blue [BDH], 0.05 M 
EDTA, [Sigma Ltd]) and carefully added to the wells of the agarose gel. With the 
exception of agarose gels run for quantification purposes (section 2.22.2), 123 bp 
molecular weight marker [Invitrogen] was included in all gels run. Unless otherwise 
stated, gels were run at 100 V for 30-60 min.
Gels were stained by immersion in ethidium bromide (0.5 pg/ml) [Sigma Ltd] at 
room temperature for 15-30 min and photographed by digital camera on a Dual 
Intensity Ultraviolet Transilluminator [Ultra Violet Products, Upland, USA], for 
printing on thermal paper [Mitsubishi Electric Europe B.V., Hatfield, Herts, UK].
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2.20 Real-Time PCR assays
In this study, real-time PCR was performed using two different models of 
LightCycler, the Idaho Technology model LC32 [BioGene Ltd, Kimbolton, UK] and 
the Roche model [Roche Diagnostics Ltd] (Figure 2.2). The overall design of these is 
summarised in Figure 2.3.
Idaho T echnology LC32 m odel R oche D iagnostics Ltd m odel
Figure 2.2 The two models of LightCycler, by Idaho Technology and Roche.
Air inJet
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Stopper motor 
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CAMaintenance-free 
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Microvolume fluoriinetet wlUi 
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to position tfie 
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/P bo tododes
Figure 2.3 Schematic representation of the components of the LightCycler 
instrument (from the LightCycler Online Resource Site, www.roche- 
applied-science.com)
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As real-time PCR using both models of LightCycler was applied extensively in the 
course of this study, a detailed explanation of the principles and applications of this 
technology will follow
The major difference between the Idaho model and the Roche model of LightCycler 
relates to the fluorimeters in each. The Idaho model measures fluorescence at two 
channels, channel one (FI) is optimised to detect emissions from fluorescent dyes 
SYBR Green 1 or fluorescein (540 nm ± 20 nm) and channel two (F2) detects 
emissions from Cy 5 dye (670 nm ± 20 nm). In contrast the Roche LightCycler 
measures fluorescence at three settings, channel one (FI) has similar settings to 
measure fluorescence at 530 nm ±10  nm, but channel two (F2) and channel three (F3) 
are optimised to measure emissions of, respectively, LightCycler Red 640 dye at 640 
nm ±10  nm and LightCycler Red 705 dye at 710 nm ± 20 nm.
2.20.1.1 The principle of rapid PCR using the LightCycler 
Some real-time PCR instruments (e.g. the Taqman) use a conventional metal block for 
thermal cycling of reactions contained in a standard plastic microtitre plate. In 
contrast, LightCycler reactions are performed in glass capillaries that have a high 
surface area to volume ratio and instead of a metal block, thermal cycling is achieved 
by flushing the reaction chamber (Figure 2.3) with air of the appropriate temperature. 
These modifications allow rapid thermal cycling and rapid heat transfer to the sample, 
thereby reducing temperature transition and reaction incubation times. A major 
advantage of a PCR assay performed in the LightCycler is that it can be completed in 
as little as 30 min.
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2.20.1.2 The principle of real-time PCR
Amplicon generation in the LightCycler can be monitored either non-specifically or 
specifically. SYBR Green 1 does not emit fluorescence when free in solution, but can 
be excited to emit a fluorescent signal at 521 nm when non-specifically bound to 
double stranded DNA. By monitoring the level of SYBR Green 1 fluorescence at the 
end of each extension stage of thermal cycling, exponential increases in levels of 
double stranded DNA can be identified (Figure 2.4). This approach is simple and 
comparatively inexpensive, but does not distinguish between specific and non-specific 
amplification.
Specificity can be improved by the inclusion of two fluorescently labelled 
hybridisation probes in the reaction mix, to monitor PCR amplification. The probes 
are designed to complement adjacent specific sequences within the amplicon, one 
probe is labelled with a ‘donor’ fluorophore (e.g. fluorescein) at the 3’ end while the 
other probe is labelled with an ‘acceptor’ fluorophore at the 5’ end (e.g. Cy5, 
LightCycler-Red 640). Monitoring of the PCR reaction is based on the principle that 
close proximity of the two dyes during hybridisation to amplicon template allows 
fluorescence resonance energy transfer (FRET). Emissions firom the donor 
fluorophore, excited by the LightCycler, in turn excite the acceptor fluorophore to 
emit a signal, recorded by the LightCycler fluorimeter (Figure 2.5).
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Figure 2.4 Schematic representation of the principle of real-time PCR in the 
LightCycler in relation to amplification curves generated.
Increased amplicons levels represented graphically by increased SYBR 
Green 1 fluorescence. Ct = Crossover Threshold.
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Acceptor dye em its no fluorescence when not 
in proximity to the donor probe dye
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(recorded by LightCycler)
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Figure 2.5 Schematic representation of dual probes for monitoring PCR
ampHHcation on the LightCycler. Acceptor probe is only activated 
to emit fluorescenee by Fluorescence Resonance Energy Transfer 
(FRET) when hybridised to specific template, in close proximity to 
donor probe.
Increased signal, recorded at each annealing stage of thermal cycling, will only occur 
if specific probe hybridisation to increasing amplicon levels oceurs. However aside 
from the increased cost, one disadvantage of such an approach is that it requires prior 
knowledge of the amplicon internal sequence. Furthermore probes must complement 
areas that are highly conserved in all test subjects, which can be difficult to achieve in 
a highly heterogeneous species like H. pylori.
2.20.2 Further Analyses on the LightCycler
Unlike conventional PCR, most real-time PCR instruments also have the capacity for 
further amplicon analyses in the same reaction as the original amplification.
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2.20.2.1 Quantification
Monitoring of amplicon generation, either specifically or non-specifically, in real time 
also has the advantage that it can allow quantification of the original levels of specific 
DNA in a sample. During the early amplification cycles, amplicon levels and 
fluorescence are too low to be displayed by the LightCycler software. Exponential 
amplification is accompanied by exponentially increasing fluorescence that is 
detectable by the LightCycler and is subsequently represented graphically as a plot of 
increased fluorescence against cycle number (Figure 2.4). The point where 
fluorescence first enters exponential increase, the threshold crossing point (Cj), 
(Figure 2.4) relates to the number of starting target molecules. By generating a 
calibration curve based on the crossing points of standards of known concentration, 
the level of initial target in an unknown sample can be determined. This approach has 
been used for quantification of both bacterial (Huang et a l 2001) and viral pathogens 
(Furuta et a l 1996;Stocher and Berg 2002;White et a l 2002). An assay for H. pylori 
quantification in gastric biopsies was described recently, based on amplification of 
glmM  (He et a l 2002).
2.20.2.2 Mutation detection
The principle of mutation detection by the LightCycler is based on the altered stability 
of a probe-template hybridisation that results firom a single base pair mismatch. By 
monitoring the hybridisation stability (as indicated by the dissociation temperature) of 
a probe spanning a sequence containing the potentially mutated bases, unknown 
sequences can be screened rapidly for mutations. Exact complementarity between 
probe and template sequence will result in a stable hybrid that has the highest 
dissociation temperature. Mutated sequence will lower the stability of the
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hybridisation and so the probe dissociation temperature. The extent to which this 
temperature is lowered depends on the number, position and nature (purine or 
pyrimidine) of mutations in the sequence, as well as being influenced by the bases 
adjacent to the mutation.
Dissociation temperatures of specific probes can be determined in the LightCycler 
by performing a probe hybridisation melting point analysis after completion of PCR 
amplification. Reactions are first heated to 95 °C to denature all double stranded 
DNA and then cooled (40 -  50 °C) to allow specific probe hybridisation. The 
temperature is then slowly raised to 85 -  95 °C, while continuously monitoring 
fluorescence. Melting curves are plotted by calculating the first negative derivative (- 
dF/dT) of fluorescence versus temperature, as illustrated in Chapters 5, 7 and 10.
By labelling the probe with a fluorescent dye, changes in fluorescent emissions 
relating to probe dissociation can allow determination of probe melting temperature. 
Various different probe designs and formats are available for mutation detection, 
including bi-probes, dual probes, Taqman probes, molecular beacons and scorpions. 
However, bi-probes and dual probes are most commonly used for the LightCycler.
Bi-probes are so-named as they contain two different labels or modifications, a 
fluorescent dye at the 5’ end (e.g. Cy 5, LightCycler Red 640, LightCycler Red 705) 
and a modification at the 3’ end (e.g. biotin, phosphate group) to prevent spurious 
priming during the PCR. As illustrated in Figure 2.6, the fluorescent labels do not 
emit a signal when probes are free in solution, but probe template hybridisation 
creates double stranded DNA, allowing SYBR Green 1 excitation. The SYBR Green 
1 emissions activate the probe dye by FRET, and these activated fluorescent dye 
emissions are recorded by the LightCycler fluorimeter. Thus probe dissociation
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results in a rapid decrease in specific fluorescence (Figure 2.6). One major advantage 
of this format is that it requires only a single probe, reducing assay costs and 
complexity of optimisation. Additionally, as single probes span only a short sequence 
region (20 - 30 bp) it easier to design assays in poorly conserved genes. For these 
reasons, all the assays described and developed in this study used a bi-probe format. 
Bi-probe LightCycler assays have been described previously in medical bacteriology, 
for example to detect bacterial antibiotic resistance (Edwards et a l 2001; Walker et a l 
2001) and to differentiate Campylobacter species (Logan et a l 2001).
Two (dual) probes can also be used to detect mutations. The principle of the probe 
dissociation monitoring is similar to that described in section 2.20.1.2, except that the 
acceptor probe is designed to span the mutated sequence.
In this study, real-time PCR and probe hybridisation melting point analysis on the 
LightCycler was applied in the detection of mutations that may confer antibiotic 
resistance and to investigate the potential contribution of TPMs A, B and C in cagA to 
H. pylori virulence. The second round of nested assays (sections 2.16.3.2 and
2.16.5.1) were adapted for the LightCycler also.
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Materials and Methods
2.20.3 Preparation of LightCycler master mix
For LightCycler assays described in sections 2.20.5 and 2.20.6, stock master mixes 
were prepared in advance (Table 2.9). Master mixes were aliquoted into 50 pi 
volumes and stored (-20 °C) until required.
Table 2.9 Contents of LightCycler master mix
Reagent [manufacturer] Concentration Volume (pi) Final Concentration (2x*)
Sterile distilled water 68
PCR Bufferf [BioGene Ltd] lOX 25 2X
dNTPs [Invitrogen] 2 mM (each) 25 400 pM
MgCl2 [Invitrogen] 50 mM 5 6.0 mM
Platinum Taq [Invitrogen] 5U/pl 2 0.8 U
*Master mixes were diluted 1 in 2 for the final reaction mix described in section 
2.20.4.
tidaho technology buffer (1 X) comprises 50 mM TrisHCl, pH 8.3,2 mM MgClj.
2.20.4 Preparation of LightCycler assay reactions
Reaction mixes for real-time PCR assays described in sections 2.20.5 and 2.20.6 for 
both models of LightCycler [BioGene Ltd and Roche Diagnostics Ltd] were prepared 
as described in Table 2.10, except that for the Roche model, twice the volumes 
described were used, giving a final reaction volume of 20 pi instead of the 10 pi used 
in the Idaho model.
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Table 2.10 Contents of LightCycler assay reactions
Reagent [manufacturer] Concentration Volume (pi) Final Concentration
Master mix (Table 2.9) 2X 5.0 IX
Sterile distilled water 1.5
SYBR Green 1 [BioGene Ltd] 1/1000 1.0 1/10 000
Primers [MWG Biotech Ltd] 5 pM (each) 1.0 0.5 pM (each)
Probe [MWG Biotech Ltd] 5 pM 0.5 0.25 pM
Subsequent processing of reactions is described in sections 2.20.5 and 2.20.6.
2.20.5 Determination of clarithromycin (CLA) resistance by LC-CLA assay
Point mutations in the 23 S rRNA gene associated with the acquisition of CLA 
resistance were detected using a modification of an assay (designated LC-CLA) 
developed previously for the Idaho LightCycler (Gibson et al. 1999). Briefly, a 93-bp 
fi*agment of the 23 S rRNA gene containing the two adenine residues that can mutate 
to confer CLA resistance was amplified and probe melting point hybridisation 
analysis performed. The labelled bi-probe (23SPr) sequence was complementary to 
the wild type CLA sensitive 23 S rDNA sequence. Any resistant strains tested 
containing mutations A2142G, A2143G or A2142C would mismatch with this probe 
and lower the probe-template dissociation temperature, as described in section
2.20.2.2 and illustrated in Figure 2.6.
Reaction mixes (9 pi), prepared as stated in section 2.20.4, containing primers 23SF 
(5’- CAA CCA GAG ATT CAG TGA AA - 3’) and 23SR (5'- GTG CTA AGT TGT 
AGT AAA GGT - 3’) and fluorescently labelled probe 23SPr (5’- Cy5-GGC AAG 
ACG GAA AGA CCC-biotin - 3’) were mixed in the reservoir section of a glass 
reaction capillary [BioGene Ltd] with 1 pi of DNA (10 ng/pl) extracted from culture
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as described in section 2.9 or 1 pi of DNA extracted from gastric biopsies as described 
in section 2.11.2.1. Mixed reactions were then deposited in the glass capillary section 
of the reaction vessel by pulse centrifugation (2000 rpm) and placed in the 
LightCycler carousel (Figure 2.3) for amplification and probe hybridisation analysis. 
The thermal cycling and hybridisation conditions were as described previously 
(Gibson et al. 1999), but with the modification that amplification was increased to 75 
cycles (Table 2.11). Examples of a wild-type gene, an A->G and an A ^ C  mutation 
were included as controls in every run (Appendix A.2.1) to allow comparison with 
reactions of unknown 23 S rDNA sequence.
Table 2.11 LightCycler [BioGene] amplification and melting cycles for 
LC-CLA assay
Stage (no. of cycles) Target temp 
(°C)
Incubation 
time (s)
Temp transition 
rate (°C/s)
Dénaturation (1) 94 20 20
Amplification (75)* 92 0 20
50 0 20
55 0 3
72 5 20
Melting (l)f 92 0 20
40 10 20
90 0 0.4
Fluorimeter gains was set at 8 for both channel 1 and channel 2.
*Single fluorescent acquisition at the end of each extension (72 °C) stage. 
^Continuous fluorescent acquisition at temperature increment (40 -  90 °C) stage.
119
Materials and Methods
2.20.6 Identification of cagA TPMs A, B and C.
Three novel assays were developed for the LightCycler [Roche Diagnostics Ltd] to 
identify strains that contained the putative cagA TPMs A, B or C described earlier 
(section 1.12.2). Multiple alignment of six complete cagA sequences held in public 
databases [Entrez nucleotide] (Appendix B.3) was carried out in GeneBase [Applied 
Maths]. Primer pairs were designed for each assay (Table 2.12) by selecting conserved 
regions of cagA flanking the proposed TPMs, to generate cagA fragments containing 
the relevant TPM site. The sequences of probes MotAPr, MotBPr and MotCPr (Table 
2.12) were identical to the cagA sequences of strains that contained motifs A, B and C, 
respectively. Any strain that contained these motifs would have a higher melting curve 
peak than strains where the motif was absent. The position of primers and probes in 
cagA for each assay is illustrated in Figure 2.7.
Table 2.12 Details of primer and labelled probes for three novel cagA TPM 
detection assays for the LightCycler [Roche Diagnostics Ltd]
TPM Primer/Probe* Sequence (5' 3')
A CagMotAF
CagMotAR
MotAPr*
GAT AGG GAT AAC AGG CAA G 
GTG TTG ATT TTA GAC GGA TC 
Cy5-GAA ATT TGG GGA TCA GCG TTA C-biotin
B CagMotBF
CagMotBR
CagMotBPr*
AAC CCT AGT CGC TAA TGG 
GCA ACT TGA GCG TAA ATG G 
Cy5-AAT AAT GGA CTC AAA AAC AGC ACA GA-biotin
C CagMotCF
CagMotCR
MotCPr*
CAA GCG GTA TCA GAA GCT A 
TTA ATG CGT GTG TGG CTG TT 
Cy5-AGC TCA AAG ATT CTA CAA AAT ACA AT-biotin
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Materials and Methods
Reaction mixes (20 jxl) were prepared as stated in section 2.20.4 and contained the 
appropriate primers and probe for detection of either TPM A, B or C (Table 2.12).
These were mixed with 2 pi template DNA (10 ng/pl) or 2 pi gastric biopsy DNA 
extract (prepared as described in sections 2.9 and 2.11.2.1, respectively) and then 
processed as described in section 2.20.5. Fragments of cagA were amplified by PCR 
and screened for specific motifs by probe hybridisation melting point analysis under the 
appropriate cycling programme (Table 2.13). Control strains that contained the relevant 
motif (Appendix A.2.3) were included in every run for comparison of melting peaks.
Table 2.13 LightCycler [Roche Diagnostics Ltd] amplification and melting
cycles for cagA TPM (A, B and C) detection assays
Stage (no. of cycles)
Target temp Incubation time
(s)
Temp (°C/s) 
transition rate
A
Motif
B C
Motif
A B C A
Motif 
B C
Dénaturation (1) 95 10 20
Amplification (50)* 94 0 20
53 48 56 0 20
51 0 3
72 10 20
Melting (l)f 43 94 45 0 5 10 0
45 10 20
90 0 0.2 0.3 0.3
Cooling 30 30 20
Fluorimeter gains settings at each channel were FI = 20, F2 = 15, F3 = 50. 
*Single fluorescent acquisition at the end of each extension (72 °C) stage. 
"["Continuous fluorescent acquisition at temperature increment (45 -  90 °C) stage.
122
Materials and Methods
2.20.7 Detection offrxA frameshift mutation53
A novel assay (FS-53) was designed to detect a frameshift mutation in frxA  that 
results from deletion of a single adenine residue at nucleotide 53, to assess the 
significance of this in relation to MTZ resistance. Novel primers EFR-lmod (5’- TCT 
CAA GCG GAA AAA TCC - 3 ’) and fi%R(FS) (5’- ATC TTC TTT CAT GCG TTC 
A -3’) targeting conserved regions offrxA flanking nucleotide 53 were designed 
following multiple alignment of the frxA sequences determined in the course of this 
study, to amplify 265-bp gene fragments. Amplicons were screened for deletion 
mutation 53 by melting point analysis of a labelled probe FS-53Pr (5’- LC Red 640- 
ATT TGC TGC AAA AAA TAC GAT C-P -3 ’) that was designed to complement 
and span the mutated sequence. Amplicons containing this mutation generated a 
melting peak indicating a higher probe-template dissociation temperature than was 
observed for products lacking the deletion. This assay differed from those described 
in sections 2.20.5 and 2.20.6, as commercial FastStart DNA Master SYBR Green 1 
master mix was used according to the manufacturer’s protocol [Roche Diagnostics 
Ltd]. Briefly, 18-pl reactions containing, 1 X master mix [Roche Diagnostics Ltd], 6 
mM MgClz, 0.5 pM each primer [MWG Biotech Ltd], 5 pM probe [TIB MOLBIOL, 
Berlin, Germany] were mixed with 2 pi DNA (10 ng/pl) in the cup section of the glass 
reaction capillaries [Roche Diagnostics Ltd], and deposited in the capillary section by 
pulse centrifugation (2000 rpm) [Roche Diagnostics Ltd]. Following capillary 
loading of the LightCycler carousel [Roche Diagnostics Ltd] PCR products were 
amplified and probe hybridisation melting point analysis performed following the 
cycling conditions described (Table 2.14).
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Table 2.14 LightCycler [Roche Diagnostics Ltd] amplification and melting 
cycles for FS-53 assay
Stage (no. of cycles) Target temp 
(°C)
Incubation 
time (s)
Temp transition 
rate (°C/s)
Dénaturation (1) 95 600 20
Amplification (50)* 95 0 20
45 0 20
48 1 4
72 5 20
Melting (1) f 95 0 20
45 0 20
85 0 0.1
Cooling (1) 30 30 20
Fluorimeter gains settings at each channel were FI = 1, F2 = 12, F3 = 50. 
*Single fluorescent acquisition at the end of each extension (72 °C) stage. 
"["Continuous fluorescent acquisition at temperature increment (45 -  85 °C) stage.
2.20.8 Nested PCR amplifying Æ py/orf-specific 16S rDNA
The first round of 16S rDNA amplification was conducted as described (section 
2.16.1.3). Nested PCR was conducted in real-time on the LightCycler. First-round 
amplicon (0.5 pi) was mixed with reaction mix (19.5 pi) containing 1 X FastStart 
DNA Master SYBR Green 1 master mix [Roche Ltd], 3 mM MgClj and 0.3 pM 
(each) primer Hpl and Hp2 (Table 2.4). Reaction capillaries were filled by pulse- 
centrifugation (2000 rpm) and PCR products amplified following a 10-min incubation 
(95 °C), to activate hot-start Taq polymerase, by 50 cycles of dénaturation (95 °C for 
0 s), annealing (52 °C for 5 s) and extension (72 °C for 10 s). Amplicon generation 
was monitored by SYBR Green 1 fluorescence measurement at the end of each
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extension stage. This signal was subsequently measured continuously during 
amplicon melting points analysis over the temperature range 45 °C to 95 °C 
(temperature increment 0.1 °C/s).
2.20.9 Nested PCR amplifying H, py/on-specific ahpC
The second round of the ahpC nested PCR assay was adapted to a real-time format on 
the LightCycler. Following first-round PCR as described in section 2.16.5.1, 0.5 pi of 
amplicon template was mixed with 19.5 pi reaction mix, that was identical to that 
described above (2.20.8) except that 0.1 pM (each) primer SA-F and SA-R2 (section
2.16.5.1) was used. Nested amplicons were generated, following a 10-min incubation 
at 95 °C, by 50 cycles of dénaturation (94 °C for 0 s), annealing (62 °C raised to 64 
°C for 3 s) and extension (72 °C for 10s). Conditions for amplicon melting point 
analysis were identical to those described above (2.20.8).
2.21 Amplified Fragment Length Polymorphism (AFLP)
Restriction endonuclease (RE) enzymes cut DNA at specific recognition sequence 
sites, generating multiple fragments of varying size that can be separated by gel 
electrophoresis. The range and number of fragment sizes generated by this restriction 
fi*agment length polymorphism (RFLP) is sequence-dependent and can be used to 
distinguish organisms at the genus, species or intra-species level. RE digestion of 
bacterial genomic DNA can produce many fragments, leading to complex RFLP 
profiles that can be extremely difficult to interpret. In addition, large initial quantities 
of DNA are required for visualisation in a gel. AFLP is a PCR-based modification of 
RFLP, where, following RE digestion, specific adapter oligonucleotides are ligated to
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DNA fragment ends that can then be amplified by PCR, using primers complementary 
to the ligated adapters. This amplification increases sensitivity of the method and thus 
less initial genomic material is required. By extending primer sequences one specific 
base downstream of the adapter sequence, amplification can be tailored so that only 
fragments containing the base complementary to this will be amplified. This 
modification reduces the number of fragments amplified and thereby simplifies the 
profile generated to facilitate interpretation and definition of genotypes.
AFLP was performed following the method described by Gibson et al (1997). 
Aliquots (4 pg) of extracted genomic DNA were digested in a 20 pi reaction volume 
containing 1 pi 0.1 M spermidine trihydrochloride [Sigma Ltd], 2 pi 10 X React 2 
buffer [Invitrogen] and 2 pi restriction endonuclease Hindill (10 U/pl) [Invitrogen] at 
37 °C for 16 -18 h. A 5-pi aliquot of approximately 1 pg of digested DNA was then 
used in a 20 pi ligation reaction containing 0.2 pg of each adapter (ADHl 5’-ACG 
GTA TGC GAC AG-3’ and ADH2 5’-AGC TCT GTC GCA TAC CGT GAG-3’) 
[MWG Biotech Ltd] and lU  T4 DNA ligase [Invitrogen] in single strength ligase 
buffer (50 mM Tris-HCl, pH 7.6, 10 mM MgClj, 1 mM ATP, 1 mM dithiorthreitol,
5.0 % (w/v) polyethylene glycol-8000). Ligation occurred during incubation (3 h) at 
room temperature and T4 DNA ligase was inactivated by subsequent incubation at 65 
°C for 10 min. Digested ligated DNA was then diluted 1/5 (v/v) in distilled water and 
fragments of DNA to which adapters had been ligated were amplified in a 50-pl PCR 
reaction containing 5 pi of diluted digested ligated DNA, 200 pM (each) dNTPs 
[Invitrogen], 2.7 nM primer (HI-A 5’ GGT ATG CGA CAG AGC TTA 3’) [MWG 
Biotech], 1.5 mM MgCl; and 1 U of Taq polymerase [Invitrogen] in PCR buffer (20 
mM TrisHCl, pH 8.4, 50 mM KCl, 0.2 % (v/v) glycerol). The PCR reaction was
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incubated for 4 min at a dénaturation temperature of 94°C, followed by 33 cycles of 
dénaturation (94°C for 1 min), armealing (60°C for 1 min) and extension (72°C for 2.5 
min).
Fragments of amplified DNA were separated by electrophoresis in a 1.5 % (w/v) 
agarose gel at 100 V for 3 h 40 min and stained in ethidium bromide (0.5 pg/ml) 
[Sigma Ltd]. AFLP profiles generated were considered identical if  there were no 
differences between isolates and similar if  they differed by one band.
2.22 Sequencing of amplicons
Fragments of DNA amplicons can be sequenced by a modification of the PCR 
reaction that includes dideoxynucleotide trisphosphates (ddNTPs) along with higher 
concentrations of normal dNTPs. The ddNTPs lack a 3’ hydroxy group, thus strand 
extension by addition of dNTPs via a phosphodiester bond cannot occur. During 
synthesis of the complementary DNA strand, random incorporation of a specific 
ddNTP in place of a normal dNTP results in chain termination. At the end of the 
sequencing reaction, numerous fragments of different lengths exists, each terminated 
by the incorporation of a specific dideoxy base. By labelling each ddNTP with a 
different fluorescent dye, the terminating bases of each fragment can be distinguished. 
Separation of labelled fragments according to fragment length and sequential 
monitoring of the fluorescent dye on each fragment enables the DNA sequence to be 
determined. As the probability of generating a long fragment without random 
incorporation of a ddNTP is low, compared with the frequency of generation of short 
fragments, the intensity of fluorescent signal and quality of sequence decreases as 
fragment size increases, limiting the length of fragment that can be sequenced in a
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single PCR reaction. Larger genes are often sequenced by generating multiple 
overlapping amplicons.
2.22.1 Amplicon purification
Unincorporated primers, dNTPs and MgClj can interfere with the sequencing PCR 
reaction, so amplicons to be used as a template for sequencing reaction were purified.
Amplicons sequenced earlier in this study (16S rRNA, vacA, cagA and rdxA genes) 
were purified using a commercial kit (Wizard® PCR preps DNA Purification System) 
according to the manufacturer’s instructions [Promega UK Ltd]. Briefly, amplicon 
(5 0 -1 0 0  pi) was bound to PCR Preps DNA Purification Resin in the presence of 
GuSCN-containing buffer, this was transferred to a 5-ml sterile syringe and pushed 
into a Wizard® Minicolumn. Amplicon/resin complexes were washed once by gentle 
pushing of 80 % (v/v) isopropanol through the Minicolunm using the same syringe 
and the resin dried by brief centrifugation of the Minicolumn (10 000 rpm for 2 min). 
Amplicon was eluted by addition of 50 pi sterile distilled water, followed by 
centrifugation of the Minicolumn (10 000 rpm for 20 s).
Amplicons that were sequenced later in the study (frxA and ahpC) were separated 
fi*om unincorporated reagents by vacuum filtration (635 Torr) in MultiScreen®-PCR 
plates [Millipore Ltd] for 10 min and then resuspended by 15 min agitation in 50 pi 
molecular grade water [Promega UK Ltd] as directed by the manufacturer’s protocol 
[Millipore Ltd].
2.22.2 Quantification of sequencing template
Low DNA Mass Ladder [Invitrogen] comprises an equimolar mixture of six DNA 
fragments of known concentration, ranging in size from 100 bp -  2000 bp.
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Comparison of band intensities of unknown DNA with a standard band of this ladder, 
approximately equivalent in size, allows quantification of unknown samples.
Aliquots (1 pi and 0.5 pi) of purified amplicon and 2 pi and 1 pi Low DNA Mass 
Ladder I were electrophoresed in a 1.0 % (w/v) gel at 135 V for 2.5 h and stained in 
ethidium bromide (0.5 pg/ml). Amplicon concentration was calculated by visual 
comparison of band intensities, and amplicon diluted to 100 finol for sequencing.
2.22.3 Sequencing reaction
Briefly, 27/50 rdxA amplicons, 10/37 cagA PCR products as well as 8/15 amplicons 
fi*om bladder biopsies were sequenced commercially [MWG Biotech Ltd and 
Cytomyx, Cambridge, UK]. All remaining amplicons, including all frxA  and ahpC 
genes were sequenced in-house.
Amplicons were sequenced following a modification of the manufacturer’s protocol 
for the CEQ Dye Terminator Cycle Sequencing (DTCS) Quick Start Kit [Beckman 
Coulter Inc, High Wycombe, Buckinghamshire, UK]. All sequences were determined 
in both forward and reverse directions in two separate reactions. Briefly sequencing 
fragments were generated in a 20 pi reaction containing 100 finol purified amplicon,
3.2 pmol of the appropriate primer and 8 pi DTCS Quick Start master mix (containing 
sequencing reaction buffer, dNTPs, dye labelled ddUTP, ddGTP, ddCTP and ddATP 
and polymerase enzyme) by 40 thermal cycles [DNA engine MJ Research] at 96 °C 
for 20 s, 46 °C for 35 s and 60 °C for 4 min.
2.22.4 Purification of sequencing fragments
Sequencing reactions were stopped by the addition of 5 pi stop solution -1.5 M 
sodium acetate [Sigma Ltd], 50 mM EDTA [Sigma Ltd] and 20 pg glycogen 
[Beckman Coulter Inc]. Fragments were purified in CEQ2000 sample plates
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[Beckman Coulter Inc] following the manufacturer’s instructions. Briefly, fragments 
were precipitated in ethanol 95 % (v/v) [BDH] at -20 °C for 10 min, centrifuged at 4 
°C (14 000 rpm for 30 min) and pellets washed twice with cold ethanol 70 % (v/v), 
dried and resuspended in 40 pi Sample Loading Solution [Beckman Coulter Inc]. 
Reactions were covered with one drop of mineral oil [Beckman Coulter Inc], to 
prevent degradation of fluorescent dyes. Sequencing fragments labelled with 
fluorescent terminator dyes were separated and analysed by gel electrophoresis in 
commercial polyacrylamide gel [Beckman Coulter Inc] in an automated sequencer 
CEQ2000 [Beckman Coulter Inc].
2.22.5 Sequence analysis
Sequences obtained in the forwards direction were aligned with the reverse 
complemented matched sequence determined in the reverse reaction in GeneBase 
version 1 [Applied Maths] to identify any sequence mismatches that suggested 
inaccurate or poor quality data. Sequence chromatograms of both forward and reverse 
reactions were then examined in Chromas version 1.42 [Griffith University, Brisbane, 
Australia], to correct any discrepant bases identified. Corrected sequences were then 
stored in GeneBase version 1 for further analysis of nucleic acid and translation to 
amino acid sequences.
2.22.6 BLASTn analysis of sequences
BLASTn (Basic Local Alignment Search Tool nucleotide) is a program that allows 
comparison of sequences with all those available in public databases. The matches 
identified by BLAST with known sequences provides the basis for identification of 
unknown sequences.
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Amplicons generated from bladder biopsies were identified by BLASTn analysis of 
determined sequences (http://www.ncbi.nlm.nih.gov/BLAST). Additionally, potential 
specificity of all primer sequences designed in the course of this study and of selected 
published primers was assessed by BLASTn analysis.
2.23 Detection of H, pylori antigens from stool specimens
H. pylori specific antigen can be detected in stool specimens by an Enzyme Linked 
Immunosorbent Assay (ELISA) method. Two commercial ELISA kits were 
examined in this study, the Premier Platinum HpSA kit [Meridian Diagnostics, USA] 
and the Amplified IDEIA HpStAR kit [DakoCytomation, Cambridgeshire, UK]. The 
principle of both kits is similar and is summarised in Figure 2.8. Briefly, diluted stool 
specimens are added to wells coated in specific anti-LT. /?y/or/-antigen antibody. If 
present in the stool, H. pylori antigen will be captured and can be detected by anti-Æ 
pylori antibody conjugate labelled with the marker enzyme horseradish peroxidase. If 
a specimen is H. j^y/ori-positive, the antigen-antibody conjugate complex will remain 
bound in the wells following repeated washing steps. This can be detected by the 
addition of chromogenic substrate, trimethylbenzidine, that will be hydrolysed by the 
bound marker enzyme to produce a colour change from colourless to blue 
(subsequently changes to yellow on addition of sulphuric acid to stop the reaction). 
This colour change can be recorded visually or spectrophotometrically. Stools 
specimens that had been collected originally for PCR-based analyses also were 
examined for specific antigen by the two commercial kits.
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Figure 2.8: Schematic representation of the detection of Æ pylori specific
antigen in stools by Enzyme-Linked Immunosorbent Assay 
(ELISA)
2.23.1 Detection oïH. pylori stool antigen by Premier Platinum HpSA kit
The HpSA kit captures H. pylori antigen in wells coated with specific polyclonal 
antibodies. These antigens were detected from stool samples following the 
manufacturer’s protocols [Meridian Diagnostics]. Briefly, approximately 0.1 g stool 
was emulsified in 200 pi sample diluent and mixed by vortexing. Diluted stool (50 
jLtl) was added to the antibody-coated well, along with one drop of the kit antibody 
conjugate. Plates were incubated at room temperature for 1 h and then manually 
washed 5 times with the buffer provided. Bound antigen-antibody complexes were 
detected by incubation in the dark with enzyme substrate at room temperature for 10
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min, after which time stop solution was added and spectrophotometric absorbances 
measured at 450 and 630 nm, within 30 min, by a Labsystems Multiskan RC version
6.0 [Labsystems Oy, Helsinki, Finland]. Samples were defined as either negative, 
equivocal or positive on the basis of OD450/630 readings of <0 .1 0 0 , >0 .1 0 0  and <0 .1 2 0 , 
and >0 .1 2 0 , respectively.
2.23.2 Detection of H, pylori stool antigen by Amplified IDEIA HpStAR kit
The Amplified IDEIA HpStAR kit differs from the HpSA kit in that wells are coated 
with specific monoclonal antibodies. The procedure stated by the manufacturers 
[Dako Cytomation] is similar to that described above (2.23.1). Stool was emulsified 
in 500 pi sample diluent then, following vortexing, centrifuged (5000 rpm for 5 min) 
and 50 pi supernatant added to antibody-coated wells, along with 50 pi enzyme 
conjugate. Following incubation (ambient temperature for 1 h), wells were washed 
using a Well Wash 4 automated plate washer [Denley] and 100 pi substrate added. 
The reaction was stopped after incubation at ambient temperature for 10 min in the 
dark by the addition of 1 0 0  pi stop solution and results recorded as described above. 
Samples were defined as either negative or positive on the basis of OD450/630 readings 
of <0.150 and >0.150, respectively.
2.23.3 Detection ofH, pylori stool antigen by ImmunoCard STAT! HpSA kit
In addition to ELISA, a rapid immunoassay was evaluated, that identified H. pylori- 
positive patients by a lateral flow chromatography-based method capturing specific 
antigen from stools via a specific monoclonal antibody immobilised in a test cassette. 
Tests were performed according to the manufacturer’s instructions [Meridian 
Diagnostics]. Approximately 5 - 6  mm stool was added to vials containing 1 ml 
sample diluent and emulsified by vortexing for 15 s. The tip of the vial was broken
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off and four drops of stool suspension added to the sample port of the test cassette. 
The test was read after exactly 5 min incubation at ambient temperature. Tests were 
interpreted as negative if  there was a blue line in the control (C) window only and 
positive if there was any evidence of an additional pink line in the test (T) window.
2.24 Calculation of test sensitivity and specificity
Specificity and sensitivity of tests were calculated using the following formulae 
(www.musc. edu/dc/icrebm/sensitivity) :
% Sensitivity = ^  ^
o  T  TN X  100
% Specificity = TN + FP T "
Where TP = True Positives, TN = True Negatives, FP = False Positives, FN = False 
Negatives.
2.25 Statistical analyses.
All statistical analyses were performed using GraphPad InStat, version 3.05 
[GraphPad, San Diego, USA]. The following tests were applied to data sets.
2.25.1 Means, standard deviations and 95 % confidence intervals 
The mean OD450/630 values generated by each stool antigen kits (2.23.1 and 2.23.2) 
were calculated to compare the relative performances of each kit and also the 
performance of these in relation to that of the ImmunoCard STAT! test (2.23.3).
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The mean of the crossover threshold (CT) values (the point where amplicon 
generation enters the exponential phase) for LightCycler TPM assays CagMotA and 
CagMotB (2.20.6) were calculated to interpret performance of these when applied to 
gastric biopsies.
2.25.2 Unpaired  ^test
Mean values generated above (2.25.1) were compared for significant differences by 
the unpaired t test. This is an appropriate test for comparison of two sets of 
independent quantitative data that do not differ significantly and have similar standard 
deviations (Swinscow 1996b;Swinscow 1996c). A p value of less than 0.05 indicated 
significant differences.
2.25.3 Fisher’s exact test
Potential associations between putative virulence factors (yacA genotype and cagA 
TPMs) and disease outcome and PCR positivity and interstitial cystitis were analysed 
by Fisher’s exact test. This test is appropriate for such data where both the input 
variable (e.g. virulence factor) and output variable (e.g. disease outcome) are nominal, 
and the study population size is small (Swinscow 1996a;Swinscow 1996c). A p value 
of less than 0.05 indicated significant differences.
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Chapter 3: Evaluation of the effects of different conditions for transport of
gastric biopsies on PCR-based detection oiH. pylori,
3.1 Background
A prerequisite of any diagnostic method is that it should offer high sensitivity and 
specificity. The performance of a PCR-based detection assay can be affected by 
various factors, including the nature and quality of a clinical specimen, the method of 
DNA extraction, the primers used and the conditions of the PCR. To ensure that 
PCR-based detection of H. pylori from clinical specimens was as sensitive and 
specific as possible, these factors required evaluation, to optimise methodologies for 
all further investigations.
Previous studies have demonstrated that the transport conditions of gastric biopsies 
significantly affect success of culture oïH. pylori (Han et al. 1995;Heep et al. 1999). . 
Although it is accepted that PCR is capable of detecting bacteria in a variety of 
metabolic states, including dead or non-cultivable cells, the effects of transport 
conditions on the outcome of PCR detection for H. pylori have not been investigated. 
As was discussed in section 1.7, numerous H. /?y/on-specific detection assays have 
been described, but the high inter-assay performance variability could significantly 
affect the outcome of PCR-based testing of clinical specimens. In addition, the DNA 
extraction method should be rapid and simple (to allow high throughput processing of 
clinical samples) while also able to produce a sufficient yield of quality template 
DNA to allow sensitive and specific detection. Many clinical samples contain 
substances, such as haem, bile salts and polysaccharides that are inhibitory to the 
PCR, and an extraction method must also remove as many of these inhibitors as 
possible. The methods of DNA extraction described for gastric biopsies range from
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simple vortexing or boiling of specimens (Bickley et a l 1993;Lage et a l 
1995;Wahlfors et a l 1995) to more complex approaches involving phenol chloroform 
extractions (Chong e /ûf/. 1996;Lage a/. 1995;Li a/. 1996;Mapstone e/a/. 1993a).
However few studies have compared the effects of different extraction methods on the 
outcome of PCR testing for helicobacters (Thoreson et a l 1995; Wang et a l 1993). 
The aims of the study presented in this chapter were:
1) To establish a method of DNA extraction from gastric biopsies that was rapid but 
that could provide DNA template containing minimal levels of PCR-inhibitors.
2) To determine the optimal conditions for transport of clinical samples for sensitive 
and specific detection of H. pylori.
3) To compare the performances of three assays targeting different areas of the H. 
pylori genome, namely, glmM, 16S rRNA and vacA genes, in order to select the 
best assay(s) for subsequent analyses.
3.2 Results
3.2.1 Comparison of extraction methods
Ten gastric biopsies that were culture-positive for H. pylori were homogenised in 
sterile saline and divided into two aliquots. One aliquot was extracted by the boiling 
method (2.11.1) while the other was processed by the digestion method (2.11.2.1).
3.2.1.1 Internal control PCR to confirm removal of inhibitory substances
A PCR assay that specifically amplifies a fragment of a human cytochrome oxidase 
gene (2.15.1) was applied to all 20 biopsy DNA extracts as an internal control to 
evaluate the ability of each extraction method tested to remove PCR-inhibitory 
substances. Amplicons of the appropriate size (823 bp) were generated in all DNA 
preparations from gastric biopsies, regardless of extraction method.
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3.2.1.2 PCR-based evaluation of DNA recovery
The g/mM gene-specific PCR assay generated amplicons from 9/10 biopsy DNA 
preparations, regardless of the extraction method used. However, the intensity of the 
amplified fragments was generally slightly higher for some of the DNAs extracted by 
the digestion method, as illustrated in Figure 3.1.
B D B  D B D B D B D  -ve M
w  294  bp
< ------- 123 bp
Figure 3.1 Examples of H, pylori detection by glmM  amplification using DNA 
extracted from human gastric biopsies by boiling (B) or digestion 
(D) methods. Lane 1-10, DNA from human gastric biopsies extracted 
by B or by D method; lane 11, negative control; lane 12, 123 bp 
molecular weight marker (M).
3.2.2 Comparison of effects of transport methods on PCR
The effect of six different combinations of transport conditions on the performance of 
three PCR assays was evaluated. The biopsies studied were collected from dyspeptic
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patients as part of a routine endoscopic examination. Seven biopsy groups were 
defined according to source, method of determination oïH. j^j^/on-status and 
conditions of storage and transport. The H. pylori status of biopsies was determined 
by culture and histology in Groups 1 - 5 ,  obtained from Chelmsford PHL. All 
biopsies in Groups 1 and 5 were H. j^y/on-positive, while for Groups 2, 3 and 4, 
biopsies were obtained prospectively and 11/41,16/70 and 17/121, respectively, were 
H. /y/on-positive. Group 6 (n = 30) comprised a miscellaneous collection of biopsies 
submitted to the HRU for routine culture. Additional biopsies had undergone 
histological examination at the respective hospital. The Group 6 biopsies had been 
received firom the Royal Free Hospital, London (n = 7), the University College 
Hospital, London (n = 4) and King’s College Hospital, London (n = 19); 19/30 of 
these were H. jcy/on-positive. Group 7 was obtained from North Middlesex 
University Hospital, where demonstration of rapid urease activity (CLO test) 
confirmed the presence of H. pylori in 60/72 biopsies.
Transport conditions for each biopsy group, summarised in Table 3.1, were as 
follows:
Group 1 : Specimens had been frozen in physiological saline at the primary
laboratory at the time of culture and all cultures and matched biopsies 
forwarded to the HRU at room temperature where they were stored (- 
20 °C) for further processing.
Group 2: Biopsies were not frozen at the primary laboratory but both culture-
positive and negative specimens were forwarded to the HRU as 
described for Group 1.
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Group 3: Transport conditions for biopsies were identical to those of Group 2,
except that Dent’s transport medium was used instead of saline.
For both Groups 2 and 3, there was a 3-4 day delay between the time that the biopsy 
was taken by endoscopy and receipt of specimen in the HRU.
Group 4: Specimens were frozen in Dent’s medium on the day of endoscopy and
were maintained at -20 °C for storage, including transport to the HRU 
until DNA extraction.
Group 5: Biopsies, collected for a previous study (Peters et al. 1997), had been
transported and maintained under identical conditions as for Group 4. 
Group 6: Biopsies were transported in Dent’s medium to the HRU for routine
culture on the same day as endoscopy and were stored (-20 °C) for 
molecular analyses.
Group 7: Biopsies were tested for rapid urease activity (CLO test) at North
Middlesex University Hospital and were transported each week in 
batches to the HRU in the original CLO test media.
All gastric biopsies were tested for H. pylori DNA by three assays targeting glmM,
16S rRNA and vacA genes. The results of these analyses are presented in section 
3.2.4.
Selected biopsies from these defined groups were used also in additional studies 
presented in Chapters 4 - 7 .
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Table 3.1 : Summary of storage and transport conditions of human gastric
biopsies analysed by PCR.
Transport Biopsy Group
(number of samples)
Conditions 1
(14)
2
(41)
3
(70)
4
(121)
5*
(39)
6
(30)
7
(72)
Initial storage 
Temp.(°C)
-20 4 4 -20 -20 4 NRt
Transit 
Temp. (°C)
ambient ambient ambient <0 <0 ambient ambient
Transport
media
Saline Saline Dent’s Dent’s Dent’s Dent’s CLO test
Mean transit 
time to HRU
NR IlO h 93 h 2 h 2 h 3-4 h >72 h
* Archival collection 
 ^Not Recorded
3.2.3 Development and optimisation of novel H, /;j/on-specific PCR assay 
HpVac
Alignment of 30 complete vacA sequences retrieved from GenBank (Appendix B.l) 
identified conserved regions at the 3’ end suitable for design of primers that would 
amplify all H. pylori strains. BLASTn analysis of candidate primers demonstrated 
that primers vac3624F and vac3853R were H. /?y/on-specific, and no significant 
homologies with human DNA sequences were found. Initial application of the 
resultant PCR assay (HpVac) to 30 clinical isolates of H. pylori generated specific 
(230 bp) product in all cases. Analysis of five H. ^/on-positive and five H. pylori- 
negative biopsies selected from Groups 4 and 5 generated specific amplicon in all 
positive biopsies. However, larger non-specific bands were also observed in 7/10 
biopsies and although raising the annealing temperature to 53 °C decreased the 
intensity of these bands it did not eliminate non-specific amplification in 3/10
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biopsies. Further attempts to optimise MgCli and primer concentration failed to 
reduce the generation of non-specific bands. Examples of amplicons generated from 
three patients in Group 7 are provided in Figure 3.2, to illustrate the quality of results 
obtained.
2 3  4 5 6 7  8 9 10
glm M  16S rRNA HpVac
;S: V ■ - i i |
^ — 294  bp 
4 — 230  bp 
^ — 109 bp
Figure 3.2: Examples of H. pylori detection in Group 7 gastric biopsies by
three different H, /Tp/ori-specific PCR assays targeting glmM, 16S 
rRNA and vac4 genes. Patient A, lanes 1, 4 & 7; Patient B, lanes 2, 5 
& 8; Patient C, lanes 3,6 & 9. 123 bp ladder, lane 10. All biopsies 
were positive for all PCR assays, except for a false negative result 
generated by the glmM assay for patient C (lane 3).
3.2.4 Determination of sensitivities and specificities of H. pylori-specific PCR 
detection assays
The relative sensitivity of each PCR assay was determined by testing of serial decimal 
dilutions of H. pylori (NCTC 11637) DNA ranging from 100 ng -  10 fg. The 
detection limit was 100 fg for the HpVac assay, and 1000 fg for both the 16S rRNA 
and the glmM assays.
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The sensitivity and specificity of the three assays when applied to gastric biopsies 
was determined for each by the formulae described in section 2.24. A biopsy that was 
positive by culture, histology or CLO-test but was PCR-negative was considered 
falsely-negative while amplicon generation in a biopsy that had been negative by 
culture, histology or CLO-test was classified as falsely positive. As all biopsies in 
Groups 1 and 5 were H. j^y/orz-positive and the proportion of H. /?y/on-negative 
biopsies in Group 6 was low, specificities could only be determined in Groups 2 ,3 ,4  
and 7. Calculated sensitivities and specificities for individual PCR assays when 
applied to each gastric biopsy group are presented in Table 3.2.
Table 3.2: Effect of transport conditions on sensitivity and specificity of
H, /iy/or/-specific PCR assays targeting g/mM, 16S rDNA and vacA
Biopsy Group* (n)
PCR Assay 1 2 3 4 5 6 7
(14) (41) (70) (121) (39) (30) (72)
glmM Sensitivity (%) 28.6 18.2 56.3 8Z3 92.3 84.2 55.0
Specificity (%) naf 100.0 98.1 99.0 na na 833
16S rDNA Sensitivity (%) 57.0 72.7 87.5 823 92.3 84.2 76.7
Specificity (%) na 100.0 92.5 98.1 na na 833
HpVac Sensitivity (%) 57.0 81.8 93.8 883 92.3 89.5 78.3
Specificity (%) na 100.0 98.1 99.0 na na 833
^Biopsies grouped according to transport conditions (Table 3.1): n = number of 
samples.
^Not applicable as all biopsies were culture-positive.
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3.3 Discussion
3.3.1 Evaluation of DNA extraction methods for gastric biopsies
Many clinical samples contain substances that inhibit the action of Taq polymerase in 
the PCR reaction (Lantz et al. 2000; Wilson 1997), with complex specimens such as 
blood, saliva and stools being particularly problematic. PCR-based amplification of 
H. pylori DNA direct from gastric biopsies is widely reported, with numerous 
different DNA extraction methods described. The approaches described range from 
simple vortexing and/or boiling (Clayton et al. 1992;Thoreson et al. 1999;Wahlfors et 
al. 1995) or digestion in lysis buffer (Marais e/a/. 1999;Namavar g/ a/. 1995;Weiss g/ 
al. 1994) to more complex multiple-step protocols involving phenol chloroform 
extraction (Chong e/a/. 1996;Engstrand a/. 1992;Hammar e /<3/. \992\IA et al.
1996) or commercial extraction kits (Lu et al. 1999). Although essential for some 
specimen types containing high levels of inhibitors, complex DNA extraction 
protocols are undesirable as they lengthen the overall processing time and increase the 
risk of introducing DNA from exogenous sources. A previous study using internal 
control PCR demonstrated that 42 % of gastric biopsies contained inhibitory 
substances (Thoreson et al. 1999), while another study suggested that greater DNA 
yield was obtained from biopsies extracted by phenol chloroform-based methods 
(Wang et al. 1993). A priority of this study was to establish a method of DNA 
extraction that was rapid, simple and effective, to minimise the potential for false- 
positive PCR results due to DNA contamination or false-negative results due to PCR 
inhibition.
Two extraction methods described previously (Bickley et al. 1993;Marais et al. 
1999) were evaluated; both of which met these criteria. An internal control PCR 
targeting the human cytochrome oxidase gene demonstrated that extracts prepared by
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either method did not contain significant levels of PCR inhibitors. While the heating 
steps employed in both methodologies would denature proteins and degrade other 
labile substances, neither contained steps specifically aimed at removing inhibitory 
substances. It is likely, therefore, that human gastric biopsies are not a source of 
substances inhibitory to PCR, even in specimens where blood is clearly visible. Of 
the two methods tested, the boiling method of Bickley et al (1993) was simpler and 
approximately 50 minutes faster than the digestion method described by Marais et al 
(1999). Although both methods were equally sensitive in detecting the glmM  gene of 
H. pylori, visual comparison of intensity of PCR bands in an agarose gel showed that 
in some cases the digestion method generated stronger amplicons. As the recovery of 
specific DNA was apparently less efficient by boiling than by digestion, all 
subsequent gastric biopsies were extracted by the digestion method.
3.3.2 Evaluation of the effects of biopsy transport conditions on H, pylori 
detection by PCR
At the time this study was initiated over 15 different PCR assays targeting various 
genes had been developed for the detection of H. pylori, as described in section 1.7.
In the majority of cases these assays were reported to be highly sensitive and specific, 
however many had not been evaluated critically or employed subsequently by other 
workers. One such independent study compared the five PCR assays of Ho et al 
(1992), Hammar et al (1992), Valentine et a/ (1991), Clayton et a l{ \9 9 \)  and Brisou 
et al (1990), targeting, respectively, 16S rDNA, a 26 kDa species-specific antigen 
gene, a random sequence, the ureA and the glmM  genes. Analysis of 50 gastric 
biopsies, 24 of which were culture-positive, demonstrated that the glmM  assay was 
the most sensitive and specific (Lu et a l 1999). Consequently the glmM VCR. assay 
was selected for further evaluation in the initial stages of this study. Additionally,
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primers Hpl and Hp2 described by Ho et al (1992) were selected for evaluation as 
these had been applied successfully in a number of separate studies, albeit in different 
nested and semi-nested combinations (Chong et a l 1996;Mapstone et a l 
1993a;Nguyen e/a/. 1995;Nilsson e/a/. 1999).
Gastric biopsy specimens were collected prospectively from dyspeptic patients as 
part of routine endoscopic investigation. The biopsy Groups 1 -4  were defined on the 
basis of their chronological collection over a 10-month period and the progression in 
different transport conditions employed. Analysis of Group 1 demonstrated that 
sensitivity oîH. pylori detection was low for both PCR assays. Internal control PCR 
amplifying human cytochrome oxidase DNA demonstrated that false-negatives were 
not due to the presence of residual substances inhibitory to the PCR reaction 
following extraction. It was hypothesised that the initial ffeeze-thawing cycle may 
lyse human cells, liberating DNAses that degraded specific target during transit. 
However, the sensitivity of detection was also low for Group 2 biopsies that had not 
undergone this process. Some studies have demonstrated that transport or storage of 
H. pylori in saline decreases the recovery rate (van der Hulst et a l 1996) and cell 
stability (Heep et a l 1999), thus transport of biopsies in saline may be insufficient to 
support H. pylori survival. Autolysis of bacterial cells would expose the target DNA 
to bacterial and human DNAses, resulting in decreased sensitivity of PCR-based 
detection.
Transport of biopsies in Dent’s medium instead of physiological saline (Group 3) 
increased sensitivity of both assays but seven biopsies were still falsely negative by 
the glmM  assay. Three false-positives were generated by the assay targeting the 16S 
rRNA gene only in this group but these were too weak to allow further 
characterisation by sequencing. Although antimicrobial agents are included in Dent’s
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to inhibit growth of many contaminants, this richer medium could support the growth 
of other bacterial species. 16S rRNA genes are universally present in bacteria and 
cross-reaction with the H. j^y/on-specific 16S rRNA primers would generate falsely 
positive results. This was most likely for Groups 2 and 3 as there was a considerable 
delay (between two to four days) between receipt of the biopsy in the primary 
laboratory for culture and transit to the HRU. The delay would not only allow 
overgrowth of contaminants in Dent’s medium but prolonged incubation at 
temperatures where DNAse activity could degrade specific DNA would also account 
for the poor sensitivity of PCR detection in these samples. Further evidence that this 
may be the most likely explanation for the high rate of false-negative results was 
provided by the higher sensitivities observed for both assays when applied to stored (- 
20 °C) biopsies from Groups 4 to 6 that had immediately been frozen on the same day 
as endoscopy. In contrast, the low sensitivity of detection observed in Group 7 
biopsies that had been transported in CLO test medium provided additional evidence 
of the adverse effects of prolonged storage at >4 °C prior to DNA extraction. 
Additionally, the conditions provided by the CLO test medium might have accelerated 
cellular and DNA degradation. Culture of these biopsies on arrival in the HRU 
showed that organisms were no longer viable. Nevertheless, 80.0 % of CLO-test 
biopsies were positive by at least one PCR assay, demonstrating the power of PCR 
methodology for detection of non-viable organisms.
Loss of sensitivity of PCR-based detection due to DNA degradation has been 
described previously for the parasite Toxoplasma gondii (James et al. 1996). In the 
case of H. pylori, many reports focus on the value of PCR-based detection from 
gastric biopsies, as described in section 1.7, and yet the problems of specific DNA 
degradation were not addressed, perhaps because the investigating laboratory was in
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close proximity to the endoscopy clinic. The results presented here suggest that the 
transit time for biopsies transported at room temperature must be short (ideally < 24 
hours) or the sensitivity and specificity of PCR detection is severely compromised. 
However, where rapid transport between laboratories is difficult, for example due to 
geographical distance, the optimal handling procedure would appear to be immediate 
freezing of biopsies in Dent’s medium and maintenance of freezing until DNA 
extraction. Other workers demonstrated that sensitivity of culture from gastric 
biopsies sent to geographically distant locations was highest if  specimens were 
transported in media other than saline at a temperature of <4 °C (Heep et al. 1999). 
This issue is particularly important to a reference unit function, as PCR-based testing 
of clinical specimens could be offered as a nationwide service in the future to 
hospitals that do not culture for H. pylori. In such situations, transport delays due to 
geographical distance would be inevitable.
3.3.3 Comparison of performances of H. pylori-speciüc 16S rRNA and glmM  
PCR assays
Although specimen quality appears to be a critical factor in PCR-based detection of 
H. pylori, the different performance characteristics of individual assays documented 
previously (Lu et al. 1999) were also re-assessed in this study. Both assays (targeting 
the 16S rRNA and the genes) performed similarly when applied to serially 
diluted DNA from culture and to biopsies that had been stored at -20 °C (Groups 4 
and 5). However sensitivity of glmM VCR was lower than that of the 16S rRNA 
assay in biopsy Groups 1 to 3 and in Group 7. This suggests that for samples where 
levels of target DNA are low (either due to sample deterioration or an initially low 
bacterial load) the glmM  assay is insufficiently sensitive to be applied as a detection 
method, although it could be considered a useful indicator of sample quality.
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Originally this target was thought to be H. /7y/ori-specific (Labigne et al. 1991) but 
later was shown to encode phosphoglucosamine mutase (glmM) that is present in 
other bacterial species (De Reuse et al. 1997). In spite of the potential for cross­
reactivity, no false-positive results were generated in the present study. The 16S 
rRNA PCR assay was marginally more sensitive in the same sample groups, but 
specificity was slightly lower. Poor specificity is a potential problem with many PCR 
assays targeting rRNA genes, as those sequences are ubiquitous. Furthermore, 
contamination of gastric biopsies with other bacterial species, often from the oral 
cavity, is not infrequent in routine culture, particularly for patients on acid suppressive 
therapy. It might be expected that this assay could generate falsely positive results, 
particularly in specimens where transport to the molecular laboratory is delayed, as 
was the case in Groups 2 and 3. Specificity problems have been reported previously 
where product that was considered falsely-positive was amplified from a range of 
human clinical specimens, including gastric, colonic and liver biopsies, as well as in 
stools and in human leucocytes (Chong et al. 1996).
3.3.4 Development and evaluation of a novel H, pj/ari-specific PCR assay
As neither of the two assays discussed above achieved high-level sensitivity and 
specificity, a novel assay (HpVac) amplifying the vacA gene was developed. This 
target was selected as firstly, it is only found in H. pylori and secondly, all strains 
possess the gene, although not all express functional vacuolating cytotoxin (Cover 
1996). Consequently an assay targeting vacA has the potential to be highly specific. 
As discussed in section 1.12.1, some regions of vacA, such as the mid (m)-region, are 
highly diverse. The HpVac assay was designed to target a conserved region based on 
in silico comparisons of vacA sequences retrieved from GenBank. Despite extensive 
optimisation attempts, non-specific bands were amplified in approximately 10 % of
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gastric biopsy DNA extracts. These were significantly larger (650 bp and 1.2 kb) than 
the predicted specific 229-bp amplicon, and therefore erroneous reporting of a false- 
positive result was unlikely. The origin of these bands was not known but they were 
generated occasionally in both culture-positive and culture-negative biopsies but not 
from DNA extracted fi*om pure culture of the infecting strain of H. pylori. It was 
therefore most likely that human DNA had been amplified. Generation of non­
specific DNA bands could theoretically reduce the sensitivity of the HpVac assay by 
competitive co-amplification of specific and non-specific product. However, this was 
not observed, with strong H. /7y/or/-specific amplicons generated regardless of non­
specific amplification.
Analysis of serially diluted DNA from culture demonstrated the HpVac assay was 
more sensitive (X 10) than either the glmM ox 16S rRNA assays. Likewise, 
retrospective application of HpVac to biopsy Groups 1 to 7 demonstrated that it was 
considerably more sensitive than the glmM  assay in Groups 1 to 3 and Group 7, and 
marginally more sensitive and specific than the 16S rRNA assay. Occasional 
discrepancies between vacA and 16S rRNA results occurred that may be due to 
sequence variation at the primer binding sites generating occasional false-negative 
results. H. pylori is a highly heterogeneous species at the genome level with a 
panmictic population structure (Suerbaum et al. 1998), so the potential for primer site 
mismatch is high. It is therefore unlikely that any single PCR assay will amplify all 
H. pylori strains encountered. For this reason, both 16S rRNA and HpVac assays 
were used in subsequent studies to maximise sensitivity of detection.
3.3.5 PCR-based detection of non-viable organisms
Of all the negative biopsies analysed, four biopsies that had been designated as H. 
jcy/ori-negative were PCR-positive for all three assays. Although these results were
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included in calculations as falsely positive, it is more likely that the original 
conventional diagnostic tests were falsely negative. Only two of 198 biopsies were 
falsely negative when tested by culture and histology, indicating that this error occurs 
relatively rarely. In contrast 2/12 CLO test-negative biopsies tested were PCR- 
positive. The colour of the pH indicator in these two tests had been slightly more 
orange than the expected yellow of a negative result -  thus equivocal results that can 
be misinterpreted as negative may occur relatively frequently. H. pylori infections are 
diagnosed solely by CLO test in many gastroenterology clinics in the UK and 
elsewhere (Heep et a l 2001). Extension of this study to include larger numbers of 
CLO test-negative biopsies for PCR analysis would enable the reliability of the CLO 
test to be assessed. This highlights the power of PCR as H. pylori could not have 
been detected from these two specimens by any other means. PCR could serve as a 
supplementary method for those CLO test results that are difficult to interpret and this 
approach would not require any additional specimen collection.
3.4 Conclusions
PCR-based detection oiH. pylori direct from gastric biopsies allows rapid (potentially 
same-day) diagnosis of infection that is highly specific and relatively sensitive. 
However conditions of transport and length of time between endoscopy and DNA 
extraction play a crucial role in PCR assay sensitivity, with some tests (notably glmM) 
more affected than others (16S rRNA and HpVac). An appreciation of the problems 
of DNA degradation during transport is vital to ensure that molecular tests provide a 
robust, accurate alternative to traditional diagnostic methods. Additionally, no single 
PCR assay will detect all strains of the highly heterogeneous H. pylori and thus a 
multiple-assay approach may be the best means of maximising sensitivity. PCR can
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be useful for interpreting equivocal CLO-test results and is a powerful tool for the 
further investigation of clinical specimens. This facility will be explored in 
subsequent sections.
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Chapter 4: Development of a novel multiplex PCR assay for detection oîH .
pylori and ‘ZT. heilmanniT-lilie organisms direct from human 
gastric biopsies.
4.1 Background
The previous chapter focused on developing methods for transporting and processing 
gastric biopsies for molecular analyses. PCR based detection ofH.  pylori enables 
same-day diagnosis of infection, however a range of other diagnostic methods are also 
available. In contrast, as discussed in section 1.13.3, ‘/f. heilmannW-\ikQ organisms 
(HHLOs) remain uncultivable, with rare exceptions (Andersen et al. 1996), and 
diagnosis is primarily reliant on histology. While one PCR-based detection assay is 
described for "H. heilmanniV detection in domestic cat biopsies (Neiger et al. 1998), 
PCR-based detection of human infection is reported for a single patient only 
(Dieterich et al. 1998). As microscopy-based detection methods can be relatively 
insensitive when bacterial levels are low (Hoick et al. 1997;Megraud 1995) the 
incidence of HHLO infection may be under-reported in England and elsewhere.
The aims of the study presented in this chapter were:
1) To develop a novel PCR-based assay to detect all known HHLOs direct from 
human gastric biopsy to facilitate surveillance of such infections in England.
2) To combine this test with a PCR detection assay for H. pylori to enable rapid 
detection of both HHLO and H. pylori infections of the human gastric mucosa.
3) To apply this novel assay to a collection of biopsies that were H. pylori 
positive by either culture or CLO test to determine possible co-infection with 
HHLOs.
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4) To apply this assay to biopsies that were considered H. pylori positive by CLO 
test to investigate the possibility that misdiagnosis of H. pylori infection may 
occur as a result of HHLO urease activity.
4.2 Results
4.2.1 Biopsy specimens
Gastric biopsies analysed in this study comprised 230 human gastric biopsies selected 
from biopsy Groups 4 (n = 116), 5 (n = 39), 6 (n = 15) and 7 (n = 60), defined in 
Chapter 3, and an additional 15 feline gastric biopsies collected from domestic cats 
undergoing routine veterinary investigation.
4.2.2 Development and evaluation of an HHLO specific assay
Primers that amplified a specific fragment of the 16S rRNA gene of HHLOs were 
developed as described in section 2.16.1.4. Application of the resultant HHLO- 
specific assay, termed HHLO-16, to 22 strain DNAs representing 12 other species of 
Helicobacter (Appendix A.1) demonstrated that the assay did not amplify the 112-bp 
16S rDNA fragment from H. pylori or from any species of Helicobacter other than H  
felis. The latter result was consistent with the findings of a BLASTn search that 
indicated the HHLO-16 assay would theoretically detect members of the H. felis, H. 
bizzozeronii, H  salomonis group (= H. heilmannii ’ type 2). However, DNA from the 
latter two species was not available for testing. Application of the HHLO-16 assay to 
a human gastric biopsy (from Group 6) for which there was histological evidence of 
an HHLO infection (Figure 4.1) generated the expected 112-bp amplicon (Figure 4.2).
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X 100 magnification
Figure 4.1: Histological evidence of HHLO infection in a human antral gastric
biopsy that was PCR-positive by the HHLO-16 assay, but not by 
the ureB assay (slide reproduced by kind permission of Drs S. and J. 
Dobbs and Professor A. Price).
Sensitivity of the HHLO-16 assay was assessed by testing 15 gastric biopsies from 
domestic cats, where the incidence of infection with HHLOs was expected to be high 
according to reported prevalence rates (Norris et al. 1999). The HHLO-16 assay 
generated HHLO-specific amplicons in 13/15 feline biopsies, two of which were 
confirmed as containing spiral organisms by Gram stain (Table 4.1). Further analyses 
of the cat biopsies (as described in sections 2.16.2.2 and 2.16.2.3) by the two ureB 
PCR assays of Neiger et al. (1998), that were either ‘H. heilmannii' or H. felis- 
specific, demonstrated that all 13 of these were positive for ‘//. heilmanniV (= type 2), 
as indicated by visualisation of a 580-bp band, while a 1150-bp band was only 
observed in one biopsy that was thus also positive for H. felis (Table 4.1). Spiral 
organisms were observed in that particular biopsy by Gram staining and microscopy. 
The relative performances of the HHLO-16 assay and the two ureB assays in terms of
155
Results and Discussion
sensitivity and specificity, and examples of the quality of PCR products generated are 
presented in Table 4.1 and Figure 4.2, respectively.
Table 4.1 : Comparison of the performance of the novel HHLO-16 PCR assay,
applied to human and to feline gastric biopsies with Æ 
heilmanniV or H, felis specific assays targeting ureB.
Gastric PCR Assay
biopsy HHLO-16 ‘H. heilmannii"^ H. felis
(n) +(t) - +(t) - +(t)
Human (131) 3(1) 128 1(0) 130 na{ na
Feline (15) 13(2) 2 13(2) 2 1(1) 14
^Published assays targeting the urease B subunit (ureB) (Neiger et a l 1998). 
tNumber of results confirmed as positive by microscopy (histology or Gram stain). 
%H. felis assay was not applied to human gastric biopsies.
4.2.3 Determination of prevalence of infection with HHLOs in humans.
Application of the HHLO-16 assay to 131 biopsies from Groups 4 and 6 generated 
specific amplicons of 16S rDNA in 3/131 DNA extracts (Table 4.1), indicating a 
prevalence rate of 2.3 % in a sample of dyspeptic patients from South East England.
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4.2.4 Optimisation of PCR-based multiplex assay (HpHh) for simultaneous 
detection of H. pylori and HHLOs.
The HHLO-16 assay was combined in a multiplex format with the H. pylori-s^Qcific 
assay targeting vacA, described in the previous chapter. However, analysis of a DNA 
preparation from a HHLO-positive biopsy seeded with 100 ng H. pylori DNA showed 
that only the HHLO 16S rDNA fragment was amplified. A modified version of this 
assay that used a different reverse primer (vac4041) in combination with the original 
forward primer (vac3624) successfully allowed co-amplification of both targets, vacA 
and 16S rDNA (Figure 4.2). Initial evaluation of the multiplex system on fifteen 
selected feline and human gastric biopsies demonstrated that specific vacA amplicons 
were generated in all five H. pylori culture-positive biopsies tested. Specific 16S 
rDNA amplicons were generated also in all four DNA extracts from HHLO-positive 
biopsies of both human (2) and feline (2) origin (Figure 4.2). However, a band of 
similar size to that of H. /7y/or/-specific product (417 bp) was generated in a H. pylori- 
negative biopsy. This proved to be non-specific amplification and was eliminated by 
raising the annealing temperature during thermal cycling from 53 °C to 55 °C. 
However, this lowered the sensitivity of amplification of 16S rDNA fragments from 
biopsies that had previously been HHLO PCR-positive, with the generation of three 
falsely negative results. Final optimisation of the multiplex assay to include unequal 
concentrations of primers that amplified either vacA or 16S rRNA and slight lowering 
of the annealing temperature to 54 °C, successfully overcame these problems and this 
method (section 2.16.4) was subsequently applied as described below.
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1 2 3 4 5 6 7 8 9 10 11 12 13
1150bp—►
580bp —^  
417bp—►
112bp
Figure 4.2: Examples of PCR products generated by Æ heilmanniV specific
(H*) and by H. felis specific (Ff) ureB assays (Neiger et al, 1996) 
and by multiplex assay HpHh (M |) amplifying 16S rDNA and 
vacA fragments of HHLOs and H. pylori respectively.
Human biopsy: negative for "H. heilmannii’ (ureB) (lane 1), and H. 
felis (ureB) (lane 3) but positive by histology and by assay HpHh (lane
5). Feline biopsy positive by both ureB assays (lanes 2 & 4) and by 
HpHh (lane 6); lanes 7 & 8, HHLO-positive human biopsies; lanes 9 & 
10, H. pylori-^osiXiYQ human biopsies; lanes 11 & 12, HHLO-positive 
biopsies spiked with H. pylori DNA; lane 13,123-bp size marker.
4.2.5 Evaluation of H. pylori and HHLO-specific multiplex PCR assay 
The sensitivity of the optimised multiplex system, designated HpHh, was tested by 
repeat analysis of samples for which the PCR status had already been determined by
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uniplex PCR assays. Sensitivities and specificities of both assays when applied to all 
230 human and 15 feline biopsies, either individually or in the combined multiplex 
format are presented in Table 4.2.
Table 4.2: Comparison of sensitivities of the vacA and HHLO-16 assays when
applied individually and combined in a multiplex assay HpHh.
Gastric Biopsies
Origin Status*
PCR assays
H. pylori (vacA)
% Sensitivity
HHLO-16 (16S rRNA)
% Sensitivity^
Uniplex Multiplex Uniplex Multiplex
Cat C/M + 0 0 na na 13/12* 0/1* 100.0 92.3
(15) C/M- 0 15 0 2
Human C/H + 59 4 93.6 93.6 0 63 100.0 100.0
(170) C/H- 0 107 3 104
Human U + 48 12 80.0 80.0 0 60 na na
(60)
*77. pylori status determined by culture (C), Gram stain microscopy (M), histology 
(H) or rapid urease (CLO) test (U).
t  Sensitivity of HHLO-16 assay calculated on the basis that no PCR-negative biopsies 
were histology-positive.
{Results generated by uniplex/multiplex format.
4.2.6 Investigation of the frequency of dual H. pyloriVSSLO co-infections.
The HpHh multiplex PCR assay was applied to 123 human gastric biopsies that were 
positive for 77. pylori, either by culture and/or histology (n = 63) or by CLO test (n = 
60). Specific targets vacA (77. pylori) and 16S rDNA (HHLOs) were amplified in 
59/63 and 0/63 culture and/or histology-positive biopsies and in 48/60 and 0/60 of 
CLO test biopsies, respectively (Table 4.2).
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4.3 Discussion
4.3.1 Current methods for identification of HHLO infections
Although the incidence of HHLO infections is high in animals like cats, dogs and 
pigs, colonisation of the human gastric mucosa is less common (Andersen et al. 
1996;Dieterich e/a/. 1998;Hilzenrat e/a/. 1995;Holck e/a/. 1997;Jhala e/a/. 
1999;Mention et al. 1999). As discussed in section 1.13.3, PCR-based studies have 
identified 77. heilmannii’ in both human (Chen et al. 1997;Morgner et al. 2000) and 
animal (Norris et al. 1999) gastric biopsies by amplification of Helicobacter genus- 
specific fragments of 16S rDNA followed by sequence analysis. One species-specific 
PCR assay, targeting the ureB gene, has been described (Neiger et al. 1998) that has 
been applied predominantly for investigation of 77. heilmannii ’ infections in animals 
and only one human case (Dieterich et al. 1998). The development of validated 
assays for detection of HHLOs is difficult because reference material is not available. 
Although culture of an organism thought to be ‘77 heilmanniV has been reported 
(Andersen et al. 1996;Andersen et al. 1999), it was subsequently shown to be 77 
bizzozeronii (Jalava et al. 2001). Thus diagnosis of human 77. heilmannii’ inÎQcXion 
currently relies primarily on microscopy-based approaches such as histological 
examination (Debongnie e/a/. 1994;Hilzenrat e/a/. 1995;Mention e/a/. 1999;Svece/ 
al. 2000;Trebesius et al. 2001). The original case study report of this infection stated 
that histology slides had to be examined for at least five minutes, otherwise the risk of 
a false negative result would be high (McNulty et al. 1989). It is thus hypothesised 
that diagnosis by histology could be relatively insensitive and consequently, the 
incidence of human ‘77 heilmanniV infection could be underestimated in the UK and 
elsewhere.
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4.3.2 Development and evaluation of HHLO-16 assay
To test the possibility discussed above, a novel PCR based assay (HHLO-16) was 
developed to amplify fragments of the HHLO genomes directly from gastric biopsies, 
and its performance was compared with that of the assay targeting the ureB gene 
(Neiger et al. 1998). The aim was to develop an assay that could detect all known 
HHLO infections so the primers were designed by multiple sequence alignment of the 
11 16S rDNA sequences o f ‘77. heilmanniV types 1 and 2 as well as 'Candidatus H. 
suis’, 77. bizzozeronii, 77. felis and 77. salomonis sequences currently held in GenBank. 
Application of the HHLO-16 assay to 12 different species of Helicobacter confirmed 
that only members of the HHLO group would be amplified. Other assays have been 
described for use on antral biopsies. For example, a 'Candidatus H. suis’-specific 
PCR assay has been described that amplified product from porcine gastric biopsies 
(De Groote et al. 2000), while another assay for the 77. bizzozeronii, 77. felis, 77. 
salomonis group was reported recently that successfully amplified specific product 
from canine gastric biopsies (De Groote et al. 2001). BLASTn analysis of each of the 
primer pairs demonstrated that the former assay would amplify only ‘77. heilmanniV 
type 1 sequences held in GenBank while the latter assay would amplify type 2 only.
In contrast the HHLO-16 assay will amplify both types 1 and 2. As each type has 
been reported in the human stomach (Trebesius et al. 2001), this novel assay is more 
suitable for application to human gastric biopsies as it provides a rapid method of 
screening for all HHLOs in a single reaction.
Comparison of the HHLO-16 assay with the ureB assay by Neiger et al (1998) 
demonstrated that both assays generated product in 13/15 feline biopsies, but while 
three human biopsies were HHLO-16 PCR positive, only one human biopsy was 
positive by the ureB assay, and the histologically confirmed positive biopsy was PCR-
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negative. This may indicate sequence variation in ureB between human and feline 
strains and suggests that the HHLO-16 assay is more sensitive for detection of HHLO 
infection in human samples. Moreover, a GenBank BLASTn search of the ureB 
primer sequences suggested that only 4/16 strains held in GenBank would be 
amplified by this assay. It seems likely that this ureB assay is ‘77. heilmanniV type 2- 
specific and thus lacks the broad specificity needed for initial testing of human 
infections. The HHLO-16 assay gave sharper single bands than the ureB assay that 
often generated non-specific bands.
4.3.3 The prevalence of HHLO infections in Southeast England
Application of HHLO-16 to 131 gastric biopsies (Groups 4 and 6) demonstrated a 
HHLO prevalence rate of 2.3 % in the series of patients in South East England. The 
incidence was higher than reported previously in other European countries (lerardi et 
al. 2001;Mention et al. 1999) and the USA (Jhala et al. 1999;Mention et al. 1999). 
This observation suggests that histology-based studies have underestimated the true 
rate of infection or that the South East of England has a higher geographical 
prevalence. If the former were true, then patients who would benefit from specific 
eradication therapy are not being identified, highlighting the benefit of a PCR-based 
approach for detection as a more sensitive alternative to histology.
4.3.4 Evaluation of HpHh PCR assay for H. pylori and HHLO detection 
The results presented show that the incidence of HHLO infection is significantly 
lower than that of 77. pylori in the study population (2.3 % v.s. 16.8 %) so it might not 
be cost effective to perform routine PCR tests for just HHLOs. The HHLO-16 assay 
was combined therefore in a multiplex format, initially with the PCR assay that 
amplified a fragment of the 77. ^y/ori-specific vacA gene, described in Chapter 3. The 
vacA primer combination was subsequently modified to allow co-amplification of
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both vacA and the 16S rRNA genes. Evaluation of the HpHh assay on 230 human 
biopsies of known H. pylori and HHLO status demonstrated that the sensitivity and 
specificity of the HpHh assay was comparable to those of the individual PCR assays. 
In addition, DNA-seeding experiments demonstrated that both targets could be 
amplified simultaneously, so this system could potentially detect co-infections with 
both HHLOs and H. pylori. Analysis of the feline biopsies demonstrated that 
sensitivity of the HHLO-16 assay was slightly reduced, with one false negative result 
generated, in the multiplex format. As PCR reagent concentrations and cycling 
conditions were re-optimised to facilitate co-amplification of both targets, reduced 
efficiency of the HHLO-16 assay may have resulted for that sample from sequence 
variation at the primer binding sites. Comparison of sensitivity of detection of tenfold
H. felis DNA dilutions (ranging from 100 ng to 1 fg) for both assay formats 
demonstrated that both uniplex and multiplex assays detected as little as 10 pg DNA, 
but the band intensity was lower for the product generated in the multiplex format. 
Thus the multiplex assay is only slightly less sensitive for HHLO detection than the 
uniplex format.
4.3.5 H. pylori and HHLO coinfection
Although human H. pylori and HHLO co-infection has been identified by histology 
(lerardi et al. 2001), neither the incidence nor the possible significance of this in terms 
of disease development has been determined. Extensive optimisation of the novel 
multiplex assay presented here to allow co-amplification of targets from both species 
in artificially spiked samples could provide the tool to investigate this further. In this 
study, no evidence of co-infection was found. A total of 123 confirmed H. pylori- 
positive biopsies were tested by the HpHh assay, but generation of specific HHLOs 
was not observed in any of the biopsies that were PCR-positive for H. pylori. Thus it
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was not possible to investigate the clinical significance of dual infection. Given the 
observed low incidence of HHLO infection in the population investigated, it could be 
concluded that the incidence of co-infections with H. pylori is comparatively rare in 
South East England. This study was limited by specimen availability but has 
nonetheless provided a powerful tool to allow future prospective investigations of 
larger study populations, to facilitate assessment of the true incidence of co-infection 
with both species and to promote understanding of the clinical significance of these.
4.3.6 Analysis of CLO test-positive biopsies
Biopsies from Group 7 had been identified as H. /jy/ori-positive by rapid urease 
testing (CLO test). However, it should be noted that urease activity of ‘77. heilmanniV 
can also cause a CLO test colour change (McNulty et al. 1989). Consequently CLO 
test-positive results may be misinterpreted. CLO test-positive biopsies were analysed 
by the HpHh assay not only to investigate the prevalence of co-infections, as 
discussed above, but also to establish if any HHLO infections had been misdiagnosed 
as 77. py/ori-positive. As had been shown for other PCR detection assays (Chapter 3), 
the sensitivity of detection for the vacA assay was lower in these biopsies than those 
in Groups 4, 5, and 6. As discussed earlier (Chapter 3), DNA degradation may have 
occurred during transit. While no biopsies were identified that were CLO test- 
positive due to HHLO infection, the possibility of false negative results in 12 biopsies 
where specific DNA may have degraded cannot be fully excluded.
A recently reported novel fluorescent in-situ hybridisation (FISH) system 
demonstrated that ‘77. heilmanniV type 1 was the most prevalent in human infection, 
while type 2 and other novel types (3, 4 and 5) were less common, with mixed type 
infections also observed (Trebesius et al. 2001). Combination of the novel HpHh 
assay with the FISH technology would provide a comprehensive strategy for better
164
Results and Discussion
characterisation of HHLO infection in humans. The development of the HpHh assay 
provides a sensitive screening method to identify those biopsies positive for HHLOs 
that require additional, more complex testing by FISH for strain differentiation and 
characterisation. A recent report that identified H. cinaedi in the gastric biopsies of 
two patients (Pena et a l 2002) has raised the possibility that a broader range of 
helicobacters may be capable of colonising the human gastric mucosa than had been 
previously appreciated. As there is only one such report to date, further investigations 
aimed at detecting other species of Helicobacter including H. cinaedi will be 
necessary to establish the extent and significance of such infections.
4.4 Conclusions
The development and evaluation of a novel multiplex PGR assay for detection of 
HHLOs and H. pylori provides a sensitive means of direct detection of the principal 
pathogens causing gastric infection and disease in man. This is the first description of 
such an assay and its routine use would enable more accurate assessment of the 
prevalence of HHLOs infection in the dyspeptic population. Additionally this would 
facilitate studies to improve our understanding of the clinical significance and 
sources, such as domestic pets, of those infections in man, as well as enabling further 
investigation ofHHLO/Æ pylori co-infections. Future prospective analyses of gastric 
biopsies will now be possible to investigate larger study populations.
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Chapter 5: Real-time PCR determination of clarithromycin resistance directly 
from gastric biopsy samples.
5.1 Background
Chapters 3 and 4 have demonstrated the value of PCR for detection of helicobacters in 
gastric tissue. Another strength of PCR is that it allows further strain characterisation. 
As discussed earlier (section 1.10) clarithromycin (CLA) is a key component of H. 
pylori eradication triple therapy (de Boer and Tytgat 2000), but successful eradication 
is seriously compromised by the development of resistance to that antibiotic 
(Goodwin 1997;Megraud and Doermann 1998). CLA resistance rates of >10 % are 
reported in some Western European countries (Glupczynski et a l 2001). This 
highlights the need for rapid methods of antibiotic resistance monitoring, not only for 
individual patient management but also to facilitate enhanced surveillance for 
detection of temporal trends and regional variations in prevalence rates.
The mechanism of CLA activity and development of resistance is described in 
detail in section 1.11.2. As discussed in section 1.11.3, most molecular tests 
developed thus far for detection of the three most common mutations responsible for 
CLA resistance (A2142G, A2143G and A2142C) require multiple reactions and have 
been applied principally to H. pylori cultured from gastric biopsies (Stone et a l 
1997;Taylor fl/. 1997;Versalovic a/. 1996) The real-time PCR based probe 
hybridisation assay (LC-CLA) described in this chapter was initially shown to 
differentiate accurately between sensitive and resistant cultures of H. pylori (Gibson 
e ta l  1999).
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The aims of the study presented in this chapter were:
1. To develop the application of a real-time LightCycler PCR-based approach for 
determination of CLA resistance directly from gastric biopsies.
2. To investigate the utility of this assay as an alternative to culture-based CLA 
susceptibility testing methods.
5.2 Results
5.2.1 Optimisation of LC-CLA assay for application to gastric biopsies
The real-time LC-CLA assay described in section 2.20.5 developed for the Idaho 
LightCycler was applied initially to ten DNA extracts: five from H. pylori cultures 
and five from matched gastric biopsies, following the reported protocol (Gibson et al. 
1999). Increased SYBR Green 1 fluorescence, indicating amplicon generation, was 
observed in DNA extracts from all five cultures but in only two of the five biopsies. 
The experiment was repeated using raised MgCb concentrations (4.0 mM, 5.0 mM 
and 6.0 mM) but this did not improve the sensitivity. Next, the number of 
amplification cycles was increased from 50 to 75, which resulted in the generation of 
specific PCR product in all five gastric biopsy DNA extracts. These modified assay 
parameters were applied in all subsequent analyses.
5.2.2 Determination of CLA resistance from gastric biopsies by LC-CLA assay 
The LC- CLA assay (section 2.20.5) was applied to a total of 259 gastric biopsies, 87 
of which were H. /7y/on-positive by culture and/or histology (see Chapter 3).
Biopsies were selected from previously defined Groups 2 (n = 39), 3 (n = 51), 4 (n = 
121), 5 (n = 39) and 6 (n = 9). Examples of the melting peaks generated and 
sequences of control strains in relation to the probe sequence are provided in Figure
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5.1. Results generated by this assay when applied to five distinct gastric biopsy 
groups are presented in Table 5.1.
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Figure 5.1 : Examples of LC-CLA assay probe melting peaks generated
directly from gastric biopsies containing H, pylori 23S rDNA that 
is wild type, or has A2142G, A2143G or A2142C mutations, and 
sequence alignment of 23SPr with control strain sequences.
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Table 5.1: Performance of LC-CLA assay to determine CLA susceptibility
direct from gastric biopsies selected from five previously defined 
groups (Chapter 3).
Gastric biopsy Group
23S rDNA 2 3 4 5 6
(n=39) (n=51) (n=121) (n=39) (n=9)
+ - 4- - + - + +
Wild type 4 0 10 1* 11 1* 36 6
A ^ G 1 0 0 I t 1 0 2 2
A ^ C 0 0 0 2 t 1 0 0 0
PCR negative 4 t 30 3Î 34 4Î 103 I t I t
Biopsies were identified as H. pylori positive (+) or negative (-) by culture and/or 
histology.
*Biopsies were culture & histology negative but H. pylori PCR-positive (Chapter 3). 
^Biopsies were positive for 16S rDNA H. /7y/c?n-specific PCR assay (Chapter 3). 
JAll biopsies were falsely negative by at least one of three H. ^ /on-specific PCR
assays (Chapter 3).
CLA susceptibilities were determined by 23S rDNA analysis in 85.1 % (74/87) of H. 
jTy/ori-positive biopsies tested. DNA extracts from 67 biopsies produced melting 
peaks characteristic of a CLA sensitive genotype, as did two additional biopsies that 
were negative for culture and histology but were demonstrated to be H. pylori PCR- 
positive, as described in Chapter 3. Repeat PCR analyses were necessary for five 
samples to generate sufficient product to allow probe hybridisation melting point 
analysis, but amplification of 23S rDNA was not successful for 13 culture-positive 
biopsy specimens. DNA from 6/87 H. joy/on-positive biopsies generated melting 
peaks indicative of a CLA resistant genotype with an A ^ G  mutation and 1/87
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generated a peak suggesting resistance due to an A->C mutation. Melting peaks were 
generated in five biopsies that were H. /?y/ori-negative by culture and histology. 
Overall specificity of application of this assay to gastric biopsies was 97.1 %.
5.2.3 Determination of CLA susceptibility in matched culture by phenotypic 
and by genotypic (LC-CLA assay) methods
Matched isolates were available for 42 of the 84 gastric biopsies originally identified 
as H. /?y/c>r/-positive by culture. For these 42 isolates, CLA susceptibilities were 
determined by E-test and by disk diffusion. For the remaining culture-positive 
biopsies, the results of disk diffusion tests performed by the primary isolating 
laboratory (Chelmsford PHL) were obtained. Altogether CLA susceptibilities of 
matched cultures were available for 79/84 patients. For five of the biopsies that 
generated a melting peak indicative of a 23 S rRNA mutation, matched available 
cultures were also analysed by the LC-CLA assay, as were 15 other representative 
cultures grown from biopsies where melting peaks produced had suggested a wild 
type gene. A summary of the results generated in H. pylori-posiXivQ gastric biopsies 
by assay LC-CLA compared with the CLA susceptibilities determined for matched 
cultures by both genotypic and phenotypic methods is presented in Table 5.2.
Overall, antibiotic susceptibility testing by disk-diffusion or E-test of 62 available 
matched H. pylori cultures or laboratory reports confirmed that isolates from 60 
biopsies that generated a melting peak curve indicative of a wild-type 23S rDNA 
sequence were CLA sensitive. The remaining two cultures comprised mixed 
populations of CLA sensitive and resistant phenotypes. E-test results on six available 
cultures matched with the seven biopsies that had generated peaks indicative of CLA 
resistance confirmed that five of these were CLA resistant (MIC > 96 mg/ml).
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Analysis of corresponding DNA extracts by the LC-CLA assay confirmed the identity 
of mutation types A ^ G  (n = 4) and A—>C (n = 1) originally detected in matched 
biopsies. The remaining isolate was CLA sensitive by E-test, in spite of an apparently 
resistant (A-^G) LightCycler profile generated from gastric biopsy.
Table 5.2: Details of CLA susceptibilities determined genotypically from 87
H, pylori positive gastric biopsies and from 20 matched cultures 
compared with available CLA resistotypes determined 
phenotypically
Genotypic LC-CLA susceptibility test Phenotypic CLA susceptibility test*
23S rRNA 
gene mutation
Gastric Matched 
biopsy culture^
Culture data Sensitive Resistant 
available
Wild Type
A-»G  
A—^C
PCR negative
67 15
6 4 
1 1 
13 0
62 60 2{
5 1 4 
1 0 1 
11 10 1
*Disk diffusion and/or E-test.
^Number of 23 S rDNA mutations determined from biopsies that were confirmed by
matched culture LC-CLA assay analysis also
{Mixed populations of CLA sensitive and resistant strains
5.3 Discussion
5.3.1 Determination of CLA resistance
CLA is a key component of most current triple therapy regimes for treatment of H. 
pylori infection, but resistance to this drug dramatically decreases the chance of
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successful eradication (Dore et al. 2000a). The identification of specific point 
mutations, namely A2142G, A2143G or A2142C, in the 23S rRNA gene (Occhialini 
etal. 1997;Stone e /ût/. 1997;Taylor a/. 1997;Versalovic e/a/. 1996) has enabled 
development of molecular tests that allow determination of CLA resistance direct 
from biopsies, without the requirement for culture (Bjorkholm et al. 1998). As 
discussed in section 1.11.3, at the time that this study was conducted, the majority of 
these tests were based on the principle that the mutated sequences create novel 
recognition sites for restriction enzymes (REs). Although PCR-RFLP provides 
information on the position of the mutation, it is time consuming, relatively labour 
intensive and until recently (Menard et al. 2002), the A2142C mutation could not be 
detected. Furthermore, some studies reported poor sensitivity (64 %) when applied to 
gastric biopsies (Sevin et al. 1998).
Additionally, other probe hybridisation methods, described in section 1.11.3.3, 
required multiple (three or more) reactions, adding to the test time and costs incurred 
(Maeda et al. 2000;Marais et al. 1999;Trebesius et al. 2000). The LC-CLA assay 
described in this chapter was the first to use the LightCycler to provide a test that was 
simple and more rapid than tests available, and enabled all three common mutations to 
be detected in a single reaction (Gibson et al, 1999). This chapter describes the first 
application of this real-time PCR based probe melting point hybridisation assay direct 
to gastric biopsies, for determination of CLA susceptibility without the requirement 
for culture. Reactions were performed in a single reaction tube in less than 1 h, so 
avoiding the risk of cross-contamination associated with molecular PCR-based assays 
and the delay of culture-based susceptibility testing.
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5.3.2 Sensitivity of LC-CLA assay
Application of the modified assay to 87 H, j^y/ori-positive gastric biopsies from 
Groups 2 - 6  (defined in Chapter 3), demonstrated that information on the CLA 
susceptibility of the infecting strain could be determined in 85.1 % of specimens. 
Thirteen culture-positive biopsies were negative for this test, with the highest 
proportion of falsely negative results observed in biopsy Groups 2 and 3 that had 
undergone prolonged incubation at room temperature prior to DNA extraction. As 
discussed in Chapter 3, most of these samples had been falsely negative by at least 
one PCR detection assay, suggesting that specific target DNA may have degraded. 
Certainly, the detection rate increased to 90.8 % if these two groups were excluded on 
the grounds that transport had been sub-optimal. In some cases, the sensitivity of the 
LC-CLA assay may have been adversely affected by sampling error; the target copy- 
number contained in the 1 pi DNA examined could be extremely low in some 
biopsies. Further evidence to support this hypothesis was provided by the initial 
observation that fifty PCR cycles were insufficient to generate enough product for 
further analysis, with no increase in SYBR Green 1 fluorescence being observed until 
45-50 cycles for many biopsies. As described in section 2.20.2.1, measurement of the 
cycle number at which this fluorescence increases exponentially is the basis for 
quantification by the LightCycler, when compared with standard DNAs of known 
concentration. Given that PCR product was generated from the 10 ng DNA controls 
included in each run at approximately 35-40 cycles, this demonstrated that the 
biopsies contained significantly less specific target. Repeat testing of five gastric 
biopsies that had initially failed to amplify specific product was subsequently 
successful, demonstrating the potential problems of sampling errors between runs 
when target levels are so low. The simple digestion method of DNA extraction for
173
Results and Discussion
these biopsies, discussed in Chapter 3, was selected as it was sufficiently rapid to 
enable same-day diagnosis of H. pylori infection and determination of CLA 
susceptibility. However, it did not contain a precipitation/resuspension step to 
concentrate extracted DNA. Sensitivity could be improved by adopting a more 
complex method of DNA extraction such as phenol chloroform extraction or use of a 
commercial kit. Alternatively the assay could be modified to a nested PCR format, 
although this would increase the total processing time and raise the risk of sample 
contamination. Assay sensitivity could be reduced also by low levels ofPCR- 
inhibitory substances that may affect the efficiency of a LightCycler assay to a greater 
extent than that of the conventional assays.
5.3.3 Specificity of the LC-CLA assay
Of the 172 culture and histology-negative biopsies analysed, melting peaks were 
generated in only five specimens (2.9 %). The two biopsies that generated peaks 
consistent with a CLA sensitive phenotype had been demonstrated to be positive by 
H. /jy/ori-specific PCR assays applied in the study described in Chapter 3. This 
corroborative evidence suggests that these are genuine positives and that tests on these 
biopsies were falsely negative by culture and histology, neither of which are 100 % 
sensitive (El Zimaity 2000;Perez-Perez 2000). This demonstrates that PCR is not 
only able to detect H. pylori infections missed by other diagnostic methods, but 
provides information on CLA susceptibility that could not be obtained by any other 
conventional method. The remaining three biopsies produced melting peaks that were 
initially interpreted as corresponding to A—>C or A—>G mutations. However, results 
presented in Chapter 3 indicated that two of these biopsies had been PCR-positive 
only by a single H. pylori specific assay targeting 16S rRNA. These discrepant 
results were thought to be due to overgrowth of other bacterial species while the
174
Results and Discussion
biopsies were in transit. The LC-CLA assay amplifies 23 S rDNA, homologues of 
which are universally present in all bacteria (Stackebrandt and Goodfellow 1991). 
BLASTn analyses suggested that the assay primers were H. /?y/on-specific, but other 
contaminating bacterial DNA that has not yet been characterised by sequencing, and 
so is not available in GenBank, may have been amplified in these cases. The 
sequence of these amplicons would differ firom that of H. /?y/ori-specific product and 
mismatch between probe and template would lower the probe dissociation 
temperature, as was observed. Although such melting peaks generated could be 
misinterpreted as infection with a resistant strain, it is important to note that false 
results were only generated in biopsies that had been subjected to considerable delays 
in transport and that no falsely positive results were generated for any other biopsy 
group. Furthermore, interpretation of these results in conjunction with those of the H. 
^/ori-specific PCR were sufficient to highlight that these results were discrepant, 
therefore the likelihood of mis-diagnosis in a routine clinical diagnostic setting is low.
5.3.4 Accuracy of CLA resistotype determined by LC-CLA assay 
Overall, the LC-CLA assay accurately determined CLA resistotype in most (95.6 %)
H. /7y/ori-positive biopsies. For two of the three cases where biopsies generated 
profiles that did not correspond to matched isolate CLA susceptibility tests, this was 
due to mixed CLA resistotype infection. Although rare, CLA resistant strains that 
lack mutations A2142G, A2142C and A2143G are documented (Hulten et a l 
1997;Gibson et al. 1999;Fontana et al. 2002). These would not be detectable by any 
of the molecular methods described for CLA susceptibility testing (section 1.11.3), 
including the LC-CLA assay. However analysis of the two CLA resistant sub­
populations by this test demonstrated that both contained A—>G mutations, thus 
discrepant results between matched cultures and biopsies were not due to absence of
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the common mutations associated with CLA resistance. In most mixed infections in 
this study, the proportion of sensitive population exceeded that of the resistant 
population, by an estimated factor of > 100 in these two examples. The amplification 
of 23 S rDNA of the sensitive sub-population for which more starting template was 
available would be more efficient during PCR as these would enter the exponential 
phase of the reaction earlier than the resistant population. At the end of the PCR 
stage, there would be significantly higher levels of amplicon from the sensitive 
population and, as the probe was exactly complementary to the wild-type template, 
preferential hybridisation of probe to this more-abundant template would occur, 
leading to generation of a peak indicative of CLA sensitivity. These results may 
highlight a limitation of single probe-based approach, namely that sensitivity may be 
insufficient to detect a very low level CLA resistant sub-population. Furthermore, a 
LightCycler profile indicative of CLA resistance was consistently generated from one 
gastric biopsy, where the matched culture tests identified a CLA sensitive population. 
A possible explanation for this is that the in vivo infection was a mixture of both CLA 
resistant and sensitive forms but only the latter was isolated on culture. Similar 
discrepancies between mutation detection and phenotypic susceptibility testing have 
been reported previously (Matsuoka et al. 1999). This suggests that even culture 
based CLA susceptibility testing may not always detect mixed strain infections. It is 
recognised that development of antibiotic resistance can lead to decreased fitness of a 
bacterial population (Andersson and Levin 1999). The possibility that efficiency of in 
vitro culture of some resistant H. pylori strains may be slightly impeded cannot be 
excluded, particularly if  competing with a more robust sensitive co-existing 
population. A PCR-based approach has the advantage that any such differences in 
strain fitness would not affect the sensitivity of detection or probe-based analyses.
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Mixed susceptibility infections were not investigated in the original assay 
evaluation (Gibson et a l 1999), but the problem could be overcome possibly by the 
development of additional probes complementary to each mutation type as these 
would bind preferentially to any exactly matched sequence, even if present at 
comparatively low levels. The Idaho model of the LightCycler used in this study had 
the limitation that only two channels were available for fluorescence measurement, 
and these were set at wavelengths which were optimal for dyes SYBR Green 1 
(channel FI) and Cy5 (channel F2). This restriction prevented the development of 
multiplex assays with specific probes labelled with different fluorescent dyes. Thus 
for CLA susceptibility testing, four separate reactions with each different probe would 
be necessary to exclude all possibility of a mixed infection. Such an approach would 
greatly increase the cost, workload and time for each test to an extent that would be 
difficult to justify, considering the high level of accuracy demonstrated for the single 
probe-based approach.
At the same time that this study was conducted Matsumura and colleagues reported 
a similar approach for the LightCycler (Roche Instrument) (Matsumura et a l 2001). 
This assay successfully determined CLA susceptibility from all biopsies tested and 
was also highly accurate. As discussed earlier (section 2.20), the fluorescent 
chemistry of the Roche LightCycler differs from that of the Idaho model, requiring 
two probes per reaction to achieve FRET for monitoring of probe hybridisation 
melting point. For the LC-CLA assay, a single probe was sufficient to distinguish 
23S rDNA that was wild type or contained either A-^G or A—>C mutations. In 
contrast the assay described by Matsumura and colleagues is more complex and also 
more expensive, as three separate reactions containing one of three probes that were 
complementary to the wild type, the A2142G or the A2143G 23S rRNA genotype
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were required. However, although this assay was unable to detect the A-^C mutation, 
it does have the advantage of providing information on the position of the A-^G 
mutation, that may be related to MIC (Alarcon et a l 2000;Dzierzanowska-Fangrat et 
a l 2001;Piana et a l 2002;Pina et a l 1998;Versalovic et a l 1997). A small 
temperature difference between melting peak and position of the A—>G mutation was 
observed in the LC-CLA assay (J. R. Gibson, personal communication), but this was 
not marked enough to allow reliable definition of mutation type.
Since this study was conducted, the LightCycler Idaho model has been largely 
superseded by the Roche model and novel assays that identify all three common 
mutations that confer CLA resistance have been developed for the latter model 
(Lawson et a l 2002). Early studies such as the one described in this chapter and 
elsewhere (Matsuoka et a l 1999) were nonetheless invaluable in demonstrating the 
potential of the LightCycler technology in this field and have stimulated the 
development of novel assays that are currently undergoing evaluation in Germany and 
France (U. Reischl, personal communication). Recently one such assay was reported 
that can detect mixed CLA susceptibility infections directly from biopsies in a single 
reaction (Oleastro et a l  2003). Thus application of a LightCycler-based approach for 
antibiotic susceptibility testing could become more widespread in the future. 
Tetracycline (TET) resistance was shown recently to occur in H. pylori by point 
mutation in the 16S rRNA gene (Trieber and Taylor 2002). This simple mechanism 
of antibiotic resistance would be suitable for testing by an assay analogous to LC- 
CLA. The development of this in the future would provide an additional tool for 
enhanced surveillance of antibiotic resistance in H. pylori.
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5.4 Conclusions
CLA susceptibility can be determined accurately in real-time direct from gastric 
biopsies, so avoiding the associated delays of culture. This study v^as among the first 
to apply a LightCycler assay to gastric biopsies for this purpose and demonstrates the 
power and versatility of PCR as a tool for management of H. pylori infection. Rapid 
provision of CLA susceptibility information could have a significant impact on 
patient management, in terms of turnaround times, appropriate antibiotic prescription 
and ultimately treatment outcome.
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Chapter 6: Determination of vacA genotype direct from gastric biopsies in a
novel multiplex PCR assay format.
6.1 Background
PCR has proved to be a key technique for the investigation of potential virulence 
factors in a range of bacterial infections (Lehoux et al. 2001; van Doom 
2001;Weinstock 2000). In the case of H. pylori, the observed variations in disease 
progression between patients are thought to be at least partially attributable to 
differences in bacterial vimlence (van Doom 2001). The vacuolating cytotoxin gene 
(vacA) is one such marker of enhanced vimlence potential. As described earlier 
(section 1.12.1), the mosaic stmcture of vacA comprises two families of allelic 
variants of the signal sequence region (si, s2) and of the mid-region (ml, m2) 
(Atherton et al 1995). Although some studies have reported an association between 
vacA genotype and disease outcome (van Doom et al 1998, Kidd et al 1999, Rudi et 
al 1999), others have not confirmed this (Go et al 1998, Gunn et al 1998, Gold et al 
2001). Further study of larger populations from different geographical areas will be 
essential to improve understanding of the significance of vacA genotype in terms of 
vimlence potential. As discussed (section 1.12.1.2), most reports to date have defined 
vacA genotype by performing two or more PCR reactions; such studies have adopted 
PCR assays based on specific primers designed by Atherton et al (1995,1999) (Ito et 
al 1997, Evans et al 1998, Gunn et al 1998, Strobel et al 1998, Kidd et al 1999).
The aims of the study presented in this chapter were:
1. To develop PCR assays to facilitate high-throughput examination of H. pylori 
vacA allelic type direct from gastric biopsies.
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2. To apply developed assays to examine, and improve understanding of, the 
relationship between vacA genotype and disease status in South East England.
6.2 Results
6.2.1 Development and optimisation of multiplex vacA genotyping PCR assay 
Primers that had been developed previously (Atherton et al 1999) to allow 
determination of vacA signal and mid region allelic types in two separate conventional 
PCR reactions, as described in section 2.18.1.1, were initially combined in a single 
reaction in a 1:1 ratio. Application of this to 15 cultures of known vacA genotype 
successfully generated the expected type in 13/15 samples, but in some cases the mid 
region amplicon was either not generated, or was of considerably lower intensity than 
that of the signal region product. Alteration of the signahmid region primer ratio to 
1:1.6 along with a raised MgCL concentration (2.0 mM) promoted generation of the 
mid region as well as the signal region products in all 15 cultures. This optimised 
multiplex format, described in section 2.18.1.2 was evaluated further as described in 
subsequent sections.
6.2.2 Performance of multiplex vacA genotyping assay on DNA from culture
Accuracy of the multiplex vacA genotyping PCR assay was evaluated on DNA 
extracted from a total of 22 cultures of H. pylori for which the vacA genotype had 
been determined by the original two-step system described in section 2.18.1.1. The 
multiplex PCR assay developed successfully generated products of sizes relating to 
signal region types si (259 bp) and s2 (286 bp), and mid region types m l (567 bp) 
and m2 (642 bp) (Figure 6.1). The expected s/m profile was generated for 21/22 
culture DNA extracts of known vacA genotype (ten si m l, seven si m2 and four 
s2m2). In one strain (H2966) known to be type s lm l, the expected 259 bp band
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corresponding to type si and a larger fragment of approximately 1.6 kb were 
generated but no band corresponding to either m type was observed.
6.2.3 Determination of vacA genotype direct from gastric biopsies 
A total of 123 gastric biopsies, positive for H. pylori by either culture and/or histology 
or by CLO test were selected from the biopsy Groups 4 (n = 13), 5 (n = 39), 6 (n = 18) 
and 7 (n = 53), defined in Chapter 3. All were tested by both uniplex and multiplex 
PCR assays for determination of vacA genotype. Descriptions of disease status and 
macroscopic appearance of the upper gastrointestinal tract recorded for every patient 
at the time of endoscopy were available for 102/123 patients.
Initial application of the multiplex system to 15 gastric biopsies and 15 matched 
cultures generated exactly correlating genotypes that were easy to interpret in all 
cases. Examples of these are illustrated in Figure 6.1. Of the 123 H. pylori-^osiXivQ 
gastric biopsies tested, vacA genotype was determined in 101 (82.1 %) using the two- 
step system (Atherton et al 1999), and in 100 (81.3 %) biopsies by the novel single- 
step approach.
The vacA genotypes were generated in 67/70 (95.7 %) gastric biopsies where H. 
pylori status had been determined by culture and/or histology (Groups 4 - 6 )  and in 
33/53 (62.3 %) of biopsy Group 7 that were H. pylori positive by CLO test alone. 
Sensitivity in biopsy Group 7 was only slightly higher (64.2 %) when signal and mid­
region testing were performed by the original two-step Atherton method.
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Figure 6.1: vacA genotypes determined by multiplex PCR assay direct from
human gastric biopsies (B) (Groups 5 and 6) compared with 
matched cultures (C). Patient 1, type s2m2, Patients 2, 5 & 6, type 
s lm l, Patients 3 & 4 type si m2. Lane 13, s lm l control (NCTC 
11637). Lane 14, s2m2 control (Tx30a). Lane 15,123 bp molecular 
weight marker.
6.2.4 Distribution of vacA genotypes according to disease
Of the 100 vacA genotypes determined from gastric biopsies, profile s lm l accounted 
for 43.0 % of samples tested while si m2 and s2m2 accounted for 31.0 % and 26.0 %, 
respectively (Table 6.1). Accompanying clinical information was available for 35, 27 
and 23 patients infected with H. pylori of genotypes s lm l, si m2 and s2m2, 
respectively. Of the 35 slm l genotypes identified, 9 (25.7 %) were associated with 
peptic ulcer disease (PUD) and 74.3 % were from patients in the non-ulcer dyspepsia 
(NUD) group. In contrast, only 8.1 % of type slm2 and 8.7 % of type s2m2
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genotypes were identified in patients with PUD. The higher proportion of type slm l 
in PUD-associated strains compared with NUD strains is illustrated in Figure 6.2.
The PUD The NUD
Group (n = 14) Group (n = 71)
14%
s1m2
21%
slml
65%
Figure 6.2 Schematic representation of the proportions of vacA genotypes in 
the peptic ulcer disease (PUD) groups and non-ulcer dyspepsia 
(NUD) groups.
Additionally, further examination of the NUD group demonstrated that type slm l was 
found in biopsies from 15/29 patients with macroscopic signs of gastritis and/or 
duodenitis recorded at the time of endoscopy, that could potentially lead to ulcer 
development. In contrast, only 5/26 (19.2 %) of isolates of type s2m2 were associated 
with macroscopic gastroduodenal inflammation (Table 6.1). Statistical analysis by 
Fisher’s exact test (section 2.25.3) of results for patients where the disease status was 
known demonstrated that the proportion of patients with gastroduodenal symptoms 
(inflammation or ulcer) infected with strains of type slm l was significant (p value
0.008), relative to patients who were either infected with type si m2 or s2m2, or for
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whom no disease or other conditions (oesophagitis, hiatus hernia) were documented at 
the time of endoscopy. The distribution of vacA genotype in relation to specific 
disease status is presented in Table 6.1.
Table 6.1: Distribution ofH,  pylori vacA genotypes determined direct from
100 gastric biopsies in relation to patient disease status
Disease Status
sl/m l
vacA Genotype
sl/m2 s2/m2
Total
Q. Gastric ulcers 3 1 2 63O
O Duodenal ulcers 5 2 0 7
Q
PPk Gastric and duodenal ulcers 1 0 0 1
Gastritis/duodenitis only 15 9 5 29
A Normal* endoscopy 7 7 9 233Ota
O Oesophagitis 3 6 6 15
A
Hiatus hernia only 1 2 1 4
Information not available 8 4 3 15
Total 43 31 26 100
*A11 patients had dyspeptic symptoms, but no macroscopic signs of disease were 
recorded at time of endoscopy
6.3 Discussion
The use of vacA genotyping methodologies is a key feature in studies investigating 
virulence potential of H. pylori from geographically diverse localities (Ito et al 1997, 
Evans et al 1998, Go et al 1998, Gunn et al 1998, Strobel et al 1998, van Doom et al
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1998, Kidd et al 1999, Rudi et al 1999, Gold et al 2001). Many different PCR-based 
and line probe-based assays have been described for genotyping, some requiring 
multiple reactions (Atherton et al 1995, Ito et al 1997, Rudi et al 1998, Strobel et al 
1998, van Doom et al 1998) while others can be performed in just two separate PCR 
tests for the signal and for the mid-region (Atherton et al 1999). One other single-step 
vacA genotyping assay has been described previously that used the Atherton primers 
to amplify the signal region but novel primers to target the mid-region (Han et al 
1999). In contrast, the work in this chapter describes a novel one-step system that 
enables rapid and convenient genotyping of both regions of vacA\ the approach was to 
combine and re-optimise two published PCR assays. The sensitivities and 
specificities of the latter assays had been evaluated extensively as two separate 
reactions on both cultures and biopsies by the HRU and by other groups (Atherton et 
al. 1999;Kidd et a l 1999;Owen et a l 2002).
6.3.1 Performance of vacA genotyping assay (single-step vs two-step format)
Han et al (1999) reported that their multiplex assay failed to determine vacA type in 7 
% of isolates tested. Strains were defined as untypeable if no product was generated 
or if  both m types (ml and m2) or s types (si and s2) were observed. Previously, 
routine determination of vacA genotype in >400 strains in the HRU by the two-step 
PCR test (Atherton et al 1999) demonstrated that a much smaller proportion of strains 
could be classed as untypeable by these criteria (approximately 2.3 %, R. J. Owen, 
personal communication). Most “untypeable” isolates were dual m type pattems of 
both m l and m2. Investigation of multiple m types by genotyping single colony picks 
showed that dual m types resulted from mixed strain infections rather than an inability 
of the assay to correctly determine vacA type (R. J. Owen, personal communication). 
Mixed type infections have been demonstrated in line probe assay-based studies also
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(van Doom et al. 1998;van Doom et al. 1999). Thus if dual types are excluded from 
this definition of untypeable, the two vacA PCR assays that were combined in a single 
assay achieves high-level typeability. Furthermore, application of the novel multiplex 
system to DNA extracts from isolates that had been genotyped by the original two- 
step system correctly identified vacA genotype in 21/22 isolates, demonstrating that 
this new format determined vacA profiles with high-level accuracy.
For isolate H2966, a larger fragment (>1.6kb) was generated but no band 
corresponding to m type observed. Determination of m type in a separate PCR 
reaction for this isolate generated a very weak intensity band of 567 bp (ml) 
suggesting that the efficiency of this reaction was sub-optimal, possibly due to 
sequence variation at the primer binding site. Efficiency of this PCR would be further 
reduced in a multiplex format due to, for example, competition for reagents with the s 
typing reaction, and this may account for the unsuccessful amplification of m type in 
this isolate. However, this is likely to be a rare occurrence, as it was not observed in 
any of the other cultures or biopsies tested in this study.
6.3.2 Determination of vacA genotype from gastric biopsies 
There are several reports of accurate and sensitive vacA genotyping direct from 
gastric biopsies (Rudi et al, 1998, Mattar and Laudanna 2000). This is a significant 
development as it not only overcomes the considerable delays of culture, allowing 
rapid determination of vacA genotype, but it can also provide additional strain 
information from biopsies where the H. pylori is no longer viable. The performance 
of the novel multiplex PCR system developed in this study was assessed by 
examination of four different gastric biopsies groups, defined in Chapter 3, that were 
of known H. j^y/on-positive status, determined in biopsy Groups 4 -  6 by culture and 
histology, and in biopsy Group 7 by CLO test alone. Application of the single-step
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genotyping system to 15 biopsies from Groups 5 and 6 and to their matched cultures 
generated identical vacA types in each biopsy/culture pair. In addition, non-specific 
bands due to human DNA in gastric biopsies were rarely observed. Application of 
this assay directly to gastric biopsy therefore generates a profile that is both accurate 
and easy to interpret. Further testing of 55 additional biopsies from Groups 4 - 6  
demonstrated that vacA genotype could be determined with high sensitivity (95.7 %).
Lower sensitivity (62.3 %) was observed for the CLO-test positive biopsies (Group 
7) -  a figure that was also lower than sensitivities reported in other studies where 
vacA genotype was determined direct from CLO-test positive gastric biopsies (Rudi et 
al 1998, Mattar and Laudanna 2000). Determination of vacA genotype in these 
biopsies by the original two-step approach was only marginally more sensitive (64.2 
%), thus the low sensitivity observed was not due to poor performance of the 
multiplex system. As discussed in Chapter 3 the low sensitivities of PCR detection 
assays demonstrated in this biopsy group were proposed to be attributable to 
degradation of target DNA. However, while none of these biopsies contained viable 
organisms, it was still possible to determine the vacA genotype in a considerable 
proportion (62.3%) of this group.
It is evident that PCR-based systems provide an invaluable means of gaining 
additional strain information that would not be otherwise available from specimens 
that are not routinely cultured. This is particularly important for H. pylori as 
relatively few centres routinely diagnose infection by culture in the UK or in other 
European countries (Heep et al 2001). In contrast, CLO tests are used widely as they 
allow rapid detection of H. pylori, even though they provide no further strain 
information. This multiplex system therefore provides a rapid, accurate and 
economical mode of vacA genotype surveillance from a larger cross-section of the
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dyspeptic community than would be available if relying on culture alone. This should 
facilitate more extensive and comprehensive studies of the relationship between vacA 
genotype and disease status and ultimately improve understanding of pathogenicity of
H. pylori infection.
6.3.3 vacA genotype in relation to disease progression
Using gastric biopsies directly as a means of determining vacA genotype information 
demonstrated that slm l was the most prevalent genotype in South East England, 
while type si m2 and s2m2 were less common. Although no exact correlation 
between genotype and disease status was observed, genotype s lm l appeared to be 
more often associated with peptic ulcer disease and severe gastritis or duodenitis 
while types si m2 and s2m2 were more frequently observed in patients who had other 
conditions or were macroscopically normal at endoscopy. As the survey was 
relatively small, no firm conclusions can be made regarding the role of vacA genotype 
in relation to disease progression, although statistical analyses suggested that this 
association was significant. These observations support reports from other workers 
that type sl/m l strains appear to be more virulent than s2/m2 strains (Gunn et al 
1998, van Doom et al 1998, Kidd et al 1999, Rudi et al 1999). The multiplex assay 
described and its potential to be applied directly to clinical samples will however 
provide the means to study larger populations to allow further evaluation of this 
relationship.
6.4 Conclusions
The single-step multiplex PCR reaction developed in this study has provided an 
alternative means of genotyping the signal and mid-regions of vacA, based on well- 
validated primers. The assay is rapid, highly accurate and also more convenient and
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economical than existing assays, both in terms of labour and reagents. Additionally, 
this system can be applied directly to gastric biopsies analysed by the rapid urease 
(CLO) test, for which culture is not performed. This will facilitate further 
surveillance of vacA genotype and improve understanding of the role of this gene as a 
potential virulence factor in H. pylori infection.
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Chapter 7: Development and application of real-time PCR in the investigation
of H, pylori cagA tyrosine phosphorylation motifs in relation to 
strain virulence
7.1 Background
The previous chapter demonstrated the value of PCR for rapid vacA genotype 
determination from bacterial isolates and clinical samples. The results presented 
supported the previous observation that no single pathogenicity factor has yet been 
proved to be uniquely associated with the ability of H. pylori to cause gastroduodenal 
ulcer disease or cancer (Blaser 1999).
As discussed in section 1.12.2, cagA is one of 31 genes encoded on a 40-kb 
pathogenicity island (PAI) present in a subset of strains (type I) that reportedly causes 
higher levels of inflammation than strains lacking cagPAI (Censini et al. 1996). 
Recent in vitro studies suggest that H. pylori exports CagA protein via a type IV 
secretion system encoded by the cag PAI (Backert et a l 2000;0denbreit et a l 
2000;Stein et a l 2000). CagA is then translocated into the gastric epithelial cells 
where it induces host cell kinases that phosphorylate tyrosine residues in CagA 
adjacent to the site of bacterial adhesion on the host gastric epithelial cells. This in 
turn activates eukaryotic signal transduction pathways, leading to actin reorganisation 
and pedestal formation (Stein et a l 2000). Three putative nucleotide tyrosine 
phosphorylation motifs (TPMs), designated A, B and C, in the CagA protein were 
predicted with the MOTIF algorithm (Odenbreit et a l 2000). The significance of 
these in terms of bacterial virulence has not been established to date.
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The aims of the study presented in this chapter were:
1. To develop and evaluate novel real-time LightCycler PCR hybridisation 
assays for the detection of nucleotide sequence motifs in cagA corresponding 
to the amino acid TPMs A, B and C proposed by Odenbreit et al (2000).
2. To apply these assays to a set of 84 clinical isolates of H. pylori, all from one 
locality in England (mid-Essex), firstly to determine the prevalence of motifs 
A, B and C, and secondly to assess the significance of these in relation to 
disease severity.
3. To establish if the assays developed could determine cagA TPMs A, B and C 
directly from gastric biopsies.
7.2 Results
7.2.1 Bacterial stratus
Eighty-four isolates of H. pylori included in the study originated from the HRU 
collection, cultured from antral gastric biopsies from dyspeptic patients undergoing 
routine upper gastrointestinal tract endoscopy at Broomfield Hospital (Chelmsford). 
No specific clinical selection criteria were applied for inclusion of patients in the 
study, but all isolates were reported previously to carry an intact cag-VPA (Owen et al. 
2001) and vacA signal (s) and mid-region (m) type had been determined prior to this 
investigation. Isolates from five clinical disease groups, defined on the basis of 
endoscopic investigation, were examined: the duodenal ulcer (DU) group (n = 23 
strains), the gastric ulcer (GU) group (n = 14 strains), the DU and GU group (n = 4 
strains), the gastric neoplasia (GN) group (n = 2), and the non-ulcer dyspepsia (NUD) 
group (n = 41 strains). Similarly to the NUD group described in the previous chapter, 
the latter group was diverse as it contained patients diagnosed with chronic gastritis
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and/or duodenitis, and/or oesophagitis, as well as endoscopically normal oesophagus, 
stomach and duodenum.
All 84 isolates were tested for TPMs A, B and C by three novel PCR assays 
(CagMotA, CagMotB and CagMotC), developed for the LightCycler, as described in 
section 2.20.6. As this was a collaborative study within the HRU, isolates were also 
tested for TPM-A and TPM-C by three novel PCR-RFLP assays that were developed 
and evaluated in a separate study, allowing comparison of the relative performances 
of real-time versus block PCR (data made available by kind permission of S. I. Sharp 
and R. J. Owen). Further evaluation of assays was performed by direct DNA 
sequencing of representative isolates, following the protocols described in sections
2.18.2.2 and 2.22.
7.2.2 Development and evaluation of cagA TPM-A LightCycler assay 
(CagMotA).
Probe CagMotA was designed to complement sequences of control strains NCTC 
11638 and NCTC 12455 (strain 26695) that contain nucleotide sequences 
corresponding to the TPM-A described (Figure 7.1). Initial evaluation of this assay 
by testing control strain DNAs (Appendix A.2.3) demonstrated that strains containing 
the motif generated melting peaks indicating the highest probe-template dissociation 
temperature (approximately 65.0 °C) (Figure 7.1). Observed probe-template Tms of 
TPM-A positive strains varied between runs, ranging from 60.4 to 66.0 °C. In 
contrast, lower probe Tms were determined for reference strains lacking TPM-A, 
ranging from 55.6 to 61.5 °C (Figure 7.1). TPM-A positive strains were therefore 
always defined relative to the reference DNA samples.
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Figure 7.1 : Examples of melting curves generated by four H. pylori reference
strains, and alignment of CagMotA with reference strain 
sequences.
Performance of LightCycler assay CagMotA was evaluated by comparison of results 
obtained with those generated by two PCR-RFLP assays that differentiated TPM-A 
positive and negative strains on the basis of specific profiles generated following 
restriction of a 356-bp cagA fragment with either Hinji or Ddel (ST. Sharp, personal 
communication). Of the 84 isolates tested, 54 were TPM-A positive by all three 
assays. Two of these isolates were confirmed as TPM-A positive by sequencing also. 
Four isolates were negative by assay CagMotA but positive by both PCR-RFLP 
assays. Product amplification failed in the CagMotA assay in one other isolate but 
gave a positive result in both PCR-RFLP assays, while another isolate did not yield a
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PCR product for RFLP analysis but was identified as TPM-A positive by assay 
CagMotA. The 24 isolates remaining were TPM-A negative by both approaches. 
However partial digestion of amplicon was observed in 19/24 cases for one of the 
PCR-RFLP assays, and Tms generated for some isolates by the CagMotA assay were 
only slightly lower than those observed for the control TPM-A-positive strains. Thus, 
the absence of TPM-A was also confirmed by sequencing in all 24 cases (data not 
shown). Overall, TPM-A was detected by at least one of the assays in 60 isolates (71 
%), either singly (64 %) or in combination with other TPMs (7 %).
7.2.3 Development and evaluation of cagA TPM-B LightCycler assay 
(CagMotB).
Probe cagMotB was designed to complement the sequence of the reference strain 
26695 that contained TPM-B (Appendix A.2.3, Figure 7.2). While most reference 
strains lacked TPM-B due to a 6-bp deletion at nucleotide 2698, the apparent absence 
of TPM-B in reference strain J99 is due to a single substitution only (A2693G)
(Figure 7.2). TPM-B is positioned in the variable region of cagA (Odenbreit et al. 
2000;Yamaoka et al. 1998). To ensure that any probe-template mismatch was due to 
absence of TPM-B and not due to inherent sequence variation, cagMotB was designed 
to span a region that commenced 12 bp upstream of the region associated with TPM- 
B (Figure 7.2). Preliminary testing of reference strains demonstrated that the Tm of 
probe cagMotB for TPM-B-positive strain 26695 was highest (approximately 67.0 
°C), while the observed Tms for reference strains lacking TPM-B were lowered 
according to the level of sequence variation (Figure 7.2). Strain J99 was most similar 
to the probe and so generated a peak indicating a slightly lower Tm than observed for 
26695, while strains NCTC 11637 and ATCC 43526 that had the highest degree of 
mismatch generated low-intensity peaks of low Tm (Figure 7.2), A PCR-RFLP assay
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could not be developed to test for TPM-B as the level of sequence variation in this 
region of cagA is high and a suitable reeognition site for potential restriction enzyme 
(RE) digestion could not be found.
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Figure 7.2: Examples of melting curves generated by five H. pylori reference
strains, and alignment of CagMotB with reference strain 
sequences.
Application of the CagMotB assay to the collection of 84 clinical isolates identified 
TPM-B in three isolates (4 %), all in combination with other motifs. Direct DNA 
sequencing of two of the positive strains confirmed the presence of TPM-B. For four
196
Results and Discussion
other strains that generated Tms similar to that observed for strain J99, DNA 
sequencing confirmed absence of TPM-B (data not shown).
7.2.4 Development and evaluation of cagA TPM-C LightCycler assay 
(CagMotC).
Probe cagMotC was designed to match the cagA sequence of TPM-C positive 
reference strains ATCC 43526 and NCTC 11637. Initial testing of reference strains 
(Appendix A.2.3) by the CagMotC assay demonstrated that these TPM-C positive 
strains generated peaks corresponding to the highest probe-template Tm 
(approximately 66.0 °C) (Figure 7.3). The observed Tms for reference strains lacking 
TPM-C were lower, ranging from 56.0 to 63.0 °C, depending on the level of strain 
sequence variation (Figure 7.3).
Application of assay CagMotC to 84 clinical isolates identified TPM-C in four 
isolates, and generated equivocal results in two isolates, as indicated by Tms that were 
slightly lower than for the positive control strains but higher than for negative control 
strain NCTC 11638. PCR-RFLP results suggested TPM-C was present in all 6 
isolates. Sequence analyses confirmed presence of TPM-C in two isolates that were 
positive by both assays and in one of the two isolates that generated an equivocal 
CagMotC assay result (data not shown). PCR-RFLP suggested that TPM-C was 
present in an additional nine isolates (S. I. Sharp & R. J. Owen, personal 
communication) but analysis by assay CagMotC did not confirm this, nor did 
sequencing of five of these. All remaining 70 strains were negative for TPM-C by 
both CagMotC and PCR-RFLP assays. Overall, TPM-C was detected in 5 strains (6 
%) either singly (1 strain) or in combination with other motifs (4 strains). TPM-C 
was most commonly present in combination with TPM-A (4 strains).
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Figure 7.3: Examples of melting curves generated by five H. pylori reference
strains, and alignment of CagMotC with reference strain 
sequences.
7.2.5 Determination of cagA TPMs directly from gastric biopsies
This study examined a total of 79 gastric biopsies, positive for H. pylori by culture 
and/or histology that were selected from biopsy Groups 4 (n = 17), 5 (n = 39), 6 (n = 
18) and 7 (n = 5), defined in Chapter 3. Initial testing of all 79 biopsies by the cagA 
assay described earlier (2.18.2.1) generated specific amplicon in 38 biopsies, 24 of 
which were from Group 5. Very faint amplicons were observed in ethidium-bromide 
stained agarose gels in 14/38 cases.
Assays CagMotA, CagMotB and CagMotC were applied to all 24 biopsies that 
were strongly positive for cagA and to five biopsies that had generated faint
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amplicons in the initial PCR analysis for cagA. The results of these analyses are 
presented in Table 7.1. The cagA TPM-status was determined successfully at all three 
positions (A, B and C) in 12 samples, all of which were from biopsy Group 5. For the 
remaining 17 biopsies, at least one of the TPM assays failed to generate a melting 
peak at the probe hybridisation analysis stage. Probe-template Tms were determined 
successfully for TPMs A and C only in five biopsies, three of which were TPM-A- 
positive. Two biopsies generated melting peaks indicative of a cagA sequence 
lacking TPMs B and C, but TPM-A status could not be determined. Melting peaks 
were generated for assay CagMotC only in the remaining ten samples, all of which 
lacked that TPM.
Table 7.1: Determination of cagA TPM status directly from gastric biopsies
of 29 dyspeptic patients
cagA TPM Total Number
A B c of Biopsies
+ - + + -
9* 3 1* 11 0 12 12
3 2 NDt ND 0 5 5
ND ND 0 2 0 2 2
ND ND ND ND 0 10 10
*One biopsy was positive for both TPM-A and TPM-B. 
tSpecific TPM could was not determined by assay CagMotA and/or CagMotB.
For assay CagMotA, the mean cycle number where SYBR Green 1 fluorescence (= 
amplicon generation) first began exponential increase, termed the crossover threshold 
(Ct) was 2 3 .40  (± 2 .2 1 )  for biopsies where TPM-A status could be determined, but
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was 34.62 (± 2.65) for specimens where the assay failed. This is illustrated in Figure 
7.4. Similarly for the CagMotB assay, mean Ct values were higher for specimens 
where TPM-B status could not be determined (32.67 ± 2.85 vs. 25.08 ± 2.58). For 
both assays CagMotA and CagMotB, these observed differences between Cjs of 
successful and unsuccessful analyses were statistically significant by unpaired t test 
(section 2.25.2), with respective p values of 0.0001 and 0.0002.
Control
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Control
TPM A  +
Failed
Failed
Failed U.
ë
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3
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Cycle Number
Figure 7.4: PCR amplification of cagA fragments by LightCycler assay
CagMotA directly from gastric biopsies. Amplicon generation, 
represented by increased SYBR Green 1 fluorescence, occurs earlier 
for biopsies where TPM-A was successfully determined.
Only the 12 biopsies fully characterised for TPMs A, B and C were included in the 
examination of relationship between TPM and disease outcome (Table 7.2). As for 
the bacterial isolates described in section 7.2.1, patients were sub-divided on the basis 
of endoscopic investigation into either the NUD group (n = 6), the DU group (n = 4) 
or the GU group (n = 2).
200
Results and Discussion
7.2.6 Distribution of cagA TPMs by disease group.
The distribution of cagA TPMs in relation to patient disease is presented in Table 7.2.
Table 7.2: Distribution of cagA TP motifs in 84 H, pylori isolates and in 12 
gastric biopsies in relation to patient disease.
Gastric disease*
cagA
(n) No Single motifs Multiple motifs
motif A B C A,B A,C A , B, C
GU(16) 3 11 0 0 0 2 0
DU (27) 9 16 0 1 1 0 0
GU+DU (4) 1 3 0 0 0 0 0
GN(2) 0 2 0 0 0 0 0
NUD (47) 13 30 0 0 2 1 1
Total (96) 26 62 0 1 3 3 1
GU, Gastric Ulcer; DU, Duodenal Ulcer; GN, Gastric Neoplasia; NUD, Non-Ulcer 
Dyspepsia.
Overall the cagA of 72.9 % of strains contained at least one TPM (Table 7.2). The 
distribution of the TPMs among clinical isolates and biopsy specimens was slightly 
higher in GU patients (13/16, 81.3 %) compared to DU patients (18/27, 66.7 %), but 
this was not statistically significant by Fisher’s exact test (p = 0.484), described in 
section 2.25.3. The cagA TPM-A was widely distributed amongst isolates and 
specimens regardless of disease symptoms. In contrast, TPM-B and TPM-C were rare 
either as a single motif or in combination with TPM-A, and no associations with 
disease symptoms were evident. Although the prevalence of TPM-A was higher in 
isolates fi*om GU patients (13/16, 81.3 %) compared to DU patients (17/27, 63.0 %),
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again there was no significant correlation between a gastric nicer-associated strain 
and presence of that motif (p = 0.307). Comparison of the incidence of TPM-A in 
peptic ulcer disease (PUD) patients (from the GU, DU or GU and DU groups) with 
that of the NUD group demonstrated no association between PUD and TPM-A (p = 
1.000). TPM-A was also observed in the two strains associated with GN, but 
numbers examined were too small to merit statistical analysis.
7.3 Discussion
In this study, novel rapid real-time PCR hybridisation assays were developed to test 
the H. pylori genome for the presence of nucleotide sequence motifs that can be used 
to predict the corresponding deduced three CagA amino acid TPMs (A, B and C) 
described previously (Odenbreit et al. 2000;0denbreit et al. 2001). As these amino 
acid motifs are proposed to be associated with tyrosine phosphorylation of CagA 
protein, they were investigated to determine if  they might provide novel markers of 
more severe disease outcome as a result of increased H. pylori-host epithelial cell 
interactions. Polymorphisms within cagA may affect the biological function of the 
protein and might explain the lack of a consistent correlation between cagA and 
disease severity previously noted (Mitchell et al. 1996). The original studies on 
TPMs were based on only a small number of diverse isolates of H. pylori so the 
purpose of this study was to investigate TPM variation and frequency in a larger 
sample of isolates from peptic ulcer as well as NUD patients.
7.3.1 Performances of real-time PCR assays
Three LightCycler probe hybridisation PCR assays (CagMotA, CagMotB and 
CagMotC) were developed to facilitate rapid, high-throughput detection of each Cag 
TPM. Initial evaluation of each assay using reference strains of known cagA
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sequence demonstrated that determination of probe-template Tm distinguished strains 
containing the relevant TPM from those that did not. Although repeat analyses 
demonstrated minor inter-run variation of Tms, the relative differences in Tm between 
different strains remained constant for each run. This highlighted the importance of 
including appropriate reference strains in each run as controls to allow interpretation 
of melting peaks generated by unknown samples. Direct DNA sequencing was 
considered the gold standard to check assay specificities for selected samples but it 
was not feasible to confirm all results by conventional automated sequencing.
The study population had also been tested for TPMs A and C by three PCR-RFLP 
assays, two of which were TPM-A specific while the third detected TPM-C. This 
data was provided by colleagues (S. I. Sharp & R. J. Owen) to establish the relative 
performances of a real-time PCR versus a conventional block PCR approach. For 
TPM-A, both approaches successfully classified strains as positive or negative in the 
majority of cases. However, the identification by PCR-RFLP only of four strains that 
contained TPM-A demonstrated the potential pitfalls of a probe hybridisation method 
for identification of specific mutations in a highly diverse gene. Sequence variation 
anywhere in the 20 - 25 bp region of template complementary to the probe would 
lower the Tm, even if specific sequence corresponding to the TPM was present. In 
contrast RFLP was more specific as RE digestion required recognition of very few 
nucleotides ( 4 - 6  bp) that were all directly associated with the TPM amino acid 
sequence. However, the failure of the PCR-RFLP primers to amplify product in one 
strain that was successfully analysed by the LightCycler-PCR assay again highlights 
the importance of a multiple primer approach in any PCR-based investigation of a 
genomically heterogeneous species.
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For TPM-C positive strains, LightCycler PCR and sequencing results showed good 
correlation in most (7/9) cases, although only sequencing could define TPM-C status 
accurately in the two isolates that had generated equivocal melting peaks by assay 
CagMotC. In contrast, the PCR-RFLP that used RE Tsp509l was less reliable and 
misidentified TPM-C in nine isolates. It had not been possible to identify a RE 
specific for the TPM-C sequence, but examination of strain-sequences held in 
GenBank suggested that the Tsp5Q9\ recognition sequence found immediately 
downstream of the TPM-C sequence was only present in strains that contained the C- 
motif (S. I. Sharp, personal communication). However, results obtained here suggest 
that although rare, strains that lack TPM-C but contain the 7^^5091 restriction 
sequence do occur, and so the PCR-RFLP assay was not sufficiently specific.
In the case of TPM-B, it was only possible to develop a LightCycler assay.
Because of the high level of sequence diversity in this region observed in the 
reference strains, no RE could be found to identify TPM-B by PCR-RFLP analysis (S.
I. Sharp, personal communication). The LightCycler assay showed good concordance 
with direct sequencing, although interpretation was complicated by a number of 
equivocal results, probably due to the diversity in this region of cagA.
One potential limitation of the three LightCycler assays developed in this study was 
the use of the dye Cy5 to monitor probe-template dissociation. While the wavelength 
of fluorescence emitted by Cy5 is optimal for the channel settings on the Idaho 
LightCycler, it is sub-optimal for the settings of the Roche instrument that superseded 
the Idaho model and was used in this study. It was not possible to adopt the 
recommended dual-probe format for the Roche LightCycler (described in section 
2.20.2.2) as multiple alignment of cagA revealed that there was insufficient sequence 
conservation adjacent to the TPM sites. In contrast, less conservation is necessary for
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the bi-probe format that uses a single probe spanning the mutated sequence only. At 
the time that this study was conducted, Roche had advised that a bi-probe format was 
not appropriate for this instrument as FRET would not occur between the 
recommended LightCycler dyes (LC red 640 and LC red 705) and SYBR Green 1. 
Thus the use of a sub-optimal fluorescent marker (Cy5) in this study may account for 
some of the difficulties in interpreting melting curves generated, as only a small 
proportion of the total emitted fluorescence would be detectable by the Roche 
fiuorimeter. In spite of this, results were still unequivocal in most cases. However, 
assay FS-53 (described in Chapter 10) was developed subsequently and that 
demonstrated efficient FRET between SYBR Green 1 and LC Red 640. Thus 
labelling of probes used in assays CagMotA, B or C with appropriate LC Red dyes 
and assay re-optimisation would be advisable for any future studies of cagA TPMs.
Because of the high degree of inter-strain sequence diversity within cagA, 
particularly within the TPM-B region, no single PCR assay format was applicable to 
all motifs. However, LightCycler TPM assays for motifs A, B and C offer the 
advantage of simplicity (single tube reaction) and speed, with same-day results 
generated within one hour, compared to 12-24 h by conventional PCR-RFLP analysis. 
In addition, the high specificity of PCR-RFLP limits this approach to sequences in a 
gene that are recognised by an available RE, whereas a probe-based approach is 
applicable to a wider range of sequences.
7.3.2 Determination of cagA TPM status directly from gastric biopsies
Initial determination of cagA status by conventional block PCR demonstrated that 
only 48 % of the 79 gastric biopsies tested were positive. Previously, approximately 
70 % of H. pylori isolates from the same region of South East England had been 
shown to contain this gene (Owen et a l 2001) and the lower prevalence reported in
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this study is likely to relate to falsely-negative PCR rather than to true absence of 
cagA. Poor sensitivity of PCR detection assays when applied to gastric biopsies was 
described in Chapter 3, particularly for one assay targeting glmM. The cagA assay 
applied in this study may be similarly insensitive when applied to biopsies where 
lower target DNA levels exist, possibly due to sample degradation. Evidence that the 
low cagA prevalence is related to specimen quality was provided by the observation 
that cagA was detected in approximately 67 % of the 36 biopsies of Group 5. 
Sensitivity of H. pylori detection by the glmMVCK  assay had been high in this group 
also (Chapter 3). It is likely that further optimisation of the cagA assay would be 
necessary to improve sensitivity for the other biopsy groups tested. As the purpose of 
this analysis was to identify a small number of biopsies that could be tested for cagA 
TPMs, this assay was not optimised further. However, future studies investigating 
significance of the presence of this gene in relation to differing disease states and 
other virulence markers, would necessitate assay optimisation for accurate 
determination of cagA status direct from biopsies.
Application of the three LightCycler TPM PCR assays to 29 cag/4-positive 
specimens demonstrated that assay CagMotC could determine TPM-C status with 
high sensitivity (100.0 %), generating melting peaks that were easily interpreted as 
TPM-C negative in all cases. In contrast, assays CagMotA and CagMotB were less 
sensitive, with TPM status determined for each in 17/29 and 14/29 biopsies, 
respectively. All five biopsies that had been defined as weakly positive by 
conventional cagA PCR also failed to generate a result by either of these two assays. 
For both assays, amplicon was generated in all biopsies. However, analysis of C t 
values, that provide quantitative information on specific DNA levels, demonstrated 
that these were significantly higher in samples that failed to generate a result.
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indicating lower initial levels of specific DNA. These observations provide evidence 
that the most likely explanation for failure of assays CagMotA and CagMotB was that 
neither was sufficiently sensitive to analyse samples containing lower levels of target 
DNA. Chapter 8 presents evidence that the LightCycler can detect specific DNA at 
low levels from stool samples if the assay is first preceded by a round of conventional 
PCR. A similar nested format approach for the two assays discussed here could 
overcome the problems of poor sensitivity. This was not attempted for the purpose of 
this study as it is likely that, for any future investigations, all three TPM assays would 
be re-designed so that probes were labelled with optimal LC Red dyes, as discussed 
above. This alteration would maximise fluorescent emissions detectable and may be 
sufficient to improve sensitivity of probe-hybridisation melting point analysis in these 
samples. Any sensitivity problems that remained could be addressed at that stage by a 
nested-PCR format. Nevertheless, the work presented in this chapter demonstrates 
that characterisation of cagA directly fi*om gastric biopsies is possible and highlights 
the potential for PCR-based analyses of samples where culture is not available. Direct 
testing of clinical samples allows rapid investigation of a wider study population than 
would be possible by culture-based studies alone. Real-time PCR assays could 
provide a powerful strategy for investigating the significance of these putative 
virulence factors, particularly if  used in combination with real-time sequencing 
approaches such as pyrosequencing that are appropriate for short (25-50 bp) motifs 
(Monstein et a l 2001), to characterise any equivocal results generated by real-time 
PCR assays.
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7.3.3 Prevalence of cagA TPMs in English isolates and their relationship to 
disease progression
The results presented in this chapter demonstrate that TPM-A was a common feature 
(72.9 %) of the 84 H. pylori type I strains isolated and the 12 gastric biopsies 
collected from dyspeptic patients in mid-Essex, irrespective of associations with 
chronic clinical disease such as presence of gastric and/or duodenal ulcers and gastric 
cancer. By contrast, TPM-B and TPM-C were less common and detected in only 4.2 
% and 5.2 % of strains, respectively, and mostly in combination with TPM-A. 
Interestingly, the strains with no detectable motif were usually vacA m2, which is the 
strain genotype that interacts least with the host gastric mucosa (Atherton 1998). 
Although no specific associations between TPM and disease status could be made, it 
should be appreciated that any study that examines pathogenicity of a chronic 
infection such as H. pylori is limited by a lack of appropriate negative controls. All 
isolates and gastric biopsies included in this study were recovered from symptomatic 
(dyspeptic) patients. It is not possible to establish if patients in the NUD group were 
infected with less virulent strains that were unlikely to lead to further disease or if 
apparent absence of disease merely reflects early patient investigation and 
interception of natural progression to a severe clinical outcome.
A recent study investigated TPM frequencies by direct sequencing of appropriate 
regions of cagA in H. pylori type I isolates from 15 gastritis and 18 gastric cancer 
patients in Costa Rica (Occhialini et al. 2001). The relative frequencies of two of the 
TPMs were significantly higher than were found in the study presented here, with 100 
% for TPM-A, and 58 % for TPM-B, while TPM-C was not detected in any strain. 
The reasons for observed differences in both studies is unclear, particularly for motif 
B, but they could be due to intrinsic differences in the patient populations examined.
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Certainly a recent review that surveyed TPM frequencies in cagA sequences held in 
public databases reported a higher TPM-A incidence in isolates of Eastern origin than 
those from Western countries (Evans, Jr. and Evans 2001). Alternatively the 
definition of TPM-B in the Costa Rican study as amino acid sequence KNST/GEPIY 
at position 899 may account for the higher incidence reported (Occhialini et al. 2001). 
Similarly, the higher frequency of TPM-B (58 %) reported from the database survey 
may be due also to the author’s broader definition of potential motifs at this site 
(Evans, Jr. and Evans 2001). Nevertheless, as observed in this study of English 
isolates, the Costa Rican study found no association between number of TPMs and the 
type of disease from which the strain originated. However, the results presented in 
this chapter suggest a trend, albeit not statistically significant, indicating that a higher 
proportion of GU-associated compared with DU-associated strains contained TPM-A 
(81 % vs. 63 %). This observation may merit further study on a larger set of such 
isolates. Analysis of other cagA sequences also revealed that only a minority 
contained TPM-C (Evans, Jr. and Evans 2001). Studies conducted in vitro have 
demonstrated that TPM-C alone was sufficient for tyrosine phosphorylation in AGS 
cells while TPM-A was not (Puls et al. 2002), however the low frequency of this 
motif suggests that it may not play a role in the pathogenesis of H. pylori. In contrast, 
the higher prevalence TPMs A and B may be more frequently associated with disease. 
The study by Puls et al (2002) also indicated that regions of CagA other than the 
TPMs identified thus far can lead to tyrosine phosphorylation. Additional TPMs have 
been identified which are characterised by the peptide sequence EPIYA (Backert et 
a l 2001) that lead to dephosphorylation of host proteins in AGS cells (Stein et al. 
2002). This amino acid motif is also present as part of TPM-B, and occurs as multiple 
repeats, located upstream of the TPM-C site at the COOH terminus of CagA. These
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TPMs are identical to R1 repeat sequences characterised previously (Yamaoka et al. 
1998). According to that study, strains which had a CagA containing three EPIYA 
elements at the C-terminal end, were predominantly isolated from patients with 
gastric cancer and severe gastric atrophy (Type C), whereas isolates with two EPIYA 
repeats (Type A) were evenly distributed among patients with different gastric disease 
symptoms. Further analysis of the C-terminal region showed that both Type A and C 
strains lacked TPM-C. However, all Type C strains were TPM-B positive whereas 
approximately a third of the Type A strains lacked TPM-B (S. Rijpkema, personal 
communication). These findings suggested the presence of TPM-B may also enhance 
pathogenicity of H. pylori whereas the presence of TPM-A in those isolates could not 
be verified. Thus further investigation of H. pylori isolates, particularly of those 
associated with gastric cancer, is warranted. The remaining 23 isolates in our study 
did not contain motifs in the PCR assays and in that respect resembled strain J99 (US, 
duodenal ulcer isolate) although that strain had one R1 repeat 50 bp upstream of the 
non-functional TPM-C, while the incidence of EPIYA in the study population 
investigated in this chapter was not determined. Recent evidence suggests that the 
level of tyrosine phosphorylation, SHP-2 binding and cellular rearrangements relates 
to the number of EPIYA repeats in Western strains and the arrangement of cagA in 
Eastern strains leads to even greater signal transduction (Higashi et al. 2002). 
Extension of this study to examine this collection of English isolates for motif EPIYA 
also would allow associations between CagA tyrosine phosphorylation and virulence 
to be assessed more fully.
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7.4 Conclusions
The work presented in this chapter has demonstrated that real-time PCR assays 
developed for the Roche LightCycler are a rapid alternative to sequencing for large- 
scale screening of H. pylori isolates for the specific cagA TPMs described previously 
(Odenbreit et al. 2000). Additionally, TPMs can be determined directly from gastric 
biopsies, facilitating larger investigations of broader populations in the future. The 
results presented show that while TPM-A is common in patients in mid-Essex there is 
no evidence in support of a direct association between presence of that TPM or the 
other rarer TPMs (B and C) and the occurrence of peptic ulcer disease. The presence 
and disease associations of these and other TPMs such as the EPIYA repeats need to 
be investigated in a wider selection of strains in relation to the degree of inflammation 
in the host gastric tissue as well as the level of tyrosine phosphorylation of CagA 
protein in infected epithelial cells.
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Chapter 8; Comparison oiH, pylori detection in stool specimens by PCR and 
by ELISA or immunochromatography kits
8.1 Background
The previous chapters have focused on the potential of PCR for detection of 
helicobacters directly from gastric biopsies. Additionally, the power of PCR as an 
alternative to culture for gaining additional strain information has been demonstrated 
in Chapters 5 -7 .  One disadvantage of the approaches discussed thus far is that 
biopsies are collected invasively, posing a small risk to the patient, as well as 
increasing costs of patient management. Diagnosis of H. pylori infection from 
specimens collected non-invasively would clearly be a preferable alternative. As 
discussed in section 1.5.2.3, the recent development of two commercial ELISA kits. 
Premier Platinum HpSA and Amplified IDEIA HpStAR has allowed non-invasive H. 
pylori diagnosis by detection of specific antigen in stools (Vaira et a l  2000). Most 
studies to date have evaluated the former kit only, with a few exceptions that 
examined the IDEIA HpStAR kit also (Koletzko et a l 2003;Leodolter et a l 
2002;Makristathis et a l 2000). These stool tests have been shown to be highly 
sensitive and specific when applied to adult (Odaka et a l 2002;Vaira et a l 2002) and 
to paediatric populations (Konstantopoulos et a l 2001;0derda et a l 2000) for testing 
pre-treatment (Gisbert and Pajares 2001;Konstantopoulos et a l 2001 ;Makristathis et 
a l 2000;0derda et a l 2000) and post-therapy (Gisbert and Pajares 
2001;Konstantopoulos et a l 2001;Leodolter et a l 2002;Makristathis et a l 2000;Vaira 
et a l 2002). Additionally, a lateral flow immunochromatography test, ImmunoCard 
STAT! HpSA is now available in the UK, but no evaluative studies of its performance 
have yet been reported. PCR-based analysis of stool samples provides an alternative
212
Results and Discussion
to stool antigen testing for non-invasive detection oîH. pylori infection and has the 
capacity to provide further strain information such as antibiotic susceptibility. 
However as discussed in section 1.8.2, the sensitivity and specificity of PCR-based 
detection in studies examining faeces has varied depending on the individual PCR 
assay and the method of DNA extraction used. Many of the extraction methods have 
been comparatively complex, requiring multiple steps (Gramley et a l 1999;Li et a l 
1996;Makristathis et a l 1998;Monteiro et a l 2001a) so it is difficult to envisage the 
integration of such tests in the present format into a routine laboratory.
The aims of the study presented in this chapter were:
1. To compare relative performances of the two ELISA-based H. pylori stool 
antigen detection tests currently available in the UK in an adult dyspeptic 
population (pre-treatment) from mid-Essex.
2. To compare performances of H. pylori stool antigen detection by ELISA with
a rapid immunochromatographic stool antigen test recently launched in the 
UK.
3. To assess the efficacy of a range of comparatively simple manual and
automated methods for DNA extraction from stool specimens artificially 
seeded with H. pylori cells.
4. To evaluate the potential of three nested block cycler PCR assays for detection
of H. pylori in clinical stool samples.
5. To adapt the nested block cycler PCR assays for detection of H. pylori DNA
in real-time.
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8.2 Results
8.2.1 Relative performances of ELISA kits for H, pylori stool antigen detection
Faecal samples collected pre-treatment from 112 dyspeptic adults aged from 23 -  89 
years (mean age 60 years) undergoing routine endoscopic investigation in South East 
England (as described in section 2.3.2) were tested for stool antigen by two 
commercial kits following the protocols described (2.23.1 and 2.23.2). Patients were 
selected on the basis of the results of routine testing of matched patient gastric 
biopsies by culture and histology at Chelmsford PHL and Broomfield hospital 
(Chelmsford), respectively. These tests had demonstrated that 64 patients were H. 
^/on-positive by at least one of these methods while no biopsy-based evidence of 77. 
pylori infection was found in the remaining 48 patients. The results obtained by the 
two ELISA kits and the sensitivities and specificities of each test are summarised in 
Table 8.1, while the quality of the result generated by each assay is illustrated in 
Figure 8.1. The range of OD readings generated in each patient for the different 
assays are summarised in Figure 8.2.
The Premier Platinum HpSA kit generated equivocal results in 5 of 64 and 2 of 48 
samples from patients that were H. /?y/or/-positive and negative, respectively (Table 
8.1, Figure 8.2). If equivocal results were defined as stool antigen positive, this raised 
the assay sensitivity (81.3 %) but lowered the specificity (91.7 %). No equivocal 
results were generated for the Amplified IDEIA HpStAR kit (Table 8.1, Figure 8.2).
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Table 8.1 : Comparison of HpSA and HpStAR stool antigen test performances
when applied to 112 stools from patients of known H. pylori status
Stool Ag kit Patient status* (n)
Sensitivity Specificity
Name Result + (64) -(48)
HpSA + 47 2 73.4% 95.8%
E t 5 2
- 12 44
HpStAR + 60 0 93.8% 100.0 %
- 4 48
pylori status determined by culture and/or histology of gastric biopsies. 
^Equivocal results were not included as positive results in calculations of sensitivity 
and specificity.
As illustrated in Figures 8.1 and 8.2, the Amplified IDEIA HpStAR kit generated 
results that were easier to interpret than those of the HpSA kit. This is demonstrated 
also by considering OD450/630 values generated for each kit. The mean OD450/630 
values recorded for HpSA positive and negative specimens were 0.45 ±0.14 units 
above and 0.06 ± 0.01 units below the kit’s recommended cut-off value for equivocal 
results of 0.10 OD units, respectively (Figures 8.1 & 8.2). The mean OD450/630 values 
of the IDEIA HpStAR kit for positive and negative results were 1.93 ± 0.34 units 
above and 0.11 ± 0.01 units below the kit’s cut-off level (0.15 OD units) (Figures 8.1 
& 8.2). Comparison of means by unpaired t test (section 2.25.2) demonstrated that 
the OD450/630 values of the IDEIA HpStAR kit were significantly further from the 
defined cut-off than that of the HpSA kit (p = < 0.0001), and so were easier to 
interpret.
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Premier Platinum Amplified IDEIA 
HpSA HpStAR
   A .
Figure 8.1 : Examples of results generated by the HpSA kit compared with the
HpStAR kit. For both tests, stools from H. pylori culture and/or 
histology positive patients are in wells A2, A3, A7, B4, C2, C3, D l, 
D4. D7 : kit + control; D8 : kit -  control.
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Figure 8.2: Scattergraphs demonstrating the range of OD450/630 values
recorded for each stool specimen tested by the HpSA kit and by 
the HpStAR kit.
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8.2.2 Comparison of H. pylori antigen detection in stools by ImmunoCard 
ST AT! test and HpSA ELISA kit.
Eighty-seven stool samples that had been tested for stool antigen by both ELIS A- 
based kits were examined also by a novel ImmunoCard STAT! HpSA Test as 
described (2.23.3). Forty-nine of these were from patients that were H. pylori- 
positive by culture and/or histology, while the remaining 38 stools were from H. 
/?y/on-negative patients. ImmunoCard STAT! test results generated were classified as 
positive, weakly positive or negative, as illustrated in Figure 8.3.
Strong Positive xvh g 1 Weak Positive ' 2 ^ - .#
Strong Positive Negative
f
Weak Positive
-T #
Negative
. lUS
HpSA y HoSA f
jjF -
w
Figure 8.3: Illustration oiH. pylori antigen detection in stools by
ImmunoCard STAT! HpSA kit. Strong or moderate positives 
generated a clear pink band in the test (T) window, while weak 
positives generated only a faint pink band.
Results generated by the ImmunoCard STAT! HpSA test relative to those obtained for 
the 87 stools by the Premier Platinum HpSA and by the IDEIA HpStAR ELISA kits 
are presented in Table 8.2.
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Table 8.2: Results generated by the ImmunoCard STAT! HpSA test when
applied to stools from 87 dyspeptic patients, compared with results 
of the Premier Platinum HpSA ELISA and the IDEIA HpStAR 
ELISA
ImmunoCard HpSA ELISA IDEIA HpStAR ELISA
STAT! HpSA TP* TN E FN FP TP TN FN FP
Positive 
(n = 29)
25 0 1 3 0 29 0 0 0
Weak Positive 
(n=  18)
8 4 3 3 0 13 4 1 0
Negative 
(n = 40)
2 32 1 4 1 5 34 1 0
*TP = True positive, TN = True negative, E = Equivocal result, FN = False negative 
FP = False positive, defined on the basis of culture and histology testing of matched 
gastric biopsies.
Specific antigen was detected by the Premier Platinum HpSA and the IDEIA HpStAR 
ELISA kits in, respectively, 39/49 and 47/49 H. j^y/on-positive patients and in 2/38 
and 0/38 H. j^y/on-negative patients. Positive results were obtained for the 
ImmunoCard test in 43/49 positive patients and in 4/38 negative patients. The 
respective sensitivities for the HpSA ELISA, the IDEIA HpStAR and the 
ImmunoCard tests were thus 79.6 %, 95.9 % and 87.8 %, while test specificities were 
94.7 %, 100.0 % and 89.5 %, respectively. However if  five equivocal results 
generated by the HpSA ELISA were considered negative, that test sensitivity was
71.4 % while specificity was 97.3 %.
The stool specimens that were strongly positive by the ImmunoCard STAT! HpSA 
test had generated mean OD450/630 readings of 0.53 ±0.18 and 2.72 ± 0.33 for the 
HpSA and HpStAR kits, respectively. In contrast, mean OD450/630 readings for stools
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that were weakly positive or falsely negative were significantly lower for both the 
HpSA kit (0.15 ± 0.06, p = 0.0009) and the HpStAR kit (0.77 ± 0.34, p < 0.0001).
8.2.3 Comparison of methods of DNA extraction from stool samples 
Initially, faecal samples from H. ^y/on-negative patients were seeded with serial 
decimal dilutions of bacterial cells to give seven samples containing H. pylori 
concentrations ranging from approximately 10  ^to 10  ^cfii/g faeces, as assessed by 
viable count. DNA was extracted manually from 900-pl aliquots of these by the 
original and by the modified GuSCN/silica or diatom based methods described earlier 
(2.12.1), and by a commercial faecal DNA extraction kit (QIAgen Ltd) (2.12.2). 
Faecal samples (200 pi) were also extracted by the automated MagNAPure system, 
using the LC Total Nucleic Acid Isolation Kit and the LC DNA Isolation Kit III 
(Bacteria, Fungi) (sections 2.12.3). All DNA extracts were treated further by dilution 
or PVP treatment, as described in sections 2.13.1 and 2.13.2. In later experiments, 
stools were suspended in concentrated milk powder solutions (300 mg/ml) to block 
non-specific binding of PCR inhibitors to magnetic glass beads during automated 
DNA extraction.
8.2.3.1 Evaluation of inhibitor removal by DNA extraction methods
All DNA extracts were tested by internal control PCR (2.15.2) to assess the relative 
abilities of methods to remove PCR-inhibitory substances. Experiments were 
repeated using stools from different patients, to assess removal of as broad a range of 
potential PCR inhibitors as possible. The ability of each method to remove inhibitors 
and assessment of the relative convenience (labour and time) of the methodologies are 
summarised in Table 8.3.
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Table 8.3: Comparison of efficacy of PCR inhibitor removal and convenience 
of manual and automated faecal DNA extraction methods.
Inhibitor Removal*
Extraction method Post (Pref) extraction modifications Ease of use
None (Milk) 1/10 (Milk) PVP (Milk)
Manual methods
GuSCN silica ++ + ++
Modified GuSCN silica + +++ ++ ++
Modified GuSCN diatoms ++ +++ +++ ++
QIAgen kit + +++ +++ +
Automated MagNA Pure methods
Total NA isolation kit -  (+) + (+++) ++ (+++) ++++
Bacterial DNA kit III - (-) - 1 (-) -(+§) +++
^Inhibitor removal represented by the proportion of samples tested that were 16S 
internal control PCR-positive as follows: - = 0 %; + = < 50%; ++ = 50 -  99%, +++ = 
100%.
t  Additional stools suspended in milk solution (300 mg/ml) extracted by automated 
methods.
{ DNA extracted by MagNA Pure Bacterial DNA kit III was +++ at 1/100 dilution. 
§+++ if PVP-treated extracts amplified by Tth instead of Taq polymerase in a PCR 
reaction mix also containing BSA (described in section 2.14.4).
Overall, the modified GuSCN method (containing milk protein in the initial lysis 
buffer) using diatomaceous particles instead of silica was the most effective of all 
methods at removing inhibitors, particularly if combined with either dilution or PVP 
treatment post-extraction. The commercial extraction kit by QIAgen performed
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similarly but was more laborious and time consuming. Greater levels of inhibitors 
remained in the samples extracted by the automated MagNA Pure methods. For the 
LC Total Nucleic Acid Isolation kit, inhibition could be overcome by initial 
suspension of stool in milk solution, subsequently combined with either dilution 1/10 
or PVP treatment. In contrast, internal control PCR was positive in only some of the 
DNAs extracted by the Bacterial LC DNA Isolation Kit III unless stool was 
suspended in milk solution before extraction, the resultant DNA extract then PVP- 
treated, or diluted 1/100, and BSA included in the final PCR, where, additionally, Taq 
DNA polymerase was substituted with enzyme Tth, as described in section 2.14.4.
S.2.3.2 Evaluation of specific DNA recovery for each DNA extraction method 
DNA extracts were tested by Helicobacter- and H. /?y/on-specific PCR assays 
targeting 16S rRNA and vacA (sections 2.16.1.1 and 2.16.3.1), respectively, to assess 
the relative levels of specific DNA recovery. Generally, the 16S rRNA assay detected 
lower levels of H. pylori, but spiking experiments did not always generate consistent 
and reproducible results. For this reason, a qualitative summary of specific DNA 
detection by 16S rRNA PCR for each method is provided in Table 8.4.
Overall, higher yields of DNA, as indicated by PCR detection at lower target gene 
levels, were obtained for all samples following PVP treatment, compared with 
dilution as a post-extraction modification. Lowest detection limits were observed 
when diatomaceous particles were used instead of silica. Lower yields of DNA were 
obtained for the automated MagNA Pure extraction methods, for both kits tested. Of 
the limited Bacterial NA DNA extracts tested that were not PCR-inhibitory, only high 
levels of specific DNA (as much as 10  ^cfu/ml) could be detected by PCR.
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Table 8.4: Comparison of DNA recovery by various faecal DNA extraction 
methods, assessed by Helicobacier-sptciüc PCR targeting 16S 
rRNA.
Extraction method Detection limit* by 16S rRNA PCR 
1/10 PVP
Manual GuSCN silica ++ +++
Modified GuSCN silica ++ +++
Modified GuSCN diatoms ++ ++++
QIAgen ++ +++
Automated Total NA + ++
Bacterial NA +/- +/-
^Detection limit represented by qualitative scoring system as quantitative data varied 
between experiments. The lowest level of detection (++++) was 10"^  cfu/ml, while 
detection of approximately 10  ^cfu/ml is represented as +/-.
8.2.4 Detection of H. pylori in clinical stool samples by PCR
DNA from stool samples of 45 patients were extracted by the modified GuSCN- 
diatom method (section 2.12.1) and then processed further by the PVP method 
described previously (section 2.13.2). All 45 samples were positive by the internal 
control PCR assay described in section 2.15.2. Twenty-three of the 45 patients had 
been shown to be H. ;?y/on-positive by culture and/or histology, while the remaining 
22 were H. jpy/on-negative. Sensitivities and specificities of stool antigen tests when 
applied to these 45 samples were, respectively, 78.3 % and 95.5 % for the HpSA kit 
and 91.3 % and 100.0 % for the IDEIA HpStAR kit. Preliminary testing of the ten 
stools from H. /?y/c>r/-positive patients samples demonstrated that single round PCR
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assays targeting 16S rRNA and vacA (sections 2.16.1.1 and 2.16.3.1) failed to 
generate specific product. All samples were subsequently tested by three different 
nested PCR assays amplifying fi*agments of 16S rDNA, vacA and ahpC, described in 
sections 2.16.1.3, 2.16.3.2 and 2.16.5.1, respectively. The sensitivity and specificity 
of each analysis is summarised in Table 8.5 and examples of the quality of results 
generated are illustrated in Figure 8.4.
Table 8.5: Comparison of performances of three nested PCR assays targeting
ahpC, 16S rRNA and vacA genes ofH. pylori when applied to 45 
stools
PCR Assay Patient status* (n)
Sensitivity Specificity
Target Result + (23) -(22)
ahpC + 11 3Î 47.8 % 86.4%
- 12 19
16S rRNA + 8 2Î 34.8% 90.9 %
- 15 20
vacA + 6 I t 26.0% 95.5%
- 17 21
*Patient status determined by culture and histology.
tOne stool specimen from an H. /?y/on-negative patient was positive by all three PCR 
assays.
Of the 45 stool specimens examined, 10 were falsely-negative by all three assays. 
Comparison with matched stool antigen results demonstrated that one of these 
specimens was also falsely-negative by both antigen detection kits, one was falsely- 
negative by the HpSA kit only and one had generated an equivocal result by HpSA 
testing. None of the falsely-positive results generated by PCR analyses were also
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positive by stool antigen testing. Overall, the sensitivity and specificity of all three 
assays combined was 56.5 % and 86.4 %, respectively.
230  bp 
209  bp
109 bp
1 2 3 4  5 6 7
ahpC  16S rRNA
vV A
9 10 11 12 M
vacA
Figure 8.4: Illustration of PCR analyses of four stool specimens from H,
/Tp/on-positive patients (A -  D) by three nested assays targeting 
ahpC, 16S rRNA and vacA. Patient A (lanes 1, 5 & 9) positive for all 
three assays. Patient B (lanes 2, 6 & 10) positive for ahpC PCR only. 
Patient C (lanes 3, 7 & 11) positive by ahpC and 16S rRNA PCR. 
Patient D (lanes 4, 8 & 12) positive by vacA only. Lane 13, 123 bp 
marker (M).
8.2.6 Comparison of conventional nested PCR and real-time nested PCR assays 
The second round of PCR for both the 16S rRNA and the ahpC assays was carried out 
in real-time on the LightCycler as described (2.20.8 and 2.20.9, respectively) in 
addition to the conventional PCR analyses described in the section above (8.2.5). 
Positive results were indicated by an increase in S YBR Green 1 fluorescence (= DNA 
amplification) as illustrated (Figure 8.5a). Melting peaks generated by monitoring
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rate of decrease in SYBR Green 1 fluorescence with increasing temperature were 
generated in positive samples only (Figure 8,5b). The ahpC assay required 
optimisation of primer concentration to prevent generation of spurious increased 
fluorescence due to primer dimer formation. Initially, specificity of positive results 
was confirmed by additional visualisation of amplicons by gel electrophoresis (section 
2.19).
Analysis of all 45 stool samples demonstrated that results generated by real-time 
PCR for both ahpC and 16S rRNA assays were identical to those obtained by 
conventional PCR. Results were easy to interpret, with little evidence of non-specific 
amplification.
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Figure 8.5: Amplification of ahpC in real-time from clinical stool specimens in
2"^  round of hemi-nested PCR assay, a) Positive samples indicated 
by increased SYBR Green 1 fluorescence, b) SYBR Green 1 melting 
peaks generated for the positive samples and controls only.
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8.3 Discussion
The first report of culture of H. pylori from stool specimens (Thomas et al. 1992) was 
met with considerable interest as it raised the possibility of an alternative to invasive 
endoscopy that would not only allow diagnosis of infection but would provide isolates 
for further characterisation. However, the low success rate of subsequent culture 
attempts (Dore et al. 2000b;Kelly et al. 1994) suggested that generally this bile- 
sensitive organism is non-viable in the lower intestine. With the recent development 
of immunologically-based tests to detect specific faecal H. pylori antigens as well as 
the potential for PCR-based analysis, stools may still provide an invaluable, non- 
invasive, means of patient investigation.
8.3.1 Comparison of commercial stool H, pylori antigen detection ELISA kits
As discussed earlier (section 1.5.2.3), numerous studies have evaluated the potential 
of the HpSA kit for primary diagnosis of H. pylori infection as well as for patient 
follow-up after eradication therapy. Results from different studies suggested that the 
sensitivity and specificity of this test may vary according to geographical locations, 
demonstrating the need for local evaluation of kit performance prior to routine 
implementation. While one study has examined the performance of the HpSA kit in a 
paediatric patient group in South West Scotland (Shepherd et al. 2000), no other 
evaluative studies have been conducted in the UK. At the time of writing, 
comparatively few centres had yet examined the newer Amplified IDEIA HpStAR kit. 
In this chapter, both kits were evaluated to compare relative performances when 
applied to stools from dyspeptic adult patients in South East England. The aim of the 
study was not only to identify the best kit for diagnosis of infection in this geographic 
location but also to provide direct evidence of H. pylori in individual stool samples.
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The latter information would facilitate interpretation of the concomitant results of 
PCR analyses conducted in this study.
Examination of stools from 112 dyspeptic patients demonstrated that while both 
kits allowed rapid diagnosis of infection (within 1 .5 -2  hours) that was simple to 
perform, the Amplified IDEIA HpStAR kit was considerably more sensitive and 
specific. Additionally, this kit was easier to use as washing steps were automated. 
Results were easier to interpret also, with clearer distinction between positive and 
negative specimens. In contrast the HpSA kit mean OD for positive results was lower 
than that of the HpStAR kit while the mean negative OD was higher. These values 
close to the kit cut off meant that some results could not be interpreted and were 
defined as equivocal, lowering overall kit sensitivity and specificity.
Given that limited information is available about the precise components of each 
kit, it is difficult to explain the observed differences in performance. However the 
monoclonal capture antibodies in the HpStAR kit would allow highly specific binding 
o iK  pylori antigen. In contrast, the polyclonal antibodies of the HpSA kit, while 
potentially more sensitive, could theoretically bind a wider range of faecal antigens 
non-specifically, leading to higher background OD levels. Use of polyclonal 
antibodies could also lead to variation in assay performances between kit batches. 
Additionally, the preliminary centrifugation of diluted stool in the HpStAR kit 
removes insoluble faecal material, prior to incubation of samples with capture and 
conjugate antibodies. This may improve accessibility and diffusion of soluble H. 
pylori antigen and so facilitate formation of specific antigen/antibody complexes, 
leading to higher OD levels for positive results. Removal of solid particles also 
allowed washing steps to be automated and so standardised between runs. In 
contrast, the HpSA kit protocol does not include a centrifugation step and both
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insoluble and soluble faecal material is incubated with the capture and conjugate 
antibodies, which may lower the rate of specific complex formation and ultimately 
OD readings, while increasing non-specific binding and background ODs. Automated 
well washing was not possible because of the potential for equipment blockage and 
efficiency of manual washing may have varied between runs. Although care was 
taken to ensure adequate washing of wells, the amount and nature of insoluble 
material varied between specimens and so too would the levels of residual material 
that may have contributed also to the high non-specific background ODs observed in 
some samples. Of the two ELISA-based kits tested for H. pylori stool antigen 
detection, the IDEIA HpStAR kit is apparently preferable for pre-treatment H. pylori 
diagnosis in adult dyspeptic patients in South East England.
Few studies have compared the relative performances of these two kits (Koletzko et 
al. 2003;Leodolter et al. 2002;Makristathis et al. 2000). The findings of this study of 
an adult dyspeptic population were in agreement with those of an earlier study of 
paediatric patients that demonstrated marginally higher sensitivity (98.0 %) of the 
IDEIA HpStAR (= FemtoLab) kit for primary diagnosis of H. pylori infection, 
compared with the HpSA kit (93.8 %) (Makristathis et al. 2000). Additionally, that 
study demonstrated that both kits were suitable for patient follow-up post therapy. A 
subsequent study of 148 adult patients reported marginally higher sensitivity of the 
HpStAR kit for evaluating success of eradication therapy also, although the kit cut-off 
OD was lowered to 0.90 to achieve this (Leodolter et al. 2002). None of the patients 
reported on in this chapter had received specific eradication therapy, but extension of 
this study to include such patients would provide information on the utility of these 
tests for patient- follow-up, and allow appropriate cut-offs to be established for this
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application. Likewise, examination of paediatric populations will be essential to fully 
evaluate the performances of these kits in patients from the UK.
8.3.2 Detection ofH. pylori antigen in stools by ImmunoCard STAT! test 
Both ELISA-based kits required inclusion of a positive and a negative control in each 
run. It was therefore most economical to batch-test multiple stool specimens in a 
single experiment. In contrast, the immunochromatographical ImmunoCard STAT! 
HpSA test is more suitable for testing single or small numbers of stools. This test 
uses monoclonal antibodies to capture specific antigen, and results can be obtained in 
5 - 1 0  minutes, compared with 2 - 3  hours with ELISA-based methods. Analysis of 
87 stools demonstrated that stools that had generated high OD readings by ELISA 
also generated clear positive results for this test. However, weak positive results or 
falsely negative results corresponded to low OD readings by ELISA and were very 
difficult to interpret. This speed and simplicity of this test is clearly advantageous 
compared with ELISA, particularly in a laboratory that examines low numbers of 
stool specimens. High sensitivity and specificity has been reported for similar 
ImmunoCard tests available for detection of enteric pathogens E. coli 0157 
(Mackenzie et al. 2000) and Giardia lamhlia and Cryptosporidium parvum (Garcia et 
al. 2003). To date, no studies evaluating the performance of this test for H. pylori 
detection have been published. Results presented in this chapter suggest that the test 
was more sensitive, but less specific, than the HpSA ELISA and allows accurate 
detection of H. pylori from stools with higher levels of antigen. However, weakly 
positive results were defined subjectively and as for the equivocal results of HpSA 
ELISA, would be difficult to interpret in a clinical setting. Thus while this test is 
more convenient than ELISA, the higher sensitivity and specificity of the IDEIA 
HpStAR test suggests that this should be the test of choice for H. pylori antigen
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detection from stools. Examination of greater numbers of stools recovered before and 
after treatment of patients will be necessary to fully evaluate the performance of this 
test.
8.3.3 Comparison of manual and automated methods of stool DNA extraction
Stool antigen detection allows sensitive and specific detection of H. pylori. However, 
unlike PCR, it does not have the potential to provide any further strain information. 
Various strategies have been applied to extract H. pylori DNA from stool specimens, 
including immunomagnetic separation (IMS), polypropylene filtration, phenol 
chloroform extraction, commercial GuSCN-based kits and use of specific DNA 
capture probes (Gramley et al. 1999;Li et al. 1996;Monteiro et al. 2001b;Monteiro et 
al. 2001a;Parsonnet et al. 1999;Russo et al. 1999;Shuber et al. 2002;Watanabe et al. 
1998). However as many of the described methods appeared to be complex, time- 
consuming and laborious, it seems unlikely that they could be introduced into a 
routine diagnostic laboratory.
This study aimed to establish an effective extraction method that was rapid and 
comparatively simple, to reduce the risk of introduction of exogenous DNA and also 
to maximise its potential for application in routine diagnostic laboratories. 
Development of simpler extraction methods suitable for routine use could potentially 
revolutionise management of patients currently investigated non-invasively, as it 
would facilitate extensive PCR-based analyses that could allow further strain 
characterisation.
Internal control PCR demonstrated that inhibitory substances remained for extracts 
prepared by all methods examined. For the manual methods, PVP treatment or 1/10 
dilution was sufficient to remove inhibitors from DNA of all stools extracted by the 
commercial QIAgen kit. The in-house GuSCN-based method was significantly
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improved by inclusion of milk protein in the first GuSCN buffer, to block binding of 
inhibitors, and the use of diatoms, that pellet less tightly than silica and so can be 
washed more thoroughly. Assessment of DNA recovery by Helicobacter-spQcific 
PCR demonstrated that detection limits varied between different seeding experiments, 
highlighting a limitation of this artificial approach. Faecal samples were difficult to 
homogenise sufficiently to ensure identical composition of aliquots removed for 
extraction from each dilution. Unequal proportions of soluble to insoluble material 
would alter the levels of specific DNA removed for extraction, leading to variation in 
detection limits obtained. Nevertheless, the experiments conducted allowed 
qualitative assessment of relative DNA yields for each method. Although the 
modified GuSCN-diatom method was only marginally superior in terms of specific 
DNA yield, it was less laborious than the commercial kit and was one third of the cost 
(estimated reagent costs per extraction £ 0.90 £ 2.75). Of the two post-extraction
treatments, PVP is preferable as it concentrates the DNA extract whereas dilution of 
specific target would lower sensitivity.
Although simple, the modified GuSCN-diatom method is not high-throughput, with 
an estimated maximum of 30 -  40 extractions possible per day. In contrast, the 
MagNA Pure offers simple “walk away” DNA extraction of 32 samples in 
approximately 2 hours. Preliminary experiments demonstrated that DNA extracted by 
either the MagNA Pure LC Total Nucleic Acid Isolation Kit or the LC DNA Isolation 
Kit III (Bacteria, Fungi) contained higher levels of residual inhibitors than those 
extracted by manual methods. Inclusion of milk protein in the initial sample diluent 
and post-extraction PVP treatment was sufficient to remove inhibitors from the LC 
Total Nucleic Acid Isolation Kit extracts. In contrast, these plus additional 
modifications of the PCR reaction (using BSA and Tth polymerase) were necessary to
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remove the higher levels of inhibitors remaining in the LC DNA Isolation Kit III 
(Bacteria, Fungi) extracts. Furthermore, specific DNA recovery for both kits was 
substantially lower than that of the manual GuSCN-diatom method. The MagNA 
Pure system was recently reported to successfully extract DNA from stools for PCR- 
based diagnosis of microsporidia infection (Wolk 2002). The results presented here 
demonstrate that problems of residual PCR inhibitors in DNA extracted by this 
system can be overcome by a series of relatively simple modifications. However 
given the culture and PCR-based evidence to suggest that H. pylori levels are low in 
the colon, the poor recovery of specific DNA with the MagNA Pure make it 
unsuitable for sensitive H. pylori detection. For these reasons, the modified GuSCN- 
diatom extraction method combined with PVP treatment was applied in subsequent 
analyses of clinical stool specimens. Since this study was conducted, S.T.A.R. (Stool 
Transport and Recovery) Buffer has been developed that is reported by the 
manufacturers (Roche Diagnostics Ltd) to inactivate nucleases, bind inhibitors and 
stabilise nucleic acid. As this buffer is compatible with the MagNA Pure system, 
future studies should be conducted to establish if this could overcome the problems 
discussed here.
8.3.4 Detection oiH. pylori from clinical stool specimens by conventional PCR
Preliminary analyses of stool DNA extracts confirmed the results of earlier studies 
that single-round PCR was insufficiently sensitive for H. pylori detection from stools. 
Given that the large intestine is not the natural niche for H. pylori, it is likely that 
comparatively few organisms are present in stools compared with the gastric mucosa. 
It is therefore not unexpected that the PCR assays that allowed sensitive detection of
H. pylori in gastric biopsies in Chapter 3 perform differently in these samples. PCR
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assay formats (nested and hemi-nested) involving two rounds of amplification were 
applied to improve sensitivity of detection.
Three such nested PCR assays were investigated, one targeting ahpC (= 26 kDa 
specific antigen gene), that had previously been shown be highly sensitive and 
specific (Makristathis et a l 1998;Makristathis et a l 2000) and two novel assays 
targeting 16S rRNA and vacA genes. The strategy for the 16S rDNA assay was firstly 
to amplify all species of Helicobacter DNA present in stools and then to amplify only 
Fragments of the H. pylori genome in the second round. Other helicobacters have 
been identified in human stools (Fox 2002;0'Rourke et a l 2001) including H. 
pullorum that may be associated with diarrhoeal disease (Bumens et a l 1994;Stanley 
et a l 1994;Steinbrueckner et a l 1997). Higher levels of other helicobacters could 
generate positive results after the first round of PCR that would not be apparent in the 
second H. jcy/on-specific PCR. Therefore, this novel approach could have the 
potential to not only detect H. pylori infection but also to provide a means of 
surveillance of other helicobacters in the human large intestine, although no examples 
of this were found in this study. As the levels of prokaryotic 16S rDNA are extremely 
high in stool specimens, assay primers could cross-react with other bacterial species 
and lower specificity. Likewise, ahpC homologues have been shown to be present in 
other helicobacters (Lundstrom et a l 2001) that may be present in human stools 
samples. By contrast, vacA is found only in H. pylori and so a third nested assay, 
based on the novel primers designed for the HpVac assay, was designed and 
evaluated.
Application of the three PCR assays to 45 faecal DNAs extracted by the modified 
GuSCN-diatom plus PVP method demonstrated that the ahpC assay was the most 
sensitive but least specific while the vacA assay was considerably less sensitive but
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was the most specific. Overall sensitivity of H. pylori detection firom stools by the 
three PCR assays combined was 56.5 %, while specificity was 86.4 %. In contrast, 
ELISA-based testing of stools specific antigen, particularly by the IDEIA HpStAR kit 
was a more sensitive (91.3 %) and specific (100.0 %) means of H. pylori detection in 
the same stool samples.
As discussed earlier (section 1.8.2), success of PCR-based detection of H. pylori in 
stools has been variable, with wide ranges of sensitivities reported (Gramley et a l 
1999;Li et a l 1996;Makristathis et a l 1998;Makristathis et a l 2000;Mapstone et al 
1993b;Monteiro et a l 2001a;Monteiro et a l 2001b;Parsonnet et a l 1999;Russo et a l 
1999;Shuber a/. 2002;van Zwet a/. 1994;Watanabe gr a/. 1998). However 
differences in study populations, specimen storage and extraction methods as well as 
the PCR assay applied complicate comparisons between studies. Likewise it is 
difficult to establish if  poor sensitivity is due to absence of specific DNA in 
specimens or due to an inadequacy of the methodologies applied. Stool antigen 
testing provided direct evidence that 20 stools included for PCR analysis in this study 
contained H. pylori antigen. As stools were frozen immediately on receipt at the 
primary laboratory (Chelmsford PHL), culture was not attempted and so it is not 
known if these were intact cells or fragments oîH. pylori The limited success of 
culture in other studies suggest that the latter is more likely. The observed higher 
sensitivity for the ELISA kits could therefore be explained by greater stability of the 
specific antigen, compared with that of specific DNA. Results presented in Chapter 3 
suggested that H. pylori DNA may be relatively labile and subject to degradation. 
Stool samples contain many thousands of bacterial species and so numerous 
DNAases. Specific DNA degradation may be an even greater problem in stool 
specimens than in gastric biopsies. Differences between ELISA and PCR sensitivities
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could be partially attributable to sampling errors also, as 100 pi of diluted stool is 
examined by ELISA compared with 5 pi DNA extract for PCR. This may influence 
test outcome considerably, particularly if  only low levels of H. pylori are present in 
stool specimens.
One study that examined stools collected pre-treatment from 63 H. pylori-posiiiwQ 
and 37 negative patients demonstrated that the same hemi-nested PCR assay 
evaluated in this chapter was more sensitive than the HpSA kit (93.7 % vs. 88.9 %) in 
an adult dyspeptic population (Makristathis et al. 1998) as well as being more specific 
(100.0 % vs. 94.3 %). Similarly high sensitivity was reported in a subsequent study 
examining stools from 49 paediatric patients (Makristathis et al. 2000). Although the 
ahpC assay was the most sensitive of the three PCR assays examined in this chapter, 
overall sensitivity was lower than reported previously by Makristathis. In those two 
earlier studies, DNA was extracted by suspension of stools in lysis buffer, 
centrifugation, supernatant boiling, further centrifugation and then RNAse and 
proteinase K digestion of the supernatant. This was followed by addition of GuSCN 
and column chromatography, three purifications of the eluate with organic solvents 
and a final concentration by filtration. This approach may have allowed superior 
recovery of specific DNA and so higher PCR sensitivity. However the method is so 
complex, time-consuming and laborious that it seems unlikely that it could be applied 
in a routine diagnostic laboratory. Alternatively, the observed differences in assay 
performance could be due to differences in study populations or conditions of 
specimen storage. In the current study, patients were requested to bring a stool 
specimen collected the same day as endoscopy for submission at that time, but the 
actual time between specimen collection and presentation to the endoscopy clinic was 
not known. Prolonged incubation of stools at room temperature may have resulted in
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specific DNA degradation in some samples, lowering PCR sensitivity. Additionally, 
as fewer patients were examined in the current study compared with those conducted 
previously, precise comparisons between studies are difficult. Extension of the 
current study to examine a larger population would allow more accurate assessment of 
assay performance.
8.3.5 Detection of H, pylori in stools by real-time PCR
One disadvantage of nested PCR is that the second round of amplification 
substantially increases the overall test time, to about 7 -8  hours, including gel 
electrophoresis. In this study, the second PCR for the ahpC and the 16S rRNA assays 
was modified for the LightCycler, so that nested amplicon could be generated in real 
time (approximately 40 minutes, compared with 2 -  3 hr with the block cycler PCR), 
giving a total test time of approximately 4 hours. These LightCycler assays were 
equally sensitive and specific, compared with the conventional block approach, and 
were easy to interpret. This development could significantly improve total specimen 
turnaround time as not only is the second PCR round considerably faster but 
subsequent gel electrophoresis is not required. Combination of the simple extraction 
methods along with this nested real-time PCR approach allows H. pylori detection 
within 36 hours of initial specimen receipt. This is the first description of H. pylori 
detection from stool specimens by real-time PCR.
As for the conventional nested PCR assays, further optimisation of parameters 
including specimen transport and storage, DNA extraction methods and PCR assays 
will be necessary to improve sensitivity of detection. Nevertheless, the work 
presented in this chapter demonstrates the potential for examination of H. pylori 
infections non-invasively by PCR, using comparatively simple methods. This 
approach could be most valuable as a tool for investigating patients currently not
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undergoing endoscopy and culture, particularly as PCR provides a means of further 
strain characterisation, as demonstrated in Chapters 5 - 7 .  As discussed in Chapter 5, 
determination of antibiotic susceptibility is particularly important as this can have a 
significant impact on patient management and eradication therapy outcome.
As all CLA susceptibility assays described thus far (section 1.11.3) involve only one 
round of PCR, they are unlikely to be sufficiently sensitive. Molecular CLA 
susceptibility tests therefore could not be applied to stool specimens in their present 
format. Future modification of existing assays to a nested format could address 
potential problems of specificity and sensitivity and allow CLA susceptibility testing 
directly from stools. For instance, development of H. pylori-spQciîic primers to 
amplify specific fragments of 23S rDNA, followed by a second round of PCR with 
internal primers to amplify the region of 23 S rDNA for identification of mutations 
associated with CLA resistance. It has been demonstrated in this chapter that nested 
PCR from stools using the LightCycler is possible, so it is likely that a similar 
approach using a modification of the assay described in Chapter 5 could allow direct 
determination of CLA susceptibilities from stools.
8.4 Conclusions
The IDEIA HpStAR kit for specific antigen detection is a sensitive and specific test 
for non-invasive diagnosis of H. pylori infection in dyspeptic patients from South East 
England. In contrast, results generated by both the Premier Platinum HpSA kit and 
the ImmunoCard STAT! test were more difficult to interpret. Although automated 
DNA extraction by the MagNAPure system would allow high-throughput specimen 
processing, the lower yields of DNA obtained suggest that this is unlikely to allow 
sensitive detection of H. pylori from stools, compared with manual extraction
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methods. PCR-based detection o f H. pylori from stools was less sensitive and specific 
than antigen detection tests, hut that approach is unique as it could be developed to 
provide additional strain information from samples collected non-invasively. 
Additionally, it has been shown for the first time that real-time PCR based detection 
of H. pylori in stools is possible without any loss in assay sensitivity or specificity, 
compared with conventional block PCR.
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Chapter 9: PCR-based detection of Helicobacter species at extra-gastric sites.
9.1 Background
The previous chapters have focused on the use of PCR to investigate Helicobacter 
species associated with gastric disease. However PCR has also provided a powerful 
tool for investigating associations between Helicobacter infection and extra-gastric 
diseases, for example in the hepatobiliary tract (Fox et ah 1998;Lin et a l 1995;Metz 
1998;Nilsson et a l 1999;Roe et a l 1999), the cardiovascular system (Blasi et a l 
1996;Danesh 1998) and the lower gastrointestinal tract (Fanning et a l 1998;Tiveljung 
et a l 1999). In the present chapter, PCR was applied to bladder, colonic and 
bronchial biopsies to investigate the possible involvement of helicobacters, by virtue 
of their association with chronic inflammatory disease, in four chronic inflammatory 
conditions with poorly understood aetiology, namely:
Interstitial cystitis (IC), a condition characterised by chronic mucosal 
inflammation of the bladder, often accompanied by ulceration. This syndrome is 
analogous to H  pylori induced inflammation of the gastric mucosa (Warren 1994).
H  pylori can cause inflammation of the murine urinary tract (Isogai et a l 1994) while 
in humans, H. pylori eradication therapy has been reported to improve IC symptoms 
(English a/. 1998).
Crohn’s disease (CD) and ulcerative colitis (UC). Both conditions are forms of 
inflammatory bowel disease (IBD), and are thought to result either from an abnormal 
reaction to the constant antigenic stimulation provided by commensal bacteria in the 
lower GI tract, or alternatively to he attributable to specific, as yet unidentified, 
bacterial or viral infections. PCR and probe hybridisation-based studies have 
suggested the involvement of mycobacterial species, particularly in CD (Hermon-
241
Results and Discussion
Taylor 2000;0’Mahony and Hill 2002;Roholl et al. 2002;Ryan et al. 2002); however 
this association is still not universally accepted (el Zaatari et al. 2001). Interestingly, 
serological studies have indicated an inverse relationship between H. pylori infection 
and IBD symptoms (Halme et al. 1996;Kolho et al. 1998;Parente et al. 1997a;Pearce 
et al. 2000), whereas two PCR-based studies reported helicohacter DNA from the 
colon of CD patients (Tiveljung et al. 1999;Bohr et al, 2002).
Chronic persistent cough (CPC) describes a broad category with a wide range of 
recognised causes in many patients (e.g. smoking, asthma), hut with no definitive 
aetiological agent identified. CPC does not respond to conventional antibiotic 
therapies aimed at respiratory pathogens and is often observed in patients with gastro- 
oesophageal reflux disease (GERD) (Philp 1997). As discussed in sections 1.8.1 and 
1.9.1, H. pylori DNA has been detected in various sites of the oral cavity (Berroteran 
et al. 2002;Li et al. 1996;Mravak-Stipetic et al. 1998;Riggio et al. 2000), and H. 
pylori bas been recovered from tracheobronchial aspirates of mechanically ventilated 
patients (Mitz and Farher 1993). Additionally, serological studies have suggested 
higher incidences of H. pylori infection in patients with chronic bronchitis (Caselli et 
al. 1999;Roussos et al. 2002) and with bronchiectasis (Tsang et al. 1998). To date, no 
studies have examined lung tissue from CPC patients for helicobacters.
The aims of the work presented in this chapter were:
1. To investigate for the first time, potential associations between helicobacters 
and inflammatory conditions of the bladder, colon and bronchi using multiple 
PCR assays specific for the Helicobacter genus, H. pylori and HHLOs.
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2. To characterise amplicons from hiopsy tissues by sequence and BLASTn 
analyses.
9.2 Results
9.2.1 Study populations
Bladder biopsies, colonic biopsies and bronchial biopsies were collected and stored as 
described in sections 2.3.3, 2.3.4 and 2.3.5, respectively.
Bladder biopsies were collected from the right and left bladder wall of 27 patients (A 
-  Z2). Ten of these (patients F, G, J, K, L, M, N, P, T, U) had symptoms consistent 
with IC, as defined by the U.S. National Institute of Health guidelines (F.H. Anjum, 
personal communication). The remaining 17 patients, included as a control group, 
had other urological symptoms (e.g. haematuria and incontinence). Work conducted 
in Chelmsford PHL demonstrated that bladder biopsies and urine samples were 
culture-negative (for helicobacters and other bacterial species), while one IC patient 
(F) and one control patient (R) were H. j^y/ori-seropositive.
Colonic biopsies were collected from 30 patients who had either CD (9), UC (11) or 
were control patients (10) with other symptoms including rectal bleeding, intestinal 
polyps, diarrhoea and constipation. Routine histological examination of biopsies at 
St. Mark’s Hospital did not demonstrate presence of helicobacters.
Bronchial biopsies were collected from 10 patients with CPC. Routine investigations 
for respiratory pathogens carried out at Taunton PHL had failed to determine a 
conventional cause for this condition in these patients.
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9.2.2 Internal control PCR
DNA was extracted from bladder and colonic biopsies by the method described 
(section 2.11.2.1) and evaluated for gastric biopsies in Chapter 3. Visual assessment 
of bronchial biopsies suggested that these contained significantly higher levels of 
blood than all other biopsies investigated in this thesis, so these were extracted by a 
commercial kit (section 2.11.3) developed for DNA extraction from blood and 
vascular tissue. All biopsy extracts were tested by the internal control PCR described 
in section 2.15.1 to ensure that PCR inhibitors did not remain following either method 
of DNA extraction. The expected 823-hp amplicon of human cytochrome oxidase 
DNA was generated in all biopsies.
9.2.3 PCR-based detection of helicobacters in bladder biopsies
All bladder biopsies were analysed by the two Helicohacter genus-specific assays 
described in section 2.16.1.1, by the H  pylori specific assays targeting 16S rRNA and 
vacA genes described in sections 2.16.1.2 and 2.16.3.1, and also by the HHLO 
specific assay described in section 2.16.1.4. Amplicons were generated by at least 
one assay in 23/27 (85.2 %) biopsies and by two or more assays in 5/27 (18.5 %) 
specimens. Biopsies were PCR-positive by at least one assay in 9/10 (90.0 %) of the 
IC patients and in 14/17 (90.0 %) of the control group. Positive results were obtained 
by two or more PCR assays in 3/10 (30.0 %) of the IC group and 2/17 (11.8 %) of the 
control group, although these differences were not statistically significant (p =
0.3261) when analysed by Fisher’s exact test (section 2.25.3). All biopsies were 
negative by the HHLO-specific assay. Retrospective application of the prokaryote- 
specific PCR assay of Fox et al (1995), described in section 2.16.1.1 generated 
amplicon in 11/27 patients. The different combinations of PCR-positive results
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obtained are presented in Table 9.1 and examples of band intensities generated by 
each PCR assay are provided in Figure 9.1.
Table 9.1; The different combinations of results generated by five PCR assays 
when applied to human bladder biopsies from 27 urology patients
PCR assay Number
of
Patients
Patient Code
Helicobacter specific H  pylori specific
Fox*t Bohr* Logan* Ho* HpVac
+ + + + + 1 B
- + + + + 1 M
+ + + + - 2 A, F
+ + + - - 1 G
+ - + - - 7 C - E, H - J, L
- + - - - 11 N ,P ,Q -X ,Z 2
- - - - - 4 K, 0 ,  Y, Zi
*PCR assays that target 16S rRNA genes (illustrated in Figure 1.3). 
fProkaryote-specific PCR assay.
+ = PCR-positive.
- = PCR-negative.
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Helicobacter specific H, pylori specific
984  bp
123 bp
Figure 9.1: Examples of prokaryote-specific, Helicobacter genus and H  pylori
specific PCR positive results generated from bladder biopsies. For
each PCR assay, reaction order from lane 1 -  5 in each section is 
patient B (positive for all assays), patient M (positive for all assays but 
that of Fox et al (1995), patient A (positive for all assays but HpVac), 
positive control, negative control.
9.2.4 Identification of PCR products amplified from bladder biopsies
For those biopsies that generated adequate levels of product for further analysis 
(Figure 9.1), detection assay amplicons were sequenced as described in section 2.22. 
A total of 18 amplicons were sequenced, comprising 16 fragments of 16S rDNA 
generated by assays developed by Fox et al (1995) (n = 2), Logan et al (2000) (n = 8), 
Bohr et al (1998) (n = 5) (section 2.16.1.1) and Ho et al (1992) (n = 1) (section 
2.16.1.2) and also two vacA fragments generated by the HpVac assay (section 
2.16.3.1). Subsequent alignment of 16S rDNA sequences with published sequences
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held in public databases (BLASTn analysis) demonstrated that these were most 
similar (> 99 %) to H. pylori sequences while vacA sequences were up to 97 % 
similar to those held in GenBank. Similarity of 16S rRNA sequences of PCR 
products generated by the assay of Logan et al (2000) compared with selected 16S 
rRNA sequences of a range of 17 species of Helicobacter available in GenBank is 
represented in Figure 9.2.
10% (F ixed  mutation rate)
Patient A
Candidatus H. bovis
T Patient A  
Patient G 
Patient F 
Patient M  
Patient F 
\~H . py lo ri
H. nemestrinae (=  H. pylori)
Patient G 
Patient B
H. acinonychis
 Candidatus H. suis
rH .felis  
H. bizzozeronii 
H. salom onis 
— ‘H. heilm annii’ 
-H. cinaedi
H. bilis 
H. canis 
—H. muridarum  
H. mustelae
~H. fennelliae  
~H. rodentium
-E. coli
H. pullorum
Figure 9.2: Rooted tree illustrating the relationships between 16S rRNA of 17
Helicobacter species and sequences generated from bladder 
biopsies.
Alignment of the 16S sequence determined from patient E, following amplification by 
the assay of Fox et al (1995), with primer pairs for the other four assays applied
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demonstrated a mismatch between template and the primer Hp2 of Ho et al (1992). 
This is illustrated in Figure 9.3.
1 CGCTGGCGGC GTGCCTAATA CATGCAAGTC GAACGATGAA GCTTCTAGCT TGCTAGAATG CTGATTAGTG GCGCACGGGT 8 0
8 1  GAGTAACGCA TAGGTCATGT GCCTCTTAGT TTGGGATAGC CATTGGAAAC GATGATTAAT ACCAGATACT CCCTACGGGG 1 6 0
1 6 1  GAAAGATTTA TCGCTAAGAG ATCAGCCTAT GTCCTATCAG CTTGTTGGTA AGGTAATGGC TTACCAfi
Prim er 297F
2 4 1
GGC TATGACGGGT
GGC TATGACGGGT
ATCCGGCCTG AGAGGGTGAA CGGACACACT GGAACTGAGA CACGGTCCAG ACTCCTACGG GAGGCWNNAG TAGGGAATAT 3 2  0 
ATCCGGC
3 2 1  TGCTCAATGG GGGAAACCCT GAAGCAGCAA CG(tCGCGTGG AGGATGAAGG TTTTAGGATT GTAAACTCCT TTTGTTAGAG 4 0 0
Prim er HGF CGCGTGG AGGATGAAGG
4 0 1  AAGATAATGA CGGTATCTAA CGAATAAGCA CCGGCTAACT CCGTGCCAGC AGCCGCGGTA ATACGGAGGG TGCAAGCGTT 4 80  
4 8 1  ACTCGGAATC ACTGGGCGTA AAGAGCGCGT AGGCGGGATA GTCAGTCAGG TGTGAAATCC TATGGCTTAA CCATAGAACT 5 6 0
5 6 1  GCATTTGAAA CTACTATTCT AGAGTGTGGG AGAGGTAGGT GGAATTCTTG GTGTAGGGGT AAAATCCGTA GAGATCAAGA 6 4  0
6 4 1  GGAATACTCA TTGCGAAGGC GACCTGCTGG AAC,
P rim er Hp2*
lATTACTG ACGCTGATTG CGCC^VAAGCG TGGGGAGCAA ACAGGATTAG 7 2 0  
ATTACTG ACGCTGATTG TGC
7 2 1  ATACCCTGGT AGTCCACGCC CTAAACGATG GATGCTAGTT GT' GGAGGGC TTAGTCTCTC CA' 
GGAGGGC TTAGTCTCTC CAG
rAATGCA GCTAACGCAT 8 0 0  
Prim er H pl
8 0 1  TAAGCATCCC GCCTGGGGAG TACGGTCGCA AGATTAAAAC TCAAAGGAAT AGACGGGGAC CCGCACAAGC GGTGGAGCAT 8 8 0  
8 8 1  GTGGTTTAAT TCGAAGATAC ACGAAGAACC TTACCTAGGC TTGACATTGA GAGAATCCGC TAGAAATAGT GGAGTGTCTG 9 6 0
9 6 1  GCTTGCTAGA CCT1GAAAAC AGGTGCTGCA CGGqlGTCGT CAGCTCGTGT CGTGAGATGT TGGGTTAAGT CCCGCAACGA 1 0 4  0 
GAAAAC AGGTGCTGCA CG
GAAAAC AGGTGCTGCA CGGC
Prim er HGR 
Prim er 1026R
1 0 4 1  GCGCAACCCC CTTTCTTAGT TGCTAACAGG TCATGCTGAG AACTCTAAGG ATACTGCCTC CGTAAGGAGG NNNAAGGTGG 1 1 2  0
1 1 2 1  GGANGACGTC AAGTCATCAT GGCCCTTACG CCTAGGGCTA CACACGTGCT ACAATGGGGT GCACAAAGAG AAGCAATACT 1 2 0 0
1 2 0 1  GCGAAGTGGA GCCAATCTTC AAAACGCCTC TCAGTTCGGA TTGTAGGCTG CAACTCGCCT GCATGAAGCT GGAATCGCTA 1 2 8 0
1 2  8 1  GTAATCGCAA ATCAGCCATG TTGCGGTGAA TACGTTCCCG GGTCTTGTAC TCACCGCCCG TCACACCATG GGAGTTGTGT 1 3 6 0
1 3  6 1  TTGCCTTAAG TCAGGATGCT AAACTAGCTA CTGCCCACGG CACACACAGC GACT 1 4 1 4
Figure 9.3: 16S rRNA sequence amplified from the bladder of Patient E
aligned with primers of the assays of Logan, Bohr and Ho.
Alignment with primers of Ho et al (1992) demonstrates a mismatch 
between template DNA and the 3’ end of sense primer Hp2*.
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9.2.5 PCR-based analysis of colonic biopsies
All colonic biopsies were tested by the same panel of Helicobacter genus and species- 
specific PCR assays as described above for the bladder biopsies. The 16S rDNA 
assay of Bohr et al (1998) generated amplicons of approximately 639 hp in 12 
biopsies. However, amplicon quantity was insufficient for sequencing, and 
subsequent enhanced band separation in a 3.0 % agarose gel demonstrated that the 
hands were slightly larger than that of the positive control. Amplicons were not 
generated by any of the other assays applied.
9.2.6 PCR-based analysis of bronchial biopsies
All bronchial biopsies were tested for helicobacters by the same panel of PCR assays. 
No specific amplicon was generated in any of the biopsies tested.
9.3 Discussion
As discussed in section 1.9, PCR has proved to be a key technique in the investigation 
of the role of helicobacters in extra-gastric diseases. The majority of these studies 
amplified a single target with one primer pair (single round PCR) (Birek et al. 
1999;Riggio and Lennon 1999;Roe et al. 1999;Tanaka et al. 1999) or two primer 
pairs in a nested format (Blasi et al. 1996;Danesh 1998;Fanning et al.
1998;Kawaguchi «/. \996\'Lm et al. 1995;Mravak-Stipetic a/. 1998). As 
discussed in Chapter 3, reliance on a single PCR detection assay can lead to falsely 
negative results due to heterogeneity at the primer binding site, and performance of 
individual PCR assays can he differentially affected by factors such as specimen 
quality. Results presented in Chapter 8 highlighted the issue of non-specific 
amplification that can arise with nested PCR. Furthermore, the additional specimen 
manipulation of a second round of PCR increases the risk of contamination and the
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occurrence of false-positive results. These problems are particularly difficult to 
recognise in the absence of a “gold standard” method, such as culture, which would 
allow validation of a PCR assay for a novel application. In this chapter, PCR assays 
were used to investigate chronic inflammatory conditions of the genitourinary tract 
(IC), the lower gastrointestinal tract (CD and UC) and the lower respiratory tract 
(CPC). In contrast to most studies conducted to date, a panel-based approach 
comprising two Helicobacter genus-specific and three species {H. pylori and 
HHLOs)-specific PCR assays was used. This multiple assay and target (16S rRNA 
and vacA) approach was adopted to overcome the problems of false negatives 
discussed above, but also so that inter-assay correlations would corroborate any PCR- 
positive results.
9.3.1 PCR-based detection of helicobacters in bladder biopsies
Clinical features such as: rapid onset of disease; higher incidence in women; a lack of 
family history or HLA haplotype-association and presence of IgA deposits in the 
bladder epithelium suggest IC may have a bacterial aetiology (Haq et a l 2001). 
Several broad-based PCR studies that universally amplified all bacterial 16S rRNA 
have been conducted to investigate this hypothesis, and bacteria including E. coli and 
species of Prevotella, Actinomyces, Propioniobacterium and Acinetobacter have been 
detected in bladder biopsies (Domingue et a l 1995;Heritz et a l 1997;Keay et a l 
1998b). In contrast, other studies have been unable to detect any bacterial DNA at 
this site (Haarala et a l 1996;Hampson et a l 1993). No association between bacterial 
DNA and IC was demonstrated in any of these single PCR assay-based studies. The 
possibility that PCR assays failed to detect Helicobacter due to poor assay sensitivity 
cannot he excluded and consequently the hypothetical bacterial aetiology of IC 
remains unresolved.
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In this chapter, multiple genus and species-specific PCR assays were applied to 
investigate the potential role of Helicobacter in IC for the first time. PCR analyses 
demonstrated that 85.2 % of biopsies were PCR-positive by at least one assay. 
However, inter-assay correlation was poor, with some biopsies positive for 4/5 assays 
while others were positive by only one of the two Helicobacter-spQcific assays. The 
poor inter-assay corroboration raised concerns that amplification was non-specific, 
particularly as only two of the patients (F and R) were actually seropositive for H. 
pylori. Furthermore biopsies fi'om just two patients (B and M) were PCR-positive for 
the HpVac assay targeting vacA\ a gene that is present in all H. pylori isolates (Cover 
1996). As demonstrated in Chapter 3, the sensitivity of different PCR assays varies 
considerably, particularly if initial target DNA levels are low, as suggested by the 
low-intensity hands generated in many bladder biopsies. Testing of serial tenfold 
dilutions of H. pylori DNA (NCTC 11637 and NCTC 11916) demonstrated that the 
assay of Logan et al (2000) was ten times more sensitive than that of Bohr et al 
(1998), detecting as little as 100 fg. Such differences in assay performances could at 
least partially contribute to discrepancies between tests.
To facilitate interpretation of results, an additional prokaryote-specific PCR assay 
described by Fox et al (1995) was applied to all biopsies. The failure of this assay to 
generate prokaryotic amplicon in 11 patients that were weakly positive by the Bohr 
assay, suggested the latter had non-specifically amplified non-hacterial DNA, that was 
possibly of human origin. Thus, the Bohr assay may not he sufficiently specific for 
application to human tissue, a conclusion that has since been confirmed by the 
original author in a later study (Bohr et al, 2002). Furthermore, sequence data 
generated by the assay of Fox et al (1995) for patient E identified sequence variation 
at the Ho et al (1992) primer Hp2 binding site, and this may account for inter-assay
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discrepancies also. This observation again demonstrates that no single PCR assay can 
detect all strains of a bacterial species or genus, particularly one like Helicobacter that 
is highly heterogeneous at the genome level. The potential limitations of a single 
PCR-assay approach were highlighted also by one other study of IC, published in 
June 2003, that failed to amplify H  /7y/or/-specific DNA in paraffin-fixed bladder 
hiopies from 33 IC patients using the same Ho 16S rRNA PCR assay (Agarwal and 
Dixon, 2003). While this may suggest that H  pylori is not present in the human 
bladder, the negative PCR results reported may be due to insufficient sensitivity of the 
assay applied, as was observed for the study presented in this chapter.
9.3.2 Characterisation of amplified products from bladder biopsies 
BLASTn alignment of sequenced 16S rDNA amplicons demonstrated that these were 
>99 % similar to H. pylori while amplicons of the less-conserved vacA gene were <
97 % similar. This confirmed that PCR amplicons were not spurious and suggested 
that H. pylori was present in the human bladder. However, it should be noted that 
studies that rely on PCR based results alone in combination with sequencing data may 
misidentify the species detected. BLASTn searches, although useful, have the 
limitation that they can only align novel unknown sequences with a list of sequences 
currently held in public databases. A vast number of commensal bacterial species are 
likely to colonise humans that have either not yet been identified, or characterised by 
sequencing. Such sequences thus could he misidentified by BLASTn analysis. For 
this reason it is preferable to adopt a multiple target approach to increase the 
probability of correct identification of sequences and thus accurate spéciation. One 
additional advantage of the prokaryote-specific assay was that the entire 16S sequence 
spanning variable regions VI to V9 (illustrated in Figure 1.3) could he determined in 
two patients. The chances of such a large DNA sequence being misidentified by
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BLASTn analysis is extremely low and so this data provided compelling evidence of 
amplicon specificity.
As demonstrated in Chapter 8, H. pylori is often present in the stool of infected 
individuals, although it is not known if cells are intact or fragmented. It is 
hypothesised that, like most uropathogens, H. pylori may enter the bladder by an 
ascending route, although matched patient stool samples were not available to explore 
this possibility. Nevertheless, as several of the control patients were also PCR- 
positive, the association between H. pylori and development of IC cannot he 
supported. This finding is substantiated by studies that found no increased H. pylori 
seroprevalence in IC patients (English et a l 1998) or failed to demonstrate higher 
numbers of CLO test-positive results in bladders of IC patients (Haq et a l 2001). 
Culture of these biopsies in the primary laboratory (Chelmsford PHL) had been 
unsuccessful, thus essential corroborating evidence of H. pylori in the bladder was not 
available, so the possibility of specimen contamination with exogenous H. pylori 
DNA could not be excluded. Iatrogenic specimen contamination at cystoscopy via 
forceps was demonstrated previously in a PCR-based study (Keay et a l 1998a), and 
cross-contamination of gastric biopsies at endoscopy is well-documented (Akamatsu 
et a l 1996;Dehongnie and Bouckaert 1993;Miyaji et a l 1995). However, enteric 
bacteria commonly associated with bladder infections would he a more likely cause of 
cross-contamination at cystoscopy than H. pylori. Alternatively, H. pylori DNA 
could he introduced during culture of biopsies at the primary laboratory, or during 
DNA extraction. This would seem unlikely given that over 200 H. ;?y/orz-negative 
gastric biopsies were processed under identical conditions in the course of this study 
without any similar problems. Furthermore, contamination at the PCR stage was 
unlikely also, as none of the negative controls contained spurious amplicons.
253
Results and Discussion
Amplification and sequencing of 16S rDNA from various clinical specimens has 
heen key in defining the aetiology of other conditions including Whipple’s disease, 
bacillary angiomatosis and human ehrlichiosis (Wilson 1994). However in all these 
examples, additional corroborating evidence of the infectious agent (e.g. culture or 
visualisation by microscopy) was available also. Further work to examine other 
methods that would supplement the PCR-based evidence presented in the current 
study and allow in situ visualisation of infecting bacteria (e.g. histology, in situ 
hybridisation or in situ PCR), would provide a context for interpretation of PCR 
results and provide more compelling evidence that H. pylori was present in the human 
bladder. Extension of this study using these additional methods to examine a broader 
spectrum of diseases states could provide insight into the biological significance of 
helicobacters at this site.
9.3.3 Investigation of colonic biopsies
One study demonstrated the presence of helicobacters in colonic biopsies from CD 
patients by a broad range prokaryote-specific 16S rDNA PCR, followed by specific 
probe hybridisation and sequencing approach (Tiveljung et a l 1999). The authors 
speculated that helicobacters act as ulcerative pathogens, contributing to the 
pathogenesis of CD, possibly as part of a mixed microbial infection. Helicobacter 
infection was confirmed by hybridisation of a specific probe spanning the 
hypervariahle region V4 of 16S rDNA. Sequencing was unsuccessful. Assay 
specificity is particularly important in specimens like colonic biopsies that contain 
high levels of competing bacteria that may cross-react with some primer pairs. The 
work presented in this chapter describes, for the first time, the application of 
Helicobacter genus and species specific PCR assays in the investigation of the
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aetiology of CD and UC. Multiple assays were applied to facilitate interpretation of 
any positive PCR results.
In contrast to the results obtained for the bladder biopsies, application of the same 
PCR assays to colonic biopsies did not generate product in the majority of cases. In 
12/30 colonic biopsies, faint bands of approximately 639 hp were generated by the 
Helicobacter genus-specific assay of Bohr et al, 1998. These amplicons could not be 
characterised further as insufficient product was generated for sequencing. However 
improved resolution of these hands showed they were larger than the anticipated 
Helicobacter-spGciûc product. This observation, combined with the fact that no other 
PCR assay generated amplicons, suggested that these bands were non-specific, as was 
observed in the bladder biopsies. Thus, colonic biopsies were PCR negative for all 
assays applied. The poor specificity of the Bohr PCR assay highlights the problems 
of interpreting positive results from a single PCR assay not previously validated for 
that application, particularly if insufficient product is generated to allow confirmatory 
testing. The multiple assay/target approach described in this chapter quickly allowed 
false-positive results to he excluded.
Negative results could also have occurred due to insufficient assay sensitivity. The 
lack of a gold standard method to allow assessment of sensitivity of these assays when 
applied to colonic biopsies, prevents exclusion of this possibility. Although no 
helicobacters were observed by histological analyses of biopsies, specimens were 
stained by routine haematoxylin and eosin. This method is relatively insensitive for 
detection of helicobacters compared with, for example, Giemsa or Warthin Starry 
staining (El Zimaity 2000). Further investigations might include appropriate 
histological analysis of biopsies and application of a nested PCR to address the 
sensitivity issue, but interpretation of PCR results can be difficult, particularly when
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specimens are from a site rich in diverse bacterial species. Previously, a lower 
incidence of H. pylori infection in patients with IBD was demonstrated, particularly in 
those who had taken sulphasalazine, suggesting that IBD drug therapy may inhibit 
bacterial growth (Parente et al. 1997b). However, non sulpha 5 AS A medication did 
not have the same inhibitory effect (el Omar et al. 1994). In this chapter, only one 
UC patient was taking sulphasalazine; while 9/11 with UC and 1/9 with CD were 
prescribed non sulpha 5ASA (S. Bell, personal communication). Consequently, it 
seems unlikely that the negative PCR results were due to bacterial inhibition or 
eradication by IBD specific medication. The results suggest that helicobacters do not 
play a significant role in CD or UC, a conclusion that is also supported by previous 
serological based studies that found a negative association between H. pylori infection 
and IBD (Halme et al. 1996;Kolho et al. 1998;Parente et al. 1997a;Pearce et al.
2000). Recently, a German study described a novel 16S rRNA PCR assay using 
modifications of primers C97 and HGR (section 1.7.1.1) that amplified fragments of 
DNA from intestinal biopsies of 2 of 3 CD patients, hut not in any of the three UC 
patients examined (Bohr et al. 2002). Sequence analyses identified amplicons as H. 
pylori and H. pullorum. It is not known if these results indicate higher sensitivity of 
the novel PCR assay compared with those applied in this chapter or if differences in 
detection rates are due to geographical variation, hut this could he assessed by future 
application of this assay to the colonic biopsies from English patients. As few 
biopsies were examined in the Bohr study, the significance of these PCR results in 
relation to IBD remains unknown.
As discussed in sections 1.5.2.3 and 1.8.2, studies, including that presented in 
Chapter 8, have shown that H. pylori is detectable in the lower intestine, by 
demonstration of specific antigens or DNA in stools. It is not known if H. pylori in
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stools interact with the mucosa of the large intestine, leading to development of 
disease of the lower gastrointestinal tract. A previous study using nested 16S rDNA 
PCR to investigate the role of H. pylori in appendicitis failed to detect H. pylori in 
intestinal biopsies (Fanning et al. 1998), despite the enhanced sensitivity of this 
format. The results in this chapter also suggest that H. pylori and other helicobacters 
are not associated with the intestinal mucosal surface. However, further 
investigations of IBD patients of known Æ pylori status will he essential to 
substantiate this observation.
9.3.4 Investigation of bronchial biopsies
PCR-based analyses of bronchial biopsies failed to detect helicobacters in any of the 
10 patients investigated. Internal control PCR demonstrated that negative results were 
not due to inhibition of Taq polymerase and as multiple assays targeting different 
areas of the genome were applied, there is no evidence that helicobacters contributed 
to CPC in these patients. However, it should again he appreciated that this possibility 
cannot he wholly excluded, as bacterial DNA may he present below the threshold of 
detection of the PCR assays. Other studies have adopted a nested PCR approach to 
improve sensitivity of detection, this was not attempted here, given the increased risk 
of contamination that can he difficult to identify in samples for which there is no gold 
standard for comparison or assay validation. As for the bladder and colonic biopsies, 
future investigations should focus on application of more sensitive (nested) methods 
of PCR-based detection as well as confirmatory evidence provided by direct 
visualisation of helicobacters in situ.
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9.4 Conclusions
The work presented in this chapter showed for the first time that helicobacters may he 
present in the human bladder, although the clinical significance of this remains to he 
established. In contrast, no evidence of helicobacters in colonic or bronchial biopsies 
was provided following multiple analyses of samples with Helicobacter genus and 
species-specific PCR assays.
One cautionary point raised by this study is that it is difficult to fully exclude the 
possibility of contamination with extrogenous bacteria or bacterial DNA, if evidence 
of an organism’s presence is based on PCR alone. Further evidence of the infecting 
organisms, ideally by culture hut also for example by histology or by in situ 
hybridisation would corroborate any PCR-positive results and provide more 
compelling evidence of potential associations with disease. Consideration of this 
issue for future investigations will greatly improve the quality of experimental 
outcomes.
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Chapter 10: Application of PCR in the investigation of the mechanism of 
metronidazole (MTZ) resistance in H, pylori.
10.1 Background
In Chapter 5, PCR proved to he a powerful, rapid means for determination of 
clarithromycin (CLA) susceptibility. MTZ is also a key antibiotic in H. pylori 
eradication, but the utility of this is now compromised by high resistance rates world­
wide (Alarcon a/. 1999;Megraud a/. 1999). Surveillance of MTZ resistance is 
problematic as there are no standardised methods for culture-based susceptibility 
testing. Likewise, the potential development of a simple molecular test for 
determining MTZ susceptibility analogous to that for CLA has been hindered by poor 
understanding of the mechanism of MTZ action and of resistance development in H. 
pylori (Jenks and Edwards 2002;Mendz and Megraud 2002).
As discussed in section 1.11.6, current evidence suggests that genes rdxA and frxA, 
encoding an oxygen-insensitive NADPH nitroreductase and an NADPH flavin 
oxidoreductase, respectively, may be involved in MTZ metabolism and that resistance 
can develop by mutational inactivation of these (Dehets-Ossenkopp et al. 1999;Kwon 
et al. 2000d;Kwon et al. 2000h;Kwon et al. 2001b;Solca et al. 2000). However, 
reports of MTZ-R strains that possess apparently unaltered rdxA and frxA  compared 
with MTZ-S strains (Goodwin et al. 1998) indicates possible involvement of other 
genes (Kwon et al. 2001a;Tankovic et al. 2000;Wang et al. 2001). Two recent studies 
have provided protein-based evidence that a homologue of subunit AhpC of alkyl 
hydroperoxide reductase may be involved in MTZ resistance also (McAtee et al. 
2001;Trend et al. 2001).
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In this chapter, PCR-based methodologies were applied to investigate rdxA,frxA and 
ahpC in a unique collection of 50 clinical H. pylori isolates recovered from 21 
patients in England undergoing investigation for symptoms of dyspepsia.
The aims of this study were:
1) To identify mutations in rdxA, frxA  and ahpC in paired MTZ-S/MTZ-R 
isolates that may contribute to MTZ resistance in the UK.
2) To examine mixed MTZ-S/MTZ-R infections by PCR-based genotyping to 
evaluate the contribution of mixed genotype infections to treatment failure.
3) To compare gene sequences of MTZ-R strains recovered before and after 
therapy with matched pre-treatment MTZ-S strains (and MTZ-R strains, if 
present) to establish if treatment had failed due to selection of a pre-existing 
mutated MTZ-R strain or if de novo mutation of both the MTZ-S and MTZ-R 
sub-populations, leading to higher resistance levels, occurs during the 
eradication regime.
4) To determine by a novel real-time PCR assay the frequency of early frameshift 
mutations in frxA  and to assess the relationship of these to MTZ susceptibility.
10.2 Results
10.2.1 Study population
Isolates cultured from gastric biopsies of 21 dyspeptic patients from Ipswich (A -  H) 
and London (G -  U), England were included in this study. Thirteen of these patient 
sets were stored paired cultures (patients A -  M), recovered from patients before and 
after they had received MTZ-hased eradication therapy (Owen et al. 1993). A further 
four were strain pairs recovered pre-treatment from single gastric biopsies of 
dyspeptic patients (N -  Q) that were mixed MTZ susceptibility, and the remaining
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four were isolate pairs recovered pre-treatment from two gastric sites (antrum and 
corpus) of patients R -  U. MTZ susceptibilities were determined for all isolates 
following the protocols described in sections 2.7.2. Mixed MTZ-S/MTZ-R sub- 
populations were separated as described in section 2.8. AFLP types were determined 
for all isolates as described in section 2.21. Complete or partial fragments of genes 
rdxA,frxA and ahpC were amplified by PCR (section 2.17) in all strains, amplicons 
sequenced and then analysed as described (2.22).
10.2.2 Characterisation of strain resistotype
E-testing of H. pylori from patients A -  M showed that pre-treatment isolates were 
either predominantly MTZ-S with fewer MTZ-R colonies (ranging from 30 to > 100) 
growing in the zone of inhibition (n = 7), or fully MTZ-S (n = 4) or MTZ-R (n = 2) 
(Table 10.1). All patients, except for patient D, were infected with MTZ-R strains 
only post-therapy.
Mixed MTZ-S/MTZ-R resistotype pre-treatment infections were identified in 
gastric antral biopsies of patients N -  Q, while pre-treatment strains with different 
MTZ resistotypes were found in the antrum and in the body of the gastric mucosa of 
patients R -  U (Table 10.1). No post-treatment isolates were available for patients N 
-U .
10.2.3 Characterisation of strain genotype
AFLP analysis demonstrated that all 21 patients were infected by H. pylori with 
unique genotypes (Table 10.1). Examples of the AFLP profiles generated are shown 
in Figure 10.1. AFLP genotypes determined for isolate pairs from the 12 patients (A, 
B, D, E, H, I, K, M -  Q) with mixed (MTZ-S/MTZ-R) infections recovered from a 
single gastric site (pre-treatment, except for patient D) were either identical (n = 10) 
or similar, differing by a single band (n = 2), and isolate pairs of mixed (MTZ-
261
Results and Discussion
S/MTZ-R) infection recovered from patients R -  U (pre-treatment) from two separate 
gastric sites (antrum and corpus) had identical AFLP genotypes. Comparison of 
AFLP genotypes of pre-treatment isolates with those recovered post-treatment in 
patients A -  M demonstrated that these were mainly identical (n = 8) or similar (n =
3), while distinct genotypes, differing by two or more bands, were identified post­
treatment in patients H and I (Table 10.1).
Patient
8a 8b 10 10 11 13 13 13 14a 14b 15 15 15
AFLP type
A— 1230 bp
<— 123 bp
Figure 10.1: Examples of different AFLP profiles generated for paired MTZ-S 
and MTZ-R isolates. For all patients, AFLP types are in the order 
MTZ-S, MTZ-R (pre-treatment) and MTZ-R (post treatment), except 
where mixed susceptibility strains were not observed pre-treatment 
(patient L). 123 hp molecular weight marker (lanes 3 &16).
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Table 10.1: MTZ resistotypes and AFLP genotypes of 50 strains from 21 
patients
Gastric
Site
Patient
Code
Stage of 
treatment
MTZ MIC 
(gg/ml)
MTZ
Susceptibility
AFLP
Profile*
A Pre 0.25 + >256 S + R 1 ,1
Post >256 R 1
B Pre 0.19 + 16 S + R 2a, 2a
Post >256 R 2b
C Pre 0.094 S 3
Post >256 R 3
D Pre 0.19 S 4a
Post 0.25 + 64 S + R 4b , 4c
E Pre 0.25 + >256 S + R 5 ,5
Post >256 R 5
F Pre 0.064 S 6
Post >256 R 6
G Pre 96 R 7
Post >256 R 7
1 H Pre 0.5 + 128 S + R 8a + 8b
1 Post 48 R 9
< I Pre 0.25 + >256 S + R 10,10
Post >256 R 11
J Pre 96 R 12
Post >256 R 12
K Pre 0.25 + >256 S + R 13,13
Post >256 R 13
L Pre 0.38 S 14a
Post 16 R 14b
M Pre 0.5 + 256 S + R 15,15
Post >256 R 15
N Pre 0.19+ >256 S + R 16, 16
0 Pre 0.125+ >256 S + R 17, 17
P Pre 0.125+>256 S + R 18,18
Q Pre 0.25 + >256 S + R 19, 19
T3 R Pre 0.25+48 S + R 20,20
« g S Pre 0.094 + 12 S + R 21,21
T Pre 0.064 + >256 S + R 2 2 ,2 2
< U Pre 2 + >256 S + R 23 ,23
*Unrelated AFLP profiles are identified by different (arbitrary) numbers; similar but 
non-identical fingerprints are distinguished by lower-case letters (a, h, and c).
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10.2.4 Comparison of translated RdxA sequences in MTZ-S and MTZ-R strains
Comparison of all isolates with sequences held in GenBank (Appendix C.l) identified 
novel mutations, as well as those described previously (Solca et al. 2000) (Table 
10.2).
10.2.4.1 Comparison of matched pre and post treatment RdxA sequences
Of the nine matched pre and post-therapy MTZ-S and MTZ-R strains of similar AFLP 
genotypes (A -  F, K -  M), the inferred RdxA amino acid sequences were different in 
seven patients (A -  C, E, F, L, M) (Table 10.2). Nucleotide point mutations 
(corresponding to a substitution of Arginine-16 to Histidine in three of five cases) 
occurred in MTZ-R strains fi'om patients A, B, E, F and L. Frameshifts leading to 
protein truncation were seen in MTZ-R isolates from patients C and M. No mutations 
were found in the remaining two matched (MTZ-S and MTZ-R) pairs (patients D and 
K). Additionally, RdxA was identical in one of the matched pre and post-treatment 
MTZ-R pairs (patient G), while a single amino acid substitution was found in the 
other pair (patient J) (Table 10.2).
10.2.4.2 Comparison of matched pre-treatment MTZ-S and MTZ-R RdxA 
sequences
RdxA was identical in 11/16 MTZ-S and MTZ-R sub-population sets, recovered at 
the pre-treatment stage in all hut one case (patient D), either from a single or from two 
gastric sites (n = 12 and 4, respectively). Mutations in the MTZ-R sub-population 
only (patients H, I, N and O) included stop codons (n = 3) and carboxy terminus 
sequence alteration (downstream of residue 192) (n = 1) (Table 10.2). RdxA was 
truncated in both MTZ-S and MTZ-R suhpopulations of patient Q (Table 10.2).
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Table 10.2: Sequence variations in rdxA identified by comparison of matched
MTZ-S and MTZ-R strains of H. pylori recovered from patients 
before and after therapy or simultaneously as a mixed infection.
rdxA mutation type (nucleotide position)
Pre-treatment
MTZ-S MTZ-R
Post-treatment
MTZ-R
RdxA amino acid 
sequence change 
(codon) Patient
No mutation No mutation Substitution*
(G47A)
Arg->His (16) A, B,E
No mutation No mutation No mutation None K
No mutation No mutation/1 
No mutation
None D
No mutation No mutation Frameshift
(+T328)
Stop codon (110) M
No mutation Substitution
(G319T)
NDÎ Stop codon (107) H
No mutation Substitution
(C148T)
NDÎ Stop codon (50) I
No mutation NA§ Frameshift
(+A197)
Stop codon (74) C
No mutation NA§ Substitution
(C146G)
Thr—»Arg (49) F
No mutation NA§ Substitution
(C200T)
Ala^Val (67) L
NA§ No mutation No mutation None G
NA§ No mutation Substitution
(C131T)
Pro^Leu (44) J
No mutation No mutation NA None P , R - U
No mutation Frameshift
(+T575)
NA (193 onwards) 0
No mutation Frameshift
(+AT151)
NA Stop codon (56) N
Substitution
(C148T)
Substitution
(C148T)
NA Stop codon (50) Q
*Mutations in bold font have been reported previously (Solca et al. 2000). 
t  A mixed MTZ-S/MTZ-R infection was observed post-treatment in patient D, where 
rdxA sequence was identical in all strain variants.
^Comparison not done as post-treatment strains were different AFLP types.
§Not applicable as no mixed MTZ-S/MTZ-R infections were identified.
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10.2.5 Comparison of translated AhpC sequences in MTZ-S and MTZ-R strains.
Interstrain variation of as much as 5 % was observed in AhpC amino acid sequences 
but no sequence differences were found in any of the populations of each patient 
strain set. Examples of matched patient set AhpC amino acid sequences are presented 
in Figure 10.2.
P a t i e n t  A 1  
P a t i e n t  A 2  
P a t i e n t  A 3  
P a t i e n t  B 1  
P a t i e n t  
P a t i e n t  
P a t i e n t  
P a t i e n t  
P a t i e n t
B 2
B 3
E l
E 2
E 3
P a t i e n t  A 1  
P a t i e n t  A 2  
P a t i e n t  A 3  
P a t i e n t  B 1  
P a t i e n t  
P a t i e n t  
P a t i e n t  
P a t i e n t  
P a t i e n t
B 2
B 3
E l
E 2
E 3
P a t i e n t  A 1  
P a t i e n t  A 2  
P a t i e n t  A 3  
P a t i e n t  B 1  
P a t i e n t  B 2  
P a t i e n t  B 3  
P a t i e n t  E l  
P a t i e n t  E 2  
P a t i e n t  E 3
P a t i e n t  A 1  
P a t i e n t  A 2  
P a t i e n t  A 3  
P a t i e n t  B 1  
P a t i e n t  B 2  
P a t i e n t  B 3  
P a t i e n t  E l  
P a t i e n t  E 2  
P a t i e n t  E 3
1  M L V T K L A  D F  K A  A V L G N N E  V D E H F E L S K N  L G K S G A I L F F  W  K D F T F V C  T E I I A F D K R V  6 0
1    _ _       _     6 0
1           -     6 0
1  ------ T ------------       -     6 0
1  ------ T - -  - -  - -       -     6 0
1  ------ T - - ------------      -     6 0
1     - -  ---------------- ------------------- ------- N .........      6 0
1    - -       - - - N - .............. - ..........      6 0
1    - -  - - ------------------------------  - - - - N ..................    6 0
6 1  K D F Q E K G F N V  I G V S I D S E Q V  H F A W K N T  V E  K G G I G Q V T F  M V A D I T K S I S  R D Y D V L F E E A  1 2 0
6 1       - -       1 2 0
6 1        - -     ■   1 2 0
6 1               1 2 0
6 1       - -       1 2 0
6 1       - -       1 2 0
6 1       - -       1 2 0
6 1       - -       1 2 0
6 1       - -       1 2 0
1 2 1  l A L R G A F L I D  K N M K V R : A V I  N D L  L G R N A D  E M L R M V D A L L  H F E E H G E V C  A G W R K G D K G M  1 8 0
1 2 1              1 8 0
1 2 1             1 8 0
1 2 1    - - -          1 8 0
1 2 1     - - -          1 8 0
1 2 1     - - -          1 8 0
1 2 1     - - -          1 8 0
1 2 1     - - -          1 8 0
1 2 1             1 8 0
1 8 1  K A  1 8 2  
1 8 1  - -  1 8 2  
1 8 1  - -  1 8 3  
1 8 1  - -  1 8 2  
1 8 1  - -  1 8 3  
1 8 1  - -  1 8 3  
1 8 1  - -  1 8 3  
1 8 1  - -  1 8 3  
1 8 1  - -  1 8 3
*Strains numbered: 1 = MTZ-S (pre-therapy); 2 = MTZ-R (pre-therapy); 3= MTZi-R (post­
therapy)
Figure 10.2; Examples of partial AhpC amino acid sequences in matched 
patient strain sets of separated MTZ-S and MTZ-R sub­
populations (pre-treatment) and MTZ-R populations (post­
treatment)
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10.2.6 Comparison of translated FrxA sequences in MTZ-S and MTZ-R strains.
As discussed earlier (section 2.17.2), various primer combinations were required to 
amplify frxA  for sequencing. This allowed determination of the complete frxA gene in 
20/21 patients, but amplification was unsuccessful for patient R.
In 16/20 (80.0 %) patient sets examined, no mutational differences were observed 
in any of the matched populations, while fi-ameshiff mutations were observed only in 
MTZ-R populations in three patients (C, K, L) and in the MTZ-S strain only in patient 
T. Multiple alignment of FrxA sequences from this study with 23 sequences held in 
GenBank (Appendix C.2) showed that at least one strain from 18 of the 20 (90.0 %) 
patient sets had a frameshift mutation that led to premature truncation of FrxA protein 
(Table 10.3, Figure 10.3). In 14/18 patient sets, fi’ameshift mutations were observed 
in all strains, regardless of MTZ resistotype. Frameshifts occurred at nucleotide 53 in 
12/18 (66.7 %) patient sets, usually due to a single adenine deletion. In most cases 
this was predicted to lead to early protein truncation at codon 39 (Figure 10.3), with 
the exception of patient P where a G117T substitution altered codon 39 and also 
patient N where a 2-bp (AA) deletion was observed at position 53 (Figure 10.3).
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P a t i e n t F 1 M D R E Q W A L Q Î I Q R F A A K K Y D S N R R I S Q K D W E A L V E V G R L A S S I G L E W K M L L L K N E R M K 6 0
P a t i e n t B 1 M D R E Q V I A L Q H Q R F A A K K Y D N R R I S Q K D W E A L V E V G R L A S S I G L E W K M L L L K N E R M K 6 0
P a t i e n t M 1 M D R E Q W A L Q I I Q R F A A K K Y D N R R I S Q K D W E A L V E V G R L A S S I G L E W K M L L L K N E R M K 6 0
P a t i e n t C 1 M D R E Q I I A L Q K Q R F A T K K Y D N R R I S E K D W E V L V E V G R L A S S I G L E W K M L L L K N E R M K 6 0
P a t i e n t P 1 M D R E Q W A L Q
A-A*
H Q R F A A K N T I L I W F  K R I G K L W L K W G D Y L L Q S G L N H G K C F Y - 5 3
P a t i e n t A 1 M D R E Q W A L Q
A-A*
H Q R F A A K N T I L I W F  K R I G K L W L K W G D - 3 8
P a t i e n t N 1 M D R E Q W A L Q
A-AA*
H Q R F A A K I R S 2 0
P a t i e n t F 6 1 E D L K M A W G A L F G L E G A S H F V I Y L A R K G V T Y D S D Y V K K V M  H E V K K R D Y D T N S R F A Q I I K N 1 2 0
P a t i e n t B 6 1 E D L K M A W G A
A-T* 
L F W F G G S E  F C  L S C A K R R Y L - 9 1
P a t i e n t M 6 1 E D L K M A W G A
A-CT*
F W F R G S E  F C H L S C A K R R Y L 9 0
P a t i e n t C 6 1 E D L K
A-G* 
M A W G G  F L V - 7 3
P a t i e n t F 1 2 1 F Q E N D M K L N S E R S L F D W A S K Q T Y I Q M A N M M M A A A M L G I D S  C  l E G Y D Q E K V E A Y L E E K G Y 1 8 0
P a t i e n t F 1 8 1 L N T A E F G V S V M A C F G Y R N Q E I T  K T R W K T E V I Y E V I E -  2 1 7
Figure 10. 3; Examples of FrxA amino acid sequences determined for each 
frameshift mutation type observed in different patient sets
*Nucleic acid sequence changes that caused amino acid alterations 
e.g. for patient P, one adenine deletion in the nucleotide sequence 
caused frameshift leading to an altered amino acid sequence and 
creation of a stop codon.
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Table 10.3; Sequence variations in frxA identified by comparison of matched 
MTZ-S and MTZ-R strains of H, pylori recovered from patients 
before and after therapy or simultaneously as a mixed infection
frxA mutation (nucleotide position)
Pre-treatment
MTZ-S MTZ-R
Post-treatment
MTZ-R
FrxA amino acid 
sequence change 
(codon)
Patient
Frameshift (53) Frameshift (53) Frameshift (53) Stop codon (39) A, D,E
Frameshift (53) Frameshift (53) NA* Stop codon (39) H,I
Frameshift (212) Frameshift (212) Frameshift (212) Stop codon (92) B
Frameshift (211) Frameshift (211) Frameshift (211) Stop codon (91) M
No mutation Frameshift (209) Frameshift (209) Stop codon (74) K
No mutation NAf Frameshift (209) Stop codon (74) C
No mutation NAt Frameshift (53) Stop codon (39) L
Frameshift (53) Frameshift (53) NAf Stop codon (21) N
NA§ Frameshift (53) Frameshift (53) Stop codon (39) G
No mutation NAf No mutation None F
NA§ No mutation No mutation None J
Frameshift (53) Frameshift (53) NAf Stop codon (39) Q, S,U
Frameshift (24) Frameshift (24) NAf Stop codon (39) 0
Frameshift (53) Frameshift (53) NAf Stop codon (54) P
Frameshift (24) No mutation NAf Stop codon (39) T
*Not applicable as post-therapy strains had been shown to be a different AFLP genotype. 
fNot applicable as mixed susceptibility infections were not observed.
JNot applicable as no post-treatment isolates were available.
§Not applicable as only MTZ-R strains were observed pre-treatment.
10.2.7 Mutations in rdxA and frxA in relation to MIC
The combined incidences of rdxA and frxA  mutations for each patient set is 
summarised in Table 10.4. This revealed that 8/21 (38.1 %) patients (A, B, E, H, I, M
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- O) infected with highly resistant isolates (MIC >128 pg/ml) had mutations in rdxA 
of MTZ-R strains (either both pre and post-treatment or after therapy only) and in 
frxA  of all populations. Two patient sets (C and L) had mutations in rdxA and frxA  of 
MTZ-R isolates only, but the MIC of the MTZ-R isolate from one of these was 
comparatively low (16 pg/ml). Two other patient sets (F and J) had mutations in the 
rdxA only of the MTZ-R subpopulations that had high MICs (>256 pg/ml). A further
33.3 % (7/21) of patient isolates (D, G, K, P, S -  U) had mutated frxA  genes only, 
although 5/7 were highly resistant (MIC >256 pg/ml).
Table 10.4 The effects of combined rdxA and frxA  mutations in relation to 
MIC
rdxA mutations frxA mutations•' _ . MICs for
S+R S only R only* S+R S only R only* MTZ-Rstrains
- - Z Z - - A,B,E,H,I,M,N,0 >128
- - Z - - Z C,L 16- 256
- - Z - - - F,J >256
- - z - - Q >256
- - - - - z K,G >256
- - - z - - D,P,S,U 12 - 256
- - - NDf ND ND R >256
- - - - Z - T >256
^Mutations in MTZ-R strains isolated either pre or post-treatment, or at both stages. 
fNot done as frxA  sequencing failed.
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10.2.8 Distribution of the frxA frameshift 53 mutation in 119 H. pylori isolates
A novel LightCycler assay was developed for rapid identification of strains containing 
a frameshift mutation due to a single adenine deletion at nucleotide 53 as results in 
section 10.2,6 suggested that this was frequently observed in H. pylori. Probe FS- 
53Pr was designed to complement sequences containing this single adenine deletion 
(Figure 10.3). Optimisation experiments showed that probe and MgCh 
concentrations of 5 pmol and 6 mM, respectively, were required to ensure sufficiently 
high fluorescence of probe label LC-Red 640, allowing reproducible generation of 
melting peaks that allowed mutant and wild-type sequences to be easily distinguished. 
All subsequent analyses were performed as described in section 2.20.7.
Initial evaluation of the novel LightCycler assay FS-53 on isolates (from patients A 
-  Q and S -  U) where frxA  sequences had been determined demonstrated that 
sequences with a single adenine deletion at nucleotide 53, containing a run of six 
adenine residues, were exactly complementary to probe FS-53Pr and so generated a 
melting peak indicating a probe-template dissociation temperature of approximately 
61 °C (Figure 10.4). Wild-type strain sequences, that retained seven adenines, were 
mismatched with the probe and generated a melting curve indicative of a lower 
dissociation temperature of approximately 59 °C (Figure 10.4). The probe failed to 
hybridise with sequences where the first of the seven adenine residues had been 
replaced with a guanine, and additional sequence variation was found (Figure 10.4).
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Temperature fC)
F S - 5 3 P r  1 LCRed640-ATTTGCTGCAAAAAATACGATC-P 22
P a t i e n t  A 1 AGCACCAACG........................CTAATCGTCG 42
P a t i e n t  B 1 AGCACCAACG............... ATACGATCCTAATCGTCG 4 3
P a t i e n t  C 1 A A C A C C A A C G ...C . . .A C G.... ATACGATCCGAATCGCCG 43
... = Sequence homology
Figure 10.4: Melting peaks generated by LightCycler assay FS53 to screen for 
frameshift mutations at nucleotide 53, and alignment of FS-53Pr 
with frxA sequences.
Assay FS-53 was applied to 119 miscellaneous isolates recovered pre-treatment from 
dyspeptic patients from London (n = 81), Wales (n = 26) mid-Essex, (n = 3), Leeds (n 
= 7) and Portsmouth (n = 2), that were previously characterised by E-test as MTZ-S (n 
= 61) or MTZ-R (n = 58). Melting peaks indicative of frameshift 53 were generated 
in 24/119 (20.2 %) of strains. Of the 24 strains containing frameshift 53, 14/24 (58.3 
%) were MTZ-R while 10/24 (41.7 %) were MTZ-S. Distribution of frameshift 
mutation 53 in MTZ-S and MTZ-R strains from London, Wales and elsewhere in 
England is presented in Figure 10.5.
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10.3 Discussion
In this study, PCR was applied to examine the potential contribution of rdxA, ahpC 
and frxA to MTZ activity and resistance development in paired isolates of H. pylori, 
recovered before and after eradication therapy. Additionally, to further elucidate the 
significance of the observed mutations, these genes were examined pre-treatment in 
mixed susceptibility populations, to establish if mutations seen post-treatment were 
pre-existing mutations or de novo mutations that arose during therapy. Because this 
was the first investigation of isolates from the UK, the study population was extended 
to include paired MTZ-S and MTZ-R strains from a further eight patients, either from 
two gastric sites (antrum and corpus) or as part of a mixed susceptibility population 
from the gastric antrum. The study population included seven patient sets comprising 
matched pre-treatment MTZ-S and MTZ-R strains, together with matched post­
treatment MTZ-R strains. This formed a unique strain set that could provide greater
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insight into the potential role of rdxA and frxA  in MTZ metabolism and resistance 
than has been possible to date. Finally, a real-time PCR assay was developed for the 
LightCycler to allow rapid screening of clinical isolates for single adenine deletions at 
nucleotide 53 in frxA, to assess the prevalence and significance of this mutation.
10.3.1 Characterisation of study population by AFLP genotyping 
Evidence from studies in different countries suggests that many patients are co­
infected with H. pylori of mixed MTZ-S and MTZ-R phenotype, but these are usually 
closely related strains genotypically (Dore et a l 1998; Jorgensen et a l 1996;van der 
Wouden et a l 1999). Similarly, in patient sets A -  M, AFLP typing demonstrated that 
mixed MTZ-S and MTZ-R isolates fi'om individual patients were phenotypic 
variations of the same strain rather than genotypically distinct co-infections. Isolates 
recovered post-therapy were in most (11/13) cases similar or identical to pre-therapy 
strains. Re-infection with a novel strain was infrequent, observed in two patients 
only. Many patients were initially infected with a MTZ-R sub-population in addition 
to a predominant MTZ-S population, suggesting that treatment failure occurred due to 
selection of the pre-existing MTZ-R population during therapy, rather than de novo 
development of MTZ resistance. Likewise, mixed MTZ resistotype infections 
identified in patients N -  U before therapy were genotypically identical by AFLP, 
once more indicating that presence of a pre-existing MTZ-R strain variant was more 
frequently observed than mixed genotype infections.
A recent study investigating the mutagenic effects of MTZ metabolites suggested 
that MTZ-R colonies observed in the E-test zone of inhibition arose by spontaneous 
mutation and were not indicative of mixed susceptibility infections (Sisson et a l
2000). Furthermore, MTZ-R colonies were not observed in an agar dilution-based 
method that applied a serially diluted range of lower inocula (Jeong et a l 2000;Jeong
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et a l 2001;Sisson et a l 2000). As proposed, one possible interpretation of these 
results is that the high bacterial cell densities used in E-testing for H. pylori increases 
the likelihood of spontaneous mutation to form MTZ-R colonies in MTZ-S 
populations (Jeong et a l 2001). However, it is equally possible that methodologies 
using higher-level inocula simply increase the chance of isolating a pre-existing low- 
level sub-population. A recent review that compared three studies (Jeong et a l 
2001;Sisson et a l 2000;Wang et a l 2001) reported a lack of correlation between 
mutation rate and inoculum size (Mendz and Megraud 2002). Furthermore, routine 
MTZ susceptibility testing of over 400 isolates of H. pylori that were defined as 
MTZ-S in the HRU by E-test has demonstrated that the majority (>91 %) show no 
evidence of MTZ-R colonies in the zone of inhibition, despite the heavy inoculum 
applied (R. J. Owen, personal communication). This suggests that generation of 
MTZ-R colonies by spontaneous mutation occurs relatively infrequently in isolates 
from UK patients. In contrast, MTZ-R colonies were observed in approximately 54 
% of the MTZ-S isolates from patients (A -  M) who had failed treatment. While 
these strains may be hypermutable, leading to in vitro induction of MTZ-R colonies, it 
seems more likely, given the failure of eradication therapy, that these patients were 
infected with a pre-existing MTZ-R sub-population. Strains isolated from the gastric 
antrum and the corpus in patients R - U  were unequivocal examples of mixed 
susceptibility infections.
10.3.2 The role of rdxA inactivation in MTZ resistance
Mutations were demonstrated in 77.8 % of translated rdxA sequences from MTZ-R 
post-treatment isolates, compared with matched MTZ-S pre-treatment populations. 
The absence of a single universal mutation associated with MTZ resistance in UK 
isolates supports findings reported from other countries (Goodwin et a l 1998;Jenks et
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al. 1999;Kwon e/fl/. 2001a;Solcae/aA 2000;Tankovic «/. 2000). Mutations 
causing Arg(16)His substitutions and protein truncations (positions 50 and 74), 
reported previously (Solca et al. 2000) could be critical to the MTZ-R phenotype 
(Marais et al. 2002). Premature protein truncation in particular would significantly 
reduce RdxA enzyme activity. However, these stop-codon mutations were not 
observed in the pre-treatment MTZ-R strain and so cannot be essential for resistance. 
Furthermore, no differences were observed in rdxA sequences of five additional 
paired MTZ-S/MTZ-R strains recovered from patients P and R - U  before therapy. 
Although MTZ-R strains with unaltered rdxA are documented (Goodwin et al. 1998), 
this is the first report to demonstrate mutations in rdxA of MTZ-R strains post-therapy 
that are absent in matched MTZ-R and MTZ-S strains pre-therapy. Thus, MTZ-R 
strains with unaltered rdxA occur more frequently than had been hitherto indicated.
Evidence suggests that MTZ is potentially highly mutagenic (Sisson et al. 2000) 
and it may be that mutations observed in post-treatment MTZ-R H. pylori strains are 
induced during therapy, occurring coincidentally, rather than contributing to the 
MTZ-R phenotype. While mutationally inactivated rdxA genes in MTZ-R sub­
populations are reported, the majority of these had been induced from progenitor 
MTZ-S strains by serial passage on MTZ-containing media in vitro (Adamsson et al. 
2000; Jorgensen et al. 2001). Increasing MTZ concentrations may have induced the 
rdxA mutations reported. In contrast the MTZ-R sub-populations in this study were 
not induced, being observed on primary E-test.
One other study of naturally occurring mixed MTZ-S and MTZ-R populations of 
French and North African isolates, presumably collected pre-treatment, reported 
mutational differences in rdxA between resistotypes (Tankovic et al. 2000). In 
contrast, rdxA sequences were identical in most (68.8 %) mixed MTZ susceptibility
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populations investigated in this study of English isolates, again suggesting that 
mutational inactivation of this gene is not necessary for a MTZ-R phenotype. It is 
difficult to account for the differences between these findings and those reported 
earlier (Tankovic et a l 2000), particularly as relatively small numbers were 
investigated in both studies. Differences may reflect geographic variations or even 
local differences in MTZ useage and rdxA mutation rates.
Previous transformation-based studies have provided compelling evidence to 
suggest an important role for rdxA in MTZ metabolism and in development of 
resistance (Goodwin et a l 1998;Jeong et a l 2000;Kwon et a l 2000b;Paul et a l
2001), as have studies where rdxA function has been altered by knock-out 
mutagenesis (Kwon et a l 2000a;Kwon et a l 2000b;Kwon et a l 2001b).
Additionally, expression of RdxA protein is lower in MTZ-R strains (Kwon et a l 
2000c;Latham et a l 2001), so a potential role for rdxA in MTZ resistance cannot be 
dismissed. However it is proposed that altered RdxA expression in MTZ-R strains 
may not necessarily result from functional inactivation of the gene by mutation. 
Control of RdxA expression may occur by an alternative regulatory mechanism, 
possibly at the transcription or translational level. Future investigation of this 
possibility in the patient strain sets described here could improve understanding of the 
role of rdxA in MTZ resistance.
10.3.3 The role of ahpC inactivation in MTZ resistance
Two recent reports provided conflicting evidence about the involvement of 
alkylhydroperoxide reductase (AhpC) in the MTZ resistance mechanism (McAtee et 
a l 2001;Trend et a l 2001). The reported differential expression of AhpC may occur 
as a stress response to increased toxic molecules as a result of MTZ therapy. The 
study presented in this chapter was the first to examine ahpC sequences in matched
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MTZ-S and MTZ-R strains for any genotypic polymorphisms that could contribute to 
the MTZ resistotype. One other study failed to create an ahpC deficient mutant, 
suggesting that gene inactivation may be lethal in H. pylori (Lundstrom and Bolin 
2000). However, it is not known if ahpC mutations could lead to fimctional 
modification, or to enhanced expression, of this gene. Determination of 
approximately 90 % of the ahpC gene sequence revealed that there were no 
differences in matched strain sequences, regardless of MTZ phenotype. Regulation of 
ahpC expression by mutational modification is therefore unlikely, and rdxA mutations 
were not linked to ahpC sequence alterations. However, it is possible that mutations 
may exist in the final 10 % of the gene. Completion of this data may prove difficult 
as there is limited information available about the Ranking sequences of ahpC in H. 
pylori, that would allow primer design to amplify the entire gene. Future study of 
ahpC should address this limitation, in addition to examining ahpC expression at the 
transcription and translational level to elucidate any potential role in H. pylori, either 
alone or combined with mutated rdxA in MTZ resistance development.
10.3.4 The role offrxA in MTZ resistance
Translated frxA  sequences in the same unique strain set as described above for rdxA 
were identical in most (80.0 %) of the matched patient sets. However, multiple 
alignment of sequences determined in this study with frxA  sequences from non-UK 
isolates held in GenBank showed that frameshift mutations were common in UK 
isolates, whether isolated before or after therapy and regardless of MTZ resistotype. 
These were predicted to lead to protein truncation in all cases. Frameshift mutations 
in frxA  have been reported in previous investigations that examined two MTZ-S and 
four MTZ-R strains (Kwon et a l 2000a), and a total of 21 paired isolates (Kwon et a l 
2001a;Marais et a l 2003), but these were observed in MTZ-R strains only. In
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contrast, results presented in this chapter demonstrate that these mutations occur in 
MTZ-S strains also. The differences between the results of this study and those 
reported previously may be attributable to either geographical variations in frxA 
sequence, or to the examination of a larger population allowing a more representative 
characterisation of this gene. The presence of frameshift mutations in MTZ-S strains 
could be interpreted as an artefact caused by MTZ-R colonies persisting after 
purification of MTZ-S strains by replicate and selective plating. However, this 
possibility was excluded by repeat sequencing offrxA from four MTZ-S strains, 
separated from MTZ-R strains by single colony expansion, which generated identical 
sequences to those of the original purified MTZ-S sub-populations. Additionally, 
repeat E-testing of all separated MTZ-S sub-populations confirmed that these were a 
uniform phenotype.
The results presented in this chapter suggest that inactivation offrxA alone does not 
inevitably result in MTZ resistance. This is consistent with a previous study that 
demonstrated that inactivated frxA  genes did not always transform H. pylori 
phenotype from MTZ-S to MTZ-R (Jeong et a l 2000). Furthermore, purified 
recombinant FrxA protein did not reduce the MTZ drug even though E. coli could be 
transformed with frxA  to become more sensitive to MTZ, providing evidence that 
FrxA does not naturally play a role in MTZ action and in resistance development 
(Sisson et a l 2002).
In the UK isolates investigated here, frameshift offrxA due to single adenine 
deletion at nucleotide 53 was the most frequently observed mutation. As the number 
of patient isolate sets investigated by sequencing was comparatively small and from 
one geographical location, a novel PCR-based probe hybridisation melting point 
analysis assay (FS-53) was developed for the LightCycler to allow rapid screening of
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a larger, more representative, sample of MTZ-S and MTZ-R iT. pylori isolates. Assay 
FS-53 allowed easy, accurate and rapid identification of strains containing the 
deletion mutation. Application of this assay to 119 isolates of H. pylori demonstrated 
that the prevalence of adenine deletion 53 was relatively high (20.2 %) in UK isolates. 
Furthermore, this mutation was observed almost as frequently in MTZ-S as in MTZ-R 
strains (41.7 % vs 5S.3 %), providing further evidence that FrxA inactivation alone is 
unlikely to cause MTZ resistance. Results suggested that this mutation may be more 
common in isolates from patients in South East England, particularly in London 
where, compared with rural areas such as Wales, the patient population was more 
ethnically diverse and may have experienced increased exposure to MTZ for 
treatment of other infections. However, this may be a selection bias as fewer Welsh 
isolates were included in this investigation, so the significance of this distribution 
cannot be assessed at present.
Previous transformation-based studies and construction of knockout mutants have 
suggested that frxA  inactivation can lead to resistance development (Jeong et a l 
2000;Jeong et a l 2001;Kwon et a l 2000a;Kwon et a l 2000b;Kwon et a l  2001b). 
However, as the results presented in this chapter suggest that inactivation offrxA 
leading to protein truncation occurs frequently and does not necessarily lead to Mtz 
resistance, FrxA may be a non-essential enzyme. It is recognised that MTZ 
metabolism and resistance development in H. pylori is likely to be complex and 
multifactorial and thus the effects of an inactivated frxA  could be compensated for by 
enhanced or decreased expression of other, as yet unknown, genes that have similar 
functions, resulting in a MTZ-S phenotype. In transformation experiments, mutated 
exogenous frxA  is inserted into a naïve strain that may have no such compensatory 
mechanisms in place and this could result in development of phenotypic MTZ
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resistance, that possibly would not occur naturally. It is evident that it is difficult to 
gain insight into the role of a single gene in MTZ resistance, studied in isolation, 
without considering the complex interplay that may exist between several genes 
during in vitro culture, and the functions these genes may have in the natural host 
gastric environment.
A recent study suggested that frxA  expression may be negatively regulated by FdxA 
ferredoxin (Mukhopadhyay et a l 2003). The single adenine deletions in a polyA tract 
frequently observed at nucleotide 53 may indicate an additional regulatory mechanism 
whereby frxA  could be switched on and off. Such homopolymeric repeats have been 
identified in the sequenced strain 26695 (Tomb et a l 1997;Saunders et a l 1998). 
Slipped strand mispairing is an important means of translational phase variation in a 
range of H. pylori genes including those involved in lipopolysaccharide synthesis 
(Appelmelk et a l 1999), the porin gene hopZ (Peck et a l 1999) and fliP, a gene 
encoding the flagellar basal body (Josenhans et a l 2000). The role of flavin 
oxidoreductase in vivo remains to be established, so the significance of this potential 
switch mechanism is unclear.
10.3.5 Mutations in rdxA and frxA in relation to MIC
Previous reports have suggested that mutated frxA  may contribute to high level 
resistance only if  combined with mutated rdxA (Jeong et a l 2000; Jeong et a l 2001). 
MICs were determined for all isolates in this study. Selective plating on CBAMTZ to 
purify MTZ-R sub-populations may have artificially raised strain MICs, so it is 
difficult to ascribe any association between rdxA and frxA  mutations and MIC.
Raised MICs were observed in MTZ-R populations recovered post-treatment on 
standard CBA from patients B, G and J. In two patients (B and J), the possibility that 
this may be due to the novel substitution mutations observed in rdxA cannot be
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excluded. However, no differences were observed in rdxA of the MTZ-R isolate pair 
of patient G, in spite of the apparent increased resistance, although frxA  mutations 
were identified. Mutations in MTZ-R isolates firom patient L demonstrated only 
moderate-level resistance in spite of mutations in both rdxA and frxA. Furthermore, 
five isolate sets with MICs of > 256 mg/L had mutated frxA  only, indicating that high- 
level resistance can occur in isolates with apparently unaltered rdxA. However, as the 
frxA  mutations were observed in MtzS strains also, they were unlikely to contribute to 
resistance. Evidence presented in this chapter suggested that mutations in rdxA, ahpC 
and frxA  may not be essential to development of MTZ resistance. Overall, 
examination of the MICs determined for all isolates in relation to mutations in these 
genes would also support that observation.
The results presented in this chapter suggest that the area of MTZ metabolism and 
resistance in H. pylori offers many possibilities for further investigation. Future 
studies could focus on the potential role of transcriptional regulation of candidate 
genes including those described in this thesis. Techniques such as primer extension, 
generation of promoterireporter gene fusions and mRNA quantification were key in a 
series of recent studies demonstrating that expression of ureA and ure B genes is 
upregulated by a complex of Ni^^ ions and a NikR protein orthologue that binds to 
motifs in the ureA promoter, facilitating transcription by RNA polymerase (Davies et 
al. 2002;van Vliet et al. 2001;van Vliet et al. 2002). To date, no studies have 
examined the promoter sequences or the transcriptional regulation of RdxA. Given 
the evidence to suggest that RdxA protein is not expressed in MTZ-R isolates 
(Latham et al. 2001), it would be interesting to investigate this further, possibly by an 
approach similar to that described above for ureA and ureB.
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10.4 Conclusions
In the work presented in this chapter, PCR was a key technique not only in the 
examination of rdxA,frxA and ahpC in a unique strain collection but also in strain 
genotyping by AFLP and in rapid screening of a larger study population for specific 
mutations by real-time PCR. Sequence analyses demonstrated for the first time that 
while mutations occur in both rdxA and frxA, these may not necessarily be 
contributing to the MTZ-R phenotype. In contrast, no mutations were observed in 
ahpC of any matched strain pairs. There has been sufficient evidence presented 
previously to merit continued investigation of the potential role of these genes in 
MTZ metabolism and resistance development. However, a PCR-based approach has 
demonstrated that resistance may develop by mechanisms other than gene mutation 
and so development of a simple molecular test for MTZ resistance in H. pylori, 
analogous to the CLA susceptibility test described in Chapter 5, does not yet appear 
feasible. Continued investigation of alternative regulatory mechanisms for all three 
genes as well as other key enzymes at the transcription, translation and post- 
translational level will be essential in order to improve understanding of the MTZ 
resistance mechanism(s).
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Chapter 11: General discussion and conclusions 
11.1 PCR: General considerations
Since it was first described in 1983, the PCR has revolutionised clinical bacteriology, 
both in diagnostic applications and as a research tool. The speed and high sensitivity 
of the technique along with its potential to examine organisms irrespective of their 
metabolic state has meant that it has been particularly useful for the study of 
organisms that are slow or difficult to grow by conventional means, such as H. pylori 
and other species of Helicobacter. The work presented in this thesis aimed to 
evaluate and develop both conventional and real-time PCR to provide tools for 
enhanced surveillance of helicobacters infecting humans and specific genotypic 
markers associated with virulence or antibiotic resistance of H. pylori.
The analyses of clinical specimens described herein raised several issues regarding 
the potential, and also the possible limitations, of PCR based investigation of 
Helicobacter infections. Overall, results indicated that the following factors 
significantly affected the success of PCR in detection and further strain 
characterisations.
11.1.1 Specimen quality
In Chapter 3 it was shown that the sensitivity of detection from gastric biopsies for 
different H. /Ty/on-specific PCR assays was significantly reduced if the transportation 
of biopsies was prolonged in sub-optimal conditions (e.g. >4 °C). The adverse effects 
of these transport conditions were also demonstrated in subsequent PCR-based 
analyses of gastric biopsies, for identification of markers of antibiotic resistance 
(Chapter 5) and virulence (Chapters 6 and 7), where optimal results were obtained 
from specimens that had been stored, without delay, at low temperatures.
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Consequently it was concluded that unless DNA extraction could be performed the 
same day as specimen collection, all clinical samples should be immediately stored (- 
20 °C) and low temperatures maintained during subsequent transportation and storage 
until further processed. These measures to ensure the availability of good quality 
template DNA were subsequently applied for all other specimens studied (biopsies 
from extra-gastric sites and stool specimens).
11.1.2 Method of DNA extraction
A method must be selected on the basis of the method’s effectiveness at removing 
substances inhibitory to PCR, whilst still recovering high yields of target DNA. Other 
important considerations include overall processing time and labour and consumables 
costs. Preliminary experiments on gastric biopsies in Chapter 3 suggested that a 
simple DNA extraction method (homogenisation followed by digestion and boiling) 
met these criteria. Internal control PCR analyses in Chapter 9 subsequently 
demonstrated that this method was sufficient to remove PCR inhibitory substances 
from bladder and colonic biopsies, while the vascular bronchial biopsies were 
processed successfully by a commercial spin column-based kit. In contrast, faecal 
specimens were particularly refractory to molecular analyses as they contain high 
levels of competing DNA from the host and commensal flora as well as numerous 
substances such as polysaccharides, bile salts and bilirubin that are inhibitory to the 
PCR reaction. Thus, as illustrated in this study, the method of DNA extraction is 
critical to the success of H. pylori detection. Comparison of both manual and 
automated (MagNA Pure system) methods of DNA extraction in Chapter 8 
demonstrated that overall the most successful method for both inhibitor removal and 
DNA recovery was manual extraction using GuSCN buffer containing milk protein
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and diatoms, followed by post-extraction treatment with PVP. This is a novel 
modification of a previously described method (Lawson et a l 1997).
11.1.3 Primer choice for PCR-based detection
Numerous genus and species-specific PCR assays have been described previously for 
the detection of helicobacters, from a range of clinical and environmental specimens. 
However, primer binding efficiency and assay performance depends not only on the 
PCR conditions, but also on the individual primer properties and the level of sequence 
heterogeneity at the primer-binding site of the target gene. This was illustrated at 
several points in this thesis. In Chapter 3, sensitivity and specificity of H. pylori 
detection from gastric biopsies by a novel species-specific assay targeting vacA was 
significantly higher than the assay of Brisou et al (1990) amplifying glm M m d  
marginally superior to the assay reported by Ho e/ <3/ (1991) targeting 16S rDNA. 
Similarly, in Chapter 8, comparison of three nested PCR assays (both in conventional 
and real-time format) targeting ahpC, 16S rRNA and vacA genes showed that the 
ahpC assay was the most sensitive for PCR-based detection of H. pylori from stools. 
In Chapter 9, sensitivity and particularly specificity of the 16S rRNA assay by Bohr et 
al (1998) was poor compared with another genus-specific assay described by Logan et 
al (2001), while in Chapter 7, the CagMotC assay was by far the most sensitive of the 
three LightCycler assays developed to detect cagA tyrosine phosphorylation motifs 
(TPMs) when applied to gastric biopsies. In addition, sequencing of 16S rDNA 
amplicons generated from bladder biopsies in Chapter 9 demonstrated sequence 
mismatch at the binding site of the Hp2 primer of Ho et a/ (1991), highlighting the 
potential pitfalls of detection of an inherently heterogeneous organism like H. pylori 
by a single PCR assay.
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An appreciation of differential assay performance is essential, therefore, when 
selecting appropriate PCR tests for a given application and was critical to the 
interpretation of results generated in the study of extra-gastric disease in Chapter 9.
11.1.4 Target sequence for probe hybridisation melting point analysis 
Real-time PCR is significantly faster and less labour intensive than conventional PCR. 
The utility of the LightCycler instrument for the rapid and simple detection of 
sequence polymorphisms in a single reaction was demonstrated in Chapters 5, 7 and 
10. However, these studies also showed that such probe hybridisation melting point 
analyses are most suitable for conserved genes where mismatches with probe are due 
to specific mutations only (e.g. 23S rDNA). Interpretation is more difficult when this 
approach is applied to genes or regions of genes that are inherently variable (e.g. 
cagA). This is an important consideration for many regions of the H. pylori genome, 
and novel assay design requires prior knowledge of sequence data from multiple 
strains. Specific sequence polymorphisms that are located in areas of high 
heterogeneity are unlikely to be amenable to this kind of analysis.
11.2 The role of PCR in the investigation of human Helicobacter infection
It is evident that various factors require careful consideration to ensure that PCR can 
provide a useful adjunct for enhanced investigation and surveillance of human 
Helicobacter infections. Nevertheless, this study demonstrated the utility of both 
conventional and real-time PCR for detection of viable and non-viable helicobacters 
from both gastric and extra-gastric sites. Additionally, PCR, particularly the real-time 
LightCycler format, was shown to be a powerful tool in strain characterisation.
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11.2.1 Detection of helicobacters from gastric biopsies
In addition to the obvious advantage of rapid, sensitive and specific same-day 
diagnosis of infection, the power of PCR for enhanced detection of helicobacters in 
gastric biopsies was demonstrated in this study. Not only was it possible to detect 
non-viable H. pylori in biopsies collected for CLO test, but a novel PCR assay was 
developed also to detect 'H. heilmannii -like organisms (HHLOs) that are often non- 
cultivable and so have hitherto been detected in the human gastric mucosa primarily 
by histology. Application of this assay to gastric biopsies firom dyspeptic patients in 
South East England demonstrated a higher rate of infection (2.3 %) than had been 
reported previously in most other countries, either indicating a higher geographical 
prevalence or highlighting inadequate sensitivity of the histology-based approach. 
Combination of this assay with a novel vacA H. pylori-spQcific assay produced a 
multiplex test (HpHh), that could detect the two principal groups of human 
gastropathogen with sensitivity and specificity comparable to those determined for 
each individual assay. At the time of writing, this PCR assay was the only one if  its 
kind that could detect this range of helicobacters simultaneously. This allowed the 
first PCR-based assessment of the incidence of H. pylori and HHLO co-infections - 
the failure to identify any indicated that they are comparatively rare in adult dyspeptic 
patients in South East England. This novel assay will facilitate future studies to 
assess the significance of HHLO infection, either singly or as part of a co-infection, in 
relation to human gastric disease.
11.2.2 Further strain characterisation
Culture-based analysis of gastric biopsies offers the distinct advantage of providing H. 
pylori isolates for strain analyses, not only for surveillance of infection but also to 
determine strain virulence potential and antibiotic susceptibility. The ability of PCR
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to allow further strain characterisation is a key benefit of this method, particularly as 
relatively few centres, in the UK or elsewhere, perform culture.
11.2.2.1 Antibiotic resistance
Successful H. pylori eradication is threatened by the apparently global trend for 
increased prevalence of isolates that are MTZ and/or CLA resistant. Development of 
PCR-based methods for application to clinical specimens that are not currently 
undergoing culture would promote enhanced surveillance of antibiotic resistance, as 
well as improving individual patient management. The simplicity of the CLA 
resistance mechanism in H. pylori has facilitated development of a range of molecular 
susceptibility tests. The work in this thesis presents one of the first evaluations of 
real-time PCR-based methodologies for determination of CLA resistance directly 
from gastric biopsies. CLA susceptibilities were accurately determined in 95.6 % of 
the 62 biopsies tested, for which resistotype had been determined previously by 
culture-based methods. Discrepant results may occur in the case of mixed- 
susceptibility infections. Nevertheless, given that real-time PCR offers rapid, same- 
day determination of CLA resistotype in a simple, single reaction, future studies 
should focus on the development of sensitive assays that identify mixed infections. 
Additionally, following the recent report that tetracycline (TET) resistance occurs by 
point mutations in the 16S rRNA gene (Trieber and Taylor 2002), a LightCycler test 
analogous to assay LC-CLA could be developed to monitor these mutations.
In contrast, the mechanism of both MTZ action and resistance development 
remains poorly defined and this has hindered development of a molecular assay for 
rapid susceptibility testing. Nevertheless, PCR proved crucial in this study for further 
examination of the MTZ resistance mechanism. Two genes, rdxA and frxA, that are 
considered to be associated with MTZ resistance were investigated, as was ahpC. A
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unique strategy was employed, examining not only paired pre and post-treatment 
clinical isolates, but also MTZ-R sub-populations of mixed resistotype infections pre­
treatment. The results of PCR-based AFLP genotyping of matched isolates showed 
that mixed susceptibility infections pre-treatment were always phenotypic strain 
variants rather than mixed strain infections. Furthermore, treatment failure in this 
patient study group generally occurred due to persistence of the existing infection, 
possibly due to the selection of a pre-existing MTZ-R sub-population in many cases. 
Comparison of rdxA sequences of MTZ-S (pre-treatment) and MTZ-R (post­
treatment) confirmed the findings of previous studies that mutations occurred in the 
MTZ-R gene (Goodwin et al. 1998;Kwon et al. 2000;Marais et al. 2003). 
Interestingly, these were not observed in the matched MTZ-R pre-treatment strains, 
providing the first strong evidence that the contribution of mutations in the rdxA gene 
to MTZ resistance may not be as significant as had been proposed previously. In 
c o n t r a s t , w a s  identical in all populations in the majority of cases but potential 
inactivation of the gene by ffameshiff mutation, particularly at nucleotide 53, was a 
frequent event, even in MTZ-S strains. Development of a novel real-time PGR assay 
for rapid screening of a larger study population of 119 isolates from across the UK for 
frameshifr mutation 53 confirmed that this was observed in both MTZ-R and MTZ-S 
isolates. The high incidence of mutationally truncated frxA  in MTZ-S isolates 
suggests that inactivation of this gene alone does not cause MTZ resistance. Previous 
studies have indicated that frxA inactivation only contributes to the high-level 
resistance of isolates that also contain a mutated rdxA gene (Jeong et al. 2000;Jeong et 
al. 2001). That was not substantiated by the work in this thesis, where isolates were 
characterised that had high MICs but contained unaltered rdxA and mutated frxA. 
These results suggest that other enzymes are likely to contribute to MTZ resistance.
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but the demonstration that ahpC gene sequences are identical regardless of MTZ 
phenotypes indicate that mutational inactivation of alkyl hydroperoxide reductase 
does not play a significant role. Future studies to examine regulation of RdxA, FrxA 
and AhpC protein expression at the transcriptional and translational level might 
elucidate the role of these in MTZ resistance, as could examination of other candidate 
enzymes such as FdxA, FdxB, For A and PorB in this isolate set.
11.2.2.2 Strain virulence
Although not well understood, it is clear that the pathogenesis of H. pylori infection is 
complex and multifactorial, relating to bacterial, host and environmental factors 
(Gerhard et al. 2002;Moran et al. 2002;Suerbaum and Michetti 2002). The clinical 
outcome of infection is variable between patients, but identification of specific 
virulence factors may provide useful markers for predicting disease progression, and 
can be used to identify patients that might benefit from eradication therapy. Vac A 
and CagA proteins are recognised as probable virulence factors but the precise role of 
these in disease progression is still not clearly defined as they may differ globally 
according to the particular human population.
The signal and mid-region genotype of vacA is one feature that has been suggested 
to contribute to pathogenesis. To facilitate surveillance of this, a novel assay was 
developed that could determine vacA genotypes that were accurate and easy to 
interpret direct from gastric biopsy samples, as well as being more rapid and 
economical than the currently favoured uniplex methods of vacA genotyping.
Analysis of biopsies from South East England demonstrated that type s 1ml in 
particular was observed frequently in isolates associated with peptic ulcer disease, a 
finding substantiated by studies from other countries (Arents et al. 2001;Kidd et al. 
1999). Development of this convenient methodology should promote more extensive
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investigation of the relationship between vacA genotype and disease status, although 
future studies should consider other bacterial and host factors to fully elucidate this 
complex process.
Recently the CagA protein has been shown to be secreted into epithelial cells where 
specific motifs such as putative TPMs A, B and C are phosphorylated by host tyrosine 
kinases, leading to reorganisation of the host cell cytoskeleton (Higashi et a l 
2002;0denbreit et a l 2000;Stein et a l 2002). While this is thought to play a role in 
development of gastric carcinoma (GC), the precise role of this in pathogenesis is not 
yet defined. In this thesis, three real-time PCR assays were developed to allow high- 
throughput screening of isolates for TPMs A, B or C, as a faster and more economical 
alternative to sequencing. Generally, the performance of each assay depended on the 
level of sequence variation in that region of cagA, but in the majority of strains there 
was good correlation between LightCycler assays and sequencing. Some 
discrepancies were observed between the LightCycler CagMotA assay and results of 
two PCR-RFLP assays, whereas the CagMotC assay was superior to the PCR-RFLP 
assay developed for TPM C. The analysis of 84 isolates of H. pylori from dyspeptic 
patients with different diseases, demonstrated that prevalence of TPM A was high in 
South East England isolates while TPMs B and C were comparatively rare. No clear 
associations between TPMs and disease status were apparent, although few isolates 
from patients with GC were examined. The demonstration that TPM status could be 
determined directly from gastric biopsies also showed that these assays could provide 
a useful tool for more extensive study in the UK and elsewhere. Nevertheless, this 
study constitutes the largest survey conducted to date. Further investigation of 
isolates from GC patients as well as the development of methods to screen for
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additional TPMs such as the EPIYA repeats may improve understanding of the 
relationship between CagA phosphorylation and severity of disease.
11.2.3 Non-invasive detection of helicobacters
Gastric biopsies are collected by endoscopy, an invasive and costly procedure. 
Consequently, only a subset of the dyspeptic population (generally those >55 years of 
age or those with ‘alarm’ symptoms suggesting malignancy) are examined. The 
development of non-invasive methodologies, based on analysis of stool specimens 
would not only reduce the risk to the individual patient but would increase access to a 
wider cross-section of the dyspeptic population. Furthermore, non-invasive testing 
provides a means for the examination of the healthy population, that at present has 
been studied by serology-based methods only. In this thesis, detection of H. pylori 
antigen and DNA from stool specimens was compared with culture and histology of 
matched gastric biopsies. At the time of writing, most studies had evaluated 
performance of the HpSA ELISA kit for antigen detection (Gisbert and Pajares 2001). 
However, the work presented in this thesis demonstrated that performance of the 
Amplified IDEIA HpStAR kit was superior to that of the HpSA kit, confirming the 
results of the few studies described to date (Koletzko et a l 2003;Leodolter et a l 
2002;Makristathis et a l 1998;Makristathis et a l 2000). Additional evaluation of a 
simple immunochromatographic test, the ImmunoCard STAT! HpSA, demonstrated 
for the first time that it could reliably detect stool antigen from specimens that had 
generated high ODs by either ELISA, but was insufficiently sensitive for stools that 
had been weakly positive by ELISA. PCR-based detection of H. pylori was less 
sensitive and specific than specific antigen tests, and as discussed (section 11.1), the 
success of this was affected substantially by the method of DNA extraction and the 
individual assay applied. Nevertheless, it was shown that adaptation of the second
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round of nested PCR to a real-time format did not alter the assay performance, but did 
reduce the overall test time. As PCR offers the clear advantage of enabling further 
strain characterisation, particularly in a real-time format, future studies should focus 
on improving sensitivity of detection from stools, by further evaluating methods of 
DNA extraction and PCR assay format.
11.2.4 Investigation of extra-gastric diseases
The potential association between helicobacters and the chronic inflammatory 
conditions Interstitial Cystitis (IC), Inflammatory Bowel Disease (IBD) and Chronic 
Persistent Cough (CPC) were examined by PCR. As discussed, unlike many 
preceding studies, the strategy was to apply a panel of different Helicobacter genus 
and species specific assays, to overcome false-negatives due to heterogeneity at the 
primer binding site and also to provide corroborative evidence of amplicon 
specificity, together with sequencing. This approach was particularly important as 
unlike the studies on gastric biopsies and stool specimens, where the availability of 
matched cultures and/or histological results allowed validation of novel assays or 
novel assay applications, there were no such “gold standard” methods available to 
validate assay performance from these novel extra-gastric sites. No specific DNA 
was amplified in biopsies from IBD or CPC patients, suggesting that helicobacters are 
not involved in the pathogenesis of these conditions. In contrast, specific DNA was 
amplified by two or more PCR assays in 18.5 % of bladder biopsies. Inter-assay 
discrepancy of positive results were observed for these that may have been due to 
differences in assay performances as discussed in section 11.1. Sequencing and 
BLASTn analysis indicated that amplicons had highest identity with H. pylori DNA. 
These results provide the first evidence of the presence of helicobacters in the human 
bladder, although no association between this and IC could be identified. The fact
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that BLASTn analysis does not provide an exhaustive comparison with all bacterial 
and human DNA sequences means that the possibility of amplicon misidentification 
cannot be fully excluded. For this reason, future studies should aim to provide direct 
evidence of H. pylori at this site (e.g. by culture, microscopy, in situ hybridization or 
in situ PCR).
11.3 Concluding comments
This study has demonstrated the value of PCR-based methodologies as informative 
diagnostic tools for the characterisation of Helicobacter infections. It also has 
highlighted aspects of the technique that require careful evaluation and control to 
optimise quality of results. In the future the PCR-based tools developed during this 
study hopefully will facilitate new clinical and epidemiological investigations of a 
broader cross-section of the population than hitherto has been possible. Such studies 
are essential to improve our understanding of the prevalence and virulence of a 
genomically diverse species like H  pylori and of other Helicobacter species which 
are being associated with a variety of chronic human infections.
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Appendix A: Helicobacter strains used to check assay specificities and for assay 
controls
A.1 Strains used for evaluation of assay HHLO-16 specificity
H. pylori NCTC 11637^ and NCTC 11638, strains 26695, J99, and H566
H. fennelliae NCTC 11612^ and NCTC 11613
H. cinaedi NCTC 11611 and NCTC 11614
H. pullorum NCTC 12825 and NCTC 12826
H. canis NCTC 12739 and NCTC 12745
H. acinonychis NCTC 12688 and NCTC 12689
H.felis NCTC 12436^
H. hepaticus NCTC 12886^
H. nemestrinae NCTC 12491  ^(=77 pylori)
77 muridarum NCTC 12714^
77 pametensis NCTC 12888 and NCTC 12889
77 mustellae NCTC 12032
^ indicates the type strain of the species.
A.2 Control strains of 77. pylori
A.2.1 vacA genotyping assay
slm l NCTC 11637
s2m2 Tx30a
A.2.2 LightCycler LC-CLA assay
Wild type 23S rDNA NCTC 11637
Mutated 23S rDNA (A ^G ) H197*
Mutated 23S rDNA (A->C) H235*
*Clinical isolates from the Helicobacter Reference Unit collection
A.2.3 LightCycler assays CagMotA, CagMotB and CagMotC
Cag TPM A + NCTC 11638 and 26695
Cag TPM A - NCTC 11637, ATCC43526 and J99
Cag TPM B + 26695
Cag TPM B - NCTC 11637, NCTC 11638, ATCC43526 and J99
Cag TPM C + NCTC 11637 and ATCC43526 
Cag TPM C - NCTCl 1638, 26695 and J99
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Appendix B: Accession numbers of sequences retrieved from NCBI Entrez 
Nucleotide for prim er and probe design.
B.l Complete vacA sequences (for design of assays HpVac and HpHh)
U95971 AF049647 AF049636 AF049625
U05676 AF049646 AF049633 AF049620
U07145 AF049645 AF049632 AF071097
AF049652 AF049644 AF049631 AF071096
AF049651 AF049643 AF049629 AF071095
AF049650 AF049642 AF049628 AF001358
AF049649 AF049641 AF049627
AF049648 AF049638 AF049626
B.2 16S rRNA (For design of assay HHLO-16)
‘77 heilmanniV
77 felis
77 bizzozeroriii 
77 salomonis
AF25625, AF058777, AF058770, AF058771, Y18028, 
AF058773, AF058772, AF058774, AF058775, AF058776, 
L10079,L10080
M57398, M37643, U51872, U51871, U51870, AF103882, 
AF103881, AF 103880, AF103879 
Y09404, AF103883, AF302107 
U89351
Candidatus H. suis AF127028
77 pylori M88157, UO1330, U01331, U01332, UO8906, AJ011431
Flexispira rappini AF034135, AF047848
77 bovis AF127027 77 bilis AF214508, U51873, AF047844
H. cholecystusU46129 H. canis L14634, U04344, A F l77475
77. hepaticus L39122 H. cinaedi AF207738, AF207739, M88150
77 muridarum M80205 77 mustellae M35048
77 pullorum AF047850 77 rodentium U96297
77 trogontum U65103 77 ulmiensis AJ007931
B.3 cagA sequences (for design of TPM-A, TPM-B and TPM-C LightCycler 
assays)
AF202973
AE000569
AF282853
AF202972
AE001483
AB003397
AF247651
AF249275
B.4 rdxA sequences (for design of prim er )
A F l84267 
A Fl84268
AFl 84269 
AF012553
A F l84266 
AF012552
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Appendix C: Accession numbers of sequences retrieved from NCBI Entrez
Nucleotide for alignment with sequences determined in this study
C .l rdxA sequences (to identify novel mutations)
AF315501 AF180418 AF180419 A F l80420
AF180421 A Fl80422 AF180423 AFl 80424
AF3233015 AF323014 AF305358 AF305357
AF323017 AF323016 AF184267 A F l84266
AFl 84268 AF012553 AF012552 A F l84269
AJ305346 AJ305347 AJ305348 AJ305349
AY063489 AY063488 AJ305356 AFl 80395
AF323003 AF323002 AF180396 AF180397
AFl 80398 AF180399 AFl 80400 AF323005
AF323004 AJ305350 AJ305351 AF323019
AF323018 AF323007 AF323006 AF180401
AJ305355 AF180402 AF180403 A F l80404
AF3230009 AF3230008 AFl 80405 AF180406
AF180407 A Fl80408 AF180409 AF180410
AF180411 AF180412 AJ305352 AJ305353
AF180413 AF180414 AF180415 AF315502
AF180416 AF316109 AF323011 AF323010
AF323010 AF323012 AF180417
C2 frxA  sequences (to identify novel mutations)
AF322960 AF322959 AF322964 AF322963
AF183174 AF183175 AF183176 AF322966
AF322965 AF322976 AF322975 AF322974
AF322973 AF183392 AF322972 AF322971
AF322962 AF322961 AF225923 AF322968
AF322967 AF322970 AF322969
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